<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Signal Transduct Target Ther</journal-id><journal-id journal-id-type="iso-abbrev">Signal Transduct Target Ther</journal-id><journal-title-group><journal-title>Signal Transduction and Targeted Therapy</journal-title></journal-title-group><issn pub-type="ppub">2095-9907</issn><issn pub-type="epub">2059-3635</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40404619</article-id><article-id pub-id-type="pmc">PMC12098830</article-id>
<article-id pub-id-type="publisher-id">2220</article-id><article-id pub-id-type="doi">10.1038/s41392-025-02220-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2467-1776</contrib-id><name><surname>Wang</surname><given-names>Xiaoyan</given-names></name><address><email>xyzaheart@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>Liming</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wei</surname><given-names>Jianming</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zheng</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhou</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Xinjie</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Tao</given-names></name><address><email>liut47@126.com</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1871-5496</contrib-id><name><surname>Zou</surname><given-names>Yunzeng</given-names></name><address><email>zou.yunzeng@zs-hospital.sh.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013q1eq08</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of Biomedical Sciences, </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013q1eq08</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04pp8hn57</institution-id><institution-id institution-id-type="GRID">grid.5477.1</institution-id><institution-id institution-id-type="ISNI">0000000120346234</institution-id><institution>Central Diagnostics Laboratory, University Medical Center Utrecht, </institution><institution>University Utrecht, </institution></institution-wrap>Utrecht, The Netherlands </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ct4d772</institution-id><institution-id institution-id-type="GRID">grid.263826.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 0489</institution-id><institution>Jiangsu Provincial Key Laboratory of Critical Care Medicine and Department of Critical Care Medicine, School of Medicine, Zhongda Hospital, </institution><institution>Southeast University, </institution></institution-wrap>Nanjing, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zyn4z03</institution-id><institution-id institution-id-type="GRID">grid.478016.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 7664 6350</institution-id><institution>Department of Cardiovascular Medicine, </institution><institution>Anzhen Hospital Affiliated to Capital Medical University, </institution></institution-wrap>Beijing, China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, </institution><institution>Chinese Academy of Medical Sciences and Peking Union Medical College, </institution></institution-wrap>Beijing, China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ct4d772</institution-id><institution-id institution-id-type="GRID">grid.263826.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 0489</institution-id><institution>Department of Biochemistry and Molecular Biology, School of Medicine, </institution><institution>Southeast University, </institution></institution-wrap>Jiangsu, Nanjing China </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00z0j0d77</institution-id><institution-id institution-id-type="GRID">grid.470124.4</institution-id><institution>State Key Laboratory of Respiratory Disease, Joint International Research Laboratory of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, </institution><institution>the First Affiliated Hospital of Guangzhou Medical University, </institution></institution-wrap>Guangzhou, Guangdong China </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/003xyzq10</institution-id><institution-id institution-id-type="GRID">grid.256922.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9139 560X</institution-id><institution>Institutes of Advanced Medical Sciences and Huaihe Hospital, </institution><institution>Henan University, </institution></institution-wrap>Kaifeng, Henan China </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>10</volume><elocation-id>166</elocation-id><history><date date-type="received"><day>8</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Immune system plays a crucial role in the physiological and pathological regulation of the cardiovascular system. The exploration history and milestones of immune system in cardiovascular diseases (CVDs) have evolved from the initial discovery of chronic inflammation in atherosclerosis to large-scale clinical studies confirming the importance of anti-inflammatory therapy in treating CVDs. This progress has been facilitated by advancements in various technological approaches, including multi-omics analysis (single-cell sequencing, spatial transcriptome et al.) and significant improvements in immunotherapy techniques such as chimeric antigen receptor (CAR)-T cell therapy. Both innate and adaptive immunity holds a pivotal role in CVDs, involving Toll-like receptor (TLR) signaling pathway, nucleotide-binding oligomerization domain-containing proteins 1 and 2 (NOD1/2) signaling pathway, inflammasome signaling pathway, RNA and DNA sensing signaling pathway, as well as antibody-mediated and complement-dependent systems. Meanwhile, immune responses are simultaneously regulated by multi-level regulations in CVDs, including epigenetics (DNA, RNA, protein) and other key signaling pathways in CVDs, interactions among immune cells, and interactions between immune and cardiac or vascular cells. Remarkably, based on the progress in basic research on immune responses in the cardiovascular system, significant advancements have also been made in pre-clinical and clinical studies of immunotherapy. This review provides an overview of the role of immune system in the cardiovascular system, providing in-depth insights into the physiological and pathological regulation of immune responses in various CVDs, highlighting the impact of multi-level regulation of immune responses in CVDs. Finally, we also discuss pre-clinical and clinical strategies targeting the immune system and translational implications in CVDs.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Cardiology</kwd><kwd>Inflammation</kwd><kwd>Translational research</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></institution-wrap></funding-source><award-id>82000267</award-id><award-id>82230009</award-id><award-id>82430016</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Xiaoyan</given-names></name><name><surname>Zou</surname><given-names>Yunzeng</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>GZC20230505</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Xiaoyan</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; West China Hospital, Sichuan University 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Cardiovascular diseases (CVDs) remain the leading cause of global mortality and continue to be the primary contributor to the worldwide disease burden.<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref></sup> The number of CVDs patients has doubled from 1990 to 2019, and the relevant mortality has increased by 5.5 million over that period.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Meanwhile, global trends for disability-adjusted life years (DALYs) and years of life lost also increased significantly.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Therefore, it is urgently necessary to elucidate the mechanisms of CVDs progression and, based on these mechanisms, develop new drugs to significantly reduce mortality.<sup><xref ref-type="bibr" rid="CR3">3</xref></sup></p><p id="Par3">The immune system, essential for the host defending against pathogens, acts as a double-edged sword in the physiological and pathological processes of CVDs.<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup> Both the innate and adaptive immune systems play significant roles in this process.<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup> Immune cells such as macrophages, dendritic cells (DCs), T-cells, and B-cells, which are components of the immune system, are essential for maintaining vascular health and integrity.<sup><xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref></sup> The multi-level regulatory signaling pathways and mechanisms of the immune regulation also matters in CVDs.<sup><xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref></sup> In addition, there&#x02019;s great progresses in therapeutic targets and clinical research progress (e.g., FDA-approved drugs and clinical trials) regarding the immune regulations in CVDs&#x02019; treatment in recent years.<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup></p><p id="Par4">This review aims to illuminate the complex interplay between immune system and cardiovascular health. It offers a systematic exploration of the research achievement that have shaped our understanding of immune regulation in the cardiovascular system. Then the endotypes and immuno-features of CVDs are discussed in terms of both physiological and pathological. Also, the activation and regulation of immune responses in the context of CVDs are highlighted, including both innate and adaptive immune responses that contribute to CVDs progression. Furthermore, the multi-level regulatory signaling pathways and crosstalk between immune and non-immune cells in CVDs are discussed, highlighting the importance of epigenetic, post-transcriptional, and post-translational modifications in modulating immune responses. Additionally, the crosstalk of key signaling pathways, such as G protein-coupled receptor and growth factor receptor pathways, with immune responses are summarized. Importantly, the review outlines preclinical strategies and clinical progress in immune regulation for CVDs, covering potential therapeutic agents, FDA-approved drugs, and ongoing trials. This review will conclude with key insights, future research directions, and the role of immunology in CVD management, highlighting new opportunities for prevention and treatment. The systematic insights provided in this review aim to furnish a current and thorough understanding of the immune response in CVDs. This knowledge is expected to contribute significantly to the future development of the immune response in both basic research and clinical translation in CVDs.</p></sec><sec id="Sec2"><title>The past and present of immunology and immuno-therapy in CVDs</title><p id="Par5">The role of immune response in atherosclerosis was first identified by Rudolf L.C. Virchow and Nikolay Nikolaevich Anichkov more than a century ago.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> However, for decades, research mainly focused on cholesterol&#x02019;s central role rather than immune response in the development of human atherosclerosis.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> In 1985, researchers from Cambridge University confirmed Virchow and Anichkov&#x02019;s earlier views by identifying macrophage foam cell clusters forming fatty streaks in human atherosclerotic plaques.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> That year, Jonasson et al. showed that major histocompatibility complex, class II, DR Alpha (HLA-DRA), nearly absent in normal arterial walls, was significantly expressed in both immune cells and vascular smooth muscle cells (VSMCs) within atherosclerotic plaques.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> Later evidence identified monocytes, T cells as well as macrophages in these plaques, reinforcing the idea that dysregulated immune response contributes to atherosclerosis development.<sup><xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref></sup> In 1977, Andreas Gr&#x000fc;ntzig developed primary percutaneous coronary intervention (PPCI), an effective treatment for preserving viable myocardium and limiting infarct size following an acute myocardial infarction (AMI).<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup> However, myocardial reperfusion can cause additional death of previously viable cardiac myocytes, known as myocardial reperfusion injury, which can contribute up to 50% of the final infarct size.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> By the 1980s, researchers identified vascular immune dysregulation in coronary arteries before myocardial infarction (MI) and cardiac inflammation after MI. Furthermore, ischemia-reperfusion injury (IRI) is partly caused by a burst of oxygen free radicals, which leads to lipid peroxidation and membrane damage, with neutrophils as a potential source of these free radicals.<sup><xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref></sup> While most pre-clinical studies focus on biological processes induced by AMI, Sarah A. Dick and Slava Epelman highlighted that the balance between physiological and pathological immune dysregulation also influences the progression of chronic heart failure (HF).<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> In the 1990s, researchers found that low-grade chronic inflammation might contribute to clinical deterioration in patients with non-ischemic heart failure.<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup> Moreover, HF, whether ischemic or non-ischemic, is frequently linked to increased plasma levels of pro-inflammatory cytokines like tumor necrosis factor- alpha (TNF-&#x003b1;) and soluble TNF-&#x003b1; receptor, which are associated with worse clinical outcomes.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> In 1994, Attilio Maseris, a prominent cardiologist in ischemic heart disease, made significant contributions to understanding the inflammatory pathogenesis of unstable angina. His group discovered that elevated acute-phase reactants, like C-reactive protein (CRP) and serum amyloid A (SAA), predicted poor outcomes in unstable angina patients.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> This observation highlighted the role of immune system in unstable angina, and the findings were soon expanded upon by another research team. Paul Ridker et al. discovered that prediction models combining inflammatory markers (hs-CRP, SAA, interleukin-6, soluble intercellular adhesion molecule-1 (sICAM-1)) along with lipid levels more accurately predicted cardiovascular risk than models based solely on lipids.<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup> These studies established pro-inflammatory cytokines as key prognostic indicators by linking dysregulated immune response to increased cardiovascular risk. Later that year, Paul Ridker and colleagues found that elevated plasma TNF-&#x003b1; in post-MI patients was linked to a higher risk of recurrent coronary events and was predictive of CVDs prognosis.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> In 2003, Roman et al. reported that patients with chronic inflammatory diseases have an increased prevalence of underlying atherosclerosis compared with healthy controls, independent of traditional risk factors, indicating atherogenesis is associated with systemic inflammation that occurs prematurely.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> In 2005, lymphoid follicle-like structures in the aged aorta of <italic>Apoe</italic><sup>&#x02212;/&#x02212;</sup> mice, now known as tertiary lymphoid organs (TLOs), were characterized by the aggregation of T and B cells.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> Furthermore, in 2015, Andreas&#x02019; group elucidated the protective role of TLOs against atherosclerosis progression.<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> Of note, recent advances in single-cell technologies, such as single-cell mass cytometry, cellular indexing of transcriptomes and epitopes by sequencing, and single-cell RNA sequencing (scRNA-seq), have significantly enhanced our understanding of immune and non-immune cell interactions in atherosclerotic tissue, marking a major leap in studying immune heterogeneity.<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup> In 2023, Sun et al. found TLOs present in various CVDs and used 28 single-cell RNA sequencing datasets to investigate their formation and heterogeneity.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> Also, Rafael Kramann&#x02019;s group utilized single-cell spatially resolved transcriptomics to map gene regulation and cardiac remodeling in human tissue post-MI.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> Additionally, immunotherapies for cancer, like immune checkpoint inhibitors (ICIs), which boost immune surveillance against tumors and are increasingly used in various cancers, have been associated with cardiovascular events.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> The CAR-T cells in vivo by delivering modified messenger RNA (mRNA) in T cell&#x02013;targeted lipid nanoparticles (LNPs) could reduce fibrosis and restore cardiac function after injury.<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup></p><p id="Par6">Building on these significant discoveries, numerous clinical trials are currently underway to explore and validate new therapeutic strategies. In 2017, Ridker et al. reported that administering 150&#x02009;mg of canakinumab every three months significantly lowered the risk of recurrent cardiovascular events compared to placebo in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS).<sup><xref ref-type="bibr" rid="CR46">46</xref></sup> The CANTOS study was groundbreaking, being the first large-scale trial to show that targeting interleukin-1&#x003b2; (IL-1&#x003b2;) with anti-inflammatory treatment significantly reduces cardiovascular events in coronary heart disease patients. In 2019, the Colchicine Cardiovascular Outcomes Trial (COLCOT) underscored the role of inflammation in coronary atherosclerosis by demonstrating that low-dose colchicine reduces cardiovascular events in patients with a history of myocardial infarction.<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> Overall, these clinical trials emphasize the importance of targeting the immune system in individuals with residual inflammatory risk, highlighting the potential of immune-targeted therapies to improve cardiovascular health (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Timeline of key milestones in the development of immunology and immuno-therapy in CVDs in cardiovascular diseases. IRI ischemia-reperfusion injury, HLA-DR Major Histocompatibility Complex, Class II, DR, HLA-DQ Major Histocompatibility Complex, Class II, DQ, VSMCs vascular smooth muscle cells, TLOs tertiary lymphoid organs, CVDs cardiovascular diseases; CANTOS the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS), CRP C-reactive protein, SSA serum amyloid A, TNF-&#x003b1; tumor necrosis factor-&#x003b1;, HF heart failure, COLCOT the Colchicine Cardiovascular Outcomes Trial, COVID-19 Coronavirus Disease 2019, CIRT the Cardiovascular Inflammation Reduction Trial</p></caption><graphic xlink:href="41392_2025_2220_Fig1_HTML" id="d33e528"/></fig></p></sec><sec id="Sec3"><title>Immuno-features in cardiovascular system under physiological conditions</title><p id="Par7">Cardiovascular homeostasis relies on the precise coordination of immune cells, signaling pathways, and cell interactions to maintain an inflammation-free environment essential for optimal cardiac function.<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> The immune system&#x02019;s role in the heart under physiological conditions involves finely tuned responses from various immune cell types that contribute to tissue repair, maintenance, and immune surveillance without triggering an inflammatory cascade<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Immuno-features in cardiovascular system under physiological conditions. <bold>a</bold> Overview of Immune cell in cardiovascular system; <bold>b</bold> Innate and adaptive Immune Signaling Pathways in Cardiovascular Homeostasis (Created with BioRender.com, <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/i19e947">https://BioRender.com/i19e947</ext-link>)</p></caption><graphic xlink:href="41392_2025_2220_Fig2_HTML" id="d33e561"/></fig></p><sec id="Sec4"><title>Overview of immune cell in cardiovascular system</title><p id="Par8">Innate and adaptive immune cells play crucial roles in both the homeostasis and pathogenesis of the cardiovascular system.<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup> The main types of innate immune cells involved in cardiovascular diseases (CVDs) include neutrophils, monocytes/macrophages, eosinophils, dendritic cells (DCs), mast cells, natural killer cells and innate lymphoid cells.<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR51">51</xref></sup> The adaptive immune cells include CD4&#x02009;+&#x02009;T_tem, such as effector-memory CD4&#x02009;+&#x02009;T cells, CD4&#x02009;+&#x02009;T_cytox, CD4+ cytotoxic T cells, CD8&#x02009;+&#x02009;T_tem, CD8+ effector-memory T cells, CD8&#x02009;+&#x02009;T_cytox, CD8+ cytotoxic T cells, and B cells, such as marginal zone B cells, and regulatory B cells (Bregs).<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup> The origin of immune cells in the cardiovascular system is diverse.<sup><xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref></sup>Innate immune cells, like tissue-resident macrophages (C-C chemokine receptor type 2-, CCR2- macrophages), may develop from the yolk sac and fetal liver progenitors,<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup> while CCR2+ macrophages are derived from the recruited monocyte.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> Others are continuously replenished from bone marrow-derived progenitors.<sup><xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref></sup> Among the overall cell population, the largest cell populations are macrophages/monocytes and B cells, followed by Natural Killer cells (NK cells).<sup><xref ref-type="bibr" rid="CR12">12</xref></sup></p><sec id="Sec5"><title>Macrophages phagocytose bacteria, clear dead cells, and contribute to cardiac rhythm</title><p id="Par9">They are abundant within cardiac tissue and serve various functions, including phagocytosing bacteria and clearing dead cells, which help prevent tissue inflammation and support cell turnover.<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup> Notably, macrophages form direct connections with cardiomyocytes via connexin 43 (Cx43) gap junctions, enabling electrical coupling that modulates cardiomyocyte activity and contributes to cardiac rhythm maintenance without promoting inflammation.<sup><xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup> Moreover, macrophages appear to play a role in cardiac renewal. Under normal conditions, macrophages remain in an anti-inflammatory state but can shift to a pro-inflammatory phenotype in<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> response to minor injuries, facilitating repair and clearance of damaged tissue without excessive inflammatory responses.<sup><xref ref-type="bibr" rid="CR64">64</xref></sup></p></sec><sec id="Sec6"><title>NK cells inhibit cardiac fibrosis and promote vessel remodeling</title><p id="Par10">NK cells support immune regulation by controlling the extent of inflammation, preventing immune cell over-accumulation in cardiac tissue, and thus preserving cardiac stability.<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup> NK cells play a critical role in preventing cardiac fibrosis by directly limiting collagen production in cardiac fibroblasts and curbing the buildup of specific inflammatory populations and profibrotic cell types, such as eosinophils, within cardiac tissue.<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> Upon activation through IL-2 administration, NK cells facilitate blood vessel remodeling via &#x003b1;4&#x003b2;7 integrin and killer lectin-like receptor subfamily G member 1 (KLRG1), independent of their involvement in initial vascular formation.<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> Activated NK cells initially adhere to cardiac epithelial cells (CECs) through &#x003b1;4&#x003b2;7 integrin and vascular cell adhesion molecule 1 (VCAM-1), disrupting N-cadherin bonds via KLRG1.<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> This interaction translocates &#x003b2;-catenin from the cytoplasm to the nucleus, alleviating contact inhibition and promoting cellular proliferation.<sup><xref ref-type="bibr" rid="CR69">69</xref></sup></p></sec><sec id="Sec7"><title>Neutrophils prevent chronic inflammation and infections</title><p id="Par11">Neutrophils contribute to cardiovascular health by performing tissue surveillance, patrolling the vascular endothelium, and identifying potential pathogens or tissue damage, which helps maintain cardiac integrity and prevent infections.<sup><xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup> Under normal conditions, neutrophils produce reactive oxygen species (ROS) in controlled amounts, essential for pathogen defense and promoting cellular repair, with regulated ROS release avoiding oxidative stress.<sup><xref ref-type="bibr" rid="CR72">72</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup> Additionally, neutrophils release proteolytic enzymes, including elastase and matrix metalloproteinases (MMPs), which facilitate extracellular matrix remodeling and vascular adaptability.<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> Through vascular endothelial growth factor (VEGF) release, neutrophils promote angiogenesis, supporting the formation and maintenance of blood vessels crucial for oxygen supply in metabolically active cardiac tissue.<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> By signaling macrophages to phagocytize apoptotic cells, neutrophils help reduce inflammation, prevent unnecessary immune activation, and maintain cardiac immune balance.<sup><xref ref-type="bibr" rid="CR76">76</xref></sup> Overall, neutrophils play a supportive role in cardiac function by balancing immune responses, preventing chronic inflammation, and promoting tissue integrity.</p></sec><sec id="Sec8"><title>DCs present antigens and enhance immune tolerance</title><p id="Par12">DCs in cardiac tissue serve as antigen-sensing sentinels, continuously surveying for foreign antigens or cellular abnormalities, thus preventing infections while maintaining tolerance to self-antigens to avoid autoimmunity.<sup><xref ref-type="bibr" rid="CR77">77</xref></sup> They regulate local inflammation by presenting antigens to T cells and activating anti-inflammatory pathways, which minimize immune activation that could harm cardiac tissue.<sup><xref ref-type="bibr" rid="CR78">78</xref></sup> DCs also monitor endothelial health by detecting changes in the endothelial environment, supporting vascular integrity, and facilitating the clearance of apoptotic cells, thus preventing inflammatory responses caused by cellular debris and contributing to overall cardiac stability.<sup><xref ref-type="bibr" rid="CR79">79</xref></sup></p></sec><sec id="Sec9"><title>Regulatory T/B cells prevent excessive immune activation while effector T/B cells provide low-level surveillance</title><p id="Par13">By secreting anti-inflammatory cytokines like IL-10, Regulatory T cells (Tregs) prevent excessive immune activation that could lead to inflammation in cardiac tissue. This helps prevent autoimmunity and chronic inflammation within the heart, maintaining a balanced immune environment.<sup><xref ref-type="bibr" rid="CR80">80</xref></sup> While Tregs aid in immunosuppression, effector T cells provide low-level surveillance, ensuring any damaged or abnormal cells within the cardiovascular system are promptly recognized and, if necessary, cleared.<sup><xref ref-type="bibr" rid="CR81">81</xref></sup> B cells contribute to normal cardiac function by maintaining immune homeostasis within the cardiac environment. Bregs play a critical role in this process by producing anti-inflammatory cytokines, such as IL-10, which prevent excessive inflammation that could disrupt normal cardiac function.<sup><xref ref-type="bibr" rid="CR82">82</xref></sup> Furthermore, B cells produce antibodies that identify and neutralize pathogens in the bloodstream, helping to prevent infections that could indirectly affect the heart by triggering systemic immune responses.<sup><xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR84">84</xref></sup> In addition, B cells regulate autoimmune responses by controlling antibody diversity, limiting self-reactive antibodies that could target cardiac tissue and ensuring cardiac stability.<sup><xref ref-type="bibr" rid="CR85">85</xref></sup> Certain B cell subsets also release factors that support tissue repair, which is beneficial for minor myocardial injuries, enhancing cardiac resilience and structural integrity.<sup><xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR86">86</xref>,<xref ref-type="bibr" rid="CR87">87</xref></sup> Moreover, B cells interact with macrophages and T cells in the cardiac environment to promote a balanced immune response, ensuring that immune reactions are proportional and supportive of cardiac health.<sup><xref ref-type="bibr" rid="CR88">88</xref></sup> Collectively, these functions allow B cells to play a multifaceted role in preventing unnecessary inflammation, controlling autoimmunity, providing immune surveillance, and supporting tissue integrity in the heart.)</p></sec></sec><sec id="Sec10"><title>Innate and adaptive immune signaling pathways in cardiovascular homeostasis</title><sec id="Sec11"><title>Innate immune signaling pathways facilitate cell-to-cell communication, enhance efferocytosis, and prevent autoimmunity</title><p id="Par14">Certain cells, such as resident macrophages and endocrine cells, respond to external stimuli or internal signals by producing and releasing chemokines, which act as messengers to convey information to neighboring cells. These bioactive mediators can orchestrate different cell types within a particular tissue, modulating a wide range of physiological processes, such as development, growth and renewal. Furthermore, nucleic acid-recognizing molecules, such as the DNA and RNA sensors are directly involved in regulating cardiovascular behaviors through interacting with other intracellular homeostatic processes, including apoptosis and autophagy, thereby regulating cardiometabolic health.<sup><xref ref-type="bibr" rid="CR89">89</xref></sup> This biological process largely depends on their ability to discriminate self-DNA/RNA from non-self DNA/RNA, suppressing uncontrolled autoimmune response.<sup><xref ref-type="bibr" rid="CR90">90</xref></sup> Importantly, incorrect self-DNA/RNA recognition could lead to the release of specific autoantibodies, indicating that DNA/RNA sensors serve as critical immune checkpoints and control the autoimmune responses.<sup><xref ref-type="bibr" rid="CR91">91</xref></sup> On the other hand, the activation of these immune pathways in phagocytes helps facilitate the resolution of apoptotic cells harboring damaged self-DNA/RNA following programmed cell death.<sup><xref ref-type="bibr" rid="CR92">92</xref>,<xref ref-type="bibr" rid="CR93">93</xref></sup></p></sec><sec id="Sec12"><title>Adaptive immune signaling pathways contribute immunosuppression and prevent autoimmunity</title><p id="Par15">Tregs exert an immunosuppressive function through the production of anti-inflammatory cytokines like TGF-&#x003b2; and IL-10, playing a role in maintaining peripheral tolerance.<sup><xref ref-type="bibr" rid="CR94">94</xref></sup> However, they also limit sterilizing immunity against abnormal self, such as cancer cells and mutated cells.<sup><xref ref-type="bibr" rid="CR95">95</xref></sup> Usually, these transformed target cells could be eliminated by cytotoxic T lymphocytes (CTLs).<sup><xref ref-type="bibr" rid="CR96">96</xref></sup> In addition to the cell-mediated adaptive immune response, specific antibodies produced by B cells also play a role in maintaining the homeostasis of the cardiovascular system. For example, cardiovascular-reactive natural antibodies (NAbs) can be produced in the absence of infection, even under homeostatic conditions. NAbs interact with multiple self-derived antigens, providing benefits in autoimmunity prevention.<sup><xref ref-type="bibr" rid="CR97">97</xref></sup></p></sec></sec></sec><sec id="Sec13"><title>The endotypes and immuno-features Of CVDs</title><p id="Par16">CVDs encompass various endotypes such as hypertension, atherosclerosis, ischemic heart disease, cardiac remodeling, chronic heart failure, metabolic cardiomyopathy, diabetic cardiomyopathy, aortic disease, cardiac aging, arrhythmia, inflammatory and infectious cardiomyopathy, cardiotoxicity of antitumor drugs, and thrombotic disease. Traditionally, CVDs were understood through their pathophysiological aspects, like plaque buildup and heart muscle failure. However, recent advancements have revealed the immuno-features in the pathogenesis and progression of these diseases (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Mechanisms of Immune Regulation in Physiological and Pathological Processes of CVDs. <bold>a</bold> Immune regulation in various kinds of CVDs. <bold>b</bold> Physiological and pathological factors in CVDs. <bold>c</bold> Physiological and pathological immune regulation in CVDs. CVDs cardiovascular diseases, PAMPs Pathogen-Associated Molecular Patterns, DAMPs Damage-Associated Molecular Patterns, LPS Lipopolysaccharide, Tregs Regulatory T cells, Th1 cell T helper 1 cell, Th17 cell T helper 17 cell, IL-10 Interleukin-10, TGF-&#x003b2; Transforming Growth Factor-beta, SPMs Specialized Pro-resolving Mediators, IL-6 Interleukin-6, TNF-&#x003b1; Tumor Necrosis Factor-&#x003b1;(Created with BioRender.com, <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/r16i827">https://BioRender.com/r16i827</ext-link>)</p></caption><graphic xlink:href="41392_2025_2220_Fig3_HTML" id="d33e839"/></fig></p><sec id="Sec14"><title>Hypertension and immuno-dysregulation</title><p id="Par17">Hypertension is a global health challenge, impacting over 1.3 billion people worldwide, with an increasing prevalence among younger individuals.<sup><xref ref-type="bibr" rid="CR98">98</xref>,<xref ref-type="bibr" rid="CR99">99</xref></sup> Emerging evidence suggests that the development of hypertension is closely linked to immune dysregulation.<sup><xref ref-type="bibr" rid="CR100">100</xref>,<xref ref-type="bibr" rid="CR101">101</xref></sup> Genetic and integrative network analysis showed that some single-nucleotide polymorphisms (SNPs) or genes related to immune response have been implicated in hypertension.<sup><xref ref-type="bibr" rid="CR102">102</xref></sup> In individuals with immune-mediated diseases, the risk of developing hypertension increases by 22% to 90%.<sup><xref ref-type="bibr" rid="CR103">103</xref>&#x02013;<xref ref-type="bibr" rid="CR106">106</xref></sup></p><sec id="Sec15"><title>Immune regulation in normal blood pressure</title><p id="Par18">Normal blood pressure regulation is based on a delicate balance between pro-inflammatory and anti-inflammatory responses. Tregs are vital for vascular homeostasis under physiological conditions, as they suppress excessive inflammation and oxidative stress by producing anti-inflammatory cytokines like IL-10 and TGF&#x02212;&#x003b2;, thereby maintaining normal endothelial function and vascular tone.<sup><xref ref-type="bibr" rid="CR107">107</xref>,<xref ref-type="bibr" rid="CR108">108</xref></sup> Also, resident macrophages in the vessel wall and perivascular adipose tissue contribute to blood pressure regulation by modulating vascular reactivity and NO production.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> DCs maintain a tolerogenic state under normal conditions, preventing over-activated immune response that could lead to hypertension.<sup><xref ref-type="bibr" rid="CR109">109</xref>&#x02013;<xref ref-type="bibr" rid="CR111">111</xref></sup> Moreover, renal DCs interact with tubular cells to maintain normal renal sodium handling and blood pressure by regulating local inflammation.<sup><xref ref-type="bibr" rid="CR112">112</xref></sup> Additionally, the immune system closely interacts with the nervous system to regulate blood pressure. Vagus nerve activation reduces excessive inflammation by releasing acetylcholine to lower pro-inflammatory cytokines production, while the sympathetic nervous system regulates immune cell function and trafficking, maintaining balanced blood pressure.<sup><xref ref-type="bibr" rid="CR113">113</xref>,<xref ref-type="bibr" rid="CR114">114</xref></sup></p></sec><sec id="Sec16"><title>Immune dysregulation in hypertension</title><p id="Par19">Hypertension often results from chronic, dysregulated inflammation driven by various immune and non-immune cells, including T cells and endothelial cells (ECs).<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> Its onset can be triggered by factors like renin-angiotensin-aldosterone system activation, the sympathetic nervous system (SNS) stimulation, high salt intake, stress, eicosanoid changes, mechanical forces, or proteasome inhibitors treatment.<sup><xref ref-type="bibr" rid="CR109">109</xref>,<xref ref-type="bibr" rid="CR116">116</xref></sup> These pro-hypertensive stimuli drive the release of upstream inflammatory regulators, leading to local inflammation and mechanical and oxidative damage.<sup><xref ref-type="bibr" rid="CR109">109</xref>,<xref ref-type="bibr" rid="CR116">116</xref>,<xref ref-type="bibr" rid="CR117">117</xref></sup></p><p id="Par20">T cells play a vital role in the development of hypertension. The increase in CD3&#x02009;+&#x02009;CD45RO+ memory T cells, especially CD8+ effector memory T cells, which exhibit upregulation of pathways related to mitochondrial oxidative metabolism and inflammatory activation, is also associated with hypertension.<sup><xref ref-type="bibr" rid="CR118">118</xref>,<xref ref-type="bibr" rid="CR119">119</xref></sup> Moreover, activated DCs produce IL-6, IL-23, and IL-1&#x003b2;, which drive T cell polarization and the production of effector cytokines.<sup><xref ref-type="bibr" rid="CR109">109</xref></sup> In addition to immune cells, non-immune cells such as endothelial cells can also affect the progression of hypertension.<sup><xref ref-type="bibr" rid="CR109">109</xref>,<xref ref-type="bibr" rid="CR120">120</xref></sup> For example, IL-10 deficiency aggravates angiotensin II-induced endothelial dysfunction and superoxide production, which contribute to hypertension.<sup><xref ref-type="bibr" rid="CR121">121</xref></sup> This immune-endothelial crosstalk illustrates the complex interactions that drive hypertension.</p></sec></sec><sec id="Sec17"><title>Atherosclerosis and immuno-dysregulation</title><p id="Par21">Atherosclerosis, the primary underlying pathology of coronary artery disease (CAD), is characterized by the chronic accumulation or acute rupture of vessel-occluding plaques in the subendothelial intimal layer of large and medium-sized arteries.<sup><xref ref-type="bibr" rid="CR122">122</xref></sup> This process ultimately leads to significant stenosis, restricting blood flow and causing critical tissue hypoxia.</p><sec id="Sec18"><title>Immune regulation in vascular homeostasis</title><p id="Par22">Under physiological conditions, the immune system plays a critical role in maintaining vascular health through balanced inflammatory and anti-inflammatory responses. ECs are central to this process, as they maintain vascular tone, support hemostasis, and regulate thrombosis.<sup><xref ref-type="bibr" rid="CR123">123</xref>,<xref ref-type="bibr" rid="CR124">124</xref></sup> ECs respond to inflammatory signals by secreting mediators that initiate both innate and adaptive immune responses.<sup><xref ref-type="bibr" rid="CR125">125</xref></sup></p><p id="Par23">In normal inflammation, immune cells like neutrophils and macrophages produce cytokines and chemokines to amplify the localized immune response. These molecules recruit additional immune cells, creating a balance between pro-inflammatory cytokines such as TNF-&#x003b1;, IL-6, and IL-1, and anti-inflammatory mediators like IL-10 and TGF-&#x003b2;, which are essential for vascular stability and function.<sup><xref ref-type="bibr" rid="CR126">126</xref></sup> Tregs further aid in this process by modulating inflammatory responses and preventing excessive vascular inflammation.<sup><xref ref-type="bibr" rid="CR107">107</xref>,<xref ref-type="bibr" rid="CR108">108</xref></sup></p></sec><sec id="Sec19"><title>Immune dysregulation in atherosclerosis development</title><p id="Par24">The initiation of atherosclerosis is driven by immune dysregulation triggered by hemodynamic forces, particularly in regions of low shear stress. This hemodynamic environment contributes to endothelial dysfunction, allowing the infiltration of apolipoprotein B (ApoB)-containing lipoproteins into the subendothelial space.<sup><xref ref-type="bibr" rid="CR127">127</xref></sup> Upon activation, endothelial cells secrete chemokines that recruit monocytes, which differentiate into macrophages within the vascular wall. These macrophages, upon taking up lipoproteins, transform into lipid-laden foam cells, marking the onset of plaque formation.<sup><xref ref-type="bibr" rid="CR127">127</xref></sup></p><p id="Par25">Additionally, antigen-presenting cells (APCs) such as macrophages and DCs present lipid and peptide antigens to invariant natural killer T (iNKT) cells and T cells. This interaction triggers adaptive immune responses that contribute to plaque progression.<sup><xref ref-type="bibr" rid="CR128">128</xref></sup> Single-cell transcriptomics have shown that VSMC-derived foam cells constitute a significant portion of foam cells, with these cells demonstrating phenotypic plasticity.<sup><xref ref-type="bibr" rid="CR128">128</xref></sup> They can adopt macrophage-like characteristics that exacerbate lesion growth or fibroblast-like traits that stabilize plaques.<sup><xref ref-type="bibr" rid="CR129">129</xref>&#x02013;<xref ref-type="bibr" rid="CR131">131</xref></sup> Collectively, these processes worsen endothelial dysfunction and drive additional inflammation through continued monocyte recruitment, increased lipoprotein uptake (which adds to the plaque&#x02019;s lipid load), VSMC activation and proliferation, and fibroblast migration, which aids in forming the fibrous cap.</p></sec><sec id="Sec20"><title>Immune crosstalk and plaque progression</title><p id="Par26">The progression of atherosclerosis involves continuous immune cell recruitment and inflammation. Monocytes migrate to the subendothelial layer, where they differentiate into macrophages, perpetuating inflammatory responses through cytokine production and further lipoprotein uptake, which contributes to plaque lipid accumulation.<sup><xref ref-type="bibr" rid="CR126">126</xref></sup> VSMC activation and proliferation add to the plaque mass, while fibroblast migration contributes to the formation of a fibrous cap that stabilizes the plaque but can also increase the risk of rupture in vulnerable plaques.<sup><xref ref-type="bibr" rid="CR126">126</xref></sup></p><p id="Par27">The crosstalk between immune cells in atherosclerosis highlights the intricate interactions at play, involving not only the innate immune system but also adaptive immune responses that drive disease progression. This cross-talk between immune cells and vascular structures reinforces inflammation, fostering an environment conducive to plaque buildup and instability, which underpins the pathology of atherosclerosis and its progression to CAD.</p></sec></sec><sec id="Sec21"><title>Ischemia heart disease and immuno-dysregulation</title><p id="Par28">Ischemia heart disease occurs when blood flow to the heart muscle is reduced, usually due to partial or complete blockage of coronary arteries. The most common cause is atherosclerosis&#x02014;the buildup of plaque in the coronary arteries.<sup><xref ref-type="bibr" rid="CR132">132</xref></sup> Other causes can include coronary artery spasm, thrombosis, and coronary artery dissection.<sup><xref ref-type="bibr" rid="CR133">133</xref>,<xref ref-type="bibr" rid="CR134">134</xref></sup> Ischemic heart disease has the highest global age-standardized DALY at 2275.9 per 100,000.<sup><xref ref-type="bibr" rid="CR135">135</xref></sup> It occurs when blood flow to the heart muscle is reduced, usually due to partial or complete blockage of coronary arteries.</p><sec id="Sec22"><title>Immune dysregulation in ischemia heart disease</title><p id="Par29">The immune response plays a complex and stage-specific role in myocardial ischemia, encompassing both inflammatory and reparative processes. Within hours following ischemic injury, CD4&#x02009;+&#x02009;T helper cells, particularly Th1 and Th17 subsets, are recruited to the myocardium,<sup><xref ref-type="bibr" rid="CR136">136</xref></sup> where they produce pro-inflammatory cytokines, such as IFN-&#x003b3; and IL-17, which escalate inflammation and attract additional immune cells to the site.<sup><xref ref-type="bibr" rid="CR137">137</xref></sup> This early influx of pro-inflammatory cells establishes a highly reactive environment that can lead to exacerbated injury if unchecked. Tregs are also quickly activated during the early stages of the ischemic response, playing a protective role by modulating inflammation and promoting tissue repair. They secrete anti-inflammatory cytokines like IL-10 and TGF&#x02212;&#x003b2;, which help to control excessive inflammation and support the resolution phase.<sup><xref ref-type="bibr" rid="CR138">138</xref></sup> This dual response highlights the immune system&#x02019;s dynamic involvement, with both pro-inflammatory and anti-inflammatory pathways engaged in managing ischemic damage.</p><p id="Par30">B lymphocytes are activated within the first 24-48&#x02009;h post-ischemia, contributing to the early immune response through antigen presentation and production of auto-antibodies against cardiac antigens exposed during tissue damage.<sup><xref ref-type="bibr" rid="CR139">139</xref></sup> Some subsets of B cells, particularly regulatory B cells, may have a protective role by producing IL-10 and modulating T cell responses.<sup><xref ref-type="bibr" rid="CR140">140</xref></sup> Thus, modulating the activity of lymphocytes may offer promising approaches to mitigate ischemic injury and improve cardiac outcomes.</p></sec><sec id="Sec23"><title>Crosstalk and therapeutic implications in immune response to ischemia</title><p id="Par31">Crosstalk among immune cells in ischemic heart disease is critical, as it shapes the progression and resolution of inflammation in myocardial tissue. For instance, interactions between Tregs and Th17 cells modulate the intensity and duration of the inflammatory response, with an overactive Th17 response potentially leading to prolonged inflammation and myocardial damage, while Tregs help suppress excessive immune activation.<sup><xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR141">141</xref></sup> This balance is essential for tissue recovery, and dysregulation at any stage can exacerbate ischemic injury or hinder repair mechanisms.</p><p id="Par32">B cells also interact with T cells in the ischemic heart, influencing the overall immune response; while effector B cells promote inflammation through antigen presentation and antibody production, regulatory B cells help mitigate immune activation.<sup><xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR142">142</xref></sup> Understanding these interactions provides insights into potential therapeutic approaches to limit ischemic injury, highlighting the value of targeting specific immune cell types or pathways to enhance cardiac recovery and prevent further ischemic damage.</p></sec></sec><sec id="Sec24"><title>Cardiac remodeling and immuno-dysregulation</title><p id="Par33">Cardiac remodeling involves structural and functional changes in the heart due to hemodynamic overload and/or cardiac injury.<sup><xref ref-type="bibr" rid="CR143">143</xref></sup> Changes in the heart&#x02019;s size, shape, and function are clinically observed and detected through echocardiography, magnetic resonance imaging (MRI), positron emission tomography (PET) scans, ventriculography, and tomography.<sup><xref ref-type="bibr" rid="CR144">144</xref>&#x02013;<xref ref-type="bibr" rid="CR146">146</xref></sup> Remodeling can be either physiological or pathological, classified as adaptive or maladaptive.<sup><xref ref-type="bibr" rid="CR143">143</xref></sup> Physiological hypertrophy, occurring during development, pregnancy, or endurance training, is fully reversible.<sup><xref ref-type="bibr" rid="CR147">147</xref>&#x02013;<xref ref-type="bibr" rid="CR149">149</xref></sup> It features mild heart growth (10&#x02013;20% larger than normal), no reactivation of fetal genes, increased cardiomyocyte growth in both length and width, angiogenesis, and lack of apoptosis and interstitial fibrosis.<sup><xref ref-type="bibr" rid="CR143">143</xref></sup> However, pathological remodeling occurs in acute and chronic phase of MI, pressure-overloaded conditions, volume-overloaded conditions, or genetic changes.</p><sec id="Sec25"><title>Immune regulation in physiological cardiac remodeling</title><p id="Par34">The immune system plays a critical role in modulating physiological cardiac remodeling during both development and in adulthood.<sup><xref ref-type="bibr" rid="CR150">150</xref></sup> In normal conditions, cardiac-resident macrophages, derived from embryonic origins, predominate and are maintained through local proliferation. These macrophages support homeostasis by modulating local inflammation and promoting angiogenesis without triggering adverse remodeling.<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR151">151</xref>,<xref ref-type="bibr" rid="CR152">152</xref></sup> Additionally, circulating CCR2+ monocytes contribute minimally to the cardiac macrophage population under these conditions, highlighting the importance of resident macrophages in maintaining physiological homeostasis.<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR151">151</xref></sup></p><p id="Par35">Physical exercise has been shown to modulate macrophage function by promoting a shift from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages. This transition helps enhance cardiac function and minimize interstitial fibrosis, suggesting that lifestyle interventions could modulate immune responses favorably.<sup><xref ref-type="bibr" rid="CR153">153</xref></sup> Exercise also activates cardiac-resident stem cells, contributing to cardiac repair and regeneration through immune modulation.<sup><xref ref-type="bibr" rid="CR154">154</xref></sup></p></sec><sec id="Sec26"><title>Immune regulation in pathological cardiac remodeling</title><p id="Par36">Pathological cardiac remodeling occurs following cardiac injury or sustained mechanical stress. This process involves significant changes in the immune system, with infiltrating monocytes and macrophages exacerbating adverse remodeling.<sup><xref ref-type="bibr" rid="CR155">155</xref></sup> In this context, mechanical stress activates innate immune responses, leading to the recruitment of neutrophils and macrophages to the myocardium. These cells release pro-inflammatory cytokines, such as TNF-&#x003b1;, IL-1&#x003b2;, and IL-6, which contribute to cardiomyocyte hypertrophy, fibrosis, and tissue damage.</p><p id="Par37">The balance between M1 and M2 macrophages influences the progression of pathological remodeling, where an excess of M1 macrophages can drive fibrosis and hypertrophy, while M2 macrophages attempt to counteract these effects.<sup><xref ref-type="bibr" rid="CR156">156</xref></sup> Cardiac-resident macrophages exhibit a protective effect by regulating inflammation, whereas infiltrating monocyte-derived macrophages contribute to adverse outcomes. Additionally, T cells, particularly CD4&#x02009;+&#x02009;T cells, infiltrate the myocardium, promoting fibrosis and inflammation, thereby contributing to ventricular stiffness and dysfunction.<sup><xref ref-type="bibr" rid="CR142">142</xref></sup></p></sec><sec id="Sec27"><title>Immune crosstalk and heart failure development</title><p id="Par38">The development of heart failure involves intricate interactions between innate and adaptive immune responses. Initially, cardiac injury triggers the activation of innate immune cells, including macrophages and neutrophils, which release pro-inflammatory cytokines such as TNF-&#x003b1;, IL-1&#x003b2;, and IL-6.<sup><xref ref-type="bibr" rid="CR157">157</xref></sup> These cytokines promote inflammation and cardiac remodeling by promoting hypertrophy and fibrosis.<sup><xref ref-type="bibr" rid="CR157">157</xref></sup> As heart failure progresses, chronic immune activation becomes prominent, marked by the involvement of adaptive immune cells, particularly T lymphocytes. CD4+ and CD8&#x02009;+&#x02009;T cells expand systemically and infiltrate the failing myocardium.<sup><xref ref-type="bibr" rid="CR158">158</xref></sup> This persistent immune activation leads to a state of chronic low-grade inflammation that exacerbates cardiac dysfunction. Also, compensatory anti-inflammatory mechanisms are activated, including the production of IL-10 and TGF-&#x003b2;, in an attempt to resolve inflammation and promote tissue repair.<sup><xref ref-type="bibr" rid="CR159">159</xref></sup> However, the balance between pro- and anti-inflammatory processes eventually becomes dysregulated, leading to maladaptive ventricular remodeling and the progression of heart failure.<sup><xref ref-type="bibr" rid="CR159">159</xref></sup></p><p id="Par39">The neurohumoral activation induced by mechanical stress also interacts with immune responses, enhancing inflammation and contributing to adverse remodeling.<sup><xref ref-type="bibr" rid="CR160">160</xref></sup> Over time, compensatory anti-inflammatory mechanisms, such as the production of IL-10 and TGF-&#x003b2;, attempt to resolve inflammation and promote tissue repair. However, this balance between pro- and anti-inflammatory factors becomes dysregulated in chronic heart failure, leading to further deterioration.</p></sec></sec><sec id="Sec28"><title>Metabolic cardiomyopathy and immuno-dysregulation</title><p id="Par40">Metabolic cardiomyopathy is a chronic metabolic disorder characterized by structural and functional cardiac changes, occurring independently of hypertension and coronary artery disease. It involves interstitial fibrosis, diastolic and systolic dysfunction, and cardiomyocyte injury. In its early stages, metabolic disturbances may not significantly affect myocardial structure or cardiac function, but they induce low-grade inflammation in the heart, leading to impaired myocardial relaxation due to abnormalities in subcellular components, such as endoplasmic reticulum stress, oxidative stress, calcium handing, and impaired mitochondrial dysfunction. In the advanced stage, a vicious cycle of subcellular component abnormalities and immune cell infiltration leads to cardiomyocyte injury, death, and cardiac fibrosis, ultimately impairing both diastolic and systolic functions.<sup><xref ref-type="bibr" rid="CR161">161</xref></sup></p><sec id="Sec29"><title>Immune regulation in myocardial metabolism</title><p id="Par41">Recent studies have highlighted the impact of cellular metabolism on immune activation, with coordinated regulation benefiting the organism by optimizing energy resources during immune or inflammatory responses.<sup><xref ref-type="bibr" rid="CR162">162</xref></sup> Nutrient-sensing pathways can trigger immune responses, while inflammatory or stress responses inhibit anabolic pathways like insulin/insulin-like growth factor (IGF) signaling, diverting energy metabolism from synthesis to catabolism.<sup><xref ref-type="bibr" rid="CR163">163</xref></sup> A key concept in this context is &#x0201c;trained immunity,&#x0201d; which refers to the long-term functional reprogramming of innate immune cells, especially monocytes and macrophages, following metabolic stress or inflammatory stimuli. This adaptation can contribute to the sustained low-grade inflammation seen in cardiometabolic diseases.<sup><xref ref-type="bibr" rid="CR164">164</xref></sup></p></sec><sec id="Sec30"><title>Immune dysregulation in metabolic cardiomyopathy</title><p id="Par42">Emerging clinical evidence indicates strong links between the immune system and the development of metabolic cardiomyopathy.<sup><xref ref-type="bibr" rid="CR161">161</xref></sup> Macrophages play a crucial role in the development of metabolic cardiomyopathy.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> M1 macrophages secrete inflammatory cytokines that impair systemic and cardiac insulin signaling, and their presence is associated with metabolic cardiomyopathy induced by a Western diet in mice.<sup><xref ref-type="bibr" rid="CR165">165</xref></sup> Additionally, inflammation in &#x003b2;-cells leads to &#x003b2;-cell dysfunction, which combined with insulin resistance, exacerbates the condition.<sup><xref ref-type="bibr" rid="CR166">166</xref></sup></p><p id="Par43">Beyond immune cells, endothelial cells and myofibroblasts in metabolic cardiomyopathy contribute to dysregulated immune responses.<sup><xref ref-type="bibr" rid="CR167">167</xref>&#x02013;<xref ref-type="bibr" rid="CR169">169</xref></sup> For instance, in human epicardial adipose tissue treated for diabetes, pro-inflammatory cytokines like TNF-&#x003b1; and IL-1&#x003b2; induce an inflammatory phenotype in human coronary endothelial cells, resulting in diminished vascular progenitor potential and promoting cardiomyopathy development.<sup><xref ref-type="bibr" rid="CR170">170</xref>,<xref ref-type="bibr" rid="CR171">171</xref></sup> Furthermore, myofibroblasts activated by inflammatory mediators such as IL-13, IL-18, and MMPs play a significant role in initiating myocardial fibrosis. This process increases cardiac stiffness and impairs the heart&#x02019;s contractile and relaxation functions.<sup><xref ref-type="bibr" rid="CR172">172</xref></sup> The interplay between immune cells and these non-immune cells perpetuates a cycle of inflammation and fibrosis, which ultimately leads to metabolic cardiomyopathy progression.</p></sec></sec><sec id="Sec31"><title>Aortic diseases and immuno-dysregulation</title><p id="Par44">Aortic diseases are a variety of conditions affecting the aorta, the main artery, including congenital or acquired diseases of the chest and abdomen. They can be divided into three categories, thoracic aortic aneurysm (TAA), abdominal aortic aneurysm (AAA) and acute aortic syndrome (AAS).<sup><xref ref-type="bibr" rid="CR173">173</xref></sup> These conditions can result in life-threatening complications, such as aortic dissection, which carries a mortality rate exceeding 80 percent.<sup><xref ref-type="bibr" rid="CR174">174</xref></sup></p><sec id="Sec32"><title>Immune regulation in the aorta under physiological conditions</title><p id="Par45">In physiological states, the immune system plays a pivotal role in maintaining aortic homeostasis by preventing excessive inflammation and supporting vascular function.<sup><xref ref-type="bibr" rid="CR175">175</xref>,<xref ref-type="bibr" rid="CR176">176</xref></sup></p><p id="Par46">At the forefront of this regulation are Tregs, which secrete anti-inflammatory cytokines such as IL-10 and TGF-&#x003b2;.<sup><xref ref-type="bibr" rid="CR177">177</xref></sup> These cytokines are crucial in mitigating inflammation and oxidative stress, thereby preserving endothelial cell function and reducing vascular stiffness to maintain aortic integrity. Resident macrophages within the aortic wall significantly contribute to vascular stability by producing NO and anti-inflammatory cytokines.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> These macrophages regulate vascular tone and prevent inflammation, thereby protecting endothelial health.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> Additionally, endothelial cells are key regulators within this network, producing NO and modulating cytokine levels to establish an anti-inflammatory environment.<sup><xref ref-type="bibr" rid="CR178">178</xref></sup> This reduces immune cell adhesion to the aortic wall, thus preserving vascular integrity and preventing inflammation-induced injury.<sup><xref ref-type="bibr" rid="CR178">178</xref></sup> DCs are another critical element in maintaining immune tolerance within the aortic tissue.<sup><xref ref-type="bibr" rid="CR179">179</xref></sup> They help establish a regulatory environment that curtails excessive immune activation, thereby preventing potential inflammatory damage.</p><p id="Par47">Mechanical forces, such as shear stress resulting from blood flow, also play an essential role in modulating immune responses within the aorta.<sup><xref ref-type="bibr" rid="CR180">180</xref></sup> Macrophages and other immune cells can detect these forces and subsequently adjust their cytokine production to reduce inflammation, enabling them to respond to physiological changes in blood flow.<sup><xref ref-type="bibr" rid="CR180">180</xref></sup> Furthermore, aortic smooth muscle cells contribute to immune regulation by interacting with macrophages and releasing anti-inflammatory mediators, thereby maintaining a stable aortic wall and preventing inflammatory cell infiltration.<sup><xref ref-type="bibr" rid="CR181">181</xref></sup> Moreover, the SNS interacts closely with immune cells in the aorta, modulating their trafficking and activation.<sup><xref ref-type="bibr" rid="CR182">182</xref></sup> This interaction is vital to preventing excessive immune infiltration and maintaining balanced vascular reactivity.<sup><xref ref-type="bibr" rid="CR182">182</xref></sup> This neural-immune interaction is essential for maintaining vascular health and controlling inflammation within the aorta. Collectively, these cellular and molecular mechanisms underscore the intricate yet essential role of immune regulation in preserving aortic homeostasis, providing valuable insights into how immune cells and signaling pathways work in concert to maintain a healthy vascular environment.</p></sec><sec id="Sec33"><title>Immune dysregulation in aortic aneurysms</title><p id="Par48">The underlying pathology of aortic aneurysms involves significant immune cell infiltration and activation within the aneurysmal regions. This immune response contributes to inflammation and progressive structural degradation of the aortic wall.<sup><xref ref-type="bibr" rid="CR183">183</xref></sup> Macrophages, DCs, and T lymphocytes play central roles in maintaining aortic homeostasis and modulating inflammatory responses within the aorta. Macrophages are particularly abundant in aneurysmal tissue, where they accumulate and undergo local expansion through self-renewal.<sup><xref ref-type="bibr" rid="CR184">184</xref></sup> This macrophage presence is critical to aneurysm progression; macrophage depletion has been shown to disrupt endothelial integrity, leading to fibrin accumulation and microthrombus formation.<sup><xref ref-type="bibr" rid="CR185">185</xref></sup> DCs within the normal aorta have high antigen-presenting capacity and are essential in maintaining immune homeostasis by capturing and presenting antigens effectively.<sup><xref ref-type="bibr" rid="CR186">186</xref>,<xref ref-type="bibr" rid="CR187">187</xref></sup> In aneurysmal tissues, however, DCs contribute to inflammation through the recruitment and activation of T cells, exacerbating tissue remodeling.<sup><xref ref-type="bibr" rid="CR188">188</xref></sup></p><p id="Par49">T lymphocytes play an instrumental role in regulating aortic tissue integrity by secreting cytokines and modulating apoptosis and extracellular matrix remodeling. Recent single-cell transcriptome analysis reveals that T lymphocytes are abundant in aneurysmal aortic tissue and exhibit clonal expansion, suggesting their active involvement in the pathogenesis of aortic aneurysms.<sup><xref ref-type="bibr" rid="CR176">176</xref>,<xref ref-type="bibr" rid="CR189">189</xref></sup> These T cells can drive inflammation and matrix degradation, leading to compromised structural stability of the aortic wall, which increases the risk of dissection and rupture. In addition, Tregs may have a protective role in modulating excessive immune activation and tissue destruction.<sup><xref ref-type="bibr" rid="CR190">190</xref></sup> Tregs can counterbalance pro-inflammatory responses by secreting anti-inflammatory cytokines, thereby promoting tissue stability and potentially limiting aneurysm expansion. However, dysregulation in Treg activity or quantity may contribute to unchecked inflammation and accelerated aneurysm development.</p></sec></sec><sec id="Sec34"><title>Cardiac aging and immuno-dysregulation</title><p id="Par50">Cardiac aging is a gradual process that diminishes cardiac structure and function due to the cumulative impact of internal and external stressors. With aging, the myocardium undergoes structural changes, including increased cardiomyocyte hypertrophy, interstitial fibrosis, and chronic inflammation, ultimately contributing to diastolic and systolic dysfunction.<sup><xref ref-type="bibr" rid="CR191">191</xref></sup></p><sec id="Sec35"><title>Immune dysregulation in cardiac aging</title><p id="Par51">At the cellular level, various forms of cellular senescence contribute to cardiac aging. Immune cells, including T cells, mast cells, and macrophages, regulate tissue homeostasis and pathogenesis by modulating inflammatory responses and myocardial senescence in cardiac tissue.<sup><xref ref-type="bibr" rid="CR191">191</xref></sup> T cells can affect age-related diseases, including senescence, through several mechanisms, as outlined below: 1) Age-associated T cells continue to produce cytokines, such as IFN-&#x003b3; and TNF-&#x003b1;, which leads to chronic inflammation and promotes senescence of neighboring cells<sup><xref ref-type="bibr" rid="CR192">192</xref></sup>; 2) T cells enhance senescence-associated secretory phenotypes (SASP), which further exacerbate inflammation and Th17/Th1 cell differentiation, leading to tissue damage<sup><xref ref-type="bibr" rid="CR193">193</xref></sup>; 3) Dysfunctional T cells fail to clear senescent cells, leading to the accumulation of these cells and exacerbating tissue damage<sup><xref ref-type="bibr" rid="CR194">194</xref></sup>; Senescent CD8+ and CD4&#x02009;+&#x02009;T cells acquire cytotoxicity, which directly damages tissue cells.<sup><xref ref-type="bibr" rid="CR195">195</xref>,<xref ref-type="bibr" rid="CR196">196</xref></sup></p><p id="Par52">Mast cells and macrophages also contribute to cardiac aging by promoting cardiomyocyte hypertrophy and cellular senescence. Mast cells release enzymes like chymotrypsin, which influence hypertrophy, while macrophages drive senescence through the activity of connexins and pro-inflammatory cytokines.<sup><xref ref-type="bibr" rid="CR197">197</xref>,<xref ref-type="bibr" rid="CR198">198</xref></sup> Additionally, macrophages in the aging heart release cytokines, such as IL-6, TNF-&#x003b1;, and IL-1, which have been shown to induce an osteogenic phenotype in valvular interstitial cells (VICs).<sup><xref ref-type="bibr" rid="CR199">199</xref></sup> This change promotes calcification and fibrosis within heart valves, impairing valve function and exacerbating age-related cardiac dysfunction.<sup><xref ref-type="bibr" rid="CR199">199</xref></sup></p></sec><sec id="Sec36"><title>Involvement of non-immune cells in cardiac aging</title><p id="Par53">Non-immune cells, such as endothelial cells, VSMCs, and VICs, also play crucial roles in cardiac aging. Senescent endothelial cells release inflammatory chemokines and cytokines, with reduced levels of anti-inflammatory molecules, contributing to a pro-inflammatory environment.<sup><xref ref-type="bibr" rid="CR200">200</xref></sup> VSMCs display a SASP, characterized by the secretion of monocyte chemotactic protein-1 (MCP-1), chemokine (C-C motif) ligand 3/4 (CCL3/4), and various interleukins (IL-1, IL-6, IL-8), further promoting inflammation and fibrosis.<sup><xref ref-type="bibr" rid="CR201">201</xref></sup> VICs, as the primary cell type in heart valves, also undergo senescence, impairing their function and contributing to calcification and fibrosis. Pro-inflammatory cytokines released by macrophages in aging cardiac tissue further promote VIC senescence and functional decline.<sup><xref ref-type="bibr" rid="CR191">191</xref></sup></p></sec></sec><sec id="Sec37"><title>Arrhythmia and immuno-dysregulation</title><p id="Par54">Arrhythmias, including atrial fibrillation (AF) and ventricular arrhythmias, arise from disruptions in cardiac electrical activity and conduction, which are influenced by the immune system.<sup><xref ref-type="bibr" rid="CR202">202</xref></sup> Inflammatory cells, especially macrophages, are pivotal in maintaining cardiac electrical stability and have direct and indirect roles in modulating cardiac conduction.<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> These roles include influencing ion channel expression and promoting fibrotic changes that alter the electrical landscape of the myocardium.<sup><xref ref-type="bibr" rid="CR65">65</xref></sup></p><sec id="Sec38"><title>Immune regulation in cardiac conduction</title><p id="Par55">Macrophages in cardiac tissue interact with cardiomyocytes and influence electrical conduction through the modulation of ion channels. They express conduction-related genes, including those encoding ion channels such as Cacna1c (Cav1.2), Kcnj2 (Kir2.1), Kcnq1 (Kv7.1), Hcn2 (HCN2), and Kcnh2 (Kv11.1).<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> Additionally, macrophages interact with cardiomyocytes through gap junctions formed by connexin 43 (Cx43), impacting both resting and action potentials in cardiomyocytes.<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> Through these mechanisms, macrophages contribute to arrhythmogenesis by altering the electrophysiological properties of the heart.</p></sec><sec id="Sec39"><title>Immune regulation in arrhythmia</title><p id="Par56">A strong link exists between inflammation and arrhythmias,<sup><xref ref-type="bibr" rid="CR202">202</xref></sup> including ventricular tachyarrhythmias due to myocarditis.<sup><xref ref-type="bibr" rid="CR203">203</xref></sup>New-onset AF is common in acute sepsis.<sup><xref ref-type="bibr" rid="CR204">204</xref></sup> Existing studies suggest that inflammatory signaling in cardiomyocytes has a key role in the development of AF, and in particular, NLR family pyrin domain containing 3 (NLRP3) inflammatory vesicles are particularly associated with cardiomyocyte-mediated inflammatory signaling in AF.<sup><xref ref-type="bibr" rid="CR205">205</xref></sup> Autoantibodies contribute to the development of arrhythmias by modulating the function of cardiac ion channels and significantly affecting cardiac electrical activity.<sup><xref ref-type="bibr" rid="CR206">206</xref></sup> Bradyarrhythmias and conduction disorders: anti-Ro/SSA antibodies target L-type and T-type calcium channels, inhibit calcium currents, and affect sodium currents in the sinoatrial node (SA node) and atrioventricular node (AV node).<sup><xref ref-type="bibr" rid="CR207">207</xref>,<xref ref-type="bibr" rid="CR208">208</xref></sup></p><p id="Par57">Autoantibodies have also been implicated in arrhythmia development by targeting cardiac ion channels, thereby altering cardiac electrical activity. For example, in bradyarrhythmias, anti-Ro/SSA antibodies target L-type and T-type calcium channels, inhibiting calcium currents and impacting the SA and AV nodes.<sup><xref ref-type="bibr" rid="CR209">209</xref></sup> In conditions such as Long QT syndrome (LQTS), anti-SSA antibodies targeting K11.1V11.1&#x02009;K channels (hERG) inhibit potassium currents, resulting in delayed repolarization.<sup><xref ref-type="bibr" rid="CR210">210</xref></sup> Autoantibodies targeting K1.4V1.4&#x02009;K channels may inhibit transient outward potassium currents.<sup><xref ref-type="bibr" rid="CR211">211</xref>&#x02013;<xref ref-type="bibr" rid="CR213">213</xref></sup> Conversely, in Short QT syndrome (SQTS), autoantibodies targeting K7.1V7.1 potassium channels increase potassium currents, accelerating repolarization and predisposing the heart to arrhythmic episodes.<sup><xref ref-type="bibr" rid="CR214">214</xref></sup></p></sec></sec><sec id="Sec40"><title>Myocarditis and immuno-dysregulation</title><p id="Par58">Myocarditis is characterized by the infiltration of inflammatory cells into the myocardium, which increases the risk of cardiac dysfunction. It can be caused by a wide range of factors, classified into infectious and non-infectious types.<sup><xref ref-type="bibr" rid="CR215">215</xref></sup> The immune system&#x02019;s role in myocarditis is complex, as immune regulation is crucial for both protecting cardiomyocytes from pathogens and managing inflammation to prevent further tissue damage.</p><sec id="Sec41"><title>Immune dysregulation in infectious myocarditis</title><p id="Par59">Infectious myocarditis, commonly caused by viral infections, may also result from bacterial, protozoal, or fungal infections.<sup><xref ref-type="bibr" rid="CR216">216</xref></sup> Immunoregulatory mechanisms play a vital role in the development and progression of cardiomyopathies in both physiological and pathological states. Under normal conditions, the heart maintains a balanced immune state to protect cardiomyocytes from pathogens while avoiding tissue damage from excessive immune response.<sup><xref ref-type="bibr" rid="CR217">217</xref></sup> Following infection, immune cells in the myocardium initiate an inflammatory response upon recognizing pathogens, which is vital for controlling infections but can also damage myocardial tissue. For instance, tripartite motif-containing protein 18 (TRIM18) regulates viral myocarditis by modulating TBK1-mediated immune responses in macrophages, thereby limiting the extent of inflammation.<sup><xref ref-type="bibr" rid="CR218">218</xref></sup> Additionally, TRIM29 has been shown to control viral myocarditis through the regulation of ER stress and ROS responses in macrophages.<sup><xref ref-type="bibr" rid="CR219">219</xref></sup>Moreover, the heart-spleen axis is essential in managing the systemic inflammatory response; by preventing the recruitment of pro-inflammatory monocytes to the myocardium, this axis helps mitigate myocardial damage and chronic inflammation, emphasizing the importance of balanced immune signaling in limiting disease progression.<sup><xref ref-type="bibr" rid="CR220">220</xref></sup></p></sec><sec id="Sec42"><title>Immune dysregulation in non-infectious myocarditis</title><p id="Par60">Non-infectious myocarditis is often associated with immune-modulatory treatments, particularly immune checkpoint inhibitors (ICIs) and CAR T-cell therapy. In ICIs-induced myocarditis, CCR2+ macrophages are significantly recruited to the heart, creating a pro-inflammatory environment that accelerates myocardial damage.<sup><xref ref-type="bibr" rid="CR221">221</xref></sup> T cells also contribute to this damage through clonal expansion and recognition of myocardial antigens, which exacerbates inflammation and can lead to further myocardial injury.<sup><xref ref-type="bibr" rid="CR222">222</xref>,<xref ref-type="bibr" rid="CR223">223</xref></sup> Additionally, &#x0201c;epitope spreading&#x0201d; in this context may lead to tumor-specific T cells attacking cardiac tissue, expanding the scope of immune dysregulation.<sup><xref ref-type="bibr" rid="CR223">223</xref></sup></p><p id="Par61">In CAR T cell therapy, myocarditis can arise through multiple mechanisms: 1) Cytokine Release Syndrome (CRS): The anti-tumor activity of CAR T cells often triggers CRS, a systemic inflammatory response associated with high circulating cytokine levels, which correlates with the severity of adverse cardiac events.<sup><xref ref-type="bibr" rid="CR224">224</xref>&#x02013;<xref ref-type="bibr" rid="CR226">226</xref></sup> 2) Cross-Reactivity with Myocardial Antigens: CAR T cells may inadvertently target myocardial proteins, as seen with melanoma-associated antigen-3 (MAGE-3), which cross-reacts with titin, a myocardial protein, leading to fulminant myocarditis<sup><xref ref-type="bibr" rid="CR227">227</xref></sup>; 3) Off-Target Effects: Immune responses directed at non-tumor antigens unrelated to the intended targets of CAR T therapy can also result in cardiac injury, underscoring the broad impact of immune dysregulation on myocardial health.<sup><xref ref-type="bibr" rid="CR224">224</xref>,<xref ref-type="bibr" rid="CR225">225</xref></sup></p></sec></sec><sec id="Sec43"><title>Cardiotoxicity and immuno-dysregulation</title><p id="Par62">Cardiotoxicity, a severe adverse effect of numerous drugs, particularly those used in cancer chemotherapy and anti-viral treatments, poses significant challenges in clinical applications and patient management. The immune system plays a crucial role in the cardiotoxicity caused by various anti-tumor and anti-viral drugs.</p><p id="Par63">Many anti-tumor drugs, such as anthracyclines (doxorubicin and pirarubicin), triptolide, antibody-Drug Conjugates (ADCs) are widely associated with cardiotoxicity. Anthracyclines (doxorubicin and pirarubicin) are widely associated with cardiotoxicity due to its oxidative stress induction and DNA damage in cardiomyocytes.<sup><xref ref-type="bibr" rid="CR228">228</xref></sup> Studies indicate that doxorubicin activates an immune response, recruiting inflammatory cells to the heart and initiating pro-inflammatory cytokine release.<sup><xref ref-type="bibr" rid="CR229">229</xref></sup> This inflammation often leads to fibrosis and eventual heart failure. The presence of T cells, specifically CD8+ cytotoxic T cells, exacerbates this cardiac damage by promoting fibrosis and systolic dysfunction.<sup><xref ref-type="bibr" rid="CR230">230</xref></sup> Triptolide, derived from the herb <italic>Tripterygium wilfordii</italic>, is a highly potent anti-tumor agent but is limited by its cardiotoxicity.<sup><xref ref-type="bibr" rid="CR231">231</xref>,<xref ref-type="bibr" rid="CR232">232</xref></sup> Triptolide induces mitochondrial damage in cardiac cells, leading to dysfunction in energy production and increased oxidative stress. It also triggers an immune response, with macrophages playing a key role in the resultant inflammation.<sup><xref ref-type="bibr" rid="CR231">231</xref></sup> ADCs are engineered to target specific tumor cells, but their toxic payloads can lead to unintended cardiac toxicity.<sup><xref ref-type="bibr" rid="CR233">233</xref></sup> ADCs may cause off-target effects, where immune cells, particularly macrophages, respond to the cytotoxic payload released in cardiac tissue.<sup><xref ref-type="bibr" rid="CR234">234</xref></sup> This immune activation leads to the release of pro-inflammatory cytokines such as TNF&#x02212;&#x003b1; and IL-6, which promote inflammation, oxidative stress, and endothelial damage, thereby exacerbating cardiac injury. Some ADCs can trigger delayed hypersensitivity reactions, where immune cells initiate a T-cell-mediated response.<sup><xref ref-type="bibr" rid="CR235">235</xref></sup> This response involves the release of cytotoxic mediators that target cardiac cells, leading to inflammation and subsequent myocardial fibrosis and heart failure.</p><p id="Par64">Anti-viral treatments are associated with an increased risk of cardiotoxicity, which may involve immune activation. For example, abacavir induces pro-inflammatory cytokine release, promoting endothelial dysfunction and atherosclerosis, which increases cardiovascular risk.<sup><xref ref-type="bibr" rid="CR236">236</xref></sup> Ritonavir acts as a CYP3A inhibitor, affecting the metabolism of various cardiac medications and leading to immune cell activation and oxidative stress.<sup><xref ref-type="bibr" rid="CR237">237</xref>,<xref ref-type="bibr" rid="CR238">238</xref></sup> This immune reaction can increase pro-inflammatory cytokines, causing myocardial strain, especially in critical COVID-19 cases where the immune response is already heightened.</p></sec><sec id="Sec44"><title>Thrombotic diseases and immuno-dysregulation</title><p id="Par65">Thrombosis is the localized formation of blood clots that can affect arterial or venous circulation, potentially leading to severe conditions like myocardial infarction, pulmonary embolism, and thrombotic microangiopathy.<sup><xref ref-type="bibr" rid="CR239">239</xref></sup></p><sec id="Sec45"><title>Immune regulation in the blood coagulation system under physiological conditions</title><p id="Par66">Under physiological conditions, immune regulation within the blood coagulation system is crucial for maintaining balance between coagulation and immune defense, ensuring that clot formation and inflammation are appropriately controlled.<sup><xref ref-type="bibr" rid="CR199">199</xref></sup> The complement system, for example, directly influences coagulation through its interaction with fibrin clots, which can activate pathways that prevent excessive inflammation and regulate clot formation.<sup><xref ref-type="bibr" rid="CR199">199</xref></sup> Factor H, a key regulator in this process, mitigates immune activation by binding to fibrin clots, thus ensuring a controlled immune response while supporting hemostasis.<sup><xref ref-type="bibr" rid="CR240">240</xref></sup></p><p id="Par67">Interactions between the immune system and coagulation cascade are central to cardiovascular health.<sup><xref ref-type="bibr" rid="CR241">241</xref>,<xref ref-type="bibr" rid="CR242">242</xref></sup> Pro-inflammatory cytokines, often released during immune responses, can trigger coagulation factors, which in turn help regulate inflammation and prevent infections.<sup><xref ref-type="bibr" rid="CR243">243</xref></sup> Immune cells like neutrophils and monocytes participate actively in the coagulation cascade by releasing factors that promote clotting when an immune response is necessary, thereby protecting tissue integrity and limiting pathogen spread.<sup><xref ref-type="bibr" rid="CR242">242</xref></sup> However, their activity is tightly regulated to avoid excessive clot formation, which could otherwise lead to thrombosis.<sup><xref ref-type="bibr" rid="CR242">242</xref></sup></p><p id="Par68">Additionally, the immune-coagulation interplay is critical for managing immune responses in aging population.<sup><xref ref-type="bibr" rid="CR244">244</xref>,<xref ref-type="bibr" rid="CR245">245</xref></sup> With age, immune cells may exhibit changes that impact coagulation, as evidenced by single-cell analyses showing alterations in immune and hematopoietic cell function related to immune aging.<sup><xref ref-type="bibr" rid="CR244">244</xref>,<xref ref-type="bibr" rid="CR245">245</xref></sup> This balance is particularly crucial in the aging population, where dysregulated coagulation can contribute to age-related diseases.</p><p id="Par69">These findings underscore the complex, tightly regulated relationship between the immune and coagulation systems under physiological conditions, where immune and metabolic signals finely tune clot formation and inflammation to maintain overall homeostasis and vascular health.</p></sec><sec id="Sec46"><title>Immune dysregulation in thrombotic diseases</title><p id="Par70">The rupture of an atherosclerotic plaque exposes the subendothelial matrix and releases tissue factor (TF), activating the coagulation cascade and promoting leukocyte recruitment via platelet adhesion and activation.<sup><xref ref-type="bibr" rid="CR246">246</xref>&#x02013;<xref ref-type="bibr" rid="CR248">248</xref></sup> Platelets, in particular, play a pivotal role by releasing chemokines and cytokines, including CCL5 and chemokine (C-X-C motif) ligand 4 (CXCL4), which recruit bone marrow-derived progenitor cells and leukocytes to the plaque site.<sup><xref ref-type="bibr" rid="CR249">249</xref>&#x02013;<xref ref-type="bibr" rid="CR252">252</xref></sup> These cells aid in vascular repair and mediate inflammatory responses that can stabilize or destabilize the plaque, influencing thrombus formation.</p><p id="Par71">In acute conditions, such as COVID-19, immune dysregulation is evident in the form of neutrophil extracellular traps (NETs). Neutrophils interacting with platelets laden with pathogens release NETs that entrap pathogens and promote thrombosis.<sup><xref ref-type="bibr" rid="CR253">253</xref>,<xref ref-type="bibr" rid="CR254">254</xref></sup> This process is intricately regulated by Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase and protein-arginine deiminase type 4 (PAD4), which are essential for modulating the immune response and preventing excessive thrombus formation.<sup><xref ref-type="bibr" rid="CR255">255</xref>,<xref ref-type="bibr" rid="CR256">256</xref></sup> NETs play a dual role in immunity and thrombosis by targeting pathogens while inadvertently promoting clot formation, which can lead to microvascular obstruction and tissue ischemia in severe infections.</p><p id="Par72">Platelets act as critical mediators of the immune response in thrombotic diseases. They release high-mobility group box 1 (HMGB1), which binds to receptors such as receptor for advanced glycation endproducts (RAGE) and Toll-like receptors (TLR2) on monocytes.<sup><xref ref-type="bibr" rid="CR257">257</xref></sup> This interaction triggers NET release from neutrophils and amplifies the inflammatory and coagulation cascade, further intensifying thrombus formation. Additionally, monocytes release TF, which activates both the extrinsic and intrinsic coagulation pathways, reinforcing clot formation and sustaining the cycle of inflammation and coagulation.<sup><xref ref-type="bibr" rid="CR241">241</xref></sup></p></sec></sec></sec><sec id="Sec47"><title>The Immune Signaling Pathways in Cvds</title><sec id="Sec48"><title>Innate immune response</title><p id="Par73">The innate immune system matters in CVDs.<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> Pattern recognition receptors (PRRs), such as TLRs, are key components of the innate immune response that recognize damage-associated molecular patterns in cardiovascular tissues and initiate inflammatory cascades.<sup><xref ref-type="bibr" rid="CR258">258</xref></sup> Innate immune cells like macrophages and neutrophils contribute to both the progression and resolution of inflammation in CVDs, highlighting their dual role in tissue damage and repair.<sup><xref ref-type="bibr" rid="CR259">259</xref></sup> Sustained activation of innate immune signaling can lead to maladaptive inflammatory responses that promote cardiovascular dysfunction<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Innate Immune Signaling pathway in CVDs. <bold>a</bold> TLRs-Dependent Innate Immune Signaling pathway; <bold>b</bold> NLRs-dependent innate immune signaling pathway; <bold>c</bold> cGAS-STING signaling pathway; <bold>d</bold> ALRs-dependent innate immune signaling; <bold>e</bold> RLRs-dependent innate immune signaling; <bold>f</bold> The complement system-dependent pathways. TLR Toll-like receptor, LPS Lipopolysaccharide, IRAK Interleukin-1 receptor-associated kinase, TRAF6 TNF receptor-associated factor 6, TAB2/3 TGF-beta activated kinase 1/MAP3K7 binding protein 2/3, TAK1 Transforming growth factor beta-activated kinase 1, MAPK Mitogen-activated protein kinase, NF-&#x003ba;B Nuclear factor kappa-light-chain-enhancer of activated B cells, RIP1 Receptor-interacting serine/threonine-protein kinase 1, TRAF3 TNF receptor-associated factor 3, TBK1 TANK-binding kinase 1, IRF3/7 Interferon regulatory factor 3/7, NOD1/2 Nucleotide-binding oligomerization domain-containing protein 1/2, NLRP3 NLR family pyrin domain containing 3, GSDMD Gasdermin D, RIPK2 Receptor-interacting serine/threonine-protein kinase 2, LUBAC Linear ubiquitin chain assembly complex, ATP Adenosine triphosphate, ZBP1 Z-DNA binding protein 1, AIM2 Absent in melanoma 2, NLRP12 NLR family pyrin domain containing 12, IFN Interferon, cGAS Cyclic GMP-AMP synthase, STING Stimulator of interferon genes, GTP Guanosine triphosphate, 2'3&#x02019;-cGAMP 2'3&#x02019;-cyclic GMP-AMP, DDX41 DEAD-box helicase 41, HIN200 hematopoietic interferon-inducible nuclear proteins with a 200-amino-acid repeat, ASC Apoptosis-associated speck-like protein containing a CARD, CASP-1 Caspase-1, IFI16 Interferon-gamma inducible protein 16, MAVS Mitochondrial Antiviral Signaling Protein, pARP9 Poly(ADP-Ribose) Polymerase 9, AKT3 AKTserine/threonine kinase 3, IL Interleukin, TNF-&#x003b1; Tumor necrosis factor-&#x003b1;, RIG Retinoic acid-inducible gene, MASP Mannose-binding lectin-associated serine protease (Created with BioRender.com, <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/e69d507">https://BioRender.com/e69d507</ext-link>)</p></caption><graphic xlink:href="41392_2025_2220_Fig4_HTML" id="d33e1795"/></fig></p><sec id="Sec49"><title>TLRs-dependent innate immune response</title><sec id="FPar1"><title>TLRs</title><p id="Par74">TLRs were the first family of PRRs discovered in the innate immune system.<sup><xref ref-type="bibr" rid="CR260">260</xref></sup> Ten TLRs (TLR1-10) have been identified in humans, each responsible for recognizing specific pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).<sup><xref ref-type="bibr" rid="CR261">261</xref></sup>They are single-spanning receptors anchored in membrane structures, such as cell membranes, endosomes, and lysosomes. Leucine-rich repeats (LRRs), a conserved structural element in the extracellular region of TLRs, form the horseshoe-shaped ligand-binding domain responsible for binding a variety of PAMPs or DAMPs, such as lipopolysaccharides (LPS), peptidoglycans, flagellin, nucleic acids and oxidized low-density lipoprotein (ox-LDL).<sup><xref ref-type="bibr" rid="CR262">262</xref>,<xref ref-type="bibr" rid="CR263">263</xref></sup> TLRs can be further categorized based on their cellular localization. For instance, TLR1, TLR2, TLR5, TLR6 and TLR10, are located on the plasma membrane to recognize extracellular pathogens. In contrast, endosomal TLRs such as TLR3, TLR7, TLR8, and TLR9 recognize nucleic acids from bacteria or viruses during endosomal or lysosomal degradation.<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> TLR4 is unique in its localization, initially residing on the plasma membrane and later translocating to the endosomal membrane following endocytosis<sup><xref ref-type="bibr" rid="CR264">264</xref></sup>(Fig. <xref rid="Fig4" ref-type="fig">4a</xref>).</p></sec><sec id="FPar2"><title>TLRs signaling pathways</title><p id="Par75">Ligand binding initiates dimerization of TLR ectodomains, which in turn causes dimerization of the intracellular Toll/Interleukin-1 receptor (TIR) domains of each TLR, activating downstream pathways and triggering inflammatory responses. Generally, TLR signaling pathways primarily rely on two key protein adapters: myeloid differentiation factor 88 (MyD88) and TIR domain-containing adapter-inducing IFN-&#x003b2; factor (TRIF). These adapters are recruited to the cytoplasmic TIR domain of TLRs to initiate downstream signaling cascades.</p><p id="Par76">MyD88 is utilized by all plasma membrane TLRs and most endosomal TLRs, with the exception of TLR3. Upon dimerization of TIR domains, MyD88 binds to these domains and recruits IL-1 receptor-associated kinases (IRAK), including IRAK4, IRAK1, IRAK2, and IRAK-M, to form a protein complex known as the myddosome.<sup><xref ref-type="bibr" rid="CR265">265</xref>,<xref ref-type="bibr" rid="CR266">266</xref></sup> Subsequently, IRAK1 undergoes autophosphorylation and then phosphorylates tumor necrosis factor receptor&#x02013;associated factor 6 (TRAF6), which serves as a scaffold for other components.<sup><xref ref-type="bibr" rid="CR267">267</xref>,<xref ref-type="bibr" rid="CR268">268</xref></sup> The adapter proteins TAK1-binding proteins 2 and 3 (TAB2 and TAB3) bring transforming growth factor-&#x003b2;-activated kinase 1 (TAK1) into proximity with IRAK1, activating TAK1 through close proximity-dependent transphosphorylation.<sup><xref ref-type="bibr" rid="CR269">269</xref></sup> Eventually, phosphorylated TAK1 activates the nuclear factor&#x02014;&#x003ba;B (NF-&#x003ba;B) and mitogen-activated protein kinases (MAPKs) pathways.</p><p id="Par77">TRIF is specifically recruited to TLR3 and TLR4 when these receptors localize to endosomes. TRIF binds to and activates TRAF3, forming a complex known as the triffosome.<sup><xref ref-type="bibr" rid="CR270">270</xref></sup> TRAF3 activates the TBK1 and is an inhibitor of NF-&#x003ba;B kinase (IKKi) along with NF-&#x003ba;B essential modulator (NEMO). Subsequently, TBK1 phosphorylates and activates IFN regulatory factor 3 and 7 (IRF3/7). Phosphorylation and dimerization of IRF3 and IRF7 facilitate their translocation into the nucleus, where they drive IFN production and subsequent IFN-stimulated genes (ISGs) expression<sup><xref ref-type="bibr" rid="CR271">271</xref>&#x02013;<xref ref-type="bibr" rid="CR273">273</xref></sup>(Fig. <xref rid="Fig4" ref-type="fig">4a</xref>).</p></sec><sec id="FPar3"><title>Role of TLRs signaling pathways in CVDs</title><p id="Par78">TLR signaling pathways play crucial roles in cardiac ischemia. In myocardial ischemia (MI), endogenous DAMPs, such as heat shock proteins, HMGB1, and nucleic acids, are released from damaged myocardial cells. TLRs are activated upon binding to these DAMPs, promoting the expression of inflammatory cytokines. Of note, the mRNA levels of TLR2, 3, 4 are approximately 10-fold higher than that of TLR1, 5 - 10.<sup><xref ref-type="bibr" rid="CR274">274</xref></sup> The mRNA and protein levels of TLR4 were elevated in the infarct and remote area post-MI compared to sham mice.<sup><xref ref-type="bibr" rid="CR275">275</xref></sup> TLR4 deficiency resulted in smaller infarct areas and less inflammation in mice subjected to myocardial IRI compared with wild-type (WT) mice.<sup><xref ref-type="bibr" rid="CR276">276</xref></sup> Similarly, inhibition of TLR4 with eritoran significantly reduced MI/R injury and mitigated inflammatory responses.<sup><xref ref-type="bibr" rid="CR277">277</xref></sup> Aside from TLR4, mice with TLR2 gene knockout (KO) exhibited less myocardial fibrosis and a higher survival rate, despite having infarct sizes and inflammation levels comparable to WT mice.<sup><xref ref-type="bibr" rid="CR278">278</xref></sup> Also, increased expression and signaling by TLR2 and TLR4 could be observed in the hearts of patients with advanced heart failure, contributing to the sustained activation of innate immunity in the failing hearts.<sup><xref ref-type="bibr" rid="CR279">279</xref></sup> TLR2 or TLR4 induced cardiac hypertrophy and fibrosis in mice by regulating immune microenvironment.<sup><xref ref-type="bibr" rid="CR280">280</xref>,<xref ref-type="bibr" rid="CR281">281</xref></sup> Additionally, activation of TLR7/8 leads to autoimmune vasculopathy and results in severe pulmonary arterial hypertension.<sup><xref ref-type="bibr" rid="CR282">282</xref></sup></p><p id="Par79">Several factors act as pro-inflammatory stimuli in the vascular system, with ox-LDL being identified as one of the most potent DAMPs driving atherogenesis.<sup><xref ref-type="bibr" rid="CR263">263</xref></sup> Ox-LDL particles can be recognized by TLR ligands, inducing lipid-laden macrophages to release inflammatory cytokines.<sup><xref ref-type="bibr" rid="CR283">283</xref></sup> TLR2 and TLR4 are particularly important in vascular inflammatory responses due to their high abundance in atheromatous plaques.<sup><xref ref-type="bibr" rid="CR284">284</xref></sup> Loss-of-function studies have demonstrated the significant role of TLRs in the pathogenesis of atherosclerosis. Deficiency of TLR4 in macrophages protects them from transforming into foam cells, thereby mitigating the severity of atherosclerosis.<sup><xref ref-type="bibr" rid="CR285">285</xref></sup> In addition to affecting innate immune cells, lipid accumulation can induce non-immune cells to adopt a maladaptive phenotype in the vascular wall. Ox-LDL upregulates TLR2 and TLR4 expression in endothelial cells, concomitant with increased levels of adhesion molecules like VCAM-1, ICAM-1, and MCP-1.<sup><xref ref-type="bibr" rid="CR285">285</xref></sup> A recent study also demonstrated that a TLR2 agonist significantly promotes chondrogenic differentiation of VSMCs, an initial step towards arterial calcification.<sup><xref ref-type="bibr" rid="CR286">286</xref></sup> Overall, the role of TLRs signaling pathway has been well characterized and widely implicated in CVDs.</p></sec></sec><sec id="Sec50"><title>Nucleotide oligomerization domain (NOD)-like receptors (NLRs)-dependent innate immune response</title><sec id="FPar4"><title>NLRs</title><p id="Par80">NLRs, a large family of cytosolic sensors, activate innate immune and inflammatory responses by recognizing intracellular PAMPs and DAMPs. Specific domains largely determine the distinct functions of NLR family proteins. Mammalian NLRs share a similar architecture, categorized into three core domains: (1) an N-terminal variable domain for initiating downstream signaling; (2) a central nucleotide-binding domain (NBD) for oligomerization; and (3) a C-terminal horseshoe-shaped leucine-rich repeat (LRR) domain.<sup><xref ref-type="bibr" rid="CR287">287</xref></sup> Mammalian NLRs can be divided into four major subfamilies based on their different N-terminal domain structures: acidic transactivating domain-containing NLR (NLRA), baculovirus inhibitor of apoptosis protein repeat-containing NLR (NLRB), caspase activation and recruitment domain (CARD)-containing NLR (NLRC), and pyrin domain-containing NLR (NLRP).</p></sec><sec id="FPar5"><title>NLR signaling pathways</title><p id="Par81">NLR family members are crucial in regulating various innate immune pathways, including NF-&#x003ba;B signaling, and cytokine and chemokine production. The functions of NLRs are diverse. Some modulate MHC class I or II genes and even Th2 response, while others form multi-protein complexes like inflammasomes or PANoptosomes.<sup><xref ref-type="bibr" rid="CR288">288</xref>&#x02013;<xref ref-type="bibr" rid="CR291">291</xref></sup> These complexes trigger caspase cleavage, leading to the maturation of IL-1&#x003b2; and IL-18 and subsequent cell death. For instance, nucleotide-binding and oligomerization domain-like receptors 1 and 2 (NOD1 and NOD2) are prominent in NLR-mediated inflammation in CVDs.<sup><xref ref-type="bibr" rid="CR292">292</xref></sup> NLRP3 is the most extensively studied NLR, recognized for its role in inflammasome or PANoptosome formation (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>).</p></sec><sec id="FPar6"><title>NOD1 and NOD2-dependent pathway</title><p id="Par82">NOD1 and NOD2 are cytosolic sensors of bacterial peptidoglycans, essential for host defense and inflammation. Specifically, diaminopimelic acid binds to NOD1, and muramyl dipeptides bind to NOD2.<sup><xref ref-type="bibr" rid="CR293">293</xref>,<xref ref-type="bibr" rid="CR294">294</xref></sup> NOD1 and NOD2 are associated with endosomal membranes, where they bind bacterial breakdown products transported through those membranes. Under steady-state conditions, NOD1 or NOD2 exists as an inactive monomer in the cytosol. Upon recognizing their specific ligands via the LRR regions, NOD1 and NOD2 self-oligomerize, undergoing a conformational change to recruit receptor-interacting serine/threonine kinase 2 (RIPK2) through homotypic CARD-CARD interactions.<sup><xref ref-type="bibr" rid="CR295">295</xref></sup> Subsequently, RIPK2 serves as a scaffolding protein that provides an organizing center for downstream signaling proteins.<sup><xref ref-type="bibr" rid="CR296">296</xref>,<xref ref-type="bibr" rid="CR297">297</xref></sup> Further, the linear ubiquitin assembly complex (LUBAC) is recruited, mediating the recruitment of transforming growth factor &#x003b2;-activated kinase 1 (TAK1) and TAB1, TAB2 or TAB3, which forms a multi-protein complex termed as nodosome.<sup><xref ref-type="bibr" rid="CR298">298</xref></sup> Finally, these events contribute to the activation of MAPK pathways, NF-&#x003ba;B signaling and even IL-13 effector response.<sup><xref ref-type="bibr" rid="CR299">299</xref>,<xref ref-type="bibr" rid="CR300">300</xref></sup> Alternatively, studies have shown that NOD1 binding to its ligand activates the serine-threonine kinase RICK and the TRAF3 complex, resulting in the phosphorylation of IRF3 and IRF7, which induces expression of type-1 IFN genes<sup><xref ref-type="bibr" rid="CR301">301</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>).</p></sec><sec id="FPar7"><title>NLRP3-dependent inflammasomes and PANoptosomes</title><p id="Par83">NLRP3 has recently garnered considerable attention due to its critical role in assembling inflammasomes. Mechanistically, the activation of NLRP3 inflammasome requires a 2-step process: priming (step 1) and protein complex assembly (step 2). Studies have shown that upregulation of NLRP3, pro-caspase-1, pro-IL-1&#x003b2;, and pro-IL-18 mRNA level via NF-&#x003ba;B pathway, mediated by TLR4 and NOD1/2, primes the activation of NLRP3-dependent inflammasome.<sup><xref ref-type="bibr" rid="CR302">302</xref>,<xref ref-type="bibr" rid="CR303">303</xref></sup> During priming, inflammasome formation can be fine-tuned by various posttranslational modifications of NLRP3, including phosphorylation, deubiquitination, and sumoylation.<sup><xref ref-type="bibr" rid="CR304">304</xref>&#x02013;<xref ref-type="bibr" rid="CR306">306</xref></sup> The subsequent activation process involves NLRP3 oligomerization via homotypic NACHT-NACHT interactions, leading to the binding of apoptosis-associated speck-like protein containing a CARD (ASC) to NLRP3 and the recruitment of pro-caspase-1.<sup><xref ref-type="bibr" rid="CR307">307</xref></sup> During this step, signals of cellular instability and damage - such as potassium ion efflux, adenosine triphosphate release, and/or leakage of lysosomal contents - are proposed to induce NLRP3 inflammasome activation.<sup><xref ref-type="bibr" rid="CR308">308</xref></sup> Recent studies suggest that these cellular indicators may function via ROS, which are crucial for the interaction between NIMA-related kinase (NEK7) and NLRP3, thereby inducing inflammasome formation and activation.<sup><xref ref-type="bibr" rid="CR309">309</xref>,<xref ref-type="bibr" rid="CR310">310</xref></sup> Inflammasomes activate caspase-1, which cleaves IL-1&#x003b2; and IL-18 precursors into their mature forms, thereby triggering and amplifying inflammatory responses that contribute to diseases such as chronic rhinosinusitis,<sup><xref ref-type="bibr" rid="CR289">289</xref></sup> very-early-onset inflammatory bowel disease,<sup><xref ref-type="bibr" rid="CR311">311</xref></sup> bronchiectasisand and non-T2 asthma.<sup><xref ref-type="bibr" rid="CR312">312</xref>,<xref ref-type="bibr" rid="CR313">313</xref></sup> In addition, NLRP3, functioning as a key component of the PANoptosome - a complex involved in pyroptosis, apoptosis, and necroptosis - interacts with various NLRs and non-NLR sensors to form multi-protein complexes essential for innate immune responses<sup><xref ref-type="bibr" rid="CR314">314</xref>&#x02013;<xref ref-type="bibr" rid="CR316">316</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>).</p></sec></sec></sec><sec id="Sec51"><title>Role of NLRs signaling pathways in CVDs</title><sec id="Sec52"><title>Role of NOD1 and NOD2 signaling pathways in CVDs</title><p id="Par84">The NOD1 and NOD2 signaling pathways have been associated with myocardial infarction, heart failure, and diabetic cardiomyopathy. Yang et al. first demonstrated that activating NOD1 with DAP (a synthetic activator) significantly worsened cardiac I/R injury and induced cardiomyocyte apoptosis in mice.<sup><xref ref-type="bibr" rid="CR317">317</xref></sup> Specifically, NOD1 activation induced myocardial fibrosis in diabetic mouse hearts.<sup><xref ref-type="bibr" rid="CR318">318</xref></sup> Similarly, Shen et al. reported NOD2 upregulation in diabetic cardiomyopathy in a mouse model of diabetes, and inhibiting NOD2 improved diabetes-induced myocardial fibrosis and cell apoptosis.<sup><xref ref-type="bibr" rid="CR319">319</xref></sup> However, NOD2 deficiency exacerbated cardiac hypertrophy and fibrosis in mice with pressure-overload-induced heart failure, indicating a unique role of NOD2 in various CVDs.<sup><xref ref-type="bibr" rid="CR320">320</xref></sup> Except for myocardial infarction, Kanno et al. reported that oral administration of a NOD1 ligand accelerated the progression of atherosclerosis in <italic>ApoE</italic>-/- mice by inducing vascular inflammation, whereas reduced development of atherosclerotic lesions was observed in <italic>ApoE</italic> and <italic>Nod1</italic> double-knockout mice.<sup><xref ref-type="bibr" rid="CR321">321</xref></sup> Similarly, the NOD2 cognate ligand increased lesion burden and vascular inflammation in atherotic cores in <italic>Ldlr</italic>-/- mice.<sup><xref ref-type="bibr" rid="CR322">322</xref></sup> Conversely, <italic>ApoE</italic> and <italic>Nod2</italic> double KO mice showed significant elevation in pro-inflammatory cytokines and atherosclerotic lesions.<sup><xref ref-type="bibr" rid="CR323">323</xref></sup> To investigate NOD2-mediated innate immune signaling in atherosclerosis, Liu et al. performed liquid chromatography coupled with tandem mass spectrometry to study the eicosanoid profiles after NOD2 activation. They discovered that NOD2 preferentially upregulated the prostaglandin E2 (PGE2) pathway. The role of PGE2 in atherosclerosis is complex, as it exhibits both pro-inflammatory and anti-inflammatory effects depending on cell types and PGE2 receptor subtypes, indicating a nuanced role for NOD2 in atherosclerosis.<sup><xref ref-type="bibr" rid="CR324">324</xref></sup> Intriguingly, a novel crosstalk between TLR4- and NOD2-mediated signaling was uncovered; NOD2 can sense the intensity of TLR4 signaling and modulate NF-&#x003ba;B pathway activation.<sup><xref ref-type="bibr" rid="CR325">325</xref></sup> This finding suggests that NOD2 serves as an immune initiator and functions as an immune regulator.<sup><xref ref-type="bibr" rid="CR326">326</xref></sup></p></sec><sec id="Sec53"><title>Role of NLRP3-dependent inflammasomes and PANoptosomes in CVDs</title><p id="Par85">NLRP3 is a prominent research topic in CVDs due to its involvement in myocardial infarction, cardiac hypertrophy, and atherosclerosis. In the ischemic heart of the mouse model, heightened inflammasome activation is evident from increased NLRP3 expression, elevated caspase-1 activity, and higher levels of IL-1&#x003b2; and IL-18.<sup><xref ref-type="bibr" rid="CR327">327</xref></sup> Inhibition of NRLP3-dependent inflammasome reduced cardiac inflammation and MI/R injury in mouse models.<sup><xref ref-type="bibr" rid="CR327">327</xref></sup> Similarly, treatment with the selective NLRP3-inflammasome inhibitor, MCC950, reduced infarct size and improved cardiac function in a pig model of myocardial infarction.<sup><xref ref-type="bibr" rid="CR328">328</xref></sup> While ischemia-induced NLRP3 inflammasome activation primarily occurs in immune cells,<sup><xref ref-type="bibr" rid="CR329">329</xref></sup> it has also been observed in non-immune heart cells like fibroblasts and cardiomyocytes. In vivo study, NLRP3 inflammasome could be activated after hypoxia/reoxygenation in cardiac fibroblasts.<sup><xref ref-type="bibr" rid="CR330">330</xref></sup> Moreover, MCC950-mediated NLRP3 suppression attenuated Ang II-induced hypertrophy and pyroptosis in neonatal mouse ventricular myocytes.<sup><xref ref-type="bibr" rid="CR331">331</xref></sup> Additionally, PANoptosis plays a role in the progression of various cardiovascular diseases, including heart failure,<sup><xref ref-type="bibr" rid="CR332">332</xref></sup> and NLRP3-dependent PANoptosis exacerbates doxycycline-induced cardiotoxicity in cardiomyocyte<sup><xref ref-type="bibr" rid="CR333">333</xref></sup> Of note, pro-atherogenic DAMPs, including oxidized low-density lipoprotein, free fatty acids, and cholesterol crystals, are potent triggers for NLRP3 inflammasome activation in macrophages, vascular smooth muscle cells or endothelial cells, driving the progression of atherosclerosis.<sup><xref ref-type="bibr" rid="CR334">334</xref>&#x02013;<xref ref-type="bibr" rid="CR338">338</xref></sup></p></sec></sec><sec id="Sec54"><title>RNA sensor-dependent innate immune signaling</title><sec id="Sec55"><title>RNA sensors</title><sec id="FPar8"><title>Retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs)</title><p id="Par86">The RLRs are RNA helicases, RIG-I, melanoma differentiation-associated factor 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2) - that function as cytoplasmic sensors of PAMPs.<sup><xref ref-type="bibr" rid="CR261">261</xref></sup> They recognize viral RNA and are involved in initiating and regulating innate immune response. RIG-I and MDA5 share similar structural features: an N-terminal region with tandem CARDs, a central DExD/H box RNA helicase domain capable of RNA binding, and a C-terminal repressor domain (RD) within the C-terminal domain (CTD) that autoregulates RIG-I.<sup><xref ref-type="bibr" rid="CR339">339</xref>,<xref ref-type="bibr" rid="CR340">340</xref></sup> However, LGP2, a homolog of RIG-I and MDA5, competes with them for viral RNA binding, thereby inhibiting downstream signaling activation<sup><xref ref-type="bibr" rid="CR261">261</xref>,<xref ref-type="bibr" rid="CR341">341</xref></sup>(Fig. <xref rid="Fig4" ref-type="fig">4c</xref>).</p></sec><sec id="FPar9"><title>Poly (ADP-ribose) polymerase family member 19 (PARP9)</title><p id="Par87">Besides the canonical RNA sensors known as RLRs, PARP9 is an inactive mono-ADP-ribosyltransferase within the PARP family.<sup><xref ref-type="bibr" rid="CR342">342</xref>&#x02013;<xref ref-type="bibr" rid="CR344">344</xref></sup> Recent findings indicate that PARP9 preferentially recognizes and binds to viral double-stranded RNA ranging from 1.1&#x02009;kb to 1.4&#x02009;kb, acting as a noncanonical MAVS-independent RNA sensor during RNA virus infections<sup><xref ref-type="bibr" rid="CR345">345</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>).</p></sec><sec id="FPar10"><title>RLRs signaling pathways</title><p id="Par88">RIG-I signaling mechanisms are currently the most extensively studied among RLRs Canonically, RIG-I can be activated by short double-stranded RNA (&#x02009;&#x0003c;&#x02009;300&#x02009;bp) and 5&#x02019;-triphosphate single-stranded RNA.<sup><xref ref-type="bibr" rid="CR346">346</xref></sup> Upon binding to viral RNA at the CTD domain, RIG-I undergoes conformational changes that release the CARDs from RD repression, enabling interaction with its adaptor protein, mitochondrial antiviral-signaling protein (MAVS). This interaction activates the IRF3/7 and NF-&#x003ba;B pathways, leading to the expression of type I IFN and other pro-inflammatory cytokines.<sup><xref ref-type="bibr" rid="CR340">340</xref>,<xref ref-type="bibr" rid="CR347">347</xref>,<xref ref-type="bibr" rid="CR348">348</xref></sup> Notably, Liu et al. identified a novel RNA sensor, Gasdermin B (GSDMB), which shares similar characteristics with RLRs in activating ISG expression and downstream inflammation, significantly expanding our understanding of RLRs-dependent innate immune signaling<sup><xref ref-type="bibr" rid="CR273">273</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>).</p></sec><sec id="FPar11"><title>PARP9 signaling pathways</title><p id="Par89">PARP9 identifies and binds to viral dsRNA from reovirus in the cytoplasm, which triggers the recruitment and activation of phosphoinositide 3-kinase (PI3K) and AKT3 pathway, which occurs independently of MAVS. This activation of PI3K/AKT3 pathway subsequently phosphorylates IRF3/7, resulting in the production of type I interferon<sup><xref ref-type="bibr" rid="CR345">345</xref>,<xref ref-type="bibr" rid="CR349">349</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>).</p></sec><sec id="FPar12"><title>Role of RLRs signaling pathways in CVDs</title><p id="Par90">RIG-I-mediated inflammation has recently garnered interest and is being actively investigated in cardiovascular diseases. Li et al. found that RLRs stimulation in human cardiac cells led to significant pro-inflammatory cytokines expression in fibroblasts, suggesting a pathogenic role for RIG-I in heart disease.<sup><xref ref-type="bibr" rid="CR350">350</xref></sup> Recent bioinformatics analysis identified RIG-I as a key gene in ischemic heart failure progression, with high RIG-I staining observed in human heart failure samples by immunohistochemistry.<sup><xref ref-type="bibr" rid="CR351">351</xref></sup> Indeed, RIG-I is expressed in intimal macrophages in human atherosclerotic lesions, and IFN-&#x003b3; enhances its expression in macrophages, highlighting its role in atherosclerosis.<sup><xref ref-type="bibr" rid="CR352">352</xref></sup> In addition, RIG-I activation induced endothelial dysfunction by ROS accumulation and pro-inflammatory cytokines release during atherogenesis.<sup><xref ref-type="bibr" rid="CR353">353</xref></sup> Considering the critical role of innate immunity and inflammation in CVDs, along with RIG-I&#x02019;s established involvement in cardiac reprogramming, investigating RIG-I&#x02019;s function in the cardiovascular system warrants further study.</p></sec><sec id="FPar13"><title><italic>Role of PARP9 signaling pathways in CVDs</italic></title><p id="Par91">Bioinformatics analysis pinpointed PARP9 as a key gene with significant clinical diagnostic potential. Subsequent in vivo studies revealed that pirfenidone attenuated Ang II-induced myofibroblast differentiation and fibrosis by decreasing PARP9 expression triggered by Ang II.<sup><xref ref-type="bibr" rid="CR354">354</xref></sup> Consistently, PARP inhibition prevented the cardiac hypertrophy and contractile dysfunction in pressure overload-induced heart failure.<sup><xref ref-type="bibr" rid="CR355">355</xref></sup> Also, PARP inhibition could offer a promising new therapeutic approach to prevent postinfarction myocardial remodeling.<sup><xref ref-type="bibr" rid="CR356">356</xref></sup> However, the role of PARP9 in detecting cytoplasmic dsRNA and facilitating type I interferon production in relation to CVDs remains poorly understood.</p><p id="Par92">PARP9 has been shown to be involved in atherogenesis. The PARP9 - PARP14 network, revealed through proteomics screening in cultured macrophages, demonstrated a notably stronger association with the human coronary artery disease gene module than with other cardio-metabolic diseases. Immunohistochemistry results confirmed that macrophages are a major source of PARP9 and PARP14 in human atherosclerotic lesions.<sup><xref ref-type="bibr" rid="CR344">344</xref></sup> Furthermore, inhibition of PARP with INO-1001 treatment markedly reduced atherosclerotic lesion development, as indicated by mitigated inflammatory reactions within the lesion.<sup><xref ref-type="bibr" rid="CR357">357</xref></sup>The molecular mechanisms underlying these effects of PARP9 on vascular inflammation have yet to be thoroughly investigated.</p></sec></sec></sec><sec id="Sec56"><title>DNA sensor-dependent innate immune signaling</title><sec id="Sec57"><title>DNA sensors</title><sec id="FPar14"><title>cyclic GMP-AMP synthase (cGAS)</title><p id="Par93">cGAS belongs to the ancient cGAS/DncV-like nucleotidyltransferase (CD-NTase) protein family, which produces various cyclic oligonucleotide second messengers in response to DNA, whether exogenous (from bacteria and viruses) or endogenous (from dying cells and damaged mitochondria).<sup><xref ref-type="bibr" rid="CR358">358</xref>,<xref ref-type="bibr" rid="CR359">359</xref></sup> Upon recognizing DNA, cGAS dimers form ladder-like networks and phase-separated structures.<sup><xref ref-type="bibr" rid="CR360">360</xref></sup> These spatially restricted higher-order assemblies of cGAS-DNA on longer DNA stretches are crucial for biological functions. This mechanism prevents erroneous activation of cGAS by short or limited dsDNA, serving as an effective built-in immune checkpoint.<sup><xref ref-type="bibr" rid="CR360">360</xref></sup> STING (also known as MITA), consists of a short cytosolic N-terminal segment, a four-span transmembrane domain, a connector region, and a cytosolic ligand-binding domain (LBD) with a C-terminal tail (CTT).<sup><xref ref-type="bibr" rid="CR360">360</xref>,<xref ref-type="bibr" rid="CR361">361</xref></sup> It is capable of binding the second messenger 2'3&#x02019; cyclic GMP-AMP (cGAMP), which is synthesized by cGAS.<sup><xref ref-type="bibr" rid="CR362">362</xref></sup> Upon binding to cGAMP produced during cGAS activation, STING undergoes conformational changes and forms a domain-swapped homodimer to initiate downstream signaling<sup><xref ref-type="bibr" rid="CR363">363</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>).</p></sec><sec id="FPar15"><title>DEAD-box helicase 41(DDX41)</title><p id="Par94">DDX41 is part of the DEAD-box protein family which consists of ATP-dependent RNA helicases, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD). Despite of the DEAD motif, DDX41 also contains other conserved domains, such as a helicase C-terminal domain and sites for ATP binding and hydrolysis. It has been reported that the helicase DDX41 functions as a DNA sensor by recognizing viral DNA.<sup><xref ref-type="bibr" rid="CR364">364</xref></sup> Additionally, DDX41 recognizes bacterial secondary messengers, including cyclic di-GMP (c-di-GMP) or cyclic di-AMP (c-di-AMP), to activate innate immune response<sup><xref ref-type="bibr" rid="CR365">365</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>).</p></sec></sec><sec id="Sec58"><title>cGAS and <italic>stimulator of interferon genes (</italic>STING)-dependent pathway</title><sec id="FPar16"><title>cGAS and STING-dependent pathway</title><p id="Par95">cGAS undergoes conformational changes and synthesizes cGAMP (2&#x02019;,5&#x02019;-cyclic GMP-AMP dinucleotide) from guanosine 5&#x000b4;-triphosphate (GTP) and adenosine 5&#x000b4;-triphosphate (ATP) upon recognizing cytosolic dsDNA.<sup><xref ref-type="bibr" rid="CR362">362</xref></sup> cGAMP binds to STING, prompting STING to move from the ER to the ER-Golgi intermediate compartment (ERGIC) and the Golgi apparatus through the canonical ER-to-Golgi transport via COPII vesicles. Once STING reaches the ERGIC and Golgi apparatus, it recruits TBK1, which then undergoes self-phosphorylation and activates the transcription factors IRF3 and NF-&#x003ba;B pathways, thereby increasing the expression of type I IFN, ISGs expression and even IL-17 production.<sup><xref ref-type="bibr" rid="CR366">366</xref>,<xref ref-type="bibr" rid="CR367">367</xref></sup> Notably, Liu et al. uncovered a crucial mechanism where GSDMB interacts with the C-terminus of STING, mediating STING&#x02019;s translocation to the Golgi, significantly promoting downstream cascade<sup><xref ref-type="bibr" rid="CR362">362</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>).</p></sec><sec id="FPar17"><title><italic>DDX41-dependent pathway</italic></title><p id="Par96">DDX41 utilizes its DEAD domain to identify double-stranded DNA (dsDNA). Once the ligand is recognized, DDX41 associates with STING, which in turn activates the NF-&#x003ba;B and IRF3, ultimately leading to the production of type I interferon and other inflammatory genes.<sup><xref ref-type="bibr" rid="CR368">368</xref>,<xref ref-type="bibr" rid="CR369">369</xref></sup> Moreover, Bruton&#x02019;s tyrosine kinase (BTK) enhances DDX41 activation by phosphorylating the HELICc domain, thereby improving its binding to STING<sup><xref ref-type="bibr" rid="CR370">370</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>).</p></sec><sec id="FPar18"><title>Role of cGAS and STING-dependent pathway in CVDs</title><p id="Par97">The release of DAMPs, such as cytosolic DNA from necrotic tissue, following cardiac cell injury and death induced by MI, initiates the cGAS-STING pathway. Cao et al. observed MI-induced activation of the cGAS-STING pathway in mice, with significant upregulation of its transcriptional targets such as CXCL10, interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), IFIT3, and IRF7.<sup><xref ref-type="bibr" rid="CR371">371</xref></sup> Inactivating cGAS signaling promoted myocardial repair by enhancing cardiac angiogenesis, reparative macrophage transformation, and myofibroblast transformation, and significantly reduced infarct size in mice with myocardial IRI.<sup><xref ref-type="bibr" rid="CR371">371</xref>,<xref ref-type="bibr" rid="CR372">372</xref></sup> Pressure-overload induced HF, characterized by cardiac hypertrophy and fibrosis, was associated with elevated expressions of type I IFN and STING. Remarkably, mice deficient in STING exhibited improved cardiac function, with alleviated cardiac dysfunction and fibrosis, highlighting a direct role of cGAS-STING pathway in HF pathogenesis.<sup><xref ref-type="bibr" rid="CR373">373</xref></sup> Strikingly, Luo et al. found that doxorubicin-induced cardiac endothelial dysfunction via the cGAS-STING pathway modulated NAD homeostasis and mitochondrial bioenergetics in cardiomyocytes,<sup><xref ref-type="bibr" rid="CR374">374</xref></sup> indicating an intricate role of the cGAS-STING pathway in cell-cell crosstalk.</p><p id="Par98">Cytosolic DNA from damaged cells and extracellular vesicles contributes to vascular inflammation, particularly in atherosclerosis.<sup><xref ref-type="bibr" rid="CR375">375</xref></sup> Activation of the cGAS-STING pathway in endothelial cells increases the expression of adhesion molecules, such as VCAM-1 and ICAM-1, aiding infiltration of innate immune cells into the arterial wall and contributing to the formation of early atherosclerotic lesions.<sup><xref ref-type="bibr" rid="CR376">376</xref>,<xref ref-type="bibr" rid="CR377">377</xref></sup> However, activation of the cGAS-STING pathway in macrophages specifically enhances lipid uptake and foam cell formation, which are critical factors driving atherosclerosis.<sup><xref ref-type="bibr" rid="CR377">377</xref></sup> Furthermore, genetic or pharmacological suppression of STING in macrophages downregulates inflammatory cytokine expression, thereby mitigating atherosclerosis progression in mice.<sup><xref ref-type="bibr" rid="CR378">378</xref></sup> Therefore, targeting this pathway may illuminate strategies to prevent the progression of atherosclerotic lesions.</p></sec><sec id="FPar19"><title>Role of DDX41-dependent pathway in CVDs</title><p id="Par99">While current studies have not widely investigated the direct role of DDX41 in CVDs, there is emerging evidence suggesting its potential significance.<sup><xref ref-type="bibr" rid="CR379">379</xref></sup> Mutations in DDX41 have been associated with CVDs.<sup><xref ref-type="bibr" rid="CR380">380</xref></sup> The DDX41/cGAS/STING-mediated interferon inflammation has been linked to an increased risk of adverse outcomes in coronary artery disease due to the deletion of myocyte enhancing factor 2 (MEF2).<sup><xref ref-type="bibr" rid="CR381">381</xref></sup> These findings suggest that DDX41 may play a role in the regulation of cardiovascular conditions, highlighting the urgent need for further research into its clinical applications.</p></sec></sec><sec id="Sec59"><title>Absent in melanoma 2 (AIM2)-like receptors (ALRs) - dependent innate immune signaling</title><sec id="FPar20"><title>ALRs</title><p id="Par100">ALRs are cytosolic and nuclear DNA sensors detecting bacterial and viral DNA, composed of an N-terminal PYD domain and one or two C-terminal hematopoietic expression, interferon inducibility, nuclear localization (HIN200) domain for DNA-binding.<sup><xref ref-type="bibr" rid="CR382">382</xref></sup> Similar to NLRs, the PYD functions as the effector region, transmitting downstream signals to the cellular machinery. Several ALR family members, including the IFN-inducible protein 16 (IFI16), AIM2 and IFI207, have been well characterized and implicated in the pathogenesis of various innate immune-related diseases<sup><xref ref-type="bibr" rid="CR383">383</xref>&#x02013;<xref ref-type="bibr" rid="CR385">385</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4e</xref>).</p></sec><sec id="FPar21"><title>ALRs-dependent signaling pathways</title><p id="Par101">AIM2, the first identified ALR family protein for innate immune signaling, detects long dsDNA via its hematopoietic interferon-inducible nuclear antigens with HIN200 domains.<sup><xref ref-type="bibr" rid="CR382">382</xref></sup> Upon binding with a double-strand DNA (dsDNA), AIM2 interacts with the adapter protein ASC, whose CARD domain interacts with the CARD domain of pro-caspase-1 to form inflammasomes, leading to the release of mature IL-1&#x003b2; and IL-18.<sup><xref ref-type="bibr" rid="CR386">386</xref>,<xref ref-type="bibr" rid="CR387">387</xref></sup> Another ALR, IFI16, also functions as a dsDNA sensor, inducing type I IFN expression and activating inflammasomes in a similar manner.<sup><xref ref-type="bibr" rid="CR388">388</xref></sup> Additionally, IFI207 co-localizes with active RNA polymerase II (RNA Pol II) and IRF7 in the nucleus, enhancing the induction of IRF7-dependent gene expression<sup><xref ref-type="bibr" rid="CR383">383</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4e</xref>).</p></sec><sec id="FPar22"><title>ALRs-dependent signaling pathways in CVDs</title><p id="Par102">Studies have shown that ALRs-dependent signaling pathways contributes to both cardiac and vascular inflammation.<sup><xref ref-type="bibr" rid="CR389">389</xref></sup> For instance, the AIM2 inflammasome contributed to chronic inflammation in human and murine failing hearts, and its inactivation by probenecid improved outcomes in pressure overload-induced HF in rats.<sup><xref ref-type="bibr" rid="CR390">390</xref></sup> Also, AIM2 inflammasome activation is implicated in the proliferation of cardiac M1 macrophages and the expansion of infarct areas post-MI.<sup><xref ref-type="bibr" rid="CR391">391</xref></sup> In contrast, inactivation of the AIM2 inflammasome by Rg1 significantly reduced cardiac fibrosis and macrophage polarization, highlighting its potential as a crucial regulator of cardiac inflammation.<sup><xref ref-type="bibr" rid="CR392">392</xref></sup> In vascular inflammation, the AIM2 inflammasome is constitutively expressed in the healthy arterial wall but can become over-activated under atherosclerosis conditions.<sup><xref ref-type="bibr" rid="CR393">393</xref></sup> Moreover, the injection of AIM2 inflammasome agonist in ApoE<sup>-/-</sup> mice resulted in impaired endothelium-dependent vasodilation, increased endothelial cells apoptosis, enhanced endothelium permeability, and elevated adhesion molecule expression.<sup><xref ref-type="bibr" rid="CR394">394</xref></sup> Additionally, AIM2 inflammasomes promoted MMP2 expression through the TGF-&#x003b2;/Smad signaling pathway in VSMCs.<sup><xref ref-type="bibr" rid="CR395">395</xref></sup> Genetic or pharmacological inactivation of AIM2 reduced levels of IL-1&#x003b2; and IL-18 in the necrotic core and destabilized atherosclerotic plaques.<sup><xref ref-type="bibr" rid="CR396">396</xref></sup> Apart from AIM2, IFI16 protein promotes inflammation in endothelial cells by activating of p38 MAPK and NF-&#x003ba;B p65, thereby contributing to vascular inflammation.<sup><xref ref-type="bibr" rid="CR396">396</xref></sup></p></sec></sec><sec id="Sec60"><title>The complement system-dependent pathways</title><sec id="FPar23"><title>Classical pathway</title><p id="Par103">The classical pathway of the complement system is considered as the key bridge between the innate and adaptive immune systems. It is initiated by antigen-antibody complexes that involve IgM-class antibodies or specific IgG antibody sub-classes.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> This process begins when C1q, along with the serine proteases C1r and C1s, assembles into the macromolecular C1 complex, which then binds to the Fc region of complement-fixing antibodies.<sup><xref ref-type="bibr" rid="CR397">397</xref></sup> Notably, C1q can bind directly to various ligands - including C-reactive protein, DNA, annexins A2, and A5 - independently of IgM or IgG, thereby triggering the complement cascade.<sup><xref ref-type="bibr" rid="CR398">398</xref>,<xref ref-type="bibr" rid="CR399">399</xref></sup> Upon binding antigen-antibody complexes, each C1 complex must bind to at least two constant regions of antibodies to establish a stable C1q-antibody interaction. This interaction induces a conformational change in one of the C1r proteins, activating and converting it into an active serine protease enzyme. Subsequently, the activated C1s cleaves C4 and C2 into larger fragments (C4b and C2a) and smaller fragments (C4a and C2b), respectively.<sup><xref ref-type="bibr" rid="CR400">400</xref>,<xref ref-type="bibr" rid="CR401">401</xref></sup> The larger fragments associate with the formation of a C4bC2a complex on pathogenic surfaces, which acts as a C3 convertase, converting C3 into its enzymatically active forms: C3a and C3b. Specifically, the C3 convertase cleaves C3 into the anaphylatoxin C3a and the opsonin C3b<sup><xref ref-type="bibr" rid="CR402">402</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4f</xref>).</p></sec><sec id="FPar24"><title>Lectin pathway</title><p id="Par104">In contrast to the antigen-antibody complex dependency of the classical pathway, the lectin pathway utilizes lectins such as collectins and ficolins as PRRs to recognize specific carbohydrate components.<sup><xref ref-type="bibr" rid="CR403">403</xref></sup> The lectin pathway of complement activation activates a C3 convertase (4bC2a) like the classical pathway, despite differences in their initiation processes. Several PRRs, including mannose-binding lectin (MBL) in the collectin family (collectin-10 and collectin-11) and ficolins (ficolin-1, ficolin-2, and ficolin-3), have been identified as specific receptors of the lectin pathway.<sup><xref ref-type="bibr" rid="CR404">404</xref>,<xref ref-type="bibr" rid="CR405">405</xref></sup> These proteins share a collagen-like triple helix linked to a carbohydrate recognition structure.<sup><xref ref-type="bibr" rid="CR403">403</xref>,<xref ref-type="bibr" rid="CR406">406</xref>&#x02013;<xref ref-type="bibr" rid="CR408">408</xref></sup> MBL is constitutively expressed in the liver and secreted into the plasma to recognize carbohydrate PAMPs on bacteria, viruses, and parasites.<sup><xref ref-type="bibr" rid="CR409">409</xref>,<xref ref-type="bibr" rid="CR410">410</xref></sup> It forms a complex with MASPs (MBL-associated serine proteases)-1, -2, and -3, which are functionally and structurally similar to C1s and C1r of the C1 complex in the classical pathway.<sup><xref ref-type="bibr" rid="CR411">411</xref>&#x02013;<xref ref-type="bibr" rid="CR413">413</xref></sup> Among these three MASP subtypes, MASP-2 is recognized as the primary initiator of the MBL pathway.<sup><xref ref-type="bibr" rid="CR414">414</xref>,<xref ref-type="bibr" rid="CR415">415</xref></sup> When MBL binds to pathogenic surfaces, it activates the associated MASPs, leading to the cleavage of C2 and C4 and the formation of the C3 convertase C4bC2a<sup><xref ref-type="bibr" rid="CR416">416</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4f</xref>).</p></sec><sec id="FPar25"><title>Alternative pathway</title><p id="Par105">The alternative pathway of complement activation begins with the generation of C3(H2O), facilitating rapid immune responses against exogenous pathogens or endogenous damaged cells, independently of antibody-antigen complexes.<sup><xref ref-type="bibr" rid="CR417">417</xref></sup> After C3 undergoes spontaneous hydrolysis to form C3(H2O), this molecule binds to factor B, allowing factor D to cleave factor B into Bb and Ba, thereby creating the initial C3 convertase, C3(H2O)Bb.<sup><xref ref-type="bibr" rid="CR418">418</xref></sup> This C3 convertase then cleaves C3 into C3b and C3a. C3b subsequently binds to factor B, which is then activated by factor D to form the main C3 convertase, C3bBb.<sup><xref ref-type="bibr" rid="CR419">419</xref></sup> Properdin (Factor P) stabilizes this complex, amplifying the alternative pathway of complement activation.<sup><xref ref-type="bibr" rid="CR420">420</xref></sup> In addition to this &#x0201c;tickover&#x0201d; pathway, which involves the above four serum components&#x02014;C3, factor B, factor D, and properdin&#x02014;two other initiation modes have been identified. One of these is initiated by properdin, while the other is triggered by proteases such as thrombin and kallikrein<sup><xref ref-type="bibr" rid="CR421">421</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4f</xref>).</p></sec><sec id="FPar26"><title>The complement system-dependent pathways in CVDs</title><p id="Par106">The complement system is implicated in the pathogenesis and development of various CVDs. Signs of complement activation are commonly observed in infarcted myocardium, failing hearts, and atherosclerotic arterial walls. For example, high-fat diet elevates plasma and local aortic complement expression levels, including C1q, C1s, C3, C4, and C9.<sup><xref ref-type="bibr" rid="CR422">422</xref>&#x02013;<xref ref-type="bibr" rid="CR424">424</xref></sup> C3-derived leukotactic fragments increased neutrophil infiltration in ischemic rat heart tissue and elevated plasma C3 levels correlate with the severity of atherosclerosis.<sup><xref ref-type="bibr" rid="CR425">425</xref>,<xref ref-type="bibr" rid="CR426">426</xref></sup> Treatment with C3 inactivator reduced C3-derived leukotactic activity in the infarcted myocardium.<sup><xref ref-type="bibr" rid="CR427">427</xref></sup> Additionally, deposition of complement activation products C3d and C5b-9 was observed in ischemic human heart tissue, with more intense complement activation in patients who underwent reperfusion therapy or experienced reinfarction.<sup><xref ref-type="bibr" rid="CR428">428</xref></sup> Conversely, the absence of human complement components C1q in the classical pathway was associated with a higher incidence of cardiovascular events.<sup><xref ref-type="bibr" rid="CR429">429</xref></sup> Complement C1q reduces early atherosclerosis in Ldlr<sup>-/-</sup> mice by clearing apoptotic cells.<sup><xref ref-type="bibr" rid="CR430">430</xref></sup> Also, lectin pathway is the key driver of tissue damage in CVDs.<sup><xref ref-type="bibr" rid="CR431">431</xref>&#x02013;<xref ref-type="bibr" rid="CR433">433</xref></sup> Mice lacking MBL or treated with an anti-MBL monoclonal antibody showed significantly reduced infarct size and cardiac inflammation.<sup><xref ref-type="bibr" rid="CR432">432</xref></sup> Similarly, in thrombosis progression, the complement system acts as a central hub and can be activated through the classical, alternative, or lectin pathways, leading to the production of complement factors like C3a and C1q.<sup><xref ref-type="bibr" rid="CR434">434</xref></sup> Moreover, thrombin produced during coagulation not only promotes fibrin generation, but also directly activates components of the complement system, such as C3 and C5, enhancing the complement cascade reaction.<sup><xref ref-type="bibr" rid="CR435">435</xref></sup> Consequently, the interaction between the complement system and the coagulation cascade response amplifies inflammation, leading to thrombus formation and tissue damage.<sup><xref ref-type="bibr" rid="CR436">436</xref></sup></p></sec></sec></sec><sec id="Sec61"><title>Adaptive immune response</title><p id="Par107">The adaptive immune system consists mainly of T and B lymphocytes (T and B cells) and APCs. It works together with the innate immune system to collectively defend the organism against foreign substances (&#x0201c;non-self&#x0201d;).<sup><xref ref-type="bibr" rid="CR437">437</xref>,<xref ref-type="bibr" rid="CR438">438</xref></sup> In detail, antigenic molecules (either protein- or lipid-based) are phagocytosed and processed.<sup><xref ref-type="bibr" rid="CR439">439</xref></sup> Professional APCs like DCs, macrophages, and B cells process exogenous antigens via MHC class II molecules, presenting epitopes to CD4+ Th cells. In contrast, all nucleated cells process peptide fragments of endogenous antigens via the MHC class I pathway, presenting epitopes to CD8&#x02009;+&#x02009;CTLs.<sup><xref ref-type="bibr" rid="CR440">440</xref>,<xref ref-type="bibr" rid="CR441">441</xref></sup> Of note, not all antigens will provoke a specific immune response. For instance, individuals are constantly exposed to harmless foreign antigens, such as food proteins and dust components, as well as &#x0201c;self&#x0201d; antigens. The immune response to these antigens is highly suppressed, preventing potentially harmful processes to the host, known as tolerance.<sup><xref ref-type="bibr" rid="CR442">442</xref></sup> The adaptive immune system includes cell-mediated and antibody-mediated responses and is distinguished from the innate system by its specificity, diversity, memory, and self/non-self recognition (Fig. <xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>Adaptive immune response in CVDs. <bold>a</bold> Hallmarks of adaptive immunity in CVDs; <bold>b</bold> antigen-presenting cells (APCs); <bold>c</bold> Function of T lymphocytes and B lymphocytes. (Created with BioRender.com, <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/w51n151">https://BioRender.com/w51n151</ext-link>)</p></caption><graphic xlink:href="41392_2025_2220_Fig5_HTML" id="d33e2786"/></fig></p><sec id="Sec62"><title>T lymphocytes</title><p id="Par108">T cells are produced in the bone marrow and then travel through the bloodstream to the thymus, where they mature and acquire the &#x0201c;T&#x0201d; designation. There are three primary types of T cells: cytotoxic, helper, and suppressor T cells.<sup><xref ref-type="bibr" rid="CR443">443</xref>,<xref ref-type="bibr" rid="CR444">444</xref></sup> Cytotoxic T cells destroy virally infected, damaged, and cancerous cells through cell-mediated immune responses and release cytokines to activate other immune cells.<sup><xref ref-type="bibr" rid="CR445">445</xref></sup> Helper T cells activate both cell-mediated and antibody-mediated immune responses by recognizing antigens bound to class II MHC molecules and initiating adaptive immune responses.<sup><xref ref-type="bibr" rid="CR446">446</xref></sup> Some helper T cells also differentiate into memory T cells after clearing an antigen, retaining antigen-specific characteristics to rapidly activate the adaptive immune system upon re-exposure.<sup><xref ref-type="bibr" rid="CR447">447</xref>,<xref ref-type="bibr" rid="CR448">448</xref></sup></p><sec id="FPar27"><title>T lymphocyte-mediated adaptive immune response</title><p id="Par109">Na&#x000ef;ve T cells express either CD4 or CD8 molecules on their surface, classifying them as CD4+ or CD8&#x02009;+&#x02009;T cells.<sup><xref ref-type="bibr" rid="CR449">449</xref>,<xref ref-type="bibr" rid="CR450">450</xref></sup> They are activated into Th lymphocytes when they encounter APCs displaying antigens on MHC II molecules. Once activated, Th cells stimulate other immune cells and secrete cytokines to alert additional effector cells to the pathogenic threat. There are two primary subtypes of Th cells: Th1 and Th2. Th1 cells activate cytotoxic T cells through cytokine secretion, while Th2 cells stimulate na&#x000ef;ve B cells to produce specific antibodies that target and eliminate pathogenic antigens.<sup><xref ref-type="bibr" rid="CR451">451</xref>&#x02013;<xref ref-type="bibr" rid="CR453">453</xref></sup> Unlike CD4&#x02009;+&#x02009;T cells, CD8&#x02009;+&#x02009;T cells are directly activated into cytotoxic T lymphocytes (CTLs) when interacting with antigens presented on MHC I molecules by APCs. These T cells, with diverse T cell receptors, achieve specificity through precise antigen-MHC recognition. After clonal selection, CD8&#x02009;+&#x02009;T cells proliferate and target specific cells, inducing apoptosis.<sup><xref ref-type="bibr" rid="CR454">454</xref>&#x02013;<xref ref-type="bibr" rid="CR456">456</xref></sup> Additionally, CTLs can recognize and destroy infected cells before intracellular pathogens replicate and escape, thereby preventing further infection.<sup><xref ref-type="bibr" rid="CR457">457</xref>,<xref ref-type="bibr" rid="CR458">458</xref></sup></p></sec><sec id="FPar28"><title>T lymphocyte-mediated adaptive immune response in CVDs</title><p id="Par110">T lymphocytes of adaptive immunity play significant roles in myocardial IRI mechanisms CVDs. Lymphopenia observed after primary percutaneous coronary intervention is linked to poor patient prognosis, possibly due to lymphocyte recruitment to ischemic myocardium.<sup><xref ref-type="bibr" rid="CR459">459</xref>,<xref ref-type="bibr" rid="CR460">460</xref></sup> CD8&#x02009;+&#x02009;T cells increase in aneurysmal aortic walls, promoting apoptosis and matrix remodeling by releasing IFN-&#x003b3;.<sup><xref ref-type="bibr" rid="CR461">461</xref></sup> CD8-deficient mice exhibited reduced cardiomyocyte injury but had impaired necrotic tissue clearance, leading to inadequate scar formation and a higher risk of cardiac rupture.<sup><xref ref-type="bibr" rid="CR460">460</xref></sup> Furthermore, a non-cytotoxic CD8&#x02009;+&#x02009;AT2R&#x02009;+&#x02009;T cell subset recruited to rat infarct areas post-MI, which produces IL-10 upon angiotensin II stimulation and promotes cardiac repair.<sup><xref ref-type="bibr" rid="CR462">462</xref></sup> In atherosclerosis development, <italic>ApoE</italic><sup>&#x02212;/&#x02212;</sup>
<italic>Cd8</italic><sup>&#x02212;/&#x02212;</sup> mice showed no difference in plaque size compared to <italic>ApoE</italic>&#x02009;&#x02212;&#x02009;/&#x02212; controls. However, <italic>ApoE</italic>&#x02009;&#x02212;&#x02009;/&#x02212; <italic>Cd4</italic>&#x02009;&#x02212;&#x02009;/&#x02212; mice had significantly increased early lesions, and early depletion of CD4&#x02009;+&#x02009;T cells accelerated atherosclerosis, indicating that early CD4&#x02009;+&#x02009;T cell-mediated responses are largely protective against the disease.<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR463">463</xref>&#x02013;<xref ref-type="bibr" rid="CR465">465</xref></sup> In addition, CD4&#x02009;+&#x02009;T cells activate macrophages and induce smooth muscle cell apoptosis by secreting Th1 cytokines and Th2 cytokines.<sup><xref ref-type="bibr" rid="CR461">461</xref></sup> Tregs are also crucial for myocardial repair. Their depletion resulted in larger infarcts, increased local inflammation, reduced collagen deposition, and impaired survival.<sup><xref ref-type="bibr" rid="CR466">466</xref>&#x02013;<xref ref-type="bibr" rid="CR468">468</xref></sup> These effects may be due to Treg-derived cytokines like IL-10 and TGF-&#x003b2;.<sup><xref ref-type="bibr" rid="CR469">469</xref>,<xref ref-type="bibr" rid="CR470">470</xref></sup></p></sec></sec><sec id="Sec63"><title>B lymphocytes</title><p id="Par111">B cells originate in the bone marrow, naming them &#x0201c;B&#x0201d;. Subsequently, they mature into specialized adaptive immune cells. Upon stimulation by Th2 cells, na&#x000ef;ve B cells differentiate into antibody-secreting plasma cells.<sup><xref ref-type="bibr" rid="CR471">471</xref>,<xref ref-type="bibr" rid="CR472">472</xref></sup> Generally, antibodies produced by activated B cells perform six functions: 1) Neutralizing pathogens or toxins; 2) Agglutinating pathogens to aid in clearance; 3) Opsonizing pathogens to attract phagocytic cells; 4) Activating complement by binding to pathogens, which starts the complement cascade; 5) Enhancing cell-mediated immune responses by recruiting cytotoxic cells, leading to antibody-dependent cell-mediated cytotoxicity (ADCC); 6) Inducing degranulation in granulocytes.<sup><xref ref-type="bibr" rid="CR473">473</xref>,<xref ref-type="bibr" rid="CR474">474</xref></sup></p><sec id="FPar29"><title>B lymphocyte-mediated adaptive immune response</title><p id="Par112">Na&#x000ef;ve B cells form a diverse population with numerous B cell receptors (BCRs) that bind and internalize foreign antigens.<sup><xref ref-type="bibr" rid="CR475">475</xref></sup> After processing the antigens, B cells present them on MHC II molecules to be recognized by Th2 cells. Plasma cells then rapidly produce and release significant quantities of antibodies that match the antigen recognition pattern of the BCRs into the bloodstream.<sup><xref ref-type="bibr" rid="CR476">476</xref>,<xref ref-type="bibr" rid="CR477">477</xref></sup> Some activated B cells develop into memory cells to respond if the same antigen reappears. Antibody binding marks invading pathogens for destruction, primarily by facilitating their uptake by phagocytic cells.<sup><xref ref-type="bibr" rid="CR471">471</xref></sup></p></sec><sec id="FPar30"><title>B lymphocyte-mediated adaptive immune response in CVDs</title><p id="Par113">Studies in mice have shown that B cell accumulation occurs in the infarcted myocardium following myocardial infarction.<sup><xref ref-type="bibr" rid="CR139">139</xref></sup> Typically, B cells produce natural IgM antibodies against non-myosin heavy chain II, which can damage the heart because their response in generating specific antibodies is delayed.<sup><xref ref-type="bibr" rid="CR139">139</xref></sup> Furthermore, mature B lymphocytes selectively produced Ccl7 and induce the mobilization and recruitment of Ly6C<sup>hi</sup> monocyte to the heart after myocardial infarction, leading to decreased myocardial function.<sup><xref ref-type="bibr" rid="CR478">478</xref></sup> It&#x02019;s important to note that not all B cells are harmful. A subset of B cells that produce IL-10 may aid in resolving inflammation and promoting heart recovery after myocardial infarction.<sup><xref ref-type="bibr" rid="CR479">479</xref></sup> During arrhythmia development, autoantibodies alter the function of cardiac ion channels, significantly impacting cardiac electrical activity.<sup><xref ref-type="bibr" rid="CR206">206</xref></sup> For example, anti-Ro/SSA antibodies target L-type and T-type calcium channels, inhibit calcium currents, and affect sodium currents in the sinoatrial node and atrioventricular node.<sup><xref ref-type="bibr" rid="CR207">207</xref>,<xref ref-type="bibr" rid="CR208">208</xref></sup> Anti-SSA antibodies also target K11.1V11.1&#x02009;K channels (hERG), inhibiting potassium currents involved in rapid repolarization<sup><xref ref-type="bibr" rid="CR211">211</xref>,<xref ref-type="bibr" rid="CR213">213</xref></sup></p></sec></sec></sec><sec id="Sec64"><title>Other signaling pathways in immune response</title><sec id="Sec65"><title>Hippo/YAP pathway</title><p id="Par114">The Hippo-YAP signaling pathway is highly conserved among various species.<sup><xref ref-type="bibr" rid="CR480">480</xref></sup> Recent findings have revealed that components of the Hippo-YAP pathway, including MST1/2 (mammalian Ste20-like kinases 1/2), MAP4Ks, LATS1/2, NDR1/2, and YAP/TAZ are crucial regulators of innate immune responses.<sup><xref ref-type="bibr" rid="CR481">481</xref></sup> YAP has been shown to suppress interferon response by targeting TBK1 and disrupting its interaction with IRF3.<sup><xref ref-type="bibr" rid="CR482">482</xref></sup> Furthermore, Wang et al. showed that YAP can interact with IRF3, preventing its dimerization and nuclear translocation, thereby reducing IFN-&#x003b2; and ISG production.<sup><xref ref-type="bibr" rid="CR483">483</xref></sup> However, the Hippo/YAP pathway can be activated downstream of TLRs, ultimately amplifying the NF-&#x003ba;B signaling.<sup><xref ref-type="bibr" rid="CR484">484</xref></sup> This indicates that the Hippo/YAP pathway has a complex role in modulating innate immune response (Fig. <xref rid="Fig6" ref-type="fig">6a</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><p>Other immune signaling pathways in CVDs. <bold>a</bold> Hippo/YAP pathway, <bold>b</bold> Wnt/&#x003b2;-catenin pathway, <bold>c</bold> JAK/STAT pathway. MAP4Ks Mitogen-Activated Protein Kinase Kinase Kinase Kinase, MST1/2 Mammalian Sterile 20-like kinases 1/2, LATS1/2 Large Tumor Suppressor Kinase 1/2, NRD1 Nuclear pre-mRNA Down-regulation 1, YAP/TAZ Yes-Associated Protein/Transcriptional coActivator with PDZ-binding motif, IRF3/7 Interferon Regulatory Factor 3/7, LRP5/6 Low-density lipoprotein Receptor-related Protein 5/6, GSK-3&#x003b2; Glycogen Synthase Kinase 3 beta, JAK Janus Kinase, STAT Signal Transducer and Activator of Transcription, IFN Interferon, IL Interleukin, TBK1 TANK Binding Kinase 1, CKI&#x003b1; Casein Kinase I alpha (Created with BioRender.com, <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/k49g175">https://BioRender.com/k49g175</ext-link>)</p></caption><graphic xlink:href="41392_2025_2220_Fig6_HTML" id="d33e3037"/></fig></p><sec id="FPar31"><title>Role of Hippo/YAP pathway-mediated immune response in CVDs</title><p id="Par115">The involvement of the Hippo/YAP pathway in modulating inflammation and immune responses in CVDs has gained significant attention recently.<sup><xref ref-type="bibr" rid="CR485">485</xref>,<xref ref-type="bibr" rid="CR486">486</xref></sup> Emerging studies indicate that MI triggered the activation of Hippo pathway kinases, leading to enhanced caspase activation and elevated levels of phosphorylated YAP, which subsequently caused cardiomyocyte apoptosis.<sup><xref ref-type="bibr" rid="CR487">487</xref>,<xref ref-type="bibr" rid="CR488">488</xref></sup> Importantly, the YAP/TEAD1 complex in cardiomyocytes modulated the expression of TLR genes during MI.<sup><xref ref-type="bibr" rid="CR489">489</xref>,<xref ref-type="bibr" rid="CR490">490</xref></sup> The cardiomyocyte-specific overexpression of YAP has been shown to improve cardiac function and survival after MI in mice.<sup><xref ref-type="bibr" rid="CR491">491</xref></sup> Meanwhile, this process was accompanied by the reduced expression of TLRs, particularly TLR2 and TLR4, suggesting the upstream regulation of Hippo-Yap pathway in TLRs-dependent immune response.<sup><xref ref-type="bibr" rid="CR489">489</xref>,<xref ref-type="bibr" rid="CR492">492</xref></sup> Furthermore, activation of YAP in tissue samples from hypertrophic cardiomyopathy and in TAC-induced failing hearts from mice, suggesting that the Hippo/YAP signaling pathway plays a role in the development of cardiac hypertrophy and HF.<sup><xref ref-type="bibr" rid="CR493">493</xref></sup> Cardiomyocyte-specific inhibition of MST1 reduced neutrophil and macrophage infiltration in the heart and suppressed the release of inflammatory cytokines in the progression of diabetic cardiomyopathy.<sup><xref ref-type="bibr" rid="CR494">494</xref></sup></p><p id="Par116">The inflammatory response regulated by the Hippo/YAP pathway has been linked to the process of vascular remodeling. In the atherosclerotic arteries, prominent YAP/TAZ staining was observed in the endothelium, media layer, and intimal hyperplastic plaque.<sup><xref ref-type="bibr" rid="CR495">495</xref></sup> Activation of YAP/TAZ triggered the expression of pro-inflammatory mediators, including IL-6, IL-8, and CCL2, and enhanced monocyte adhesion to endothelial cells, implying that endothelial YAP/TAZ activation plays a role in the early stages of atherosclerosis.<sup><xref ref-type="bibr" rid="CR495">495</xref>,<xref ref-type="bibr" rid="CR496">496</xref></sup> Moreover, in the aortas of hypertensive mice induced by Angiotensin II, treatment with the YAP/TAZ inhibitor decreased the infiltration of inflammatory cells and the production of pro-inflammatory cytokines.<sup><xref ref-type="bibr" rid="CR497">497</xref></sup></p></sec></sec><sec id="Sec66"><title>Wnt/&#x003b2;-catenin pathway</title><p id="Par117">The Wnt signaling pathways consist of both canonical and noncanonical routes. The canonical Wnt/&#x003b2;-catenin pathway is characterized by the translocation of &#x003b2;-catenin to the nucleus, whTCFere it activates target genes through T-cell factor/lymphoid enhancer-binding factor (TCF/LEF).<sup><xref ref-type="bibr" rid="CR498">498</xref></sup> This pathway is structured into four main components:the extracellular, membrane, cytoplasmic, and nuclear segments. Extracellular signals are primarily mediated by Wnt ligands, such as Wnt3a, Wnt1, and Wnt5a. The membrane segment mainly includes Wnt receptors, including Frizzled (a seven-transmembrane receptor) and lipoprotein receptor-related protein (LRP) 5/6. The cytoplasmic segment encompasses key proteins like &#x003b2;-catenin, glycogen synthase kinase-3&#x003b2; (GSK-3&#x003b2;), and casein kinase I (CK1). In the nuclear segment, &#x003b2;-catenin translocates into the nucleus, where it interacts with TCF/LEF family members to regulate the expression of downstream target genes.<sup><xref ref-type="bibr" rid="CR499">499</xref>,<xref ref-type="bibr" rid="CR500">500</xref></sup> Recent studies reveal that the WNT/&#x003b2;-catenin pathway and TLR-mediated NF-&#x003ba;B signaling pathways interact, influencing each other&#x02019;s functions.<sup><xref ref-type="bibr" rid="CR501">501</xref></sup> The Wnt/&#x003b2;-catenin pathway plays a dual role, exhibiting both pro-inflammatory and anti-inflammatory effects, which are partly due to its modulation of the NF-&#x003ba;B pathway. Similarly, the TLR signaling pathway also serves as a either positive or negative regulator of Wnt/&#x003b2;-catenin signaling<sup><xref ref-type="bibr" rid="CR501">501</xref>,<xref ref-type="bibr" rid="CR502">502</xref></sup> (Fig. <xref rid="Fig6" ref-type="fig">6b</xref>).</p><sec id="FPar32"><title>Role of Wnt/&#x003b2;-catenin pathway-mediated immune response in CVDs</title><p id="Par118">Growing evidence suggests that Wnt signaling is activated during the pathological progression of MI injury, as evidenced by elevated expressions of Wnt ligands, including <italic>Wnt2</italic>, <italic>Wnt4</italic>, <italic>Wnt10b</italic>, and <italic>Wnt11</italic> after MI.<sup><xref ref-type="bibr" rid="CR503">503</xref></sup> Wnt5a has been identified as specifically expressed in cardiomyocytes, where it plays a key role in triggering the release of pro-inflammatory cytokines after MI.<sup><xref ref-type="bibr" rid="CR504">504</xref>,<xref ref-type="bibr" rid="CR505">505</xref></sup> Endogenous Wnt pathway inhibitors, such as SFRPs, have been shown to protect against MI by preventing leukocyte activation and cytokine production.<sup><xref ref-type="bibr" rid="CR506">506</xref></sup> The activation of &#x003b2;-catenin in cardiomyocytes led to increased levels of inflammatory markers such as TNF-&#x003b1;, p-NF-&#x003ba;B, and IL-8, and enhanced the nuclear accumulation of NF-&#x003ba;B. This indicates that &#x003b2;-catenin contributes to post-MI inflammation by activating the NF-&#x003ba;B pathway.<sup><xref ref-type="bibr" rid="CR507">507</xref></sup> Dysregulated Wnt/&#x003b2;-catenin activation has also been observed in the pathogenesis of pressure overload-induced cardiac hypertrophy cardiac hypertrophy in mice, while interruption of Wnt signaling was found to attenuatecardiac dysfunction.<sup><xref ref-type="bibr" rid="CR508">508</xref></sup></p><p id="Par119">Canonical Wnt/&#x003b2;-catenin signaling has been implicated in the pathogenesis of atherosclerosis. The transcriptional level of Wnt5a has been reported to be induced by oxLDL in macrophage-rich areas of human atherosclerotic plaques, where Frizzled 5 and Wnt5a cooperated to promote the expressions of pro-inflammatory markers to further amplify the local inflammation.<sup><xref ref-type="bibr" rid="CR509">509</xref>,<xref ref-type="bibr" rid="CR510">510</xref></sup> Additionally, Wnt5a has been shown to exert a relatively long-lasting and sustained impact on the NF-&#x003ba;B pathway, thereby enhancing the innate immune response in the atherosclerotic plaques.<sup><xref ref-type="bibr" rid="CR511">511</xref></sup> Consistently, the Wnt receptor LRP5 expression was elevated in macrophages within advanced plaques compared to early ones, suggesting a crucial role of Wnt-mediated regulation of macrophages in the pathophysiology of atherosclerosis.<sup><xref ref-type="bibr" rid="CR512">512</xref></sup> Furthermore, myeloid &#x003b2;-catenin deficiency could exacerbate atherosclerosis in mice.<sup><xref ref-type="bibr" rid="CR513">513</xref></sup> These evidence demonstrate that targeting Wnt/&#x003b2;-catenin pathway in macrophages within plaques could offer a promising strategy for treating atherosclerosis.</p></sec></sec><sec id="Sec67"><title>JAK/STAT pathway</title><p id="Par120">The JAK/STAT pathway includes four JAK proteins - JAK1, JAK2, JAK3, and TYK2 - and seven STATs proteins - STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6.<sup><xref ref-type="bibr" rid="CR514">514</xref></sup> The canonical signaling pathway is initiated when cytokines interact with their specific receptors, which consist of different chains that undergo oligomerization. This oligomerization of the cytokine receptor leads to the separation of the intracellular segments, distancing the receptor-bound JAKs from one another.<sup><xref ref-type="bibr" rid="CR515">515</xref>,<xref ref-type="bibr" rid="CR516">516</xref></sup> This process removes the constitutive inhibition, resulting in JAK activation. The activated JAKs then phosphorylate the intracellular domain of cytokine receptors, creating selective binding site for STAT proteins.<sup><xref ref-type="bibr" rid="CR517">517</xref></sup> STATs are subsequently phosphorylated on tyrosine residues by JAKs, leading inactive STAT monomers to undergo conformational changes, enabling them to form active homodimers, heterodimers, or tetramers. These activated STAT complexes then translocate to the nucleus, where they act as transcription factors to regulate downstream target gene expression.<sup><xref ref-type="bibr" rid="CR518">518</xref></sup> The JAK/STAT signaling pathway is essential for coordinating immune and inflammatory responses, as numerous inflammatory cytokines, such as IFN&#x003b1;/&#x003b2;/&#x003b3; and IL-4/6/11, activate this pathway<sup><xref ref-type="bibr" rid="CR519">519</xref></sup> (Fig. <xref rid="Fig6" ref-type="fig">6c</xref>).</p><sec id="FPar33"><title>Role of JAK/STAT pathway-mediated immune response in CVDs</title><p id="Par121">The involvement of the JAK/STAT pathway in IR injury has been well investigated. McCormick et al. found that myocardial ischemia triggered enhanced STAT3 phosphorylation, which further augmented following reperfusion in rat.<sup><xref ref-type="bibr" rid="CR520">520</xref></sup> Using JAK2 inhibitor AG490, increased apoptosis and caspase-3 activity were observed in rat following I/R injury.<sup><xref ref-type="bibr" rid="CR521">521</xref></sup> Furthermore, overexpression of STAT3 protected mice against doxorubicin-induced cardiomyopathy.<sup><xref ref-type="bibr" rid="CR522">522</xref></sup> Similarly, cardiac-specific STAT3-deficient mice were more vulnerable to I/R-induced cardiac injury, as indicated by larger infarct areas and increased apoptosis after reperfusion, compared to wild-type controls.<sup><xref ref-type="bibr" rid="CR523">523</xref></sup> Furthermore, IL-6 and NF-&#x003ba;B activity are necessary for ischemic preconditioning and may act synergistically with the JAK/STAT pathway.<sup><xref ref-type="bibr" rid="CR524">524</xref>,<xref ref-type="bibr" rid="CR525">525</xref></sup></p><p id="Par122">The JAK/STAT pathway regulates the inflammatory processes in vascular cells, contributing to the development of atherosclerosis. JAK2/STAT3 pathway modulates arterial adventitia inflammation via crosstalk with NF-&#x02223;B pathway. Dotan et al. demonstrated that <italic>Apoe</italic><sup>&#x02212;<italic>/&#x02212;</italic></sup> mice deficient in macrophage <italic>Jak2</italic> developed accelerated atherosclerosis.<sup><xref ref-type="bibr" rid="CR526">526</xref></sup> Additionally, An et al. found that STAT3/NF-&#x02223;B decoy oligodeoxynucleotides (ODNs) reduced atherosclerosis by modulating the STAT/NF-&#x02223;B signaling pathway in mice.<sup><xref ref-type="bibr" rid="CR527">527</xref></sup></p></sec></sec></sec></sec><sec id="Sec68"><title>Multi-level regulatory signaling pathways/crosstalks in CVDs</title><sec id="Sec69"><title>Epigenetic, post-transcriptional, post-translational modification regulatory mechanisms of immune response in CVDs</title><p id="Par123">Epigenetic processes, including DNA methylation, histone modifications, non-coding RNA, RNA modifications, and post-translational modifications, mediate the diversity of gene expression patterns across different cells and tissues. These modifications establish a molecular framework through which environmental factors can impact gene expression. They play a crucial role in the activation and functional differentiation of immune cells and cardiomyocytes, thereby significantly influencing the development of CVDs (Fig. <xref rid="Fig7" ref-type="fig">7</xref>).<fig id="Fig7"><label>Fig. 7</label><caption><p>Epigenetic, post-transcriptional, post-translational modification regulatory mechanisms of immune response in CVDs. <bold>a</bold> DNA methylation; <bold>b</bold> Histone modification; <bold>c</bold> Types of coding or non-coding RNA; <bold>d</bold> mRNA modification; <bold>e</bold> Protein modification. NK cell Natural Killer cell, UTR Untranslated Region (Created with BioRender.com, <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/i78n158">https://BioRender.com/i78n158</ext-link>)</p></caption><graphic xlink:href="41392_2025_2220_Fig7_HTML" id="d33e3299"/></fig></p><sec id="Sec70"><title>DNA methylation</title><p id="Par124">DNA methylation acts as an annotation system for the genetic code, delivering essential instructions on when and how to read genetic information and control transcription. Unlike inherited genetic sequences, methylation patterns are formed through a programmed process that persists throughout development, leading to stable gene expression profiles.<sup><xref ref-type="bibr" rid="CR528">528</xref></sup> In terms of mechanism, DNA methyltransferases (DNMTs) covalently transfer a methyl group from S-adenosyl methionine to the C-5 position of cytosine, forming 5-methylcytosine (5mC).<sup><xref ref-type="bibr" rid="CR529">529</xref></sup></p><p id="Par125">Emerging evidences has highlighted the role of DNA methylation in regulating immune cell functions,<sup><xref ref-type="bibr" rid="CR530">530</xref>&#x02013;<xref ref-type="bibr" rid="CR532">532</xref></sup> providing comprehensive insights into how DNA methylation affects immune cell behavior and contributes to CVDs. The CARDIA study discovered that the methylation risk score significantly improved the discrimination capacity for coronary artery calcification status compared to the cardiovascular health (CVH) score alone, and it was associated with the risk of incident coronary artery calcification 5&#x02013;10 years later, independent of the cumulative CVH score.<sup><xref ref-type="bibr" rid="CR533">533</xref></sup> Shifting macrophage polarization from a pro-inflammatory (M1) to an anti-inflammatory (M2) state through epigenetic modifications could be a potential therapeutic strategy for conditions like atherosclerosis.<sup><xref ref-type="bibr" rid="CR534">534</xref>,<xref ref-type="bibr" rid="CR535">535</xref></sup> In addition, DNMT1 regulates macrophage motility and mechanical properties by controlling cellular cholesterol accumulation and lipid homeostasis, affecting wound healing and macrophage chemotactic migration<sup><xref ref-type="bibr" rid="CR536">536</xref></sup> (Fig. <xref rid="Fig7" ref-type="fig">7a</xref>).</p></sec><sec id="Sec71"><title>Histone modification</title><p id="Par126">Histone modifications regulate chromatin structure and gene expression by chemically altering amino acids on histone tails, including acetylation, methylation, phosphorylation, ubiquitination, and sumoylation. These changes influence chromatin openness, controlling gene activation or silencing, and impacting cell differentiation, development, stress responses, and disease progression.<sup><xref ref-type="bibr" rid="CR537">537</xref>&#x02013;<xref ref-type="bibr" rid="CR540">540</xref></sup></p><p id="Par127">Histone modifications significantly impact the occurrence and progression of CVDs by mediating immune regulation through mechanisms such as inflammation response, immune cell function, cardiac remodeling, and vascular function. Histone lactylation in monocytes promotes early activation of reparative gene expression, crucial for immune homeostasis and cardiac repair post-myocardial infarction, by regulating anti-inflammatory and pro-angiogenic activities.<sup><xref ref-type="bibr" rid="CR541">541</xref></sup> Inhibition of DYRK1A via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after MI.<sup><xref ref-type="bibr" rid="CR542">542</xref></sup> Also, nucleophosmin1 recruits histone demethylase KDM5b to the TSC1 promoter, reducing H3K4me3 and TSC1 expression. This enhances mTOR-related inflammatory glycolysis and abolishes macrophage repair.<sup><xref ref-type="bibr" rid="CR543">543</xref></sup> Similarly, HDAC3 controls macrophage polarization and inflammation, with its deficiency leading to increased IL-4-induced polarization and atherosclerotic plaque size. Upregulated in ruptured plaques, HDAC3 inversely correlates with TGF-&#x003b2;1, and its knockdown reduces macrophage inflammation and pro-inflammatory mediators.<sup><xref ref-type="bibr" rid="CR544">544</xref></sup> Additionally, histone acetyltransferase pathways upregulate NADPH oxidase 5 in human macrophages during inflammation, potentially leading to excessive ROS production in atherosclerosis<sup><xref ref-type="bibr" rid="CR545">545</xref></sup> (Fig. <xref rid="Fig7" ref-type="fig">7b</xref>).</p></sec><sec id="Sec72"><title>Non-coding RNA</title><p id="Par128">Non-coding RNA (ncRNA) comprises RNA molecules that do not encode proteins but are essential for gene expression regulation, genome stability, post-transcriptional modification, and translation control.<sup><xref ref-type="bibr" rid="CR546">546</xref>,<xref ref-type="bibr" rid="CR547">547</xref></sup> Present in eukaryotes, prokaryotes, and viruses, ncRNAs include microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNA), Piwi-interacting RNAs (piRNAs), and ribosomal RNAs.<sup><xref ref-type="bibr" rid="CR548">548</xref>,<xref ref-type="bibr" rid="CR549">549</xref></sup> These molecules modulate gene function and cellular processes by interacting with DNA, RNA, and proteins.<sup><xref ref-type="bibr" rid="CR550">550</xref></sup></p><p id="Par129">LncRNA has gained increased interest in the cardiovascular community for their ability to modulate cellular responses.<sup><xref ref-type="bibr" rid="CR551">551</xref></sup> For example, LncRNA-H19 regulates lipid metabolism and inflammation in ox-LDL-treated Raw264.7 cells via the H19-miR130b pathway, decreasing lipid accumulation and pro-inflammatory factors while increasing anti-inflammatory factors.<sup><xref ref-type="bibr" rid="CR552">552</xref></sup> The lncRNA MIAT is a newly identified regulator of cellular processes in advanced atherosclerosis, influencing the proliferation, apoptosis, and phenotypic transition of SMCs, as well as the pro-inflammatory characteristics of macrophages.<sup><xref ref-type="bibr" rid="CR553">553</xref>,<xref ref-type="bibr" rid="CR554">554</xref></sup> The lncRNA SIMALR, suppresses inflammatory macrophage apoptosis via NTN1 (Netrin-1).<sup><xref ref-type="bibr" rid="CR555">555</xref></sup> LncRNA CCRR reduced infarct size and improved cardiac function by inhibiting the secretion of proinflammatory factors through the suppression of TLR2 and TLR4.<sup><xref ref-type="bibr" rid="CR556">556</xref></sup> miRNAs also play a role in the progression of CVDs. Overloaded hearts in mice revealed that miR-21 is crucial for macrophage polarization towards an M1-like phenotype, miR-21 primarily determined macrophage-fibroblast communication, promoting the transition from quiescent fibroblasts to myofibroblasts.<sup><xref ref-type="bibr" rid="CR557">557</xref></sup> miR-214 shows the highest induction in response to Ang II-mediated hypertension. Global deletion of miR-214 prevents Ang II-induced periaortic fibrosis, vascular stiffening, and T-cell recruitment. Thus, <italic>miR-214</italic>&#x02212;/&#x02212; mice are shielded from endothelial dysfunction and oxidative stress, underscoring miR-214&#x02019;s involvement in pathological perivascular fibrosis through T cell recruitment and the release of pro-fibrotic cytokines.<sup><xref ref-type="bibr" rid="CR558">558</xref></sup> Moreover, circRNA_002581 can sponge miR-122, a micRNA that targets genes involved in inflammation. By sponging miR-122, circRNA_002581 promotes a pro-inflammatory macrophage phenotype, which contributes to vascular inflammation and cardiac hypertrophy.<sup><xref ref-type="bibr" rid="CR559">559</xref></sup> circRNA_010567 promotes the activation of the NF-&#x003ba;B pathway by sponging miR-141, which targets a key inhibitor of NF-&#x003ba;B. In M2 macrophage-derived small extracellular vesicles (SEVs), circUbe3a promotes myocardial fibrosis by targeting the microRNA-138-5p/RhoC axis, driving cardiac fibroblast proliferation, migration, and phenotypic transformation, thereby worsening myocardial fibrosis after MI<sup><xref ref-type="bibr" rid="CR560">560</xref></sup> (Fig. <xref rid="Fig7" ref-type="fig">7c</xref>).</p></sec><sec id="Sec73"><title>RNA modification</title><p id="Par130">RNA modification is essential for cellular function by regulating gene expression.<sup><xref ref-type="bibr" rid="CR561">561</xref>,<xref ref-type="bibr" rid="CR562">562</xref></sup> Key modifications include m6A (N6-Methyladenosine), which methylates adenine residues and is added by the methyltransferase Like 3 METTL3-METTL14 complex and removed by demethylases like fat mass and obesity-associated protein (FTO) and AlkB homolog 5 (ALKBH5); m5C (5-Methylcytosine), which methylates the fifth carbon of cytosine and is added by methyltransferases such as DNA methyltransferase 2 (DNMT2) or NOP2/Sun RNA methyltransferase family member 2 (NSUN2); and m7G (7-Methylguanylate), which is capped at the 5&#x02019; end of mRNA by capping enzymes. These modifications influence various aspects of gene expression, including splicing, maturation, transport, stability, and translation.<sup><xref ref-type="bibr" rid="CR563">563</xref>,<xref ref-type="bibr" rid="CR564">564</xref></sup></p><p id="Par131">Dynamic alterations in RNA modifications across different types of RNA are crucial for the development and functioning of the immune system.<sup><xref ref-type="bibr" rid="CR565">565</xref></sup>
<italic>METTL3</italic>-deficient dendritic cells display immature characteristics and extend allograft survival.<sup><xref ref-type="bibr" rid="CR566">566</xref>,<xref ref-type="bibr" rid="CR567">567</xref></sup> Also, METTL3-dependent N6-methyladenosine modification of Braf mRNA amplifies the macrophage inflammatory response and accelerates atherosclerosis in mice.<sup><xref ref-type="bibr" rid="CR568">568</xref></sup> Similarly, METTL14 exacerbates endothelial inflammation and atherosclerosis by increasing N6-methyladenosine modifications on FOXO1 and mediates the inflammatory response of macrophages through the NF-kB/IL-6 signaling pathway.<sup><xref ref-type="bibr" rid="CR569">569</xref>,<xref ref-type="bibr" rid="CR570">570</xref></sup> Seven key m6A regulators - Wilms tumor 1 associated protein (WTAP), Zinc Finger CCCH-Type Containing 13 (ZCH3H13), YTH domain-containing protein 1 (YTHDC1), Fragile X Messenger Ribonucleoprotein 1 (FMR1), FTO, RNA Binding Motif Protein 15 (RBM15), and YTH N6-methyladenosine RNA Binding Protein 3 (YTHDF3)&#x02014;could serve as novel biomarkers for the precise diagnosis of ischemic cardiomyopathy (ICM).<sup><xref ref-type="bibr" rid="CR571">571</xref></sup> In addition, Kun Wang et al. reveal that piRNA-mediated m5C methylation is involved in the regulation of cardiomyocyte necroptosis. Heart necroptosis-associated piRNA (HNEAP) regulates cardiomyocyte necroptosis by inhibiting the m5C methylation of Atf7 mRNA<sup><xref ref-type="bibr" rid="CR572">572</xref></sup> (Fig. <xref rid="Fig7" ref-type="fig">7d</xref>).</p></sec><sec id="Sec74"><title>Post-translational modification</title><p id="Par132">Post-translational modification (PTM) involves the covalent and enzymatic alteration of proteins after biosynthesis, impacting their function, localization, and cellular interactions.<sup><xref ref-type="bibr" rid="CR573">573</xref>,<xref ref-type="bibr" rid="CR574">574</xref></sup> Key PTMs include phosphorylation, ubiquitination, and methylation.</p><p id="Par133">Post-translational modifications like phosphorylation and polyubiquitination strongly regulate innate inflammatory responses by affecting the activation, translocation, and interaction of innate receptors and signaling molecules in response to harmful signals.<sup><xref ref-type="bibr" rid="CR575">575</xref>&#x02013;<xref ref-type="bibr" rid="CR577">577</xref></sup> In atherosclerosis, IL-8 binds to CXC motif chemokine receptor 2 (CXCR2) on neutrophils, promoting NET formation through Src, extracellular signal-regulated kinases (ERK), and p38 MAPK phosphorylation. This activates the TLR9/NF-&#x003ba;B pathway in macrophages, increasing IL-8 release and worsening disease, highlighting NETs as a therapeutic target.<sup><xref ref-type="bibr" rid="CR578">578</xref></sup> In obesity-induced cardiomyopathy, deleting or inhibiting doublecortin-like kinase 1 (DCLK1) in macrophages protects against high-fat diet-induced heart dysfunction, hypertrophy, and fibrosis by suppressing receptor-interacting serine/threonine-protein kinase 2 (RIP2) phosphorylation and inhibiting RIP2/TAK1-mediated inflammation.<sup><xref ref-type="bibr" rid="CR579">579</xref></sup> Also, TRAF6, downstream of IL-1&#x003b2;, ubiquitinates YAP at K252, enhancing its nuclear translocation and disrupting interaction with angiomotin, leading to increased macrophage infiltration and atherosclerotic lesions.<sup><xref ref-type="bibr" rid="CR580">580</xref></sup> WWP2, an E3 ubiquitin ligase, regulates cardiac fibrosis in non-ischemic cardiomyopathy by modulating the CCL5/Ly6chigh monocyte axis. WWP2 affects Ly6c high monocytes, promoting IRF7 mono-ubiquitination, nuclear translocation, and transcriptional activity, leading to CCL5 upregulation and reduced myofibroblast trans-differentiation.<sup><xref ref-type="bibr" rid="CR581">581</xref></sup> RNF5 inhibits cardiac hypertrophy by promoting STING degradation via K48-linked polyubiquitination, thereby reducing inflammation and immune responses.<sup><xref ref-type="bibr" rid="CR582">582</xref></sup> Additionally, interferon-stimulated gene 15 (ISG15) induces vascular damage in hypertension by promoting oxidative stress and inflammation, leading to endothelial dysfunction and vascular remodeling through post-translational modification (ISGylation) of macrophages.<sup><xref ref-type="bibr" rid="CR583">583</xref></sup> In ischemic myocardium, pharmacologically-induced hyper-O-GlcNAcylation enhances M2-like macrophage reparative activation. Myeloid knockdown of O-GlcNAcase, leading to hyper-O-GlcNAcylation, positively regulates M2-like activation and reduces post-MI hyper-inflammation.<sup><xref ref-type="bibr" rid="CR584">584</xref></sup></p><p id="Par134">The regulatory mechanisms of epigenetic, post-transcriptional, and post-translational modifications are crucial for understanding immune responses in CVDs. These modifications&#x02014;including DNA methylation, histone alterations, non-coding RNAs, and protein modifications&#x02014;interact in complex ways to influence gene expression patterns that are vital for immune cell function and the progression of CVDs. Investigating these processes not only reveals the underlying biological mechanisms of CVDs but also opens innovative pathways for therapeutic interventions aimed at modulating these modifications to improve patient outcomes (Fig. <xref rid="Fig7" ref-type="fig">7e</xref>).</p></sec></sec><sec id="Sec75"><title>Integration of key signaling pathway in CVDs with immune response</title><p id="Par135">Key signaling pathways in CVDs interplay with immune responses, which matters in CVDs. The crosstalk among those pathways highlights the importance of immune responses in CVDs (Fig. <xref rid="Fig8" ref-type="fig">8</xref>).<fig id="Fig8"><label>Fig. 8</label><caption><p>Integration of key signaling pathway in CVDs with immune response. <bold>a</bold> G protein-coupled receptor (GPCR) signaling pathway; <bold>b</bold> GFR-related pathway; <bold>c</bold> Oxidative stress-related pathway; <bold>d</bold> Cell metabolism-related pathway; <bold>e</bold> Cell death-related pathway. GPRC G Protein-Coupled Receptor, DAG Diacylglycerol, cAMP Cyclic Adenosine Monophosphate, IP3 Inositol Trisphosphate, GFR Growth factor receptor, EGF Epidermal growth factors, IGF Insulin-like growth factors, EGFR Epidermal growth factor receptors, IGFR Insulin-like growth factor receptors, sMaf Small Musculoaponeurotic Fibrosarcoma, Nrf2 Nuclear Factor Erythroid 2-Related Factor 2, ARE Antioxidant Response Element, ATP Adenosine Triphosphate, TCA Tricarboxylic Acid cycle, BCAAs Branched-Chain Amino Acids, TLR Toll-Like Receptor, I&#x003ba;B Inhibitor of kappa B, NF-&#x003ba;B Nuclear Factor Kappa-light-chain-enhancer of activated B cells, P50 Nuclear Factor NF-kappa-B p50 subunit, P65 Nuclear Factor NF-kappa-B p65 subunit (Created with BioRender.com, <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/p48m296">https://BioRender.com/p48m296</ext-link>)</p></caption><graphic xlink:href="41392_2025_2220_Fig8_HTML" id="d33e3586"/></fig></p><sec id="Sec76"><title>G protein-coupled receptor (GPCR)-signaling pathway</title><p id="Par136">GPCR signaling pathways are intricate signaling processes initiated by GPCRs, a vast and diverse group of membrane receptors. Upon ligand binding to a GPCR, a conformational change occurs, which in turn activates an associated G protein by facilitating the exchange of GDP for GTP on the G&#x003b1; subunit. This activation causes the G protein to dissociate into G&#x003b1; and G&#x003b2;&#x003b3; subunits, both of which interact with various downstream effectors. These interactions produce second messengers, such as cyclic AMP (cAMP) or inositol triphosphate (IP3), which further propagate the signal. The signaling cascade ultimately leads to a wide range of cellular responses. GPCR pathways are fundamental for numerous physiological functions, including sensory perception, immune response, mood regulation, and metabolism.<sup><xref ref-type="bibr" rid="CR585">585</xref></sup></p><p id="Par137">The GPCR signaling pathway modulates immune cell behavior and the expression of inflammatory mediators, playing a crucial role in maintaining immune system balance and ensuring appropriate inflammatory responses. This regulation is essential for orchestrating an effective immune response while preventing excessive inflammation that could lead to tissue damage.<sup><xref ref-type="bibr" rid="CR586">586</xref></sup> Chemokine receptors (CCR) are a large family of seven transmembrane domain GPCRs that are differentially expressed across various cell types.<sup><xref ref-type="bibr" rid="CR587">587</xref></sup> Single-cell RNA sequencing reveals that tissue-resident cardiac macrophages guide monocyte fate differently. Selective depletion of CCR2- or CCR2+ macrophages before myocardial infarction has distinct effects on left ventricular function, myocardial remodeling, and monocyte recruitment.<sup><xref ref-type="bibr" rid="CR588">588</xref></sup> Mechanistically, these CCR2- macrophages communicated with adjacent cardiomyocytes through focal adhesion complexes and were activated by mechanical stretch via a transient receptor potential cation channel subfamily V member 4 (TRPV4)-dependent pathway, regulating growth factor expression.<sup><xref ref-type="bibr" rid="CR589">589</xref></sup> Furthermore, CXCR7 meticulously regulates the dosage and signaling of adrenomedullin, a mitogenic peptide hormone essential for cardiovascular development. The loss of this decoy receptor leads to postnatal lethality due to abnormal cardiac development<sup><xref ref-type="bibr" rid="CR590">590</xref></sup> (Fig. <xref rid="Fig8" ref-type="fig">8a</xref>).</p></sec><sec id="Sec77"><title>Growth factor receptor (GFR)-related pathway</title><p id="Par138">GFR-related pathway involves cellular signaling processes that start with growth factors binding to their receptors on the cell surface. This binding triggers a cascade of intracellular events leading to various cellular responses, including proliferation, differentiation, migration, and survival. Growth factors, such as the epidermal growth factors (EGF) and the insulin-like growth factors (IGF), are proteins that interact with specific transmembrane receptors possessing intrinsic tyrosine kinase activity.<sup><xref ref-type="bibr" rid="CR591">591</xref></sup></p><p id="Par139">The EGFR pathway mediates macrophage responsiveness to specific diseases, impacting cardiac function and remodeling after acute ischemic injury. Myeloid cell-specific EGFR deletion leads to increased cardiomyocyte hypertrophy and worsened cardiac function and repair after acute myocardial infarction, with decreased levels of pro-reparative mediators such as Vegfa and Il10, and reduced capillary density.<sup><xref ref-type="bibr" rid="CR592">592</xref></sup> In addition to EGFR, inflammatory cells secrete myeloid-derived growth factor (MYDGF) to aid tissue repair and regeneration following acute myocardial infarction. MYDGF levels rise in the left ventricular myocardium and blood plasma of pressure-overloaded mice, which enhances sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) expression, reduces hypertrophy and dysfunction, and improves survival rates in both mice and patients with severe aortic stenosis.<sup><xref ref-type="bibr" rid="CR593">593</xref></sup> Furthermore, EGFR blockade in CD4&#x02009;+&#x02009;T cells induces T cell anergy and reduces the development of atherosclerosis. EGFR inhibition decreases T cell proliferation, activation, and cytokine production, leading to reduced T cell infiltration in atherosclerotic lesions.<sup><xref ref-type="bibr" rid="CR594">594</xref></sup> Additionally, IL-35 promotes the survival of reparative CX3CR1+Ly6Clow macrophages, which in turn reduces cardiac rupture, improves wound healing, and attenuates cardiac remodeling after MI by enhancing &#x003b1;-SMA and collagen expression.<sup><xref ref-type="bibr" rid="CR595">595</xref></sup> Thrombospondin-1 (TSP1), a well-known inhibitor of angiogenesis, exerts its effects by interacting with cell surface receptors such as CD36 and CD47. TSP1 suppressed lymphangiogenesis and inhibited VEGF-C-induced AKT and eNOS activation in lymphatic endothelial cells (LEC). CD47 silencing in LEC prevented these effects, and Cd47 knockout mice showed reduced atherosclerosis and higher lymphatic vessel density.<sup><xref ref-type="bibr" rid="CR596">596</xref></sup> Insulin-like growth factor-1 (IGF1R) signaling in macrophages suppresses foam cell accumulation and reduces plaque vulnerability in atherosclerotic lesions. IGF1R-deficient macrophages showed enhanced pro-inflammatory responses and reduced lipid efflux, increasing atherosclerosis and plaque instability.<sup><xref ref-type="bibr" rid="CR597">597</xref></sup> Eosinophils and eosinophil cationic protein (ECP) promote SMC calcification and atherogenesis via the BMPR-1A/1B-Smad-1/5/8-Runx2 signaling pathway. Eosinophil deficiency in &#x00394;dblGATA mice slowed atherogenesis, increased SMC content, and reduced calcification.<sup><xref ref-type="bibr" rid="CR598">598</xref></sup> TGF(transforming growth factor)-&#x003b2; activates Smad3 in macrophages, enhancing phagocytosis and anti-inflammatory transition. Smad3 knockout in macrophages leads to increased mortality, adverse remodeling, and impaired anti-inflammatory responses post-myocardial infarction.<sup><xref ref-type="bibr" rid="CR599">599</xref></sup> Fibroblast growth factor 10 (FGF10) coacervate injection significantly attenuated MI injury by preserving cardiac function, reducing inflammation and fibrosis, improving vascular stabilization, and activating phosphorylated fibroblast growth factor receptor (p-FGFR), PI3K/AKT, and ERK1/2 pathways more effectively than free FGF10 or heparin united FGF10<sup><xref ref-type="bibr" rid="CR600">600</xref></sup> (Fig. <xref rid="Fig8" ref-type="fig">8b</xref>).</p></sec><sec id="Sec78"><title>Oxidative stress-related pathway</title><p id="Par140">Oxidative stress-related pathways refer to the cellular signaling processes triggered by an imbalance between the production of ROS, reactive nitrogen species (RNS) and the cell&#x02019;s antioxidant defenses. This imbalance leads to oxidative damage to proteins, lipids, and DNA, which can disrupt normal cellular function.<sup><xref ref-type="bibr" rid="CR601">601</xref></sup></p><p id="Par141">In MI, mitochondria-targeted ROS scavenging mitigated impairments, enhanced myofibroblast function in vivo, and decreased mortality in mKO mice. These results underscore the crucial role of mitochondria in resolving inflammation and facilitating tissue repair through the modulation of efferocytosis and interaction with fibroblasts, holding significant potential for improving post-MI recovery and addressing other inflammatory conditions.<sup><xref ref-type="bibr" rid="CR602">602</xref></sup> The mitochondrial deacetylase Sirtuin3 (Sirt3) plays a crucial role in regulating metabolic and antioxidant functions linked to hypertension. Sirt3 depletion in hypertension leads to endothelial dysfunction, vascular hypertrophy, inflammation, and end-organ damage. Targeting Sirt3 expression has therapeutic potential for vascular dysfunction and hypertension<sup><xref ref-type="bibr" rid="CR603">603</xref></sup> (Fig. <xref rid="Fig8" ref-type="fig">8c</xref>).</p></sec><sec id="Sec79"><title>Cell metabolism-related pathway</title><p id="Par142">Cell metabolism-related pathways encompass biochemical processes that convert nutrients into energy and essential building blocks for cellular functions. Key pathways include glycolysis, the citric acid cycle, and oxidative phosphorylation, all of which generate ATP. The pentose phosphate pathway produces NADPH and ribose-5-phosphate for biosynthesis. Lipid metabolism processes fatty acids for energy storage and membrane synthesis. AMPK and mTOR signaling are among the best-understood metabolite-sensing and signaling pathways. These pathways regulate cellular energy balance, growth, and responses to environmental changes, supporting vital functions such as cell proliferation, differentiation, and survival.<sup><xref ref-type="bibr" rid="CR604">604</xref></sup></p><p id="Par143">Dysregulation of cell metabolism can lead to diseases like cancer, CVDs, and metabolic disorders.<sup><xref ref-type="bibr" rid="CR605">605</xref>,<xref ref-type="bibr" rid="CR606">606</xref></sup> In CAD patients&#x02019; monocytes and macrophages, excessive glucose metabolism enhances IL-6 and IL-1&#x003b2; production through mitochondrial ROS and nuclear PKM2, driving systemic inflammation. Targeting glycolysis, superoxide, and PKM2 tetramerization could potentially correct this pro-inflammatory phenotype.<sup><xref ref-type="bibr" rid="CR607">607</xref></sup> Macrophages from CAD patients are prolific producers of T cell chemo attractants (CXCL9, CXCL10), pro-inflammatory cytokines (IL-1&#x003b2;, IL-6), and the immunosuppressive ligand PD-L1, highlighting their significant role in exacerbating the inflammatory environment.<sup><xref ref-type="bibr" rid="CR608">608</xref></sup> NPM1 recruits histone demethylase KDM5b to the Tsc1 promoter, erasing H3K4me3 marks, inhibiting TSC1 expression, and enhancing mTOR signaling. Deficiency of NPM1 in macrophages mitigates myocardial ischemic injury, improves cardiac function, and promotes tissue repair after myocardial infarction by shifting cardiac macrophages towards oxidative phosphorylation metabolism and a reparative phenotype<sup><xref ref-type="bibr" rid="CR543">543</xref></sup> (Fig. <xref rid="Fig8" ref-type="fig">8d</xref>).</p></sec><sec id="Sec80"><title>Cell death-related pathway</title><p id="Par144">Cell death-related pathways regulate programmed cell death mechanisms such as apoptosis, necroptosis, and autophagy. Apoptosis involves caspase activation triggered by intrinsic (mitochondrial) or extrinsic (death receptor) pathways, leading to DNA fragmentation and cell dismantling. Necroptosis, a form of regulated necrosis, is mediated by RIPK1, RIPK3, and MLKL, causing cell membrane rupture. Autophagy involves the formation of autophagosomes that enclose cellular components, which are subsequently degraded by lysosomes, playing a crucial role in regulating the immune system<sup><xref ref-type="bibr" rid="CR609">609</xref></sup> (Fig. <xref rid="Fig8" ref-type="fig">8e</xref>).</p><p id="Par145">The roles of immunogenic cell death in cardiac disease have yet to be fully defined, and biology-based strategies to inhibit cell death in various cardiac syndromes are also explored.<sup><xref ref-type="bibr" rid="CR610">610</xref></sup> In macrophages, ER stress activates the UPR, leading to apoptosis, with the PI3K/Akt pathway providing anti-apoptotic protection; JNK1 opposes Akt signaling, affecting atherosclerosis progression and plaque stability.<sup><xref ref-type="bibr" rid="CR611">611</xref></sup> CD47, an anti-phagocytic molecule that makes cells resistant to efferocytosis, is associated with atherosclerosis. CD47-blocking antibodies reverse this defect, normalize the clearance of diseased vascular tissue, and ameliorate atherosclerosis.<sup><xref ref-type="bibr" rid="CR612">612</xref></sup> Efferocytosis-derived nucleotides activate a DNA-PKcs-mTORC2/Rictor pathway, promoting non-inflammatory macrophage proliferation, apoptotic cell clearance, and tissue resolution, aiding in atherosclerosis regression and plaque stabilization.<sup><xref ref-type="bibr" rid="CR613">613</xref></sup> Myeloid CD147 promotes atherosclerosis by enhancing inflammation via the TRAF6-IKK-IRF5 pathway and inhibiting efferocytosis by suppressing GAS6. Anti-human CD147 antibodies reduce atherosclerosis, suggesting a new therapeutic approach.<sup><xref ref-type="bibr" rid="CR614">614</xref></sup> Serum immunity-related GTPase family M protein (IRGM) is linked to plaque rupture in STEMI patients. IRGM/Irgm1 deficiency increases plaque stability and suppresses macrophage apoptosis by inhibiting ROS production and MAPK signaling.<sup><xref ref-type="bibr" rid="CR615">615</xref></sup> Solute Carrier Family 26 Member 4 (SLC26A4), identified as a potential asthma target,<sup><xref ref-type="bibr" rid="CR616">616</xref></sup> also contributes to cardiac hypertrophy by promoting autophagy and inducing apoptosis in cardiomyocytes.<sup><xref ref-type="bibr" rid="CR617">617</xref></sup> In an in vitro starvation model, neonatal mouse cardiomyocytes from WT mice and those with macrophage migration inhibitory factor (MIF) depletion showed a significant reduction in starvation-induced autophagic vacuole formation and an increase in starvation-induced cell death in H9C2 cells. These results suggest that MIF plays a supportive role in maintaining cardiac contractile function during starvation by regulating autophagy.<sup><xref ref-type="bibr" rid="CR618">618</xref>,<xref ref-type="bibr" rid="CR619">619</xref></sup> SIRT1 levels are repressed, and acetylated p53 levels are enhanced in CAD patient monocytes, increasing pro-apoptotic events and pro-inflammatory responses, contributing to vessel damage and long-term recurrent ischemic events.<sup><xref ref-type="bibr" rid="CR620">620</xref></sup></p><p id="Par146">By integrating multi-disciplinary efforts that include genomic, epigenetic, and immune response studies, we can identify novel biomarkers and therapeutic targets. This can facilitate the development of personalized treatments that modulate immune responses and key signaling pathways involved in CVD progression. Additionally, adopting flexible clinical trial designs, akin to those used in cancer research, will allow for rapid validation of new therapies and improved patient outcomes. Ultimately, these innovations promise to advance the clinical translation of cardiovascular research, offering new hope for better management of heart diseases.</p><p id="Par147">The integration of key signaling pathways in CVDs highlights the complex interplay between immune responses and cardiovascular mechanisms. This intricate crosstalk, involving pathways such as GPCR, growth factor receptors, oxidative stress, and cell metabolism, underscores the importance of understanding how these processes influence immune regulation in CVDs. By investigating these connections through multidisciplinary efforts&#x02014;including genomic, epigenetic, and immune response studies&#x02014;researchers can uncover novel biomarkers and therapeutic targets that facilitate the development of personalized treatments. Such approaches aim to modulate immune responses and regulate key signaling pathways, enhancing cardiac repair, reducing inflammation, and ultimately improving patient outcomes. Adopting flexible clinical trial designs, similar to those used in oncology, will further accelerate the validation of new therapies and support the clinical translation of cardiovascular research, offering renewed hope for advancing CVDs management.</p></sec></sec></sec><sec id="Sec81"><title>Immune-based therapeutic strategies for targeting CVDs</title><p id="Par148">Immune-based therapeutic strategies for targeting CVDs represent a growing field aimed at modulating the immune system to prevent and treat these conditions. This approach categorizes potential therapeutic agents into three main groups: biologics, gene and molecular therapies, and chemical Drugs, based on existing preclinical studies. Given the current landscape, there is a pressing need to identify new targets and develop innovative treatment strategies for effective cardiovascular disease management (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Selected published articles on immune-regulating therapeutic agents in preclinical development</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drugs</th><th>Indication</th><th>Therapeutic agents</th><th>Targets</th></tr></thead><tbody><tr><td>HCW-9302<sup><xref ref-type="bibr" rid="CR622">622</xref></sup></td><td>Atherosclerosis</td><td>Peptide-fusion proteins</td><td>IL-2R Factor VIII</td></tr><tr><td>Anti-CD45 antibody-drug conjugate<sup><xref ref-type="bibr" rid="CR628">628</xref></sup></td><td>Atherosclerosis</td><td>Antibody-drug conjugates</td><td>CD45</td></tr><tr><td>APTA-5278<sup><xref ref-type="bibr" rid="CR635">635</xref>,<xref ref-type="bibr" rid="CR636">636</xref></sup></td><td>Atherosclerosis</td><td>Chemical drugs</td><td>NOX</td></tr><tr><td>AZ-6983<sup><xref ref-type="bibr" rid="CR637">637</xref></sup></td><td>Atherosclerosis</td><td>Small molecule drugs</td><td>&#x003b1;7nAChR</td></tr><tr><td>VSB-16<sup><xref ref-type="bibr" rid="CR625">625</xref></sup></td><td>Atherosclerosis</td><td>Monoclonal antibody</td><td>CCL4L1</td></tr><tr><td>CD40L/Mac-1 interaction inhibitors<sup><xref ref-type="bibr" rid="CR627">627</xref></sup></td><td>Atherosclerosis</td><td>Antibody peptide</td><td>CD11b CD40LG ITGB2</td></tr><tr><td>BRP-187<sup><xref ref-type="bibr" rid="CR638">638</xref></sup></td><td>Atherosclerosis</td><td>Chemical drugs</td><td>LOX5 FLAP</td></tr><tr><td>Endothelial lipase inhibitors<sup><xref ref-type="bibr" rid="CR639">639</xref></sup></td><td>Atherosclerosis</td><td>Chemical drugs</td><td>LIPG</td></tr><tr><td>NLRP3 inflammasome inhibitor<sup><xref ref-type="bibr" rid="CR647">647</xref></sup></td><td>Myocardial infarction</td><td>Chemical drugs</td><td>NLRP3</td></tr><tr><td>NH2-terminally truncated galectin-3<sup><xref ref-type="bibr" rid="CR632">632</xref>,<xref ref-type="bibr" rid="CR634">634</xref></sup></td><td>Myocardial infarction</td><td>Recombinant peptide</td><td>LGALS3</td></tr><tr><td>SIM-339<sup><xref ref-type="bibr" rid="CR639">639</xref></sup></td><td>Cerebral hemorrhage Myocardial infarction</td><td>Peptide-coupled drug</td><td>JNK</td></tr><tr><td>RBB-004<sup><xref ref-type="bibr" rid="CR624">624</xref></sup></td><td>Myocardial infarction</td><td>Antibody-fusion proteins</td><td>HSP70</td></tr><tr><td>TNAX-103A<sup><xref ref-type="bibr" rid="CR626">626</xref></sup></td><td>Myocardial infarction</td><td>Humanized monoclonal antibodies</td><td>CD300A</td></tr><tr><td>NWL-283<sup><xref ref-type="bibr" rid="CR631">631</xref></sup></td><td>Myocardial infarction</td><td>Peptidomimetic drug</td><td>CASP3</td></tr><tr><td>APD-588<sup><xref ref-type="bibr" rid="CR643">643</xref>,<xref ref-type="bibr" rid="CR644">644</xref></sup></td><td>Heart failure</td><td>Chemical drugs</td><td>S1PR</td></tr><tr><td>SR-9009<sup><xref ref-type="bibr" rid="CR645">645</xref></sup></td><td>Myocardial infarction Heart failure</td><td>Chemical drugs</td><td>REV-ERB</td></tr><tr><td>SA-12<sup><xref ref-type="bibr" rid="CR641">641</xref></sup></td><td>Heart failure</td><td>Chemical drugs</td><td>MPO</td></tr><tr><td>GDF15 modulator<sup><xref ref-type="bibr" rid="CR646">646</xref></sup></td><td>Congestive heart failure</td><td>Chemical drugs</td><td>GDF15</td></tr><tr><td>CAR-T cells<sup><xref ref-type="bibr" rid="CR45">45</xref></sup></td><td>Cardiac fibrosis</td><td>Adoptive T cell transfer</td><td>FAP</td></tr><tr><td>In vivo-generated CAR T cells<sup><xref ref-type="bibr" rid="CR15">15</xref></sup></td><td>Cardiac fibrosis</td><td>LNP-encapsulated modified mRNA</td><td>FAP</td></tr></tbody></table><table-wrap-foot><p><italic>IL-2R</italic> Interleukin-2 Receptor, <italic>CD45</italic> Cluster of Differentiation 45, <italic>NOX</italic> NADPH Oxidase, &#x003b1;7nAChR Alpha-7 Nicotinic Acetylcholine Receptor, <italic>MPO</italic> Myeloperoxidase, <italic>CCL4L1</italic> C-C Motif Chemokine Ligand 4-Like 1, <italic>CD11b</italic> Cluster of Differentiation 11b, <italic>CD40LG</italic> CD40 Ligand, <italic>ITGB2</italic> Integrin Beta-2, <italic>LOX5</italic> 5-Lipoxygenase, <italic>FLAP</italic> 5-Lipoxygenase Activating Protein, <italic>LIPG</italic> Endothelial Lipase (LIPG), <italic>HDAC6</italic> Histone Deacetylase 6, <italic>NLRP3</italic> NOD-like Receptor Pyrin Domain Containing 3, <italic>LGALS3</italic> Galectin-3, <italic>JNK</italic> c-Jun N-terminal Kinase, <italic>HSP70</italic> Heat Shock Protein 70, <italic>CD300A</italic> Cluster of Differentiation 300a, <italic>CASP3</italic> Caspase-3, <italic>S1PR</italic> Sphingosine-1-Phosphate Receptor, <italic>REV-ERB</italic> REV-ERB Nuclear Receptors (including REV-ERB&#x003b1; and REV-ERB&#x003b2;), <italic>GDF15</italic> Growth Differentiation Factor 15, <italic>FAP</italic> Fibroblast Activation Protein</p></table-wrap-foot></table-wrap></p><sec id="Sec82"><title>Biologics</title><p id="Par149">Biologics, as defined by the FDA, are products made of sugars, proteins, nucleic acids, or their combinations, including live cells and tissues, and encompass vaccines, blood components, allergenic drugs, somatic cells, gene therapies, tissues, and recombinant proteins.<sup><xref ref-type="bibr" rid="CR621">621</xref></sup> Relevant biologics for CVDs treatment include key subcategories such as fusion proteins, monoclonal antibodies, antibody peptides, CAR-T cell therapy, and peptidomimetic. Notably, fusion proteins like HCW-9302 and peptide-fusion proteins such as RBB-004 have shown promise in preclinical models. HCW-9302 targets IL-2R to promote the expansion of regulatory T cells for treating atherosclerosis in mice.<sup><xref ref-type="bibr" rid="CR622">622</xref></sup> RBB-004 targets HSP70 in myocardial infarction, where extracellular HSP70 enhances the innate immune response as an immunomodulator.<sup><xref ref-type="bibr" rid="CR623">623</xref>,<xref ref-type="bibr" rid="CR624">624</xref></sup> Also, monoclonal antibodies and humanized monoclonal antibodies are essential for modulating immune responses in CVDs. VSB-16 targets CCL4L1 to stabilize atherosclerotic plaques and reduce inflammation by inhibiting metalloproteinases, decreasing pro-inflammatory cytokine production, and suppressing the NF-&#x003ba;B signaling pathway.<sup><xref ref-type="bibr" rid="CR625">625</xref></sup> TNAX-103A targets CD300A in myocardial infarction, enhancing efferocytosis by infiltrating myeloid cells.<sup><xref ref-type="bibr" rid="CR626">626</xref></sup> Antibody peptides and antibody-drug conjugates further broaden the range of therapeutic options. CD40L/Mac-1 interaction inhibitors prevent the recruitment of inflammatory leukocytes and reduce inflammation in atherosclerosis by targeting CD11b, CD40LG, and integrin subunit beta 2 (ITGB2).<sup><xref ref-type="bibr" rid="CR625">625</xref>,<xref ref-type="bibr" rid="CR627">627</xref></sup> The novel anti-CD45 ADC, initially used for anti-tumor therapy, is now being used to treat atherosclerosis by reducing the atherosclerotic plaque burden.<sup><xref ref-type="bibr" rid="CR628">628</xref></sup> Moreover, CAR-T cell therapy is currently under development. Antigen-specific CD8 T cells are used for adoptive transfer to effectively target and ablate cardiac fibroblast proteins, thereby reducing cardiac fibrosis.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> Additionally, peptidomimetics and peptide-conjugated drugs such as NWL-283 and SIM-339 target Caspase3 and c-Jun NH2-terminal Kinase (JNK), respectively, to reduce apoptosis and inflammatory responses in myocardial infarction and cerebral hemorrhage.<sup><xref ref-type="bibr" rid="CR629">629</xref>&#x02013;<xref ref-type="bibr" rid="CR631">631</xref></sup> Galectin-3 (Gal-3) inhibitors, which target the protein involved in collagen synthesis, macrophage infiltration, and interstitial fibrosis, are being explored to treat myocardial infarction.<sup><xref ref-type="bibr" rid="CR632">632</xref>&#x02013;<xref ref-type="bibr" rid="CR634">634</xref></sup></p></sec><sec id="Sec83"><title>Gene and molecular therapies</title><p id="Par150">Gene and molecular therapies involve the manipulation of genetic material to treat diseases. This category includes viral gene delivery systems and LNP-encapsulated modified mRNA. A notable approach includes generating antifibrotic CAR T cells in vivo by delivering modified mRNA via T cell-targeted LNPs. These cells have shown promise in mice, effectively reducing fibrosis and restoring cardiac function.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup></p></sec><sec id="Sec84"><title>Chemical drugs</title><p id="Par151">Chemical drugs encompass a wide range of compounds with diverse mechanisms of action. For atherosclerosis, several targets have been identified to reduce inflammatory responses and arterial plaque formation. APTA-5278, an inhibitor targeting NADPH oxidase-dependent ROS formation, reduces oxidative stress and inflammation.<sup><xref ref-type="bibr" rid="CR635">635</xref>,<xref ref-type="bibr" rid="CR636">636</xref></sup> AZ6983 activates &#x003b1;7nAChR to inhibit atherosclerosis and enhance phagocytosis in myeloid cells.<sup><xref ref-type="bibr" rid="CR637">637</xref></sup> BRP-187 is a leukotriene synthesis inhibitor that prevents the assembly of the FLAP complex, reducing the production of pro-inflammatory leukotrienes.<sup><xref ref-type="bibr" rid="CR638">638</xref></sup> Endothelial lipase inhibitors target LIPG to reduce pro-inflammatory effects and improve high-density lipoprotein levels.<sup><xref ref-type="bibr" rid="CR639">639</xref>,<xref ref-type="bibr" rid="CR640">640</xref></sup> For heart failure, myeloperoxidase (MPO) inhibitors such as SA-12 significantly improve cardiac function and inhibit myocardial structural changes in non-ischemic heart failure mouse models.<sup><xref ref-type="bibr" rid="CR641">641</xref></sup> APD588, a selective S1P receptor modulator, regulates inflammatory responses and improves cardiac functional recovery following myocardial infarction.<sup><xref ref-type="bibr" rid="CR642">642</xref>&#x02013;<xref ref-type="bibr" rid="CR644">644</xref></sup> SR9009, a synthetic compound activating REV-ERB receptors, aids in long-term cardiac repair following myocardial ischemia-reperfusion.<sup><xref ref-type="bibr" rid="CR645">645</xref></sup> GDF-15 modulators are used to treat congestive heart failure by mitigating inflammation and tissue damage.<sup><xref ref-type="bibr" rid="CR646">646</xref></sup> In myocardial infarction, early inhibition of NLRP3 activation can reduce infarct size and protect cardiac function, making inflammasome inhibitors a promising treatment for acute myocardial infarction.<sup><xref ref-type="bibr" rid="CR647">647</xref></sup> Additionally, DNMT inhibitors and other epigenetic therapies might help modulate macrophage functions to prevent or treat CVDs. Indeed, inhibition of DNMT3b has been found to increase the expression of Tregs while decreasing the levels of pro-inflammatory cytokines such as IL-1&#x003b2; and IFN-&#x003b3;, thereby regulating the inflammatory response and the development of atherosclerosis.<sup><xref ref-type="bibr" rid="CR648">648</xref>&#x02013;<xref ref-type="bibr" rid="CR650">650</xref></sup> In heart transplantation, FNVs@RAPA utilize a ROS-responsive bio-orthogonal chemistry approach for active targeting delivery to the heart graft site, effectively alleviating IRI and promoting the polarization of Ly6C&#x02009;+&#x02009;Ly6G-inflammatory macrophages towards an anti-inflammatory phenotype.<sup><xref ref-type="bibr" rid="CR651">651</xref></sup> The MNPs/Alg hydrogel, composed of melanin nanoparticles and alginate, eliminates ROS, promotes macrophage polarization to regenerative M2 macrophages, and provides antioxidant, anti-inflammatory, and proangiogenesis effects, showing great potential for myocardial infarction treatment and cardiac repair.<sup><xref ref-type="bibr" rid="CR652">652</xref></sup></p></sec></sec><sec id="Sec85"><title>Clinical trials</title><p id="Par152">Current clinical trials on immunomodulation in CVDs encompass broad-spectrum immunosuppressants, target-inflammatory treatments, cell therapies, and novel immunomodulatory targets, primarily targeting atherosclerosis and acute myocardial infarction (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Clinical trials with immunomodulatory therapeutics for cardiovascular diseases</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study names</th><th>Drugs</th><th>Mechanism of action</th><th>Targets</th><th>Phase</th><th>Patient cohort</th><th>Primary endpoints</th><th>Main outcomes</th><th>NCT number</th></tr></thead><tbody><tr><td>Lodoco2 (2020)<sup><xref ref-type="bibr" rid="CR690">690</xref></sup></td><td>Colchicine</td><td>Microtubule inhibitor</td><td>TUBB</td><td>Phase3</td><td>Patients with CAD</td><td>MACE</td><td>Low-dose colchicine significantly reduced cardiovascular events.</td><td>ACTRN12614000093684</td></tr><tr><td>COLCOT (2019)<sup><xref ref-type="bibr" rid="CR47">47</xref></sup></td><td>Colchicine</td><td>Microtubule inhibitor</td><td>TUBB</td><td>Phase3</td><td>Patients with MI</td><td>MACE</td><td>0.5&#x02009;mg daily colchicine significantly reduced ischemic cardiovascular risk</td><td>NCT02551094</td></tr><tr><td>NA</td><td>Colchicine</td><td>Microtubule inhibitor</td><td>TUBB</td><td>Phase 2</td><td>Patients with HFpEF</td><td>Change in hs-CRP</td><td>NA</td><td>NCT04857931</td></tr><tr><td>NA</td><td>Colchicine</td><td>Microtubule inhibitor</td><td>TUBB</td><td>NA</td><td>Patients with AAA</td><td>Changes in maximum diameter of AAA</td><td>NA</td><td>NCT05361772</td></tr><tr><td>NA</td><td>Colchicine</td><td>Microtubule inhibitor</td><td>TUBB</td><td>Phase 3</td><td>Patients with CHD requiring PCI</td><td>MACE</td><td>NA</td><td>NCT06472908</td></tr><tr><td>COCS (2024)</td><td>Colchicine</td><td>Microtubule inhibitor</td><td>TUBB</td><td>Phase4</td><td>Patients awaiting elective cardiac surgery (CABG/AVR)</td><td>Postoperative atrial fibrillation incidence</td><td>NA</td><td>NCT04224545</td></tr><tr><td>CIRT (2018)<sup><xref ref-type="bibr" rid="CR653">653</xref></sup></td><td>Methotrexate</td><td>Broad immuno&#x02014;suppression dihydrofolate reductase inhibitor</td><td>A2AR</td><td>Phase3</td><td>Patients with prior MI or multivessel CAD by angiography</td><td>MACE</td><td>Methotrexate didn&#x02019;t reduce IL-1&#x003b2;, IL-6, CRP, or cardiovascular events</td><td>NCT01594333</td></tr><tr><td>NA</td><td>Methotrexate</td><td>Broad immuno&#x02014;suppression dihydrofolate reductase inhibitor</td><td>A2AR</td><td>Phase4</td><td>Patients with RA</td><td>Change in peripheral SBP</td><td>NA</td><td>NCT03254589</td></tr><tr><td>CAPRI (2020)<sup><xref ref-type="bibr" rid="CR654">654</xref></sup></td><td>Ciclosporin</td><td>Broad immuno&#x02014;suppression Calcineurin inhibitors</td><td>MPTP</td><td>Phase2</td><td>Patients with STEMI and undergoing PCI</td><td>Change in infarct size</td><td>Single ciclosporin bolus had no effect on infarct size or LV remodeling</td><td>NCT02390674</td></tr><tr><td>Mohd Ali et al. (2018)<sup><xref ref-type="bibr" rid="CR655">655</xref></sup></td><td>Sirolimus</td><td>Broad immuno&#x02014;suppression mTOR inhibitors</td><td>FKBP 12</td><td>Phase1</td><td>Patients with coronary DES restenosis</td><td>Late lumen loss</td><td>Novel SCB vs. proven PCB for coronary DES ISR shows similar angiographic outcomes</td><td>NCT02996318</td></tr><tr><td>ORAR<sup><xref ref-type="bibr" rid="CR656">656</xref></sup></td><td>Rapamycin</td><td>mTOR inhibitor</td><td>mTOR</td><td>Phase3</td><td>Patients with BMS implantation</td><td>Cost differences in revascularization for de novo lesions</td><td>No outcome difference between oral rapamycin + BMS and DES for de novo lesions</td><td>NCT00552669</td></tr><tr><td>CLEVER--ACS<sup><xref ref-type="bibr" rid="CR657">657</xref></sup></td><td>Everolimus</td><td>mTOR inhibitor</td><td>mTOR</td><td>Phase1/2</td><td>Patients with STEMI</td><td>MI size measured by MRI</td><td>Treatment didn&#x02019;t reduce MI size or MVO at 30 days</td><td>NCT01529554</td></tr><tr><td>CANTOS (2017)<sup><xref ref-type="bibr" rid="CR46">46</xref></sup></td><td>Canakinumab</td><td>Anti--interleukin-1&#x003b2; antibodies</td><td>IL-1&#x003b2;</td><td>Phase 3</td><td>Patients with MI</td><td>MACE</td><td>150&#x02009;mg canakinumab every 3 months significantly lowered recurrent cardiovascular events versus placebo</td><td>NCT01327846</td></tr><tr><td>VCUART3 (2020)<sup><xref ref-type="bibr" rid="CR659">659</xref></sup></td><td>Anakinra</td><td>IL-1 receptor antagonist</td><td>IL-1Ra</td><td>Phase 2</td><td>Patients with STEMI</td><td>The AUC for hsCRP</td><td>Compared to placebo, it significantly reduces the systemic inflammatory response</td><td>NCT01950299</td></tr><tr><td>MAGiC-ART(2020)</td><td>Anakinra</td><td>IL-1 receptor antagonist</td><td>IL-1Ra</td><td>Phase 2</td><td>Patients with cardiac sarcoidosis</td><td>Change in inflammation marker</td><td>NA</td><td>NCT04017936</td></tr><tr><td>Myachikova et al. <sup><xref ref-type="bibr" rid="CR660">660</xref></sup></td><td>Goflikicept</td><td>IL-1 inhibitor</td><td>IL-1&#x003b2;</td><td>Phase 2/3</td><td>Patients with idiopathic recurrent pericarditis</td><td>Time to first pericarditis recurrence was evaluated</td><td>Goflikicept reduced recurrence risk vs. placebo</td><td>NCT04692766</td></tr><tr><td>Sayed et al.<sup><xref ref-type="bibr" rid="CR658">658</xref></sup></td><td>Xilonix</td><td>IL-1&#x003b1; inhibitor</td><td>IL-1&#x003b1;</td><td>Phase 2</td><td>Patients after PCI</td><td>Target vessel restenosis, time to restenosis, and MACE incidence</td><td>At 12 months, no significant difference in MACE or target vessel restenosis between groups</td><td>NCT01270945</td></tr><tr><td>RESCUE <sup><xref ref-type="bibr" rid="CR661">661</xref></sup></td><td>Ziltivekimab</td><td>IL-6-targeting monoclonal antibody</td><td>IL-6</td><td>Phase 2</td><td>Patients with moderate to severe CKD</td><td>12-week change in hs-CRP</td><td>Ziltivekimab markedly reduced atherosclerosis--related inflammation and thrombosis biomarkers</td><td>NCT03926117</td></tr><tr><td>ARTEMIS (2024)</td><td>Ziltivekimab</td><td>IL-6-targeting monoclonal antibody</td><td>IL-6</td><td>Phase3</td><td>Patients with AMI</td><td>Time to first 3-component MACE</td><td>NA</td><td>NCT06118281</td></tr><tr><td>ATHENA (2024)</td><td>Ziltivekimab</td><td>IL-6-targeting monoclonal antibody</td><td>IL-6</td><td>Phase3</td><td>Patients with HF</td><td>Change in KCCQ-CSS</td><td>NA</td><td>NCT06200207</td></tr><tr><td>ASSAIL-MI (2021)<sup><xref ref-type="bibr" rid="CR663">663</xref></sup></td><td>Tocilizumab</td><td>IL-6-targeting monoclonal antibody</td><td>IL-6</td><td>Phase 2</td><td>Patients with STEMI within 6&#x02009;h undergoing PCI</td><td>Myocardial salvage index (%)</td><td>Tocilizumab increased myocardial salvage in patients with acute STEMI</td><td>NCT03004703</td></tr><tr><td>Kleveland. et al. <sup><xref ref-type="bibr" rid="CR662">662</xref></sup></td><td>Tocilizumab</td><td>IL-6-targeting monoclonal antibody</td><td>IL-6</td><td>Phase 2</td><td>Patients with NSTEMI</td><td>Between-group AUC difference for hs-CRP (days 1&#x02013;3)</td><td>Tocilizumab attenuated the inflammatory response</td><td>NCT01491074</td></tr><tr><td>IMICA (2021)<sup><xref ref-type="bibr" rid="CR664">664</xref></sup></td><td>Tocilizumab</td><td>IL-6-targeting monoclonal antibody</td><td>IL-6</td><td>Phase2</td><td>Patients with out-of-hospital cardiac arrest</td><td>Reduction in CRP levels at 72&#x02009;h</td><td>Tocilizumab reduced systemic inflammation and myocardial injury in comatose patients post-cardiac arrest.</td><td>NCT03863015</td></tr><tr><td>NA</td><td>NT-0796</td><td>NLRP3 inhibitor</td><td>NLRP3</td><td>Phase 2</td><td>Patients with BMI&#x02009;&#x02265;&#x02009;30 and &#x02264;40&#x02009;kg/m<sup>2</sup></td><td>Change in hsCRP levels</td><td>NA</td><td>NCT06129409</td></tr><tr><td>NA</td><td>DFV890</td><td>NLRP3 inhibitor</td><td>NLRP3</td><td>Phase 2</td><td>Patients with MI (ages 18&#x02013;85, BMI 18&#x02013;45&#x02009;kg/m&#x000b2;, hsCRP&#x02009;&#x02265;&#x02009;2&#x02009;mg/L)</td><td>Serum levels of IL-6 and IL-18</td><td>NA</td><td>NCT06031844</td></tr><tr><td>Wohlford et al. <sup><xref ref-type="bibr" rid="CR667">667</xref></sup></td><td>Dapansutrile</td><td>Selective NLRP3 Inflamma--some Inhibitor</td><td>NLRP3</td><td>Phase 1b</td><td>Patients with stable systolic HF, LVEF&#x02009;&#x02264;&#x02009;40%, NYHA II-III symptoms</td><td>AEs</td><td>14-day dapansutrile treatment was safe and well-tolerated in stable HFrEF patients</td><td>NCT03534297</td></tr><tr><td>CATCH-AMI (2013)</td><td>Balixafortide (POL6326)</td><td>CXCR4 antagonist</td><td>CXCR4</td><td>Phase IIa</td><td>Patients with reperfused STEMI</td><td>Change in LVEF determined by MRI</td><td>NA</td><td>NCT01905475</td></tr><tr><td>NA</td><td>Etanercept</td><td>TNF-&#x003b1; inhibitor</td><td>TNF-&#x003b1;</td><td>Phase4</td><td>Patients with AMI</td><td>MACE</td><td>NA</td><td>NCT01372930</td></tr><tr><td>Colombo et al. <sup><xref ref-type="bibr" rid="CR669">669</xref></sup></td><td>Bindarit</td><td>Selective inhibitor of monocyte chemotactic protein-1 (MCP-1/CCL2)</td><td>MCP-1/CCL2</td><td>Phase IIa</td><td>Patients with coronary BMS</td><td>In-segment late loss</td><td>Bindarit significantly reduced in-stent late loss, indicating potential vessel wall benefits post-angioplasty</td><td>NCT01269242</td></tr><tr><td>NA</td><td>BRB-002</td><td>Novel Anti-CD47 Molecule</td><td>CD47</td><td>Phase 1</td><td>Healthy male volunteers</td><td>To evaluate the safety and tolerability of BRB-002</td><td>NA</td><td>ACTRN12624000405516</td></tr><tr><td>NA</td><td>Atibuclimab</td><td>Chimeric monoclonal antibody targeting CD14</td><td>CD14</td><td>Phase 1b</td><td>Patients with ACM</td><td>Safety and efficacy of the drug</td><td>NA</td><td>NCT06275893</td></tr><tr><td>Chen et al. <sup><xref ref-type="bibr" rid="CR675">675</xref></sup></td><td>RTP-026</td><td>Annexin-A1 analog</td><td>FPR2</td><td>Phase2</td><td>Patients with STEMI undergoing PCI, chest pain &#x0003c;12&#x02009;h, NLR 7-17</td><td>cTNT/CK-MB at 24&#x02009;hours</td><td>NA</td><td>NCT06465303</td></tr><tr><td>Hern&#x000e1;ndez-Jim&#x000e9;nez et al. <sup><xref ref-type="bibr" rid="CR671">671</xref></sup></td><td>ApTOLL</td><td>Toll-like receptor 4 antagonist</td><td>TLR4</td><td>Phase1</td><td>Health male volunteers</td><td>Assess safety and pharmacokinetics of 30-min IV ApTOLL infusion</td><td>No ApTOLL accumulation, confirming safety and supporting clinical trials</td><td>NCT04742062</td></tr><tr><td>SATELLITE (2023)<sup><xref ref-type="bibr" rid="CR670">670</xref></sup></td><td>AZD4831</td><td>Myelo--peroxidase inhibitor</td><td>Mpo</td><td>Phase2</td><td>Patients with HFpEF</td><td>Myeloperoxidase specific activity</td><td>AZD4831 was safe and effectively inhibited myeloperoxidase.</td><td>NCT03756285</td></tr><tr><td>RESTORE (2022)</td><td>OPL-0301</td><td>S1PR1 agonist</td><td>S1PR1</td><td>Phase 2</td><td>Patients with acute STEMI</td><td>Infarct size by CMR at Day 90</td><td>NA</td><td>NCT05327855</td></tr><tr><td>HUCV002-01 (2022)<sup><xref ref-type="bibr" rid="CR684">684</xref></sup></td><td>&#x003b1;GCDC</td><td>&#x003b1;-galactosylceramide-pulsed dendritic cells (&#x003b1;GCDCs)</td><td>INKT cell</td><td>Phase 2</td><td>Patients with CHF</td><td>Change in LVEF from baseline to 24 weeks</td><td>NA</td><td>jRCT2073210116</td></tr><tr><td>Hare et al. (2005)<sup><xref ref-type="bibr" rid="CR680">680</xref></sup></td><td>Adult hMSCs</td><td>Cell-based immuno--modulators</td><td>DMMI</td><td>Phase1</td><td>Patients with MI</td><td>AEs rates in 0.5, 1.6, and 5.0 million MSC/kg dose cohorts vs. placebo</td><td>Similar adverse event rates between hMSC and placebo groups</td><td>NCT00114452</td></tr><tr><td>Lee et al. <sup><xref ref-type="bibr" rid="CR681">681</xref></sup></td><td>SEED-MSC (BM-MSCs)</td><td>Cell-based immuno--modulators</td><td>DMAMI</td><td>Phase2/3</td><td>Patients with AMI</td><td>Absolute changes in global LVEF by SPECT</td><td>Safe and tolerable, showing modest LVEF improvement at 6 months by SPECT</td><td>NCT01392105</td></tr><tr><td>Chullikana et al. <sup><xref ref-type="bibr" rid="CR685">685</xref></sup></td><td>Stempeuce (BM-MSCs)</td><td>Cell-based immuno--modulators</td><td>DMAMI</td><td>Phase1/2</td><td>Patients with STEMI</td><td>AEs and ECG parameters</td><td>Safe and well-tolerated IV in AMI patients 2 days post-PCI</td><td>NCT00883727</td></tr><tr><td>Butler (2016)<sup><xref ref-type="bibr" rid="CR686">686</xref></sup></td><td>aMBMC</td><td>Cell-based immuno--modulators</td><td>NICM</td><td>Phase 2a</td><td>Patients with non-ischemic Heart Failure</td><td>Safety by number of AEs</td><td>Safe, immunomodulatory effects, with improved health status and functional capacity</td><td>NCT02467387</td></tr><tr><td>NA</td><td>BM-MSCs</td><td>Cell-based immuno--modulators</td><td>DMAMI</td><td>Phase3</td><td>Patients with AMI</td><td>Change in LVEF</td><td>NA</td><td>NCT01652209</td></tr><tr><td>TRIDENT (2017)<sup><xref ref-type="bibr" rid="CR687">687</xref></sup></td><td>hMSC</td><td>Cell-based immuno--modulators</td><td>ICM</td><td>Phase 2</td><td>Patients with ischemic cardiomyopathy</td><td>Number of Participants With TE-SAEs</td><td>100 million dose increased ejection fraction; both doses reduced scar size</td><td>NCT02013674</td></tr><tr><td>TAC-HFT-II (2020)</td><td>hmsc/hCSC</td><td>Cell-based immuno--modulators</td><td>DMMI</td><td>Phase1/2</td><td>Patients with chronic ischemic LV dysfunction and HF post-MI</td><td>Incidence of any TE-SAEs</td><td>NA</td><td>NCT02503280</td></tr><tr><td>WJ-MSC-AMI (2015)<sup><xref ref-type="bibr" rid="CR682">682</xref></sup></td><td>WJMSCs</td><td>Cell-based immuno--modulators</td><td>DMSTEMI</td><td>Phase2</td><td>Patients with AMI</td><td>Myocardium metabolic and perfusion measurements, global LVEF by echocardiography</td><td>Intracoronary WJMSCs safe and effective in AMI, clinically relevant therapy</td><td>NCT01291329</td></tr><tr><td>RIMECARD (2016)<sup><xref ref-type="bibr" rid="CR688">688</xref></sup></td><td>UC-MSC</td><td>Cell-based immuno--modulators</td><td>LV function in HFrEF</td><td>Phase1/2</td><td>Patients with compensated HF (dilated phase)</td><td>Change in global LVEF</td><td>IV UC-MSCs safe in stable HF with reduced LVEF</td><td>NCT01739777</td></tr><tr><td>HUC-HEART Trial <sup><xref ref-type="bibr" rid="CR689">689</xref></sup></td><td>HUC-MSCs</td><td>Cell-based immuno--modulators</td><td>ICM</td><td>Phase1/2</td><td>Patients with chronic ischemic CM</td><td>Ventricular remodeling</td><td>Intramyocardial HUC-MSCs effective in CIC</td><td>NCT02323477</td></tr><tr><td>NA</td><td>UC-MSCs</td><td>Cell-based immuno--modulators</td><td>DMMI</td><td>Phase1</td><td>Patients with MI</td><td>MACE</td><td>NA</td><td>NCT03902067</td></tr><tr><td>NA</td><td>Clinical-grade WJ-MSCs</td><td>Cell-based immuno--modulators</td><td>DMSTEMI</td><td>Phase1/2</td><td>Patients with STEMI</td><td>MI size</td><td>NA</td><td>NCT03533153</td></tr><tr><td>Qayyum. et al. <sup><xref ref-type="bibr" rid="CR683">683</xref></sup></td><td>ADSCS</td><td>Cell-based immuno--modulators</td><td>LV function in HFrEF</td><td>Phase2</td><td>Patients with HFrEF</td><td>Change in LVESV</td><td>Safe but no improvement in myocardial function or symptoms</td><td>NCT03092284</td></tr></tbody></table><table-wrap-foot><p><italic>CAD</italic> Coronary Artery Disease, <italic>MACE</italic> Major Adverse Cardiovascular Events, <italic>MI</italic> Myocardial Infarction, <italic>HFpEF</italic> Heart Failure with Preserved Ejection Fraction, <italic>hs-CRP</italic> High-Sensitivity C-Reactive Protein, <italic>AEs</italic> Adverse event, <italic>TE-SAEs</italic> Treatment emergent serious adverse events, <italic>AAA</italic> Abdominal Aortic Aneurysm, <italic>CHD</italic> Coronary Heart Disease, <italic>PCI</italic> Percutaneous Coronary Intervention, CABG Coronary Artery Bypass Grafting, AVR Aortic Valve Replacement, <italic>RA</italic> Rheumatoid Arthritis, DES Drug-Eluting Stent, BMS Bare Metal Stent, <italic>NSTEMI</italic> Non-ST-Elevation Myocardial Infarction, <italic>CKD</italic> Chronic Kidney Disease, <italic>KCCQ-CSS</italic> Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, AUC Area Under the Curve, <italic>CRP</italic> C-Reactive Protein, IL-6 Interleukin-6, IL-18 Interleukin-18, LVEF Left Ventricular Ejection Fraction, NLR Neutrophil-to-Lymphocyte Ratio, SPECT Single Photon Emission Computed Tomography, <italic>CMR</italic> Cardiac Magnetic Resonance, <italic>cTNT</italic> Cardiac Troponin T, <italic>CK-MB</italic> Creatine Kinase-MB, UC-MSC Umbilical Cord Mesenchymal Stem Cells, HUC-MSC Human Umbilical Cord Mesenchymal Stem Cells, ACM Arrhythmogenic Cardiomyopathy, CHF Congestive Heart Failure, LVESV Left Ventricular End-Systolic Volume, MVO Myocardial Viability Outcome, CM Cardiomyopathy, AMI Acute Myocardial Infarction, <italic>AE</italic> Adverse Event, STEMI ST-Elevation Myocardial Infarction, <italic>Tubb</italic> Tubulin Beta Chain, <italic>A2AR</italic> Adenosine <italic>A2A</italic> Receptor, <italic>MPTP</italic> Mitochondrial Permeability Transition Pore, <italic>FKBP12</italic> FK506 Binding Protein 12, <italic>mTOR</italic> Serine/Threonine-Protein Kinase mTOR, <italic>FPR2</italic> N-Formyl Peptide Receptor 2, <italic>TLR4</italic> Toll-Like Receptor 4, <italic>DMMI</italic> Damaged Myocardium in Myocardial Infarction, <italic>DMAMI</italic> Damaged Myocardium in Acute Myocardial Infarction, <italic>NICM</italic> Myocardium in Nonischemic Cardiomyopathy, <italic>ICM</italic> Myocardium in Ischemic Cardiomyopathy, <italic>DMSTEMI</italic> Damaged Myocardium in ST-Elevation Myocardial Infarction, <italic>HFrEF</italic> Heart Failure with Reduced Ejection Fraction</p></table-wrap-foot></table-wrap></p><sec id="Sec86"><title>Broad-spectrum immunosuppressants</title><p id="Par153">The efficacy of broad-spectrum immunosuppressants like Ciclosporin, sirolimus, rapamycin, and everolimus in CVD has been limited. The CIRT study (NCT01594333) revealed that methotrexate did not reduce inflammation markers or major adverse cardiovascular events (MACE) in coronary artery disease patients.<sup><xref ref-type="bibr" rid="CR653">653</xref></sup> Ciclosporin (NCT02390674) did not significantly impact infarct size or left ventricular remodeling in acute myocardial infarction patients.<sup><xref ref-type="bibr" rid="CR654">654</xref></sup> Studies on sirolimus (NCT02996318) and rapamycin (NCT00552669) for drug-eluting stents (DES) to inhibit restenosis also reported negative outcomes.<sup><xref ref-type="bibr" rid="CR655">655</xref>,<xref ref-type="bibr" rid="CR656">656</xref></sup> Everolimus (NCT01529554) failed to reduce myocardial infarction size in acute ST-elevation myocardial infarction patients.<sup><xref ref-type="bibr" rid="CR657">657</xref></sup> These findings suggest that while these immunosuppressants hold potential in other diseases, their effectiveness in CVDs, particularly in acute myocardial infarction and stent-related treatments, is limited.</p></sec><sec id="Sec87"><title>Target-inflammatory treatments</title><p id="Par154">IL-1 and IL-6 are central to the inflammatory response, with varying outcomes in related studies. El Sayed et al. found no significant differences in MACE and target vessel restenosis rates between groups using the IL-1&#x003b1; inhibitor Xilonix after percutaneous coronary intervention.<sup><xref ref-type="bibr" rid="CR658">658</xref></sup> The CANTOS study (NCT01327846) on 10,061 post-myocardial infarction patients showed that quarterly administration of 150&#x02009;mg canakinumab significantly reduced recurrent cardiovascular events.<sup><xref ref-type="bibr" rid="CR46">46</xref></sup> The VCUART3 study demonstrated that anakinra (an IL-1 receptor antagonist) significantly reduced systemic inflammation in 99 ST-elevation myocardial infarction patients.<sup><xref ref-type="bibr" rid="CR659">659</xref></sup> Studies have shown that IL-1&#x003b1; and IL-1&#x003b2; are key cytokines in the pathophysiology of acute pericarditis and its recurrence, with rilonacept preventing recurrences and maintaining remission in idiopathic recurrent pericarditis (IRP).<sup><xref ref-type="bibr" rid="CR660">660</xref></sup></p><p id="Par155">IL-6, as a downstream inflammatory marker of IL-1, has also been a focus of research. The RESCUE study (NCT02660034) showed that ziltivekimab, an IL-6 targeting monoclonal antibody, significantly reduced atherosclerotic inflammation markers like high-sensitivity CRP and thrombosis markers in patients with moderate to severe chronic kidney disease.<sup><xref ref-type="bibr" rid="CR661">661</xref></sup> Kleveland et al. (2016) found that tocilizumab, an IL-6 monoclonal antibody, reduced inflammation in patients with acute non-ST-elevation myocardial infarction.<sup><xref ref-type="bibr" rid="CR662">662</xref></sup> The ASSAIL-MI study (NCT03004703) indicated that tocilizumab improved the myocardial salvage index in acute ST-elevation myocardial infarction patients undergoing PCI.<sup><xref ref-type="bibr" rid="CR663">663</xref></sup> The IMICA study (NCT03640180) demonstrated that tocilizumab significantly reduced systemic inflammation and myocardial injury in out-of-hospital cardiac arrest patients.<sup><xref ref-type="bibr" rid="CR664">664</xref></sup></p><p id="Par156">The NLRP3 inflammasome, an upstream activator of IL-1&#x003b2; and IL-18, plays a crucial role in the strong inflammatory response during myocardial ischemic and non-ischemic injury.<sup><xref ref-type="bibr" rid="CR329">329</xref></sup> The non-selective NLRP3 inflammasome inhibitor colchicine has been shown to reduce cardiovascular events in coronary artery disease patients over the long term in the Lodoco2 (NCT02285360) and COLCOT (NCT02551094) trials, leading to FDA approval for cardiovascular anti-inflammatory treatment.<sup><xref ref-type="bibr" rid="CR665">665</xref></sup> Selective NLRP3 inflammasome inhibitors like dapansutrile have shown good safety and tolerability in HFrEF patients, warranting further research on their efficacy.<sup><xref ref-type="bibr" rid="CR666">666</xref>,<xref ref-type="bibr" rid="CR667">667</xref></sup> NT0796 and DFV890, also selective NLRP3 inflammasome inhibitors, are currently in phase 2 clinical trials for coronary artery disease patients (NCT06129409, NCT06031844).</p><p id="Par157">In addition to classical targeted therapies for inflammation, several non-classical inflammatory-targeted treatments have also emerged. Although, some clinical trials have yet to achieve their primary endpoints or disclose conclusive results. For instance, etanercept (NCT01372930), a TNF-&#x003b1; inhibitor, reduces inflammation by blocking TNF-&#x003b1; produced by macrophages,<sup><xref ref-type="bibr" rid="CR668">668</xref></sup> though clinical trial results are yet to be revealed. Bindarit (NCT01269242), selectively inhibiting monocyte chemoattractant protein-1 (MCP-1/CCL2), reduces monocyte chemotaxis and infiltration, significantly lowering late lumen loss in coronary bare-metal stent patients, despite not meeting primary endpoints.<sup><xref ref-type="bibr" rid="CR669">669</xref></sup> AZD4831 (NCT03756285), a myeloperoxidase (MPO) inhibitor, reduces inflammation and improves microvascular function, showing good tolerability in heart failure patients.<sup><xref ref-type="bibr" rid="CR670">670</xref></sup> ApTOLL (NCT04742062), a TLR4 antagonist, reduces inflammation following acute ischemic stroke and acute myocardial infarction by blocking TLR4 signaling, with good safety and pharmacokinetic profiles.<sup><xref ref-type="bibr" rid="CR671">671</xref></sup></p></sec><sec id="Sec88"><title>Novel immunomodulatory targets</title><p id="Par158">There also strategies focused on precisely modulating immune responses involved in tissue repair, immune cell migration, and receptor signaling. Notably, BRB-002 (ACTRN12624000405516) enhances macrophage phagocytosis and modulates atherosclerotic immune responses by blocking CD47-SIRP&#x003b1; interaction.<sup><xref ref-type="bibr" rid="CR672">672</xref></sup> RTP-026 (NCT06465303), an Annexin-A1 analog, reduces myocardial injury by regulating immune cell migration and reactivity in acute and chronic cardiovascular disease models.<sup><xref ref-type="bibr" rid="CR673">673</xref>&#x02013;<xref ref-type="bibr" rid="CR675">675</xref></sup> Atibuclimab (NCT06275893) targets CD14, regulating inflammation, apoptosis, and tissue injury responses, with ongoing evaluations of its safety and efficacy.<sup><xref ref-type="bibr" rid="CR676">676</xref></sup> POL6326 (NCT01905475), a CXCR4 antagonist, mediates angiogenesis and tissue repair through splenic Foxp3 regulatory T cells, improving cardiac function post-myocardial infarction.<sup><xref ref-type="bibr" rid="CR677">677</xref></sup> S1P receptors regulate cardiac fibroblast remodeling, proliferation, and differentiation, mediating peripheral vascular tone and endothelial responses.<sup><xref ref-type="bibr" rid="CR678">678</xref></sup> An ongoing clinical trial (NCT05327855) is held to evaluate the efficacy of OPL-0301, a S1PR1 agonist, for myocardial injury in acute myocardial infarction patients.</p></sec><sec id="Sec89"><title>Cell therapy</title><p id="Par159">It is widely acknowledged that Mesenchymal stem cells (MSCs) are highly immunomodulatory. MSCs have demonstrated promising potential in myocardial protection, mainly through their abilities to reduce inflammation, promote cardiomyocyte differentiation, enhance angiogenesis, increase anti-apoptotic capacity, and inhibit fibrosis.<sup><xref ref-type="bibr" rid="CR679">679</xref></sup></p><p id="Par160">The first clinical trial involving adult MSCs in acute myocardial infarction patients, conducted by Joshua Hare et al. (2005), confirmed their safety.<sup><xref ref-type="bibr" rid="CR680">680</xref></sup>Since then, MSCs derived from various sources, such as bone marrow, umbilical cord, and adipose tissue, have been shown to be safe and well-tolerated in clinical trials for acute myocardial infarction and heart failure patients.<sup><xref ref-type="bibr" rid="CR681">681</xref>&#x02013;<xref ref-type="bibr" rid="CR683">683</xref></sup>In addition to MSC-based therapies, other immunomodulatory cell therapies, such as &#x003b1;-galactosylceramide-pulsed dendritic cells (&#x003b1;GCDC), have shown potential for chronic heart failure, with research still ongoing (jRCT2073210116).<sup><xref ref-type="bibr" rid="CR684">684</xref></sup></p><p id="Par161">Several recent studies have focused on MSCs specifically for cardiovascular applications. In a Phase 1/2 trial (NCT00883727), Chullikana et al. demonstrated that intravenous administration of Stempeuce (BM-MSCs) was safe and well-tolerated in STEMI patients, with no significant adverse effects reported 2 days post-PCI.<sup><xref ref-type="bibr" rid="CR685">685</xref></sup> Similarly, Butler et al. conducted a Phase 2a trial (NCT02467387) using autologous bone marrow MSCs (aMBMC) in non-ischemic heart failure patients, showing that the treatment was not only safe but also had potential immunomodulatory benefits, with improved health status and functional capacity.<sup><xref ref-type="bibr" rid="CR686">686</xref></sup> Furthermore, a Phase 3 trial (NCT01652209) using BM-MSCs in AMI patients assessed changes in left ventricular ejection fraction (LVEF), although detailed efficacy results were not disclosed. The TRIDENT study (2017) (NCT02013674) extended these findings by demonstrating that a high dose of hMSCs improved ejection fraction and reduced scar size in patients with ischemic cardiomyopathy.<sup><xref ref-type="bibr" rid="CR687">687</xref></sup> Similarly, the TAC-HFT-II trial (2020) (NCT02503280) investigated a combination of hMSC/hCSC in patients with chronic ischemic LV dysfunction and heart failure post-MI, focusing on treatment-emergent serious adverse events.</p><p id="Par162">Research on MSCs from other sources, such as umbilical cord MSCs (UC-MSCs), has also progressed. The RIMECARD study (2016) (NCT01739777) found that intravenous UC-MSCs were safe in stable heart failure patients with reduced LVEF.<sup><xref ref-type="bibr" rid="CR688">688</xref></sup> Additionally, the HUC-HEART Trial (2020) (NCT02323477) demonstrated that intramyocardial HUC-MSCs effectively promoted ventricular remodeling in patients with chronic ischemic cardiomyopathy.<sup><xref ref-type="bibr" rid="CR689">689</xref></sup> Further studies included a Phase 1 trial (NCT0390206) investigating UC-MSCs in MI patients, with MACE as the primary outcome, and a separate trial (NCT03533153) examining clinical-grade WJ-MSCs in STEMI patients, with a focus on reducing myocardial infarct size.</p><p id="Par163">In brief, these studies highlight the safety and therapeutic potential of MSC-based therapies for improving cardiac function and remodeling across various cardiovascular conditions. However, to confirm these benefits and optimize the most effective MSC sources and delivery methods, further large-scale studies are essential.</p></sec><sec id="Sec90"><title>Future strategies for immunomodulation in CVDs</title><p id="Par164">In contemporary clinical research addressing CVDs, these conditions are increasingly recognized as being intricately linked to immune responses.Early clinical investigations utilized traditional broad-spectrum immunosuppressive agents, such as methotrexate, cyclosporine, sirolimus, rapamycin, and everolimus, to evaluate their efficacy in the treatment of cardiovascular diseases.<sup><xref ref-type="bibr" rid="CR681">681</xref></sup> However, these studies did not yield significant reductions in the incidence of MACE, nor did they effectively decrease inflammatory markers or ameliorate myocardial damage following acute myocardial infarction.</p><p id="Par165">The emergence of cell therapies, particularly MSCs treatments, has offered new avenues for managing cardiovascular disease. MSCs have demonstrated potential in modulating immune mechanisms, downregulating immune cell activity, and mitigating inflammatory responses. Despite the promising safety and tolerability observed in clinical trials involving MSCs derived from bone marrow, umbilical cord, and adipose tissue in patients with acute myocardial infarction and heart failure,<sup><xref ref-type="bibr" rid="CR681">681</xref>&#x02013;<xref ref-type="bibr" rid="CR683">683</xref></sup> the long-term benefits of these therapies for cardiovascular patients remain to be fully elucidated.</p><p id="Par166">While the disappointing outcomes associated with broad-spectrum immunosuppressive drugs have prompted a shift in focus, targeted anti-inflammatory medications are gaining prominence. Notably, drugs aimed at IL-1, IL-6, and NLRP3 are under active investigation.<sup><xref ref-type="bibr" rid="CR658">658</xref>&#x02013;<xref ref-type="bibr" rid="CR663">663</xref></sup> Colchicine, a microtubule inhibitor and non-selective NLRP3 inhibitor, has demonstrated significant efficacy in reducing the incidence of MACE in patients with coronary artery disease and myocardial infarction, as evidenced by the results of two large-scale clinical trials, Lodoco2 and COLCOT.<sup><xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR690">690</xref></sup> Following these findings, the FDA approved colchicine as an anti-inflammatory treatment for cardiovascular disease, marking a significant advancement in targeted anti-inflammatory strategies.</p><p id="Par167">Moreover, clinical research targeting various immune modulation pathways is continuously evolving, with ongoing studies exploring novel targets such as CXCR4, MCP-1/CCL2,<sup><xref ref-type="bibr" rid="CR669">669</xref></sup> CD14, and CD47. Currently, targeted anti-inflammatory therapy represents a crucial strategy in the immunotherapeutic approach to cardiovascular diseases; however, the number of confirmed effective targets in clinical research remains relatively limited. In the pursuit of targeted anti-inflammatory therapies, it is essential to avoid pro-inflammatory responses that may lead to detrimental effects on the body, underscoring the need to maintain a delicate balance between anti-inflammatory and immunosuppressive mechanisms. Furthermore, the development of effective targeted drug delivery systems aimed at the heart will be a vital direction for future research, enabling more precise anti-inflammatory interventions in the treatment of cardiovascular diseases.</p></sec></sec><sec id="Sec91"><title>Conclusion and perspective</title><p id="Par168">This article provides a comprehensive overview of the research history and key milestones in the immunology and immunotherapy of CVDs. It offers a broad perspective on the activation and regulation of the immune response and details the multi-level regulatory signaling pathways and their crosstalk in CVDs. We also described the mechanisms of immune regulation in physiological and pathological processes of CVDs, as well as the advancements in targeted immune response therapy both in preclinical strategies and clinical trials.</p><p id="Par169">Although the immune system plays a crucial role in CVDs, the complexity and variability of inflammatory processes across patients make it difficult to develop universally effective immune-targeted strategies. Several areas with significant gaps in mechanistic research need to be further explored: 1) There is a huge shortfall in characterizing cell-specific mechanistic pathways in CVDs. Meanwhile, understanding the complex network of interactions among various cell types is crucial for regulating CVDs. Utilize state-of-the-art techniques such as advanced in vivo imaging, genome-wide association studies, transgenic lineage tracing mice, making it possible to gain a deeper understanding of the immune landscape in CVDs; 2) The human body is an intricately regulated system of multiple interconnected systems. Therefore, it&#x02019;s of great importance to explore the circuit among cardiovascular system-immune system-other system; 3) Given the dynamic changes in immune cell populations during CVDs, providing comprehensive information on these shifts, including multi-level regulation and the roles of anti-inflammatory and pro-inflammatory responses, is crucial for developing personalized treatments tailored to different disease stages; 4) Incomplete understanding of sex-specific CVDs mechanisms, especially conditions unique to women, underscores the need for targeted research. Moreover, large-scale studies should be designed separately for men and women to address these distinct pathophysiologies and develop gender-focused research systems; 5) Since morphological and molecular changes in diseases often occur asynchronously, disease phenotyping should incorporate both morphological and molecular classifications. Integrating these classifications is crucial for a comprehensive understanding of CVDs and for advancing clinical applications. Overall, these gaps will be resolved by the continuous development of single-cell technologies and computational analysis, coupled with powerful artificial intelligence-based histology, allowing for mapping disease-specific immune profiles.</p><p id="Par170">From the perspective of cardiovascular immuno-modulatory therapies, the promising research directions are listed as follows: 1) Personalized inflammatory therapies are urgently needed for CVD treatment. Future research should focus on cell-specific mechanisms, intercellular interactions, dynamic immune changes across disease stages, and gender-specific immune regulations to translate immunological advances into clinical precision medicine; 2) Combination therapies targeting multiple immune pathways or combining immunotherapy with conventional treatments show promise in CVDs management. Moreover, considering holistic medicine, immune therapies targeted at other systems may benefit CVDs, making it possible to apply conventional medicine into new use. 3) While current research often emphasizes anti-inflammatory strategies, activating immune repair programs, such as stimulating Treg cells, could complement these therapies and help address their limitations in regulating CVDs; 4) Development of novel biomarker panels is essential to enhance cardiovascular risk prediction and guide treatment decisions. Machine learning and Mendelian randomization can enhance risk stratification and treatment selection using large-scale inflammatory biomarker data.</p><p id="Par171">Overall, the ongoing development of basic and translational researches on immunotherapy in cardiovascular medicine may pave the way for more targeted and efficacious treatments, potentially reducing the burden of CVDs on global health. However, it is imperative to approach this promising field with caution, ensuring that rigorous scientific standards are maintained and patient safety remains paramount. As our understanding of the complex interplay between the immune system and cardiovascular health deepens, we may witness a paradigm shift in how CVDs are treated and managed in the future.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Xiaoyan Wang, Liming Chen, Jianming Wei, Hao Zheng, Ning Zhou</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by grants from National Natural Science Foundation of China (82230009, 82430016, 82000267); National Key R&#x00026;D Program of China (2023YFA1800601); Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0503203); the Postdoctoral Fellowship Program of CPSF (GZC20230505).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Yunzeng Zou, Xiaoyan Wang and Tao Liu contributed to conception and manuscript design. Xiaoyan Wang, Liming Chen, Jianming Wei, Hao Zheng, Ning Zhou drafted the manuscript. Xiaoyan Wang, Liming Chen, Jianming Wei, Hao Zheng, Ning Zhou prepared the tables and figures. Xiaoyan Wang, Liming Chen, Jianming Wei, Hao Zheng, Ning Zhou collected the related references. All authors participated in the revision of the manuscript. Yunzeng Zou, Xiaoyan Wang were involved in funding acquisition. All authors have read and approved the article.</p></notes><notes id="FPar34" notes-type="COI-statement"><title>Competing interests</title><p id="Par172">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study</article-title><source>J. Am. Coll. Cardiol.</source><year>2020</year><volume>76</volume><fpage>2982</fpage><lpage>3021</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.11.010</pub-id><pub-id pub-id-type="pmid">33309175</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. <italic>J. Am. Coll. Cardiol.</italic><bold>76</bold>, 2982&#x02013;3021 (2020).<pub-id pub-id-type="pmid">33309175</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics-2018 update: a report from the American Heart Association</article-title><source>Circulation</source><year>2018</year><volume>137</volume><fpage>e67</fpage><lpage>e492</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000558</pub-id><pub-id pub-id-type="pmid">29386200</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Benjamin, E. J. et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. <italic>Circulation</italic><bold>137</bold>, e67&#x02013;e492 (2018).<pub-id pub-id-type="pmid">29386200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Kazi</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a presidential advisory from the American Heart Association</article-title><source>Circulation</source><year>2024</year><volume>150</volume><fpage>e89</fpage><lpage>e101</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000001258</pub-id><pub-id pub-id-type="pmid">38832515</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Kazi, D. S. et al. Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a presidential advisory from the American Heart Association. <italic>Circulation</italic><bold>150</bold>, e89&#x02013;e101 (2024).<pub-id pub-id-type="pmid">38832515</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>DL</given-names></name></person-group><article-title>The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls</article-title><source>Circ. Res.</source><year>2011</year><volume>108</volume><fpage>1133</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.226936</pub-id><pub-id pub-id-type="pmid">21527743</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Mann, D. L. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. <italic>Circ. Res.</italic><bold>108</bold>, 1133&#x02013;1145 (2011).<pub-id pub-id-type="pmid">21527743</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>The heart of immunology: immune mechanisms in cardiovascular medicine</article-title><source>Cardiovasc. Res.</source><year>2021</year><volume>117</volume><fpage>e166</fpage><lpage>e168</lpage><pub-id pub-id-type="pmid">34849629</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Hansson, G. K. The heart of immunology: immune mechanisms in cardiovascular medicine. <italic>Cardiovasc. Res.</italic><bold>117</bold>, e166&#x02013;e168 (2021).<pub-id pub-id-type="pmid">34849629</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>P</given-names></name><name><surname>Orecchioni</surname><given-names>M</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name></person-group><article-title>How the immune system shapes atherosclerosis: roles of innate and adaptive immunity</article-title><source>Nat. Rev. Immunol.</source><year>2022</year><volume>22</volume><fpage>251</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00584-1</pub-id><pub-id pub-id-type="pmid">34389841</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Roy, P., Orecchioni, M. &#x00026; Ley, K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. <italic>Nat. Rev. Immunol.</italic><bold>22</bold>, 251&#x02013;265 (2022).<pub-id pub-id-type="pmid">34389841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoli-Leonard</surname><given-names>F</given-names></name><name><surname>Zimmer</surname><given-names>J</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name></person-group><article-title>Innate and adaptive immunity: the understudied driving force of heart valve disease</article-title><source>Cardiovasc. Res.</source><year>2021</year><volume>117</volume><fpage>e166</fpage><lpage>e168</lpage><pub-id pub-id-type="pmid">34849629</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bartoli-Leonard, F., Zimmer, J. &#x00026; Aikawa, E. Innate and adaptive immunity: the understudied driving force of heart valve disease. <italic>Cardiovasc. Res.</italic><bold>117</bold>, e166&#x02013;e168 (2021).<pub-id pub-id-type="pmid">34849629</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets</article-title><source>Signal. Transduct. Target Ther.</source><year>2024</year><volume>9</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01840-1</pub-id><pub-id pub-id-type="pmid">38816371</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Chen, R. et al. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. <italic>Signal. Transduct. Target Ther.</italic><bold>9</bold>, 130 (2024).<pub-id pub-id-type="pmid">38816371</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Varricchi</surname><given-names>G</given-names></name><name><surname>Marone</surname><given-names>G</given-names></name><name><surname>Kovanen</surname><given-names>PT</given-names></name></person-group><article-title>Cardiac mast cells: underappreciated immune cells in cardiovascular homeostasis and disease</article-title><source>Trends Immunol.</source><year>2020</year><volume>41</volume><fpage>734</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.it.2020.06.006</pub-id><pub-id pub-id-type="pmid">32605802</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Varricchi, G., Marone, G. &#x00026; Kovanen, P. T. Cardiac mast cells: underappreciated immune cells in cardiovascular homeostasis and disease. <italic>Trends Immunol.</italic><bold>41</bold>, 734&#x02013;746 (2020).<pub-id pub-id-type="pmid">32605802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Single-cell immune landscape of human atherosclerotic plaques</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>1576</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0590-4</pub-id><pub-id pub-id-type="pmid">31591603</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Fernandez, D. M. et al. Single-cell immune landscape of human atherosclerotic plaques. <italic>Nat. Med.</italic><bold>25</bold>, 1576&#x02013;1588 (2019).<pub-id pub-id-type="pmid">31591603</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Genetic drivers of epigenetic and transcriptional variation in human immune cells</article-title><source>cell</source><year>2016</year><volume>167</volume><fpage>1398</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.10.026</pub-id><pub-id pub-id-type="pmid">27863251</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chen, L. et al. Genetic drivers of epigenetic and transcriptional variation in human immune cells. <italic>cell</italic><bold>167</bold>, 1398&#x02013;1414 (2016).<pub-id pub-id-type="pmid">27863251</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Martini</surname><given-names>E</given-names></name><etal/></person-group><article-title>Single-cell sequencing of mouse heart immune infiltrate in pressure overload-driven heart failure reveals extent of immune activation</article-title><source>Circulation</source><year>2019</year><volume>140</volume><fpage>2089</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.041694</pub-id><pub-id pub-id-type="pmid">31661975</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Martini, E. et al. Single-cell sequencing of mouse heart immune infiltrate in pressure overload-driven heart failure reveals extent of immune activation. <italic>Circulation</italic><bold>140</bold>, 2089&#x02013;2107 (2019).<pub-id pub-id-type="pmid">31661975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Abendstein</surname><given-names>L</given-names></name><etal/></person-group><article-title>Complement is activated by elevated IgG3 hexameric platforms and deposits C4b onto distinct antibody domains</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>4027</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-39788-5</pub-id><pub-id pub-id-type="pmid">37419978</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Abendstein, L., et al. Complement is activated by elevated IgG3 hexameric platforms and deposits C4b onto distinct antibody domains. <italic>Nat. Commun.</italic><bold>14</bold>, 4027 (2023).<pub-id pub-id-type="pmid">37419978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Rurik</surname><given-names>JG</given-names></name><name><surname>Aghajanian</surname><given-names>H</given-names></name><name><surname>Epstein</surname><given-names>JA</given-names></name></person-group><article-title>Immune cells and immunotherapy for cardiac injury and repair</article-title><source>Circ. Res.</source><year>2021</year><volume>128</volume><fpage>1766</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318005</pub-id><pub-id pub-id-type="pmid">34043424</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Rurik, J. G., Aghajanian, H. &#x00026; Epstein, J. A. Immune cells and immunotherapy for cardiac injury and repair. <italic>Circ. Res.</italic><bold>128</bold>, 1766&#x02013;1779 (2021).<pub-id pub-id-type="pmid">34043424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Rurik</surname><given-names>JG</given-names></name><etal/></person-group><article-title>CAR T cells produced in vivo to treat cardiac injury</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1126/science.abm0594</pub-id><pub-id pub-id-type="pmid">34990237</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. <italic>Science</italic><bold>375</bold>, 91&#x02013;96 (2022).<pub-id pub-id-type="pmid">34990237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;scher</surname><given-names>TF</given-names></name></person-group><article-title>The sooner, the better: anti-inflammation in acute myocardial infarction</article-title><source>Eur. Heart J.</source><year>2020</year><volume>41</volume><fpage>4100</fpage><lpage>4102</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa752</pub-id><pub-id pub-id-type="pmid">33249465</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">L&#x000fc;scher, T. F. The sooner, the better: anti-inflammation in acute myocardial infarction. <italic>Eur. Heart J.</italic><bold>41</bold>, 4100&#x02013;4102 (2020).<pub-id pub-id-type="pmid">33249465</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Katz</surname><given-names>LN</given-names></name></person-group><article-title>Production of experimental cholesterol-induced atherosclerosis in chicks with minimal hypercholesterolemia and organ lipidosis</article-title><source>Circulation</source><year>1950</year><volume>2</volume><fpage>705</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.2.5.705</pub-id><pub-id pub-id-type="pmid">14783822</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Stamler, J. &#x00026; Katz, L. N. Production of experimental cholesterol-induced atherosclerosis in chicks with minimal hypercholesterolemia and organ lipidosis. <italic>Circulation</italic><bold>2</bold>, 705&#x02013;713 (1950).<pub-id pub-id-type="pmid">14783822</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Aqel</surname><given-names>NM</given-names></name><name><surname>Ball</surname><given-names>RY</given-names></name><name><surname>Waldmann</surname><given-names>H</given-names></name><name><surname>Mitchinson</surname><given-names>MJ</given-names></name></person-group><article-title>Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies</article-title><source>J. Pathol.</source><year>1985</year><volume>146</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1002/path.1711460306</pub-id><pub-id pub-id-type="pmid">3897495</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Aqel, N. M., Ball, R. Y., Waldmann, H. &#x00026; Mitchinson, M. J. Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies. <italic>J. Pathol.</italic><bold>146</bold>, 197&#x02013;204 (1985).<pub-id pub-id-type="pmid">3897495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Jonasson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis</article-title><source>J. Clin. Investig.</source><year>1985</year><volume>76</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1172/JCI111934</pub-id><pub-id pub-id-type="pmid">3894417</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Jonasson, L. et al. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. <italic>J. Clin. Investig.</italic><bold>76</bold>, 125&#x02013;131 (1985).<pub-id pub-id-type="pmid">3894417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Jonasson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque</article-title><source>Arteriosclerosis</source><year>1986</year><volume>6</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.6.2.131</pub-id><pub-id pub-id-type="pmid">2937395</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Jonasson, L. et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. <italic>Arteriosclerosis</italic><bold>6</bold>, 131&#x02013;138 (1986).<pub-id pub-id-type="pmid">2937395</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Emeson</surname><given-names>EE</given-names></name><name><surname>Robertson</surname><given-names>AL</given-names><suffix>Jr.</suffix></name></person-group><article-title>T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis</article-title><source>Am. J. Pathol.</source><year>1988</year><volume>130</volume><fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">3257650</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Emeson, E. E. &#x00026; Robertson, A. L. Jr. T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis. <italic>Am. J. Pathol.</italic><bold>130</bold>, 369&#x02013;376 (1988).<pub-id pub-id-type="pmid">3257650</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>GK</given-names></name><name><surname>Holm</surname><given-names>J</given-names></name><name><surname>Jonasson</surname><given-names>L</given-names></name></person-group><article-title>Detection of activated T lymphocytes in the human atherosclerotic plaque</article-title><source>Am. J. Pathol.</source><year>1989</year><volume>135</volume><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">2505620</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Hansson, G. K., Holm, J. &#x00026; Jonasson, L. Detection of activated T lymphocytes in the human atherosclerotic plaque. <italic>Am. J. Pathol.</italic><bold>135</bold>, 169&#x02013;175 (1989).<pub-id pub-id-type="pmid">2505620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Wedler</surname><given-names>FC</given-names></name><name><surname>Hoffmann</surname><given-names>FM</given-names></name><name><surname>Kenney</surname><given-names>R</given-names></name><name><surname>Carfi</surname><given-names>J</given-names></name></person-group><article-title>Maintainance of specificity, information, and thermostability in thermophilic Bacillus sp. glutamine synthetase</article-title><source>Experientia Suppl.</source><year>1976</year><volume>26</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/978-3-0348-7675-9_15</pub-id><pub-id pub-id-type="pmid">7467</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Wedler, F. C., Hoffmann, F. M., Kenney, R. &#x00026; Carfi, J. Maintainance of specificity, information, and thermostability in thermophilic Bacillus sp. glutamine synthetase. <italic>Experientia Suppl.</italic><bold>26</bold>, 187&#x02013;197 (1976).<pub-id pub-id-type="pmid">7467</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Nallamothu</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction-4 analysis</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.578195</pub-id><pub-id pub-id-type="pmid">16401769</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Nallamothu, B. K. et al. Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction-4 analysis. <italic>Circulation</italic><bold>113</bold>, 222&#x02013;229 (2006).<pub-id pub-id-type="pmid">16401769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Yellon</surname><given-names>DM</given-names></name><name><surname>Hausenloy</surname><given-names>DJ</given-names></name></person-group><article-title>Myocardial reperfusion injury</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>357</volume><fpage>1121</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1056/NEJMra071667</pub-id><pub-id pub-id-type="pmid">17855673</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Yellon, D. M. &#x00026; Hausenloy, D. J. Myocardial reperfusion injury. <italic>N. Engl. J. Med.</italic><bold>357</bold>, 1121&#x02013;1135 (2007).<pub-id pub-id-type="pmid">17855673</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Fantone</surname><given-names>JC</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name></person-group><article-title>Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions</article-title><source>Am. J. Pathol.</source><year>1982</year><volume>107</volume><fpage>395</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">6282132</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Fantone, J. C. &#x00026; Ward, P. A. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. <italic>Am. J. Pathol.</italic><bold>107</bold>, 395&#x02013;418 (1982).<pub-id pub-id-type="pmid">6282132</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Babior</surname><given-names>BM</given-names></name><name><surname>Kipnes</surname><given-names>RS</given-names></name><name><surname>Curnutte</surname><given-names>JT</given-names></name></person-group><article-title>Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent</article-title><source>J. Clin. Investig.</source><year>1973</year><volume>52</volume><fpage>741</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1172/JCI107236</pub-id><pub-id pub-id-type="pmid">4346473</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Babior, B. M., Kipnes, R. S. &#x00026; Curnutte, J. T. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. <italic>J. Clin. Investig.</italic><bold>52</bold>, 741&#x02013;744 (1973).<pub-id pub-id-type="pmid">4346473</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Meerson</surname><given-names>FZ</given-names></name><etal/></person-group><article-title>The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart</article-title><source>Basic Res. Cardiol.</source><year>1982</year><volume>77</volume><fpage>465</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1007/BF01907940</pub-id><pub-id pub-id-type="pmid">7181828</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Meerson, F. Z. et al. The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. <italic>Basic Res. Cardiol.</italic><bold>77</bold>, 465&#x02013;485 (1982).<pub-id pub-id-type="pmid">7181828</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname><given-names>SA</given-names></name><name><surname>Epelman</surname><given-names>S</given-names></name></person-group><article-title>Chronic heart failure and inflammation: what do we really know?</article-title><source>Circ. Res.</source><year>2016</year><volume>119</volume><fpage>159</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308030</pub-id><pub-id pub-id-type="pmid">27340274</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Dick, S. A. &#x00026; Epelman, S. Chronic heart failure and inflammation: what do we really know?. <italic>Circ. Res.</italic><bold>119</bold>, 159&#x02013;176 (2016).<pub-id pub-id-type="pmid">27340274</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>B</given-names></name><etal/></person-group><article-title>Elevated circulating levels of tumor necrosis factor in severe chronic heart failure</article-title><source>N. Engl. J. Med.</source><year>1990</year><volume>323</volume><fpage>236</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1056/NEJM199007263230405</pub-id><pub-id pub-id-type="pmid">2195340</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Levine, B. et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. <italic>N. Engl. J. Med.</italic><bold>323</bold>, 236&#x02013;241 (1990).<pub-id pub-id-type="pmid">2195340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure</article-title><source>Circulation</source><year>1995</year><volume>92</volume><fpage>1479</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.92.6.1479</pub-id><pub-id pub-id-type="pmid">7664430</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ferrari, R. et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. <italic>Circulation</italic><bold>92</bold>, 1479&#x02013;1486 (1995).<pub-id pub-id-type="pmid">7664430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>E</given-names></name><etal/></person-group><article-title>Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk</article-title><source>Crit. Care Med.</source><year>1996</year><volume>24</volume><fpage>392</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1097/00003246-199603000-00006</pub-id><pub-id pub-id-type="pmid">8625625</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Borrelli, E. et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. <italic>Crit. Care Med.</italic><bold>24</bold>, 392&#x02013;397 (1996).<pub-id pub-id-type="pmid">8625625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Liuzzo</surname><given-names>G</given-names></name><etal/></person-group><article-title>The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina</article-title><source>N. Engl. J. Med.</source><year>1994</year><volume>331</volume><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1056/NEJM199408183310701</pub-id><pub-id pub-id-type="pmid">7880233</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Liuzzo, G. et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. <italic>N. Engl. J. Med.</italic><bold>331</bold>, 417&#x02013;424 (1994).<pub-id pub-id-type="pmid">7880233</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name></person-group><article-title>C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>342</volume><fpage>836</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1056/NEJM200003233421202</pub-id><pub-id pub-id-type="pmid">10733371</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Ridker, P. M., Hennekens, C. H., Buring, J. E. &#x00026; Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. <italic>N. Engl. J. Med.</italic><bold>342</bold>, 836&#x02013;843 (2000).<pub-id pub-id-type="pmid">10733371</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name></person-group><article-title>Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.15.1767</pub-id><pub-id pub-id-type="pmid">10769275</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ridker, P. M., Rifai, N., Stampfer, M. J. &#x00026; Hennekens, C. H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. <italic>Circulation</italic><bold>101</bold>, 1767&#x02013;1772 (2000).<pub-id pub-id-type="pmid">10769275</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>2149</fpage><lpage>2153</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.18.2149</pub-id><pub-id pub-id-type="pmid">10801754</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Ridker, P. M. et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. <italic>Circulation</italic><bold>101</bold>, 2149&#x02013;2153 (2000).<pub-id pub-id-type="pmid">10801754</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>349</volume><fpage>2399</fpage><lpage>2406</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa035471</pub-id><pub-id pub-id-type="pmid">14681505</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Roman, M. J. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. <italic>N. Engl. J. Med.</italic><bold>349</bold>, 2399&#x02013;2406 (2003).<pub-id pub-id-type="pmid">14681505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Moos</surname><given-names>MP</given-names></name><etal/></person-group><article-title>The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2005</year><volume>25</volume><fpage>2386</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000187470.31662.fe</pub-id><pub-id pub-id-type="pmid">16179593</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Moos, M. P. et al. The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>25</bold>, 2386&#x02013;2391 (2005).<pub-id pub-id-type="pmid">16179593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin &#x003b2; receptors</article-title><source>Immunity</source><year>2015</year><volume>42</volume><fpage>1100</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.05.015</pub-id><pub-id pub-id-type="pmid">26084025</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Hu, D. et al. Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin &#x003b2; receptors. <italic>Immunity</italic><bold>42</bold>, 1100&#x02013;1115 (2015).<pub-id pub-id-type="pmid">26084025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Depuydt</surname><given-names>MAC</given-names></name><etal/></person-group><article-title>Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics</article-title><source>Circ. Res.</source><year>2020</year><volume>127</volume><fpage>1437</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.316770</pub-id><pub-id pub-id-type="pmid">32981416</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Depuydt, M. A. C. et al. Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. <italic>Circ. Res.</italic><bold>127</bold>, 1437&#x02013;1455 (2020).<pub-id pub-id-type="pmid">32981416</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>Meta-analysis of single-cell RNA-Seq data reveals the mechanism of formation and heterogeneity of tertiary lymphoid organ in vascular disease</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2023</year><volume>43</volume><fpage>1867</fpage><lpage>1886</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.123.318762</pub-id><pub-id pub-id-type="pmid">37589134</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Sun, X. et al. Meta-analysis of single-cell RNA-Seq data reveals the mechanism of formation and heterogeneity of tertiary lymphoid organ in vascular disease. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>43</bold>, 1867&#x02013;1886 (2023).<pub-id pub-id-type="pmid">37589134</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuppe</surname><given-names>C</given-names></name><etal/></person-group><article-title>Spatial multi-omic map of human myocardial infarction</article-title><source>Nature</source><year>2022</year><volume>608</volume><fpage>766</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05060-x</pub-id><pub-id pub-id-type="pmid">35948637</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Kuppe, C. et al. Spatial multi-omic map of human myocardial infarction. <italic>Nature</italic><bold>608</bold>, 766&#x02013;777 (2022).<pub-id pub-id-type="pmid">35948637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Drobni</surname><given-names>ZD</given-names></name><etal/></person-group><article-title>Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque</article-title><source>Circulation</source><year>2020</year><volume>142</volume><fpage>2299</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.049981</pub-id><pub-id pub-id-type="pmid">33003973</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Drobni, Z. D. et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. <italic>Circulation</italic><bold>142</bold>, 2299&#x02013;2311 (2020).<pub-id pub-id-type="pmid">33003973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>TA</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name></person-group><article-title>T cells to fix a broken heart</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>23</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1126/science.abn0851</pub-id><pub-id pub-id-type="pmid">34990255</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Gao, T. A. &#x00026; Chen, Y. Y. T cells to fix a broken heart. <italic>Science</italic><bold>375</bold>, 23&#x02013;24 (2022).<pub-id pub-id-type="pmid">34990255</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Aghajanian</surname><given-names>H</given-names></name><etal/></person-group><article-title>Targeting cardiac fibrosis with engineered T cells</article-title><source>Nature</source><year>2019</year><volume>573</volume><fpage>430</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1546-z</pub-id><pub-id pub-id-type="pmid">31511695</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. <italic>Nature</italic><bold>573</bold>, 430&#x02013;433 (2019).<pub-id pub-id-type="pmid">31511695</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>1119</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id><pub-id pub-id-type="pmid">28845751</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. <italic>N. Engl. J. Med.</italic><bold>377</bold>, 1119&#x02013;1131 (2017).<pub-id pub-id-type="pmid">28845751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Tardif</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Efficacy and safety of low-dose colchicine after myocardial infarction</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>2497</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1912388</pub-id><pub-id pub-id-type="pmid">31733140</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. <italic>N. Engl. J. Med.</italic><bold>381</bold>, 2497&#x02013;2505 (2019).<pub-id pub-id-type="pmid">31733140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name></person-group><article-title>A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair</article-title><source>Signal. Transduct. Target Ther.</source><year>2021</year><volume>6</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-00455-6</pub-id><pub-id pub-id-type="pmid">33612829</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Sun, K., Li, Y. Y. &#x00026; Jin, J. A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair. <italic>Signal. Transduct. Target Ther.</italic><bold>6</bold>, 79 (2021).<pub-id pub-id-type="pmid">33612829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Simoes</surname><given-names>FC</given-names></name><name><surname>Riley</surname><given-names>PR</given-names></name></person-group><article-title>Immune cells in cardiac repair and regeneration</article-title><source>Development</source><year>2022</year><volume>149</volume><fpage>dev199906</fpage><pub-id pub-id-type="doi">10.1242/dev.199906</pub-id><pub-id pub-id-type="pmid">35502777</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Simoes, F. C. &#x00026; Riley, P. R. Immune cells in cardiac repair and regeneration. <italic>Development</italic><bold>149</bold>, dev199906 (2022).<pub-id pub-id-type="pmid">35502777</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Litvinukova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cells of the adult human heart</article-title><source>Nature</source><year>2020</year><volume>588</volume><fpage>466</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2797-4</pub-id><pub-id pub-id-type="pmid">32971526</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Litvinukova, M. et al. Cells of the adult human heart. <italic>Nature</italic><bold>588</bold>, 466&#x02013;472 (2020).<pub-id pub-id-type="pmid">32971526</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Innate lymphoid cells promote recovery of ventricular function after myocardial infarction</article-title><source>J. Am. Coll. Cardiol.</source><year>2021</year><volume>78</volume><fpage>1127</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.07.018</pub-id><pub-id pub-id-type="pmid">34503682</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Yu, X. et al. Innate lymphoid cells promote recovery of ventricular function after myocardial infarction. <italic>J. Am. Coll. Cardiol.</italic><bold>78</bold>, 1127&#x02013;1142 (2021).<pub-id pub-id-type="pmid">34503682</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Adamo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><fpage>e120137</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.120137</pub-id><pub-id pub-id-type="pmid">29875326</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Adamo, L., et al. Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury. <italic>JCI Insight</italic><bold>3</bold>, e120137 (2018).<pub-id pub-id-type="pmid">29875326</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Epelman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation</article-title><source>Immunity</source><year>2014</year><volume>40</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.11.019</pub-id><pub-id pub-id-type="pmid">24439267</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Epelman, S. et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. <italic>Immunity</italic><bold>40</bold>, 91&#x02013;104 (2014).<pub-id pub-id-type="pmid">24439267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Perdiguero</surname><given-names>EG</given-names></name><etal/></person-group><article-title>The origin of tissue-resident macrophages: when an erythro-myeloid progenitor is an erythro-myeloid progenitor</article-title><source>Immunity</source><year>2015</year><volume>43</volume><fpage>1023</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.11.022</pub-id><pub-id pub-id-type="pmid">26682973</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Perdiguero, E. G. et al. The origin of tissue-resident macrophages: when an erythro-myeloid progenitor is an erythro-myeloid progenitor. <italic>Immunity</italic><bold>43</bold>, 1023&#x02013;1024 (2015).<pub-id pub-id-type="pmid">26682973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Molawi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Progressive replacement of embryo-derived cardiac macrophages with age</article-title><source>J. Exp. Med.</source><year>2014</year><volume>211</volume><fpage>2151</fpage><lpage>2158</lpage><pub-id pub-id-type="doi">10.1084/jem.20140639</pub-id><pub-id pub-id-type="pmid">25245760</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Molawi, K. et al. Progressive replacement of embryo-derived cardiac macrophages with age. <italic>J. Exp. Med.</italic><bold>211</bold>, 2151&#x02013;2158 (2014).<pub-id pub-id-type="pmid">25245760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CZW</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name></person-group><article-title>Biology of resident tissue macrophages</article-title><source>Development</source><year>2022</year><volume>149</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1242/dev.200270</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Lee, C. Z. W. &#x00026; Ginhoux, F. Biology of resident tissue macrophages. <italic>Development</italic><bold>149</bold>, 8 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>LC</given-names></name><name><surname>Jenkins</surname><given-names>SJ</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name></person-group><article-title>Tissue-resident macrophages</article-title><source>Nat. Immunol.</source><year>2013</year><volume>14</volume><fpage>986</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1038/ni.2705</pub-id><pub-id pub-id-type="pmid">24048120</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Davies, L. C., Jenkins, S. J., Allen, J. E. &#x00026; Taylor, P. R. Tissue-resident macrophages. <italic>Nat. Immunol.</italic><bold>14</bold>, 986&#x02013;995 (2013).<pub-id pub-id-type="pmid">24048120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Daems, W. T. &#x00026; Brederoo, P. The fine structure and peroxidase activity of resident and exudate peritoneal macrophages in the guinea pig. In The Reticuloendothelial System and Immune Phenomena (eds. Di Luzio, N. R. &#x00026; Flemming, K. B. P) Advances in Experimental Medicine and Biology 15, 19&#x02013;31 (Springer, Boston, MA, 1971). 10.1007/978-1-4684-3204-6_3.</mixed-citation></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Sabin</surname><given-names>F</given-names></name><name><surname>Doan</surname><given-names>CA</given-names></name><name><surname>Cunningham</surname><given-names>RS</given-names></name></person-group><article-title>Discrimination of two types of phagocytic cells in the connective tissues by the supravital technique</article-title><source>Embryol</source><year>1925</year><volume>16</volume><fpage>125</fpage><lpage>162</lpage></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Sabin, F., Doan, C. A. &#x00026; Cunningham, R. S. Discrimination of two types of phagocytic cells in the connective tissues by the supravital technique. <italic>Embryol</italic><bold>16</bold>, 125&#x02013;162 (1925).</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Randolph</surname><given-names>GJ</given-names></name><name><surname>Ochando</surname><given-names>J</given-names></name><name><surname>Partida-Sanchez</surname><given-names>S</given-names></name></person-group><article-title>Migration of dendritic cell subsets and their precursors</article-title><source>Annu. Rev. Immunol.</source><year>2008</year><volume>26</volume><fpage>293</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090254</pub-id><pub-id pub-id-type="pmid">18045026</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Randolph, G. J., Ochando, J. &#x00026; Partida-Sanchez, S. Migration of dendritic cell subsets and their precursors. <italic>Annu. Rev. Immunol.</italic><bold>26</bold>, 293&#x02013;316 (2008).<pub-id pub-id-type="pmid">18045026</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>van Furth</surname><given-names>R</given-names></name><name><surname>Cohn</surname><given-names>ZA</given-names></name></person-group><article-title>The origin and kinetics of mononuclear phagocytes</article-title><source>J. Exp. Med.</source><year>1968</year><volume>128</volume><fpage>415</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1084/jem.128.3.415</pub-id><pub-id pub-id-type="pmid">5666958</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">van Furth, R. &#x00026; Cohn, Z. A. The origin and kinetics of mononuclear phagocytes. <italic>J. Exp. Med.</italic><bold>128</bold>, 415&#x02013;435 (1968).<pub-id pub-id-type="pmid">5666958</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>van Furth</surname><given-names>R</given-names></name><etal/></person-group><article-title>The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells</article-title><source>Bull. World Health Organ</source><year>1972</year><volume>46</volume><fpage>845</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">4538544</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">van Furth, R. et al. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. <italic>Bull. World Health Organ</italic><bold>46</bold>, 845&#x02013;852 (1972).<pub-id pub-id-type="pmid">4538544</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Parwaresch</surname><given-names>MR</given-names></name><name><surname>Wacker</surname><given-names>HH</given-names></name></person-group><article-title>Origin and kinetics of resident tissue macrophages. Parabiosis studies with radiolabelled leucocytes</article-title><source>Cell Tissue Kinet.</source><year>1984</year><volume>17</volume><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">6692464</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Parwaresch, M. R. &#x00026; Wacker, H. H. Origin and kinetics of resident tissue macrophages. Parabiosis studies with radiolabelled leucocytes. <italic>Cell Tissue Kinet.</italic><bold>17</bold>, 25&#x02013;39 (1984).<pub-id pub-id-type="pmid">6692464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Lafuse</surname><given-names>WP</given-names></name><name><surname>Wozniak</surname><given-names>DJ</given-names></name><name><surname>Rajaram</surname><given-names>MVS</given-names></name></person-group><article-title>Role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair</article-title><source>Cells</source><year>2020</year><volume>10</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.3390/cells10010051</pub-id><pub-id pub-id-type="pmid">33396359</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Lafuse, W. P., Wozniak, D. J. &#x00026; Rajaram, M. V. S. Role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair. <italic>Cells</italic><bold>10</bold>, 51 (2020).<pub-id pub-id-type="pmid">33396359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Hulsmans</surname><given-names>M</given-names></name><etal/></person-group><article-title>Macrophages facilitate electrical conduction in the heart</article-title><source>Cell</source><year>2017</year><volume>169</volume><fpage>510</fpage><lpage>522 e520</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.03.050</pub-id><pub-id pub-id-type="pmid">28431249</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Hulsmans, M. et al. Macrophages facilitate electrical conduction in the heart. <italic>Cell</italic><bold>169</bold>, 510&#x02013;522 e520 (2017).<pub-id pub-id-type="pmid">28431249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cardiac macrophages prevent sudden death during heart stress</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1910</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22178-0</pub-id><pub-id pub-id-type="pmid">33771995</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Sugita, J., et al. Cardiac macrophages prevent sudden death during heart stress. <italic>Nat. Commun.</italic><bold>12</bold>, 1910 (2021).<pub-id pub-id-type="pmid">33771995</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HX</given-names></name><etal/></person-group><article-title>CD1d-dependent natural killer T cells attenuate angiotensin II-induced cardiac remodelling via IL-10 signalling in mice</article-title><source>Cardiovasc. Res.</source><year>2019</year><volume>115</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvy164</pub-id><pub-id pub-id-type="pmid">29939225</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Wang, H. X. et al. CD1d-dependent natural killer T cells attenuate angiotensin II-induced cardiac remodelling via IL-10 signalling in mice. <italic>Cardiovasc. Res.</italic><bold>115</bold>, 83&#x02013;93 (2019).<pub-id pub-id-type="pmid">29939225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>S</given-names></name><name><surname>Rose</surname><given-names>NR</given-names></name><name><surname>Cihakova</surname><given-names>D</given-names></name></person-group><article-title>Natural killer cells in inflammatory heart disease</article-title><source>Clin. Immunol.</source><year>2017</year><volume>175</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2016.11.010</pub-id><pub-id pub-id-type="pmid">27894980</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Ong, S., Rose, N. R. &#x00026; Cihakova, D. Natural killer cells in inflammatory heart disease. <italic>Clin. Immunol.</italic><bold>175</bold>, 26&#x02013;33 (2017).<pub-id pub-id-type="pmid">27894980</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchentouf</surname><given-names>M</given-names></name><etal/></person-group><article-title>Induction of cardiac angiogenesis requires killer cell lectin-like receptor 1 and alpha4beta7 integrin expression by NK cells</article-title><source>J. Immunol.</source><year>2010</year><volume>185</volume><fpage>7014</fpage><lpage>7025</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1001888</pub-id><pub-id pub-id-type="pmid">20971926</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Bouchentouf, M. et al. Induction of cardiac angiogenesis requires killer cell lectin-like receptor 1 and alpha4beta7 integrin expression by NK cells. <italic>J. Immunol.</italic><bold>185</bold>, 7014&#x02013;7025 (2010).<pub-id pub-id-type="pmid">20971926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvain</surname><given-names>P</given-names></name><etal/></person-group><article-title>Non-invasive mapping of systemic neutrophil dynamics upon cardiovascular injury</article-title><source>Nat. Cardiovasc. Res.</source><year>2023</year><volume>2</volume><fpage>126</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/s44161-022-00210-w</pub-id><pub-id pub-id-type="pmid">39196054</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Bouvain, P. et al. Non-invasive mapping of systemic neutrophil dynamics upon cardiovascular injury. <italic>Nat. Cardiovasc. Res.</italic><bold>2</bold>, 126&#x02013;143 (2023).<pub-id pub-id-type="pmid">39196054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Phillipson</surname><given-names>M</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group><article-title>The neutrophil in vascular inflammation</article-title><source>Nat. Med.</source><year>2011</year><volume>17</volume><fpage>1381</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1038/nm.2514</pub-id><pub-id pub-id-type="pmid">22064428</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Phillipson, M. &#x00026; Kubes, P. The neutrophil in vascular inflammation. <italic>Nat. Med.</italic><bold>17</bold>, 1381&#x02013;1390 (2011).<pub-id pub-id-type="pmid">22064428</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Ofori</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Human blood neutrophils generate ROS through FcgammaR-signaling to mediate protection against febrile P. falciparum malaria</article-title><source>Commun. Biol.</source><year>2023</year><volume>6</volume><fpage>743</fpage><pub-id pub-id-type="doi">10.1038/s42003-023-05118-0</pub-id><pub-id pub-id-type="pmid">37463969</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Ofori, E. A. et al. Human blood neutrophils generate ROS through FcgammaR-signaling to mediate protection against febrile P. falciparum malaria. <italic>Commun. Biol.</italic><bold>6</bold>, 743 (2023).<pub-id pub-id-type="pmid">37463969</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Malamud</surname><given-names>M</given-names></name><etal/></person-group><article-title>Recognition and control of neutrophil extracellular trap formation by MICL</article-title><source>Nature</source><year>2024</year><volume>633</volume><fpage>442</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07820-3</pub-id><pub-id pub-id-type="pmid">39143217</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Malamud, M. et al. Recognition and control of neutrophil extracellular trap formation by MICL. <italic>Nature</italic><bold>633</bold>, 442&#x02013;450 (2024).<pub-id pub-id-type="pmid">39143217</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>KN</given-names></name><name><surname>Jones</surname><given-names>PL</given-names></name><name><surname>Rabinovitch</surname><given-names>M</given-names></name></person-group><article-title>Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease</article-title><source>J. Clin. Investig.</source><year>2000</year><volume>105</volume><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1172/JCI6539</pub-id><pub-id pub-id-type="pmid">10619858</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Cowan, K. N., Jones, P. L. &#x00026; Rabinovitch, M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. <italic>J. Clin. Investig.</italic><bold>105</bold>, 21&#x02013;34 (2000).<pub-id pub-id-type="pmid">10619858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Christoffersson</surname><given-names>G</given-names></name><etal/></person-group><article-title>VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>4653</fpage><lpage>4662</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-04-421040</pub-id><pub-id pub-id-type="pmid">22966168</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Christoffersson, G. et al. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. <italic>Blood</italic><bold>120</bold>, 4653&#x02013;4662 (2012).<pub-id pub-id-type="pmid">22966168</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><etal/></person-group><article-title>Spatiotemporal control of neutrophil fate to tune inflammation and repair for myocardial infarction therapy</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>8481</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-52812-6</pub-id><pub-id pub-id-type="pmid">39353987</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Kim, C., et al. Spatiotemporal control of neutrophil fate to tune inflammation and repair for myocardial infarction therapy. <italic>Nat. Commun.</italic><bold>15</bold>, 8481 (2024).<pub-id pub-id-type="pmid">39353987</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Dao Nyesiga</surname><given-names>G</given-names></name><etal/></person-group><article-title>Tolerogenic dendritic cells generated in vitro using a novel protocol mimicking mucosal tolerance mechanisms represent a potential therapeutic cell platform for induction of immune tolerance</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1045183</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1045183</pub-id><pub-id pub-id-type="pmid">37901231</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Dao Nyesiga, G., et al. Tolerogenic dendritic cells generated in vitro using a novel protocol mimicking mucosal tolerance mechanisms represent a potential therapeutic cell platform for induction of immune tolerance. <italic>Front. Immunol.</italic><bold>14</bold>, 1045183 (2023).<pub-id pub-id-type="pmid">37901231</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Forte</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cross-priming dendritic cells exacerbate immunopathology after ischemic tissue damage in the heart</article-title><source>Circulation</source><year>2021</year><volume>143</volume><fpage>821</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.044581</pub-id><pub-id pub-id-type="pmid">33297741</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Forte, E. et al. Cross-priming dendritic cells exacerbate immunopathology after ischemic tissue damage in the heart. <italic>Circulation</italic><bold>143</bold>, 821&#x02013;836 (2021).<pub-id pub-id-type="pmid">33297741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efferocytosis in dendritic cells: an overlooked immunoregulatory process</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1415573</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1415573</pub-id><pub-id pub-id-type="pmid">38835772</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Ma, Y. et al. Efferocytosis in dendritic cells: an overlooked immunoregulatory process. <italic>Front. Immunol.</italic><bold>15</bold>, 1415573 (2024).<pub-id pub-id-type="pmid">38835772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Nayer</surname><given-names>B</given-names></name><etal/></person-group><article-title>Local administration of regulatory T cells promotes tissue healing</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>7863</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-51353-2</pub-id><pub-id pub-id-type="pmid">39251592</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Nayer, B., et al. Local administration of regulatory T cells promotes tissue healing. <italic>Nat. Commun.</italic><bold>15</bold>, 7863 (2024).<pub-id pub-id-type="pmid">39251592</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Blanton</surname><given-names>RM</given-names></name><name><surname>Carrillo-Salinas</surname><given-names>FJ</given-names></name><name><surname>Alcaide</surname><given-names>P</given-names></name></person-group><article-title>T-cell recruitment to the heart: friendly guests or unwelcome visitors?</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2019</year><volume>317</volume><fpage>H124</fpage><lpage>H140</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00028.2019</pub-id><pub-id pub-id-type="pmid">31074651</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Blanton, R. M., Carrillo-Salinas, F. J. &#x00026; Alcaide, P. T-cell recruitment to the heart: friendly guests or unwelcome visitors?. <italic>Am. J. Physiol. Heart Circ. Physiol.</italic><bold>317</bold>, H124&#x02013;H140 (2019).<pub-id pub-id-type="pmid">31074651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="other">Huang, F. et al. B cell subsets contribute to myocardial protection by inducing neutrophil apoptosis after ischemia and reperfusion. <italic>JCI Insight</italic>. <bold>9</bold>, (2024).</mixed-citation></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Porsch</surname><given-names>F</given-names></name><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Binder</surname><given-names>CJ</given-names></name></person-group><article-title>Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies</article-title><source>Cardiovasc. Res.</source><year>2021</year><volume>117</volume><fpage>2544</fpage><lpage>2562</lpage><pub-id pub-id-type="pmid">34450620</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Porsch, F., Mallat, Z. &#x00026; Binder, C. J. Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies. <italic>Cardiovasc. Res.</italic><bold>117</bold>, 2544&#x02013;2562 (2021).<pub-id pub-id-type="pmid">34450620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Rivas</surname><given-names>G</given-names></name><etal/></person-group><article-title>The role of B cells in heart failure and implications for future immunomodulatory treatment strategies</article-title><source>ESC Heart Fail.</source><year>2020</year><volume>7</volume><fpage>1387</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1002/ehf2.12744</pub-id><pub-id pub-id-type="pmid">32533765</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Garcia-Rivas, G. et al. The role of B cells in heart failure and implications for future immunomodulatory treatment strategies. <italic>ESC Heart Fail.</italic><bold>7</bold>, 1387&#x02013;1399 (2020).<pub-id pub-id-type="pmid">32533765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>NP</given-names></name><name><surname>Goettel</surname><given-names>P</given-names></name><name><surname>Mueller</surname><given-names>J</given-names></name><name><surname>Wallukat</surname><given-names>G</given-names></name><name><surname>Schimke</surname><given-names>I</given-names></name></person-group><article-title>Functional autoantibody diseases: Basics and treatment related to cardiomyopathies</article-title><source>Front. Biosci.</source><year>2019</year><volume>24</volume><fpage>48</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.2741/4709</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Becker, N. P., Goettel, P., Mueller, J., Wallukat, G. &#x00026; Schimke, I. Functional autoantibody diseases: Basics and treatment related to cardiomyopathies. <italic>Front. Biosci.</italic><bold>24</bold>, 48&#x02013;95 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Regulatory B cells improve ventricular remodeling after myocardial infarction by modulating monocyte migration</article-title><source>Basic Res. Cardiol.</source><year>2021</year><volume>116</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1007/s00395-021-00886-4</pub-id><pub-id pub-id-type="pmid">34302556</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Jiao, J. et al. Regulatory B cells improve ventricular remodeling after myocardial infarction by modulating monocyte migration. <italic>Basic Res. Cardiol.</italic><bold>116</bold>, 46 (2021).<pub-id pub-id-type="pmid">34302556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Murine neonatal cardiac B cells promote cardiomyocyte proliferation and heart regeneration</article-title><source>NPJ Regen. Med.</source><year>2023</year><volume>8</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1038/s41536-023-00282-7</pub-id><pub-id pub-id-type="pmid">36774363</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Tan, Y. et al. Murine neonatal cardiac B cells promote cardiomyocyte proliferation and heart regeneration. <italic>NPJ Regen. Med.</italic><bold>8</bold>, 7 (2023).<pub-id pub-id-type="pmid">36774363</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Bermea</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Myocardial B cells have specific gene expression and predicted interactions in dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1327372</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1327372</pub-id><pub-id pub-id-type="pmid">38736889</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Bermea, K. C. et al. Myocardial B cells have specific gene expression and predicted interactions in dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. <italic>Front. Immunol.</italic><bold>15</bold>, 1327372 (2024).<pub-id pub-id-type="pmid">38736889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Oduro</surname><given-names>PK</given-names></name><etal/></person-group><article-title>The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy</article-title><source>Acta Pharmacol. Sin. B</source><year>2022</year><volume>12</volume><fpage>50</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.05.011</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Oduro, P. K. et al. The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy. <italic>Acta Pharmacol. Sin. B</italic><bold>12</bold>, 50&#x02013;75 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Bullen</surname><given-names>CK</given-names></name><etal/></person-group><article-title>MDA5 RNA-sensing pathway activation by Mycobacterium tuberculosis promotes innate immune subversion and pathogen survival</article-title><source>JCI Insight</source><year>2023</year><volume>8</volume><fpage>e166242</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.166242</pub-id><pub-id pub-id-type="pmid">37725440</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Bullen, C. K. et al. MDA5 RNA-sensing pathway activation by Mycobacterium tuberculosis promotes innate immune subversion and pathogen survival. <italic>JCI Insight</italic><bold>8</bold>, e166242 (2023).<pub-id pub-id-type="pmid">37725440</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Caneparo</surname><given-names>V</given-names></name><name><surname>Landolfo</surname><given-names>S</given-names></name><name><surname>Gariglio</surname><given-names>M</given-names></name><name><surname>De Andrea</surname><given-names>M</given-names></name></person-group><article-title>The absent in melanoma 2-like receptor IFN-inducible protein 16 as an inflammasome regulator in systemic lupus erythematosus: the dark side of sensing microbes</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1180</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01180</pub-id><pub-id pub-id-type="pmid">29892303</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Caneparo, V., Landolfo, S., Gariglio, M. &#x00026; De Andrea, M. The absent in melanoma 2-like receptor IFN-inducible protein 16 as an inflammasome regulator in systemic lupus erythematosus: the dark side of sensing microbes. <italic>Front. Immunol.</italic><bold>9</bold>, 1180 (2018).<pub-id pub-id-type="pmid">29892303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Doran</surname><given-names>AC</given-names></name><name><surname>Yurdagul</surname><given-names>A</given-names><suffix>Jr.</suffix></name><name><surname>Tabas</surname><given-names>I</given-names></name></person-group><article-title>Efferocytosis in health and disease</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>254</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0240-6</pub-id><pub-id pub-id-type="pmid">31822793</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Doran, A. C., Yurdagul, A. Jr. &#x00026; Tabas, I. Efferocytosis in health and disease. <italic>Nat. Rev. Immunol.</italic><bold>20</bold>, 254&#x02013;267 (2020).<pub-id pub-id-type="pmid">31822793</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Arandjelovic</surname><given-names>S</given-names></name><name><surname>Ravichandran</surname><given-names>KS</given-names></name></person-group><article-title>Phagocytosis of apoptotic cells in homeostasis</article-title><source>Nat. Immunol.</source><year>2015</year><volume>16</volume><fpage>907</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1038/ni.3253</pub-id><pub-id pub-id-type="pmid">26287597</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Arandjelovic, S. &#x00026; Ravichandran, K. S. Phagocytosis of apoptotic cells in homeostasis. <italic>Nat. Immunol.</italic><bold>16</bold>, 907&#x02013;917 (2015).<pub-id pub-id-type="pmid">26287597</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Targeting regulatory T cells for cardiovascular diseases</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1126761</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1126761</pub-id><pub-id pub-id-type="pmid">36911741</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Wang, X. et al. Targeting regulatory T cells for cardiovascular diseases. <italic>Front. Immunol.</italic><bold>14</bold>, 1126761 (2023).<pub-id pub-id-type="pmid">36911741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Vignali</surname><given-names>DA</given-names></name><name><surname>Collison</surname><given-names>LW</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name></person-group><article-title>How regulatory T cells work</article-title><source>Nat. Rev. Immunol.</source><year>2008</year><volume>8</volume><fpage>523</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/nri2343</pub-id><pub-id pub-id-type="pmid">18566595</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Vignali, D. A., Collison, L. W. &#x00026; Workman, C. J. How regulatory T cells work. <italic>Nat. Rev. Immunol.</italic><bold>8</bold>, 523&#x02013;532 (2008).<pub-id pub-id-type="pmid">18566595</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><etal/></person-group><article-title>The role of apoptosis in the development and function of T lymphocytes</article-title><source>Cell Res.</source><year>2005</year><volume>15</volume><fpage>749</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1038/sj.cr.7290345</pub-id><pub-id pub-id-type="pmid">16246265</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Zhang, N. et al. The role of apoptosis in the development and function of T lymphocytes. <italic>Cell Res.</italic><bold>15</bold>, 749&#x02013;769 (2005).<pub-id pub-id-type="pmid">16246265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Holodick</surname><given-names>NE</given-names></name><name><surname>Rodriguez-Zhurbenko</surname><given-names>N</given-names></name><name><surname>Hernandez</surname><given-names>AM</given-names></name></person-group><article-title>Defining natural antibodies</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>872</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00872</pub-id><pub-id pub-id-type="pmid">28798747</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Holodick, N. E., Rodriguez-Zhurbenko, N. &#x00026; Hernandez, A. M. Defining natural antibodies. <italic>Front. Immunol.</italic><bold>8</bold>, 872 (2017).<pub-id pub-id-type="pmid">28798747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>E</given-names></name></person-group><article-title>Majority of People Live With Uncontrolled Hypertension Worldwide</article-title><source>JAMA</source><year>2023</year><volume>330</volume><fpage>1515</fpage><pub-id pub-id-type="pmid">37792421</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Harris, E. Majority of People Live With Uncontrolled Hypertension Worldwide. <italic>JAMA</italic><bold>330</bold>, 1515 (2023).<pub-id pub-id-type="pmid">37792421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>X</given-names></name><etal/></person-group><article-title>The Minhang Pediatric Biobank cohort study: protocol overview and baseline characteristics</article-title><source>BMC Pediatr.</source><year>2024</year><volume>24</volume><fpage>282</fpage><pub-id pub-id-type="doi">10.1186/s12887-024-04763-6</pub-id><pub-id pub-id-type="pmid">38678186</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Wen, X. et al. The Minhang Pediatric Biobank cohort study: protocol overview and baseline characteristics. <italic>BMC Pediatr.</italic><bold>24</bold>, 282 (2024).<pub-id pub-id-type="pmid">38678186</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Schutte</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension</article-title><source>Cardiovasc. Res.</source><year>2023</year><volume>119</volume><fpage>381</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvac130</pub-id><pub-id pub-id-type="pmid">36219457</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Schutte, A. E. et al. Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension. <italic>Cardiovasc. Res.</italic><bold>119</bold>, 381&#x02013;409 (2023).<pub-id pub-id-type="pmid">36219457</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><collab>NCD Risk Factor Collaboration (NCD-RisC</collab></person-group><article-title>Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>957</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01330-1</pub-id><pub-id pub-id-type="pmid">34450083</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. <italic>Lancet</italic><bold>398</bold>, 957&#x02013;980 (2021).<pub-id pub-id-type="pmid">34450083</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Evangelou</surname><given-names>E</given-names></name><etal/></person-group><article-title>Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits</article-title><source>Nat. Genet.</source><year>2018</year><volume>50</volume><fpage>1412</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0205-x</pub-id><pub-id pub-id-type="pmid">30224653</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. <italic>Nat. Genet.</italic><bold>50</bold>, 1412&#x02013;1425 (2018).<pub-id pub-id-type="pmid">30224653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Garshick</surname><given-names>MS</given-names></name><name><surname>Ward</surname><given-names>NL</given-names></name><name><surname>Krueger</surname><given-names>JG</given-names></name><name><surname>Berger</surname><given-names>JS</given-names></name></person-group><article-title>Cardiovascular risk in patients with psoriasis: JACC review topic of the week</article-title><source>J. Am. Coll. Cardiol.</source><year>2021</year><volume>77</volume><fpage>1670</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.02.009</pub-id><pub-id pub-id-type="pmid">33795041</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Garshick, M. S., Ward, N. L., Krueger, J. G. &#x00026; Berger, J. S. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. <italic>J. Am. Coll. Cardiol.</italic><bold>77</bold>, 1670&#x02013;1680 (2021).<pub-id pub-id-type="pmid">33795041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Panoulas</surname><given-names>VF</given-names></name><etal/></person-group><article-title>Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis</article-title><source>Rheumatology</source><year>2007</year><volume>46</volume><fpage>1477</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kem169</pub-id><pub-id pub-id-type="pmid">17704521</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Panoulas, V. F. et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. <italic>Rheumatology</italic><bold>46</bold>, 1477&#x02013;1482 (2007).<pub-id pub-id-type="pmid">17704521</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz Aguilera</surname><given-names>E</given-names></name><etal/></person-group><article-title>Periodontitis is associated with hypertension: a systematic review and meta-analysis</article-title><source>Cardiovasc. Res.</source><year>2020</year><volume>116</volume><fpage>28</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvz201</pub-id><pub-id pub-id-type="pmid">31549149</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Munoz Aguilera, E. et al. Periodontitis is associated with hypertension: a systematic review and meta-analysis. <italic>Cardiovasc. Res.</italic><bold>116</bold>, 28&#x02013;39 (2020).<pub-id pub-id-type="pmid">31549149</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Eke</surname><given-names>PI</given-names></name><etal/></person-group><article-title>Periodontitis in US Adults: National health and nutrition examination survey 2009-2014</article-title><source>J. Am. Dent. Assoc.</source><year>2018</year><volume>149</volume><fpage>576</fpage><lpage>588.e576</lpage><pub-id pub-id-type="doi">10.1016/j.adaj.2018.04.023</pub-id><pub-id pub-id-type="pmid">29957185</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Eke, P. I. et al. Periodontitis in US Adults: National health and nutrition examination survey 2009-2014. <italic>J. Am. Dent. Assoc.</italic><bold>149</bold>, 576&#x02013;588.e576 (2018).<pub-id pub-id-type="pmid">29957185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Regulatory T cells in cardiovascular diseases</article-title><source>Nat. Rev. Cardiol.</source><year>2016</year><volume>13</volume><fpage>167</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2015.169</pub-id><pub-id pub-id-type="pmid">26525543</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Meng, X. et al. Regulatory T cells in cardiovascular diseases. <italic>Nat. Rev. Cardiol.</italic><bold>13</bold>, 167&#x02013;179 (2016).<pub-id pub-id-type="pmid">26525543</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1331609</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1331609</pub-id><pub-id pub-id-type="pmid">38558816</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Xia, Y., et al. Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets. <italic>Front. Immunol.</italic><bold>15</bold>, 1331609 (2024).<pub-id pub-id-type="pmid">38558816</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Guzik</surname><given-names>TJ</given-names></name><name><surname>Nosalski</surname><given-names>R</given-names></name><name><surname>Maffia</surname><given-names>P</given-names></name><name><surname>Drummond</surname><given-names>GR</given-names></name></person-group><article-title>Immune and inflammatory mechanisms in hypertension</article-title><source>Nat. Rev. Cardiol.</source><year>2024</year><volume>21</volume><fpage>396</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/s41569-023-00964-1</pub-id><pub-id pub-id-type="pmid">38172242</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Guzik, T. J., Nosalski, R., Maffia, P. &#x00026; Drummond, G. R. Immune and inflammatory mechanisms in hypertension. <italic>Nat. Rev. Cardiol.</italic><bold>21</bold>, 396&#x02013;416 (2024).<pub-id pub-id-type="pmid">38172242</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>RM</given-names></name><name><surname>Hawiger</surname><given-names>D</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><article-title>Tolerogenic dendritic cells</article-title><source>Annu. Rev. Immunol.</source><year>2003</year><volume>21</volume><fpage>685</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141040</pub-id><pub-id pub-id-type="pmid">12615891</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Steinman, R. M., Hawiger, D. &#x00026; Nussenzweig, M. C. Tolerogenic dendritic cells. <italic>Annu. Rev. Immunol.</italic><bold>21</bold>, 685&#x02013;711 (2003).<pub-id pub-id-type="pmid">12615891</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Higaki</surname><given-names>A</given-names></name><name><surname>Mogi</surname><given-names>M</given-names></name></person-group><article-title>Dendritic cells as potential initiators of immune-mediated hypertensive disorders</article-title><source>Hypertens. Res.</source><year>2021</year><volume>45</volume><fpage>527</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1038/s41440-021-00830-y</pub-id><pub-id pub-id-type="pmid">34961789</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Higaki, A. &#x00026; Mogi, M. Dendritic cells as potential initiators of immune-mediated hypertensive disorders. <italic>Hypertens. Res.</italic><bold>45</bold>, 527&#x02013;529 (2021).<pub-id pub-id-type="pmid">34961789</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Barbaro</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Dendritic cell amiloride-sensitive channels mediate sodium-induced inflammation and hypertension</article-title><source>Cell Rep.</source><year>2017</year><volume>21</volume><fpage>1009</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.10.002</pub-id><pub-id pub-id-type="pmid">29069584</pub-id>
</element-citation><mixed-citation id="mc-CR112" publication-type="journal">Barbaro, N. R. et al. Dendritic cell amiloride-sensitive channels mediate sodium-induced inflammation and hypertension. <italic>Cell Rep.</italic><bold>21</bold>, 1009&#x02013;1020 (2017).<pub-id pub-id-type="pmid">29069584</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Carnevale</surname><given-names>D</given-names></name><etal/></person-group><article-title>A cholinergic-sympathetic pathway primes immunity in hypertension and mediates brain-to-spleen communication</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13035</fpage><pub-id pub-id-type="doi">10.1038/ncomms13035</pub-id><pub-id pub-id-type="pmid">27676657</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Carnevale, D., et al. A cholinergic-sympathetic pathway primes immunity in hypertension and mediates brain-to-spleen communication. <italic>Nat. Commun.</italic><bold>7</bold>, 13035 (2016).<pub-id pub-id-type="pmid">27676657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlov</surname><given-names>VA</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name></person-group><article-title>Neural regulation of immunity: molecular mechanisms and clinical translation</article-title><source>Nat. Neurosci.</source><year>2017</year><volume>20</volume><fpage>156</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/nn.4477</pub-id><pub-id pub-id-type="pmid">28092663</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Pavlov, V. A. &#x00026; Tracey, K. J. Neural regulation of immunity: molecular mechanisms and clinical translation. <italic>Nat. Neurosci.</italic><bold>20</bold>, 156&#x02013;166 (2017).<pub-id pub-id-type="pmid">28092663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>BA</given-names></name><name><surname>Alexander</surname><given-names>MR</given-names></name><name><surname>Harrison</surname><given-names>DG</given-names></name></person-group><article-title>Immune mechanisms in the pathophysiology of hypertension</article-title><source>Nat. Rev. Nephrol.</source><year>2024</year><volume>20</volume><fpage>530</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1038/s41581-024-00838-w</pub-id><pub-id pub-id-type="pmid">38658669</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Nguyen, B. A., Alexander, M. R. &#x00026; Harrison, D. G. Immune mechanisms in the pathophysiology of hypertension. <italic>Nat. Rev. Nephrol.</italic><bold>20</bold>, 530&#x02013;540 (2024).<pub-id pub-id-type="pmid">38658669</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>MA</given-names></name></person-group><article-title>Mechanotransduction in vascular physiology and atherogenesis</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2009</year><volume>10</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/nrm2596</pub-id><pub-id pub-id-type="pmid">19197332</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Hahn, C. &#x00026; Schwartz, M. A. Mechanotransduction in vascular physiology and atherogenesis. <italic>Nat. Rev. Mol. Cell Biol.</italic><bold>10</bold>, 53&#x02013;62 (2009).<pub-id pub-id-type="pmid">19197332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>DG</given-names></name><name><surname>Patrick</surname><given-names>DM</given-names></name></person-group><article-title>Immune mechanisms in hypertension</article-title><source>Hypertension</source><year>2024</year><volume>81</volume><fpage>1659</fpage><lpage>1674</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.124.21355</pub-id><pub-id pub-id-type="pmid">38881474</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Harrison, D. G. &#x00026; Patrick, D. M. Immune mechanisms in hypertension. <italic>Hypertension</italic><bold>81</bold>, 1659&#x02013;1674 (2024).<pub-id pub-id-type="pmid">38881474</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Itani</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Activation of human T cells in hypertension: studies of humanized mice and hypertensive humans</article-title><source>Hypertension</source><year>2016</year><volume>68</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.116.07237</pub-id><pub-id pub-id-type="pmid">27217403</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Itani, H. A. et al. Activation of human T cells in hypertension: studies of humanized mice and hypertensive humans. <italic>Hypertension</italic><bold>68</bold>, 123&#x02013;132 (2016).<pub-id pub-id-type="pmid">27217403</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Single-cell transcriptome profiling reveals enriched memory T-cell subpopulations in hypertension</article-title><source>Front. Cell Dev. Biol.</source><year>2023</year><volume>11</volume><fpage>1132040</fpage><pub-id pub-id-type="doi">10.3389/fcell.2023.1132040</pub-id><pub-id pub-id-type="pmid">37009484</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Wang, X., et al. Single-cell transcriptome profiling reveals enriched memory T-cell subpopulations in hypertension. <italic>Front. Cell Dev. Biol.</italic><bold>11</bold>, 1132040 (2023).<pub-id pub-id-type="pmid">37009484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Pober</surname><given-names>JS</given-names></name><name><surname>Merola</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Manes</surname><given-names>TD</given-names></name></person-group><article-title>Antigen presentation by vascular cells</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1907</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01907</pub-id><pub-id pub-id-type="pmid">29312357</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Pober, J. S., Merola, J., Liu, R. &#x00026; Manes, T. D. Antigen presentation by vascular cells. <italic>Front. Immunol.</italic><bold>8</bold>, 1907 (2017).<pub-id pub-id-type="pmid">29312357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Didion</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction</article-title><source>Hypertension</source><year>2009</year><volume>54</volume><fpage>619</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.137158</pub-id><pub-id pub-id-type="pmid">19620507</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Didion, S. P. et al. Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. <italic>Hypertension</italic><bold>54</bold>, 619&#x02013;624 (2009).<pub-id pub-id-type="pmid">19620507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Inflammation in atherosclerosis</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>868</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1038/nature01323</pub-id><pub-id pub-id-type="pmid">12490960</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Libby, P. Inflammation in atherosclerosis. <italic>Nature</italic><bold>420</bold>, 868&#x02013;874 (2002).<pub-id pub-id-type="pmid">12490960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Trimm</surname><given-names>E</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name></person-group><article-title>Vascular endothelial cell development and diversity</article-title><source>Nat. Rev. Cardiol.</source><year>2023</year><volume>20</volume><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/s41569-022-00770-1</pub-id><pub-id pub-id-type="pmid">36198871</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Trimm, E. &#x00026; Red-Horse, K. Vascular endothelial cell development and diversity. <italic>Nat. Rev. Cardiol.</italic><bold>20</bold>, 197&#x02013;210 (2023).<pub-id pub-id-type="pmid">36198871</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Neubauer</surname><given-names>K</given-names></name><name><surname>Zieger</surname><given-names>B</given-names></name></person-group><article-title>Endothelial cells and coagulation</article-title><source>Cell Tissue Res.</source><year>2022</year><volume>387</volume><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1007/s00441-021-03471-2</pub-id><pub-id pub-id-type="pmid">34014399</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Neubauer, K. &#x00026; Zieger, B. Endothelial cells and coagulation. <italic>Cell Tissue Res.</italic><bold>387</bold>, 391&#x02013;398 (2022).<pub-id pub-id-type="pmid">34014399</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Pober</surname><given-names>JS</given-names></name><name><surname>Sessa</surname><given-names>WC</given-names></name></person-group><article-title>Evolving functions of endothelial cells in inflammation</article-title><source>Nat. Rev. Immunol.</source><year>2007</year><volume>7</volume><fpage>803</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1038/nri2171</pub-id><pub-id pub-id-type="pmid">17893694</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Pober, J. S. &#x00026; Sessa, W. C. Evolving functions of endothelial cells in inflammation. <italic>Nat. Rev. Immunol.</italic><bold>7</bold>, 803&#x02013;815 (2007).<pub-id pub-id-type="pmid">17893694</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>C</given-names></name><etal/></person-group><article-title>The role of immune cells in different stages of atherosclerosis</article-title><source>Int. J. Med. Sci.</source><year>2024</year><volume>21</volume><fpage>1129</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.7150/ijms.94570</pub-id><pub-id pub-id-type="pmid">38774746</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">He, C. et al. The role of immune cells in different stages of atherosclerosis. <italic>Int. J. Med. Sci.</italic><bold>21</bold>, 1129&#x02013;1143 (2024).<pub-id pub-id-type="pmid">38774746</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>GK</given-names></name><name><surname>Hermansson</surname><given-names>A</given-names></name></person-group><article-title>The immune system in atherosclerosis</article-title><source>Nat. Immunol.</source><year>2011</year><volume>12</volume><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1038/ni.2001</pub-id><pub-id pub-id-type="pmid">21321594</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Hansson, G. K. &#x00026; Hermansson, A. The immune system in atherosclerosis. <italic>Nat. Immunol.</italic><bold>12</bold>, 204&#x02013;212 (2011).<pub-id pub-id-type="pmid">21321594</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Zernecke</surname><given-names>A</given-names></name><etal/></person-group><article-title>Meta-analysis of leukocyte diversity in atherosclerotic mouse aortas</article-title><source>Circ. Res.</source><year>2020</year><volume>127</volume><fpage>402</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.316903</pub-id><pub-id pub-id-type="pmid">32673538</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Zernecke, A. et al. Meta-analysis of leukocyte diversity in atherosclerotic mouse aortas. <italic>Circ. Res.</italic><bold>127</bold>, 402&#x02013;426 (2020).<pub-id pub-id-type="pmid">32673538</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human</article-title><source>Circulation</source><year>2020</year><volume>142</volume><fpage>2060</fpage><lpage>2075</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.048378</pub-id><pub-id pub-id-type="pmid">32962412</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">Pan, H. et al. Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. <italic>Circulation</italic><bold>142</bold>, 2060&#x02013;2075 (2020).<pub-id pub-id-type="pmid">32962412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Wirka</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>1280</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0512-5</pub-id><pub-id pub-id-type="pmid">31359001</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Wirka, R. C. et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. <italic>Nat. Med.</italic><bold>25</bold>, 1280&#x02013;1289 (2019).<pub-id pub-id-type="pmid">31359001</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Feil</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis</article-title><source>Circ. Res.</source><year>2014</year><volume>115</volume><fpage>662</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.304634</pub-id><pub-id pub-id-type="pmid">25070003</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Feil, S. et al. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. <italic>Circ. Res.</italic><bold>115</bold>, 662&#x02013;667 (2014).<pub-id pub-id-type="pmid">25070003</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>The changing landscape of atherosclerosis</article-title><source>Nature</source><year>2021</year><volume>592</volume><fpage>524</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03392-8</pub-id><pub-id pub-id-type="pmid">33883728</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Libby, P. The changing landscape of atherosclerosis. <italic>Nature</italic><bold>592</bold>, 524&#x02013;533 (2021).<pub-id pub-id-type="pmid">33883728</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Bairey Merz</surname><given-names>CN</given-names></name><name><surname>Pepine</surname><given-names>CJ</given-names></name><name><surname>Walsh</surname><given-names>MN</given-names></name><name><surname>Fleg</surname><given-names>JL</given-names></name></person-group><article-title>Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade</article-title><source>Circulation</source><year>2017</year><volume>135</volume><fpage>1075</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.024534</pub-id><pub-id pub-id-type="pmid">28289007</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Bairey Merz, C. N., Pepine, C. J., Walsh, M. N. &#x00026; Fleg, J. L. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. <italic>Circulation</italic><bold>135</bold>, 1075&#x02013;1092 (2017).<pub-id pub-id-type="pmid">28289007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimiya</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mechanisms of coronary artery spasm</article-title><source>Eur. Cardiol.</source><year>2023</year><volume>18</volume><fpage>e39</fpage><pub-id pub-id-type="doi">10.15420/ecr.2022.55</pub-id><pub-id pub-id-type="pmid">37456775</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Nishimiya, K. et al. Mechanisms of coronary artery spasm. <italic>Eur. Cardiol.</italic><bold>18</bold>, e39 (2023).<pub-id pub-id-type="pmid">37456775</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Mensah</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Global burden of cardiovascular diseases and risks, 1990-2022</article-title><source>J. Am. Coll. Cardiol.</source><year>2023</year><volume>82</volume><fpage>2350</fpage><lpage>2473</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2023.11.007</pub-id><pub-id pub-id-type="pmid">38092509</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Mensah, G. A. et al. Global burden of cardiovascular diseases and risks, 1990-2022. <italic>J. Am. Coll. Cardiol.</italic><bold>82</bold>, 2350&#x02013;2473 (2023).<pub-id pub-id-type="pmid">38092509</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name><surname>Dittrich</surname><given-names>A</given-names></name><name><surname>Lauridsen</surname><given-names>H</given-names></name></person-group><article-title>Myocardial infarction and the immune response - Scarring or regeneration? A comparative look at mammals and popular regenerating animal models</article-title><source>J. Immunol. Regen. Med.</source><year>2019</year><volume>4</volume><fpage>100016</fpage></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Dittrich, A. &#x00026; Lauridsen, H. Myocardial infarction and the immune response - Scarring or regeneration? A comparative look at mammals and popular regenerating animal models. <italic>J. Immunol. Regen. Med.</italic><bold>4</bold>, 100016 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-Zas</surname><given-names>I</given-names></name><name><surname>Lemarie</surname><given-names>J</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name><name><surname>Ait-Oufella</surname><given-names>H</given-names></name></person-group><article-title>Adaptive immune responses contribute to post-ischemic cardiac remodeling</article-title><source>Front. Cardiovasc. Med.</source><year>2018</year><volume>5</volume><fpage>198</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2018.00198</pub-id><pub-id pub-id-type="pmid">30687720</pub-id>
</element-citation><mixed-citation id="mc-CR137" publication-type="journal">Santos-Zas, I., Lemarie, J., Tedgui, A. &#x00026; Ait-Oufella, H. Adaptive immune responses contribute to post-ischemic cardiac remodeling. <italic>Front. Cardiovasc. Med.</italic><bold>5</bold>, 198 (2018).<pub-id pub-id-type="pmid">30687720</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>SW</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>JH</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>HJ</given-names></name></person-group><article-title>Macrophage heterogeneity and its impact on myocardial ischemia-reperfusion injury: an integrative review</article-title><source>J. Inflamm. Res.</source><year>2023</year><volume>16</volume><fpage>5971</fpage><lpage>5987</lpage><pub-id pub-id-type="doi">10.2147/JIR.S436560</pub-id><pub-id pub-id-type="pmid">38088942</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">Xu, S. W., Xu, C., Xu, J. H., Zhang, K. &#x00026; Zhang, H. J. Macrophage heterogeneity and its impact on myocardial ischemia-reperfusion injury: an integrative review. <italic>J. Inflamm. Res.</italic><bold>16</bold>, 5971&#x02013;5987 (2023).<pub-id pub-id-type="pmid">38088942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name><surname>Zouggari</surname><given-names>Y</given-names></name><etal/></person-group><article-title>B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1273</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1038/nm.3284</pub-id><pub-id pub-id-type="pmid">24037091</pub-id>
</element-citation><mixed-citation id="mc-CR139" publication-type="journal">Zouggari, Y. et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. <italic>Nat. Med.</italic><bold>19</bold>, 1273&#x02013;1280 (2013).<pub-id pub-id-type="pmid">24037091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The role of major immune cells in myocardial infarction</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>1084460</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.1084460</pub-id><pub-id pub-id-type="pmid">36741418</pub-id>
</element-citation><mixed-citation id="mc-CR140" publication-type="journal">Feng, Q., et al. The role of major immune cells in myocardial infarction. <italic>Front. Immunol.</italic><bold>13</bold>, 1084460 (2022).<pub-id pub-id-type="pmid">36741418</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Regulatory T cells ameliorate cardiac remodeling after myocardial infarction</article-title><source>Basic Res. Cardiol.</source><year>2012</year><volume>107</volume><fpage>232</fpage><pub-id pub-id-type="doi">10.1007/s00395-011-0232-6</pub-id><pub-id pub-id-type="pmid">22189560</pub-id>
</element-citation><mixed-citation id="mc-CR141" publication-type="journal">Tang, T. T. et al. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. <italic>Basic Res. Cardiol.</italic><bold>107</bold>, 232 (2012).<pub-id pub-id-type="pmid">22189560</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Prabhu</surname><given-names>SD</given-names></name><name><surname>Bansal</surname><given-names>SS</given-names></name></person-group><article-title>CD4(+) T-lymphocytes exhibit biphasic kinetics post-myocardial infarction</article-title><source>Front. Cardiovasc. Med.</source><year>2022</year><volume>9</volume><fpage>992653</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2022.992653</pub-id><pub-id pub-id-type="pmid">36093172</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Kumar, V., Prabhu, S. D. &#x00026; Bansal, S. S. CD4(+) T-lymphocytes exhibit biphasic kinetics post-myocardial infarction. <italic>Front. Cardiovasc. Med.</italic><bold>9</bold>, 992653 (2022).<pub-id pub-id-type="pmid">36093172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Sadoshima</surname><given-names>J</given-names></name></person-group><article-title>Mechanisms of physiological and pathological cardiac hypertrophy</article-title><source>Nat. Rev. Cardiol.</source><year>2018</year><volume>15</volume><fpage>387</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1038/s41569-018-0007-y</pub-id><pub-id pub-id-type="pmid">29674714</pub-id>
</element-citation><mixed-citation id="mc-CR143" publication-type="journal">Nakamura, M. &#x00026; Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. <italic>Nat. Rev. Cardiol.</italic><bold>15</bold>, 387&#x02013;407 (2018).<pub-id pub-id-type="pmid">29674714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Frantz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies</article-title><source>Eur. Heart J.</source><year>2022</year><volume>43</volume><fpage>2549</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehac223</pub-id><pub-id pub-id-type="pmid">35511857</pub-id>
</element-citation><mixed-citation id="mc-CR144" publication-type="journal">Frantz, S. et al. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. <italic>Eur. Heart J.</italic><bold>43</bold>, 2549&#x02013;2561 (2022).<pub-id pub-id-type="pmid">35511857</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>PM</given-names></name><etal/></person-group><article-title>MR/PET imaging of the cardiovascular system</article-title><source>JACC Cardiovasc. Imaging</source><year>2017</year><volume>10</volume><fpage>1165</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2017.07.008</pub-id><pub-id pub-id-type="pmid">28982570</pub-id>
</element-citation><mixed-citation id="mc-CR145" publication-type="journal">Robson, P. M. et al. MR/PET imaging of the cardiovascular system. <italic>JACC Cardiovasc. Imaging</italic><bold>10</bold>, 1165&#x02013;1179 (2017).<pub-id pub-id-type="pmid">28982570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name><surname>Barros-Gomes</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cardiac remodeling in acute myocardial infarction: Prospective insights from multimodality ultrasound imaging</article-title><source>Echocardiography</source><year>2021</year><volume>38</volume><fpage>2032</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1111/echo.15245</pub-id><pub-id pub-id-type="pmid">34845767</pub-id>
</element-citation><mixed-citation id="mc-CR146" publication-type="journal">Barros-Gomes, S. et al. Cardiac remodeling in acute myocardial infarction: Prospective insights from multimodality ultrasound imaging. <italic>Echocardiography</italic><bold>38</bold>, 2032&#x02013;2042 (2021).<pub-id pub-id-type="pmid">34845767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Exercise-induced cardiovascular adaptations and approach to exercise and cardiovascular disease: JACC state-of-the-art review</article-title><source>J. Am. Coll. Cardiol.</source><year>2021</year><volume>78</volume><fpage>1453</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.08.003</pub-id><pub-id pub-id-type="pmid">34593128</pub-id>
</element-citation><mixed-citation id="mc-CR147" publication-type="journal">Martinez, M. W. et al. Exercise-induced cardiovascular adaptations and approach to exercise and cardiovascular disease: JACC state-of-the-art review. <italic>J. Am. Coll. Cardiol.</italic><bold>78</bold>, 1453&#x02013;1470 (2021).<pub-id pub-id-type="pmid">34593128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name><surname>De Haas</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cardiac remodeling in normotensive pregnancy and in pregnancy complicated by hypertension: systematic review and meta-analysis</article-title><source>Ultrasound Obstet. Gynecol.</source><year>2017</year><volume>50</volume><fpage>683</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1002/uog.17410</pub-id><pub-id pub-id-type="pmid">28078751</pub-id>
</element-citation><mixed-citation id="mc-CR148" publication-type="journal">De Haas, S. et al. Cardiac remodeling in normotensive pregnancy and in pregnancy complicated by hypertension: systematic review and meta-analysis. <italic>Ultrasound Obstet. Gynecol.</italic><bold>50</bold>, 683&#x02013;696 (2017).<pub-id pub-id-type="pmid">28078751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name><surname>Deb</surname><given-names>A</given-names></name><name><surname>Ubil</surname><given-names>E</given-names></name></person-group><article-title>Cardiac fibroblast in development and wound healing</article-title><source>J. Mol. Cell Cardiol.</source><year>2014</year><volume>70</volume><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2014.02.017</pub-id><pub-id pub-id-type="pmid">24625635</pub-id>
</element-citation><mixed-citation id="mc-CR149" publication-type="journal">Deb, A. &#x00026; Ubil, E. Cardiac fibroblast in development and wound healing. <italic>J. Mol. Cell Cardiol.</italic><bold>70</bold>, 47&#x02013;55 (2014).<pub-id pub-id-type="pmid">24625635</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name><surname>Jitmana</surname><given-names>R</given-names></name><etal/></person-group><article-title>Role of cardiac mast cells in exercise training-mediated cardiac remodeling in angiotensin II-infused ovariectomized rats</article-title><source>Life Sci.</source><year>2019</year><volume>219</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.01.018</pub-id><pub-id pub-id-type="pmid">30658099</pub-id>
</element-citation><mixed-citation id="mc-CR150" publication-type="journal">Jitmana, R. et al. Role of cardiac mast cells in exercise training-mediated cardiac remodeling in angiotensin II-infused ovariectomized rats. <italic>Life Sci.</italic><bold>219</bold>, 209&#x02013;218 (2019).<pub-id pub-id-type="pmid">30658099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name><surname>Lavine</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>16029</fpage><lpage>16034</lpage><pub-id pub-id-type="doi">10.1073/pnas.1406508111</pub-id><pub-id pub-id-type="pmid">25349429</pub-id>
</element-citation><mixed-citation id="mc-CR151" publication-type="journal">Lavine, K. J. et al. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>111</bold>, 16029&#x02013;16034 (2014).<pub-id pub-id-type="pmid">25349429</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Mechanistic basis of neonatal heart regeneration revealed by transcriptome and histone modification profiling</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>18455</fpage><lpage>18465</lpage><pub-id pub-id-type="doi">10.1073/pnas.1905824116</pub-id><pub-id pub-id-type="pmid">31451669</pub-id>
</element-citation><mixed-citation id="mc-CR152" publication-type="journal">Wang, Z. et al. Mechanistic basis of neonatal heart regeneration revealed by transcriptome and histone modification profiling. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>116</bold>, 18455&#x02013;18465 (2019).<pub-id pub-id-type="pmid">31451669</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><mixed-citation publication-type="other">Borges, D. et al. Exercise training and cardiac remodeling sports, health and exercise medicine. <italic>Exerc. Sport Sci. Rev</italic>. <bold>50</bold>, 137&#x02013;144 (2019).</mixed-citation></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Exercise-derived peptide protects against pathological cardiac remodeling</article-title><source>EBioMedicine</source><year>2022</year><volume>82</volume><fpage>104164</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104164</pub-id><pub-id pub-id-type="pmid">35843176</pub-id>
</element-citation><mixed-citation id="mc-CR154" publication-type="journal">Yin, A., et al. Exercise-derived peptide protects against pathological cardiac remodeling. <italic>EBioMedicine</italic><bold>82</bold>, 104164 (2022).<pub-id pub-id-type="pmid">35843176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>H</given-names></name><etal/></person-group><article-title>Tuning immunity through tissue mechanotransduction</article-title><source>Nat. Rev. Immunol.</source><year>2023</year><volume>23</volume><fpage>174</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00761-w</pub-id><pub-id pub-id-type="pmid">35974148</pub-id>
</element-citation><mixed-citation id="mc-CR155" publication-type="journal">Du, H. et al. Tuning immunity through tissue mechanotransduction. <italic>Nat. Rev. Immunol.</italic><bold>23</bold>, 174&#x02013;188 (2023).<pub-id pub-id-type="pmid">35974148</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>J</given-names></name><etal/></person-group><article-title>Macrophages in cardiac remodelling after myocardial infarction</article-title><source>Nat. Rev. Cardiol.</source><year>2023</year><volume>20</volume><fpage>373</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/s41569-022-00823-5</pub-id><pub-id pub-id-type="pmid">36627513</pub-id>
</element-citation><mixed-citation id="mc-CR156" publication-type="journal">Yap, J. et al. Macrophages in cardiac remodelling after myocardial infarction. <italic>Nat. Rev. Cardiol.</italic><bold>20</bold>, 373&#x02013;385 (2023).<pub-id pub-id-type="pmid">36627513</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name><surname>Nian</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Khaper</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name></person-group><article-title>Inflammatory cytokines and postmyocardial infarction remodeling</article-title><source>Circ. Res.</source><year>2004</year><volume>94</volume><fpage>1543</fpage><lpage>1553</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000130526.20854.fa</pub-id><pub-id pub-id-type="pmid">15217919</pub-id>
</element-citation><mixed-citation id="mc-CR157" publication-type="journal">Nian, M., Lee, P., Khaper, N. &#x00026; Liu, P. Inflammatory cytokines and postmyocardial infarction remodeling. <italic>Circ. Res.</italic><bold>94</bold>, 1543&#x02013;1553 (2004).<pub-id pub-id-type="pmid">15217919</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name><surname>Strassheim</surname><given-names>D</given-names></name><etal/></person-group><article-title>Role of inflammatory cell subtypes in heart Failure</article-title><source>J. Immunol. Res.</source><year>2019</year><volume>2019</volume><fpage>2164017</fpage><pub-id pub-id-type="doi">10.1155/2019/2164017</pub-id><pub-id pub-id-type="pmid">31565659</pub-id>
</element-citation><mixed-citation id="mc-CR158" publication-type="journal">Strassheim, D., et al. Role of inflammatory cell subtypes in heart Failure. <italic>J. Immunol. Res.</italic><bold>2019</bold>, 2164017 (2019).<pub-id pub-id-type="pmid">31565659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name><surname>Kologrivova</surname><given-names>I</given-names></name><name><surname>Shtatolkina</surname><given-names>M</given-names></name><name><surname>Suslova</surname><given-names>T</given-names></name><name><surname>Ryabov</surname><given-names>V</given-names></name></person-group><article-title>Cells of the immune system in cardiac remodeling: main players in resolution of inflammation and repair after myocardial infarction</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>664457</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.664457</pub-id><pub-id pub-id-type="pmid">33868315</pub-id>
</element-citation><mixed-citation id="mc-CR159" publication-type="journal">Kologrivova, I., Shtatolkina, M., Suslova, T. &#x00026; Ryabov, V. Cells of the immune system in cardiac remodeling: main players in resolution of inflammation and repair after myocardial infarction. <italic>Front. Immunol.</italic><bold>12</bold>, 664457 (2021).<pub-id pub-id-type="pmid">33868315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><mixed-citation publication-type="other">De Angelis, E. et al. Cross-talk between neurohormonal pathways and the immune system in heart failure: a review of the literature. <italic>Int. J. Mol. Sci</italic>. <bold>20</bold>, 1698 (2019).</mixed-citation></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>K</given-names></name><name><surname>Otsu</surname><given-names>K</given-names></name></person-group><article-title>Inflammation and metabolic cardiomyopathy</article-title><source>Cardiovasc. Res.</source><year>2017</year><volume>113</volume><fpage>389</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx012</pub-id><pub-id pub-id-type="pmid">28395010</pub-id>
</element-citation><mixed-citation id="mc-CR161" publication-type="journal">Nishida, K. &#x00026; Otsu, K. Inflammation and metabolic cardiomyopathy. <italic>Cardiovasc. Res.</italic><bold>113</bold>, 389&#x02013;398 (2017).<pub-id pub-id-type="pmid">28395010</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><article-title>Inflammation and metabolic disorders</article-title><source>Nature</source><year>2006</year><volume>444</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1038/nature05485</pub-id><pub-id pub-id-type="pmid">17167474</pub-id>
</element-citation><mixed-citation id="mc-CR162" publication-type="journal">Hotamisligil, G. S. Inflammation and metabolic disorders. <italic>Nature</italic><bold>444</bold>, 860&#x02013;867 (2006).<pub-id pub-id-type="pmid">17167474</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name><surname>Wellen</surname><given-names>KE</given-names></name></person-group><article-title>Inflammation, stress, and diabetes</article-title><source>J. Clin. Investig.</source><year>2005</year><volume>115</volume><fpage>1111</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1172/JCI25102</pub-id><pub-id pub-id-type="pmid">15864338</pub-id>
</element-citation><mixed-citation id="mc-CR163" publication-type="journal">Wellen, K. E. Inflammation, stress, and diabetes. <italic>J. Clin. Investig.</italic><bold>115</bold>, 1111&#x02013;1119 (2005).<pub-id pub-id-type="pmid">15864338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name><surname>Bahrar</surname><given-names>H</given-names></name><etal/></person-group><article-title>Innate immune memory in cardiometabolic disease</article-title><source>Cardiovasc. Res.</source><year>2024</year><volume>119</volume><fpage>2774</fpage><lpage>2786</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvad030</pub-id><pub-id pub-id-type="pmid">36795085</pub-id>
</element-citation><mixed-citation id="mc-CR164" publication-type="journal">Bahrar, H. et al. Innate immune memory in cardiometabolic disease. <italic>Cardiovasc. Res.</italic><bold>119</bold>, 2774&#x02013;2786 (2024).<pub-id pub-id-type="pmid">36795085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>G</given-names></name><etal/></person-group><article-title>Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet</article-title><source>Hypertension</source><year>2015</year><volume>65</volume><fpage>531</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.114.04737</pub-id><pub-id pub-id-type="pmid">25489061</pub-id>
</element-citation><mixed-citation id="mc-CR165" publication-type="journal">Jia, G. et al. Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet. <italic>Hypertension</italic><bold>65</bold>, 531&#x02013;539 (2015).<pub-id pub-id-type="pmid">25489061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name><surname>Eguchi</surname><given-names>K</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name></person-group><article-title>Islet inflammation in type 2 diabetes and physiology</article-title><source>J. Clin. Investig.</source><year>2017</year><volume>127</volume><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1172/JCI88877</pub-id><pub-id pub-id-type="pmid">28045399</pub-id>
</element-citation><mixed-citation id="mc-CR166" publication-type="journal">Eguchi, K. &#x00026; Nagai, R. Islet inflammation in type 2 diabetes and physiology. <italic>J. Clin. Investig.</italic><bold>127</bold>, 14&#x02013;23 (2017).<pub-id pub-id-type="pmid">28045399</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Tu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name></person-group><article-title>Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy</article-title><source>Acta Pharmacol. Sin.</source><year>2019</year><volume>40</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/s41401-018-0042-6</pub-id><pub-id pub-id-type="pmid">29867137</pub-id>
</element-citation><mixed-citation id="mc-CR167" publication-type="journal">Knapp, M., Tu, X. &#x00026; Wu, R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. <italic>Acta Pharmacol. Sin.</italic><bold>40</bold>, 1&#x02013;8 (2019).<pub-id pub-id-type="pmid">29867137</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name><surname>Abumrad</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Endothelial cell receptors in tissue lipid uptake and metabolism</article-title><source>Circ. Res.</source><year>2021</year><volume>128</volume><fpage>433</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.318003</pub-id><pub-id pub-id-type="pmid">33539224</pub-id>
</element-citation><mixed-citation id="mc-CR168" publication-type="journal">Abumrad, N. A. et al. Endothelial cell receptors in tissue lipid uptake and metabolism. <italic>Circ. Res.</italic><bold>128</bold>, 433&#x02013;450 (2021).<pub-id pub-id-type="pmid">33539224</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Fibroblast-specific activation of Rnd3 protects against cardiac remodeling in diabetic cardiomyopathy via suppression of Notch and TGF-beta signaling</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>7250</fpage><lpage>7266</lpage><pub-id pub-id-type="doi">10.7150/thno.77043</pub-id><pub-id pub-id-type="pmid">36438502</pub-id>
</element-citation><mixed-citation id="mc-CR169" publication-type="journal">Zhang, Y. et al. Fibroblast-specific activation of Rnd3 protects against cardiac remodeling in diabetic cardiomyopathy via suppression of Notch and TGF-beta signaling. <italic>Theranostics</italic><bold>12</bold>, 7250&#x02013;7266 (2022).<pub-id pub-id-type="pmid">36438502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name><surname>Ballasy</surname><given-names>NN</given-names></name><etal/></person-group><article-title>Potential role of epicardial adipose tissue in coronary artery endothelial cell dysfunction in type 2 diabetes</article-title><source>FASEB J.</source><year>2021</year><volume>35</volume><fpage>e21878</fpage><pub-id pub-id-type="doi">10.1096/fj.202100684RR</pub-id><pub-id pub-id-type="pmid">34469050</pub-id>
</element-citation><mixed-citation id="mc-CR170" publication-type="journal">Ballasy, N. N., et al. Potential role of epicardial adipose tissue in coronary artery endothelial cell dysfunction in type 2 diabetes. <italic>FASEB J.</italic><bold>35</bold>, e21878 (2021).<pub-id pub-id-type="pmid">34469050</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name><surname>Wegner</surname><given-names>M</given-names></name><name><surname>Neddermann</surname><given-names>D</given-names></name><name><surname>Piorunska-Stolzmann</surname><given-names>M</given-names></name><name><surname>Jagodzinski</surname><given-names>PP</given-names></name></person-group><article-title>Role of epigenetic mechanisms in the development of chronic complications of diabetes</article-title><source>Diabetes Res. Clin. Pr.</source><year>2014</year><volume>105</volume><fpage>164</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2014.03.019</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Wegner, M., Neddermann, D., Piorunska-Stolzmann, M. &#x00026; Jagodzinski, P. P. Role of epigenetic mechanisms in the development of chronic complications of diabetes. <italic>Diabetes Res. Clin. Pr.</italic><bold>105</bold>, 164&#x02013;175 (2014).</mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>HC</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name></person-group><article-title>Heart failure in type 2 diabetes mellitus</article-title><source>Circ. Res.</source><year>2019</year><volume>124</volume><fpage>121</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.311371</pub-id><pub-id pub-id-type="pmid">30605420</pub-id>
</element-citation><mixed-citation id="mc-CR172" publication-type="journal">Kenny, H. C. &#x00026; Abel, E. D. Heart failure in type 2 diabetes mellitus. <italic>Circ. Res.</italic><bold>124</bold>, 121&#x02013;141 (2019).<pub-id pub-id-type="pmid">30605420</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><mixed-citation publication-type="other">Isselbacher, E. M. et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. <italic>Circulation</italic><bold>146</bold>, e334&#x02013;e482 (2022).</mixed-citation></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>MR</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name></person-group><article-title>Aortic aneurysms: current pathogenesis and therapeutic targets</article-title><source>Exp. Mol. Med.</source><year>2023</year><volume>55</volume><fpage>2519</fpage><lpage>2530</lpage><pub-id pub-id-type="doi">10.1038/s12276-023-01130-w</pub-id><pub-id pub-id-type="pmid">38036736</pub-id>
</element-citation><mixed-citation id="mc-CR174" publication-type="journal">Cho, M. J., Lee, M. R. &#x00026; Park, J. G. Aortic aneurysms: current pathogenesis and therapeutic targets. <italic>Exp. Mol. Med.</italic><bold>55</bold>, 2519&#x02013;2530 (2023).<pub-id pub-id-type="pmid">38036736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing reveals the cellular heterogeneity of aneurysmal infrarenal abdominal aorta</article-title><source>Cardiovasc. Res.</source><year>2021</year><volume>117</volume><fpage>1402</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvaa214</pub-id><pub-id pub-id-type="pmid">32678909</pub-id>
</element-citation><mixed-citation id="mc-CR175" publication-type="journal">Zhao, G. et al. Single-cell RNA sequencing reveals the cellular heterogeneity of aneurysmal infrarenal abdominal aorta. <italic>Cardiovasc. Res.</italic><bold>117</bold>, 1402&#x02013;1416 (2021).<pub-id pub-id-type="pmid">32678909</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Single-cell transcriptome analysis reveals dynamic cell populations and differential gene expression patterns in control and aneurysmal human aortic tissue</article-title><source>Circulation</source><year>2020</year><volume>142</volume><fpage>1374</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.046528</pub-id><pub-id pub-id-type="pmid">33017217</pub-id>
</element-citation><mixed-citation id="mc-CR176" publication-type="journal">Li, Y. et al. Single-cell transcriptome analysis reveals dynamic cell populations and differential gene expression patterns in control and aneurysmal human aortic tissue. <italic>Circulation</italic><bold>142</bold>, 1374&#x02013;1388 (2020).<pub-id pub-id-type="pmid">33017217</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name><surname>Smigiel</surname><given-names>KS</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Stolley</surname><given-names>JM</given-names></name><name><surname>Campbell</surname><given-names>DJ</given-names></name></person-group><article-title>Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation</article-title><source>Immunol. Rev.</source><year>2014</year><volume>259</volume><fpage>40</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1111/imr.12170</pub-id><pub-id pub-id-type="pmid">24712458</pub-id>
</element-citation><mixed-citation id="mc-CR177" publication-type="journal">Smigiel, K. S., Srivastava, S., Stolley, J. M. &#x00026; Campbell, D. J. Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. <italic>Immunol. Rev.</italic><bold>259</bold>, 40&#x02013;59 (2014).<pub-id pub-id-type="pmid">24712458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><mixed-citation publication-type="other">Dri, E. et al. Inflammatory mediators of endothelial dysfunction. <italic>Life</italic>. <bold>13</bold>, 1420 (2023).</mixed-citation></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name><surname>Bobryshev</surname><given-names>YV</given-names></name></person-group><article-title>Dendritic cells and their role in atherogenesis</article-title><source>Lab Investig.</source><year>2010</year><volume>90</volume><fpage>970</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2010.94</pub-id><pub-id pub-id-type="pmid">20458277</pub-id>
</element-citation><mixed-citation id="mc-CR179" publication-type="journal">Bobryshev, Y. V. Dendritic cells and their role in atherogenesis. <italic>Lab Investig.</italic><bold>90</bold>, 970&#x02013;984 (2010).<pub-id pub-id-type="pmid">20458277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Laminar shear stress inhibits inflammation by activating autophagy in human aortic endothelial cells through HMGB1 nuclear translocation</article-title><source>Commun. Biol.</source><year>2022</year><volume>5</volume><fpage>425</fpage><pub-id pub-id-type="doi">10.1038/s42003-022-03392-y</pub-id><pub-id pub-id-type="pmid">35523945</pub-id>
</element-citation><mixed-citation id="mc-CR180" publication-type="journal">Meng, Q. et al. Laminar shear stress inhibits inflammation by activating autophagy in human aortic endothelial cells through HMGB1 nuclear translocation. <italic>Commun. Biol.</italic><bold>5</bold>, 425 (2022).<pub-id pub-id-type="pmid">35523945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Macrophages regulate vascular smooth muscle cell function during atherosclerosis progression through IL-1beta/STAT3 signaling</article-title><source>Commun. Biol.</source><year>2022</year><volume>5</volume><fpage>1316</fpage><pub-id pub-id-type="doi">10.1038/s42003-022-04255-2</pub-id><pub-id pub-id-type="pmid">36456628</pub-id>
</element-citation><mixed-citation id="mc-CR181" publication-type="journal">Xue, Y. et al. Macrophages regulate vascular smooth muscle cell function during atherosclerosis progression through IL-1beta/STAT3 signaling. <italic>Commun. Biol.</italic><bold>5</bold>, 1316 (2022).<pub-id pub-id-type="pmid">36456628</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name><surname>Kenney</surname><given-names>MJ</given-names></name><name><surname>Ganta</surname><given-names>CK</given-names></name></person-group><article-title>Autonomic nervous system and immune system interactions</article-title><source>Compr. Physiol.</source><year>2014</year><volume>4</volume><fpage>1177</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1002/j.2040-4603.2014.tb00574.x</pub-id><pub-id pub-id-type="pmid">24944034</pub-id>
</element-citation><mixed-citation id="mc-CR182" publication-type="journal">Kenney, M. J. &#x00026; Ganta, C. K. Autonomic nervous system and immune system interactions. <italic>Compr. Physiol.</italic><bold>4</bold>, 1177&#x02013;1200 (2014).<pub-id pub-id-type="pmid">24944034</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Abdominal aortic aneurysm: roles of inflammatory cells</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>609161</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.609161</pub-id><pub-id pub-id-type="pmid">33613530</pub-id>
</element-citation><mixed-citation id="mc-CR183" publication-type="journal">Yuan, Z. et al. Abdominal aortic aneurysm: roles of inflammatory cells. <italic>Front. Immunol.</italic><bold>11</bold>, 609161 (2020).<pub-id pub-id-type="pmid">33613530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>FM</given-names></name><name><surname>Gallagher</surname><given-names>KA</given-names></name></person-group><article-title>Epigenetic mechanisms in monocytes/macrophages regulate inflammation in cardiometabolic and vascular disease</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2019</year><volume>39</volume><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.312135</pub-id><pub-id pub-id-type="pmid">30760015</pub-id>
</element-citation><mixed-citation id="mc-CR184" publication-type="journal">Davis, F. M. &#x00026; Gallagher, K. A. Epigenetic mechanisms in monocytes/macrophages regulate inflammation in cardiometabolic and vascular disease. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>39</bold>, 623&#x02013;634 (2019).<pub-id pub-id-type="pmid">30760015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Aortic intimal resident macrophages are essential for maintenance of the non-thrombogenic intravascular state</article-title><source>Nat. Cardiovasc. Res.</source><year>2022</year><volume>1</volume><fpage>67</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/s44161-021-00006-4</pub-id><pub-id pub-id-type="pmid">35599984</pub-id>
</element-citation><mixed-citation id="mc-CR185" publication-type="journal">Hernandez, G. E. et al. Aortic intimal resident macrophages are essential for maintenance of the non-thrombogenic intravascular state. <italic>Nat. Cardiovasc. Res.</italic><bold>1</bold>, 67&#x02013;84 (2022).<pub-id pub-id-type="pmid">35599984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves</article-title><source>J. Exp. Med.</source><year>2009</year><volume>206</volume><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1084/jem.20082129</pub-id><pub-id pub-id-type="pmid">19221394</pub-id>
</element-citation><mixed-citation id="mc-CR186" publication-type="journal">Choi, J. H. et al. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. <italic>J. Exp. Med.</italic><bold>206</bold>, 497&#x02013;505 (2009).<pub-id pub-id-type="pmid">19221394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><article-title>Dendritic cells and the control of immunity</article-title><source>Nature</source><year>1998</year><volume>392</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/32588</pub-id><pub-id pub-id-type="pmid">9521319</pub-id>
</element-citation><mixed-citation id="mc-CR187" publication-type="journal">Banchereau, J. &#x00026; Steinman, R. M. Dendritic cells and the control of immunity. <italic>Nature</italic><bold>392</bold>, 245&#x02013;252 (1998).<pub-id pub-id-type="pmid">9521319</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma-Krupa</surname><given-names>W</given-names></name><etal/></person-group><article-title>Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis</article-title><source>J. Exp. Med.</source><year>2004</year><volume>199</volume><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1084/jem.20030850</pub-id><pub-id pub-id-type="pmid">14734523</pub-id>
</element-citation><mixed-citation id="mc-CR188" publication-type="journal">Ma-Krupa, W. et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. <italic>J. Exp. Med.</italic><bold>199</bold>, 173&#x02013;183 (2004).<pub-id pub-id-type="pmid">14734523</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name><surname>Jauhiainen</surname><given-names>S</given-names></name><name><surname>Kiema</surname><given-names>M</given-names></name><name><surname>Hedman</surname><given-names>M</given-names></name><name><surname>Laakkonen</surname><given-names>JP</given-names></name></person-group><article-title>Large Vessel Cell Heterogeneity and plasticity: focus in aortic aneurysms</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2022</year><volume>42</volume><fpage>811</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.121.316237</pub-id><pub-id pub-id-type="pmid">35587695</pub-id>
</element-citation><mixed-citation id="mc-CR189" publication-type="journal">Jauhiainen, S., Kiema, M., Hedman, M. &#x00026; Laakkonen, J. P. Large Vessel Cell Heterogeneity and plasticity: focus in aortic aneurysms. <italic>Arterioscler. Thromb. Vasc. Biol.</italic><bold>42</bold>, 811&#x02013;818 (2022).<pub-id pub-id-type="pmid">35587695</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Aorta regulatory T cells with a tissue-specific phenotype and function promote tissue repair through Tff1 in abdominal aortic aneurysms</article-title><source>Adv. Sci.</source><year>2022</year><volume>9</volume><fpage>e2104338</fpage><pub-id pub-id-type="doi">10.1002/advs.202104338</pub-id></element-citation><mixed-citation id="mc-CR190" publication-type="journal">Li, J., et al. Aorta regulatory T cells with a tissue-specific phenotype and function promote tissue repair through Tff1 in abdominal aortic aneurysms. <italic>Adv. Sci.</italic><bold>9</bold>, e2104338 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets</article-title><source>Cell Death Discov.</source><year>2024</year><volume>10</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.1038/s41420-023-01792-5</pub-id><pub-id pub-id-type="pmid">38355681</pub-id>
</element-citation><mixed-citation id="mc-CR191" publication-type="journal">Luan, Y. et al. Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets. <italic>Cell Death Discov.</italic><bold>10</bold>, 78 (2024).<pub-id pub-id-type="pmid">38355681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name><surname>Desd&#x000ed;n-Mic&#x000f3;</surname><given-names>G</given-names></name><etal/></person-group><article-title>T cells with dysfunctional mitochondria induce multimorbidity and premature senescence</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>1371</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1126/science.aax0860</pub-id><pub-id pub-id-type="pmid">32439659</pub-id>
</element-citation><mixed-citation id="mc-CR192" publication-type="journal">Desd&#x000ed;n-Mic&#x000f3;, G. et al. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. <italic>Science</italic><bold>368</bold>, 1371&#x02013;1376 (2020).<pub-id pub-id-type="pmid">32439659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name><surname>Faust</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis</article-title><source>J. Clin. Investig.</source><year>2020</year><volume>130</volume><fpage>5493</fpage><lpage>5507</lpage><pub-id pub-id-type="doi">10.1172/JCI134091</pub-id><pub-id pub-id-type="pmid">32955487</pub-id>
</element-citation><mixed-citation id="mc-CR193" publication-type="journal">Faust, H. J. et al. IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis. <italic>J. Clin. Investig.</italic><bold>130</bold>, 5493&#x02013;5507 (2020).<pub-id pub-id-type="pmid">32955487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name><surname>Ovadya</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Impaired immune surveillance accelerates accumulation of senescent cells and aging</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>5435</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-07825-3</pub-id><pub-id pub-id-type="pmid">30575733</pub-id>
</element-citation><mixed-citation id="mc-CR194" publication-type="journal">Ovadya, Y., et al. Impaired immune surveillance accelerates accumulation of senescent cells and aging. <italic>Nat. Commun.</italic><bold>9</bold>, 5435 (2018).<pub-id pub-id-type="pmid">30575733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name><surname>Elyahu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Aging promotes reorganization of the CD4 T cell landscape toward extreme regulatory and effector phenotypes</article-title><source>Sci. Adv.</source><year>2019</year><volume>5</volume><fpage>eaaw8330</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aaw8330</pub-id><pub-id pub-id-type="pmid">31457092</pub-id>
</element-citation><mixed-citation id="mc-CR195" publication-type="journal">Elyahu, Y., et al. Aging promotes reorganization of the CD4 T cell landscape toward extreme regulatory and effector phenotypes. <italic>Sci. Adv.</italic><bold>5</bold>, eaaw8330 (2019).<pub-id pub-id-type="pmid">31457092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>BI</given-names></name><etal/></person-group><article-title>Sestrins induce natural killer function in senescent-like CD8(+) T cells</article-title><source>Nat. Immunol.</source><year>2020</year><volume>21</volume><fpage>684</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0643-3</pub-id><pub-id pub-id-type="pmid">32231301</pub-id>
</element-citation><mixed-citation id="mc-CR196" publication-type="journal">Pereira, B. I. et al. Sestrins induce natural killer function in senescent-like CD8(+) T cells. <italic>Nat. Immunol.</italic><bold>21</bold>, 684&#x02013;694 (2020).<pub-id pub-id-type="pmid">32231301</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>PH</given-names></name><name><surname>Chen</surname><given-names>HZ</given-names></name></person-group><article-title>Cardiomyocyte senescence and cellular communications within myocardial microenvironments</article-title><source>Front. Endocrinol.</source><year>2020</year><volume>11</volume><fpage>280</fpage><pub-id pub-id-type="doi">10.3389/fendo.2020.00280</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">Tang, X., Li, P. H. &#x00026; Chen, H. Z. Cardiomyocyte senescence and cellular communications within myocardial microenvironments. <italic>Front. Endocrinol.</italic><bold>11</bold>, 280 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>GP</given-names></name></person-group><article-title>Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases</article-title><source>Curr. Pharmacol. Des.</source><year>2013</year><volume>19</volume><fpage>1114</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.2174/1381612811319060012</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">He, A. &#x00026; Shi, G. P. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases. <italic>Curr. Pharmacol. Des.</italic><bold>19</bold>, 1114&#x02013;1125 (2013).</mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name><surname>Grim</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Secreted factors from proinflammatory macrophages promote an osteoblast-like phenotype in valvular interstitial cells</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2020</year><volume>40</volume><fpage>e296</fpage><lpage>e308</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.120.315261</pub-id><pub-id pub-id-type="pmid">32938214</pub-id>
</element-citation><mixed-citation id="mc-CR199" publication-type="journal">Grim, J. C. et al. Secreted factors from proinflammatory macrophages promote an osteoblast-like phenotype in valvular interstitial cells. <italic>Arterioscler. Thromb. Vasc. Biol.</italic><bold>40</bold>, e296&#x02013;e308 (2020).<pub-id pub-id-type="pmid">32938214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name><surname>Bloom</surname><given-names>SI</given-names></name><name><surname>Islam</surname><given-names>MT</given-names></name><name><surname>Lesniewski</surname><given-names>LA</given-names></name><name><surname>Donato</surname><given-names>AJ</given-names></name></person-group><article-title>Mechanisms and consequences of endothelial cell senescence</article-title><source>Nat. Rev. Cardiol.</source><year>2023</year><volume>20</volume><fpage>38</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/s41569-022-00739-0</pub-id><pub-id pub-id-type="pmid">35853997</pub-id>
</element-citation><mixed-citation id="mc-CR200" publication-type="journal">Bloom, S. I., Islam, M. T., Lesniewski, L. A. &#x00026; Donato, A. J. Mechanisms and consequences of endothelial cell senescence. <italic>Nat. Rev. Cardiol.</italic><bold>20</bold>, 38&#x02013;51 (2023).<pub-id pub-id-type="pmid">35853997</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>SE</given-names></name><name><surname>Humphry</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>MR</given-names></name><name><surname>Clarke</surname><given-names>MC</given-names></name></person-group><article-title>Senescent vascular smooth muscle cells drive inflammation through an interleukin-1&#x003b1;-dependent senescence-associated secretory phenotype</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2015</year><volume>35</volume><fpage>1963</fpage><lpage>1974</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.115.305896</pub-id><pub-id pub-id-type="pmid">26139463</pub-id>
</element-citation><mixed-citation id="mc-CR201" publication-type="journal">Gardner, S. E., Humphry, M., Bennett, M. R. &#x00026; Clarke, M. C. Senescent vascular smooth muscle cells drive inflammation through an interleukin-1&#x003b1;-dependent senescence-associated secretory phenotype. <italic>Arterioscler. Thromb. Vasc. Biol.</italic><bold>35</bold>, 1963&#x02013;1974 (2015).<pub-id pub-id-type="pmid">26139463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name><surname>Grune</surname><given-names>J</given-names></name><name><surname>Yamazoe</surname><given-names>M</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name></person-group><article-title>Electroimmunology and cardiac arrhythmia</article-title><source>Nat. Rev. Cardiol.</source><year>2021</year><volume>18</volume><fpage>547</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/s41569-021-00520-9</pub-id><pub-id pub-id-type="pmid">33654273</pub-id>
</element-citation><mixed-citation id="mc-CR202" publication-type="journal">Grune, J., Yamazoe, M. &#x00026; Nahrendorf, M. Electroimmunology and cardiac arrhythmia. <italic>Nat. Rev. Cardiol.</italic><bold>18</bold>, 547&#x02013;564 (2021).<pub-id pub-id-type="pmid">33654273</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name><surname>Baksi</surname><given-names>AJ</given-names></name><name><surname>Kanaganayagam</surname><given-names>GS</given-names></name><name><surname>Prasad</surname><given-names>SK</given-names></name></person-group><article-title>Arrhythmias in viral myocarditis and pericarditis</article-title><source>Card. Electrophysiol. Clin.</source><year>2015</year><volume>7</volume><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.ccep.2015.03.009</pub-id><pub-id pub-id-type="pmid">26002391</pub-id>
</element-citation><mixed-citation id="mc-CR203" publication-type="journal">Baksi, A. J., Kanaganayagam, G. S. &#x00026; Prasad, S. K. Arrhythmias in viral myocarditis and pericarditis. <italic>Card. Electrophysiol. Clin.</italic><bold>7</bold>, 269&#x02013;281 (2015).<pub-id pub-id-type="pmid">26002391</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>M</given-names></name><etal/></person-group><article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title><source>JAMA</source><year>2016</year><volume>315</volume><fpage>801</fpage><pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmid">26903338</pub-id>
</element-citation><mixed-citation id="mc-CR204" publication-type="journal">Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). <italic>JAMA</italic><bold>315</bold>, 801 (2016).<pub-id pub-id-type="pmid">26903338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrev</surname><given-names>D</given-names></name><etal/></person-group><article-title>Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology</article-title><source>Nat. Rev. Cardiol.</source><year>2023</year><volume>20</volume><fpage>145</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/s41569-022-00759-w</pub-id><pub-id pub-id-type="pmid">36109633</pub-id>
</element-citation><mixed-citation id="mc-CR205" publication-type="journal">Dobrev, D. et al. Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology. <italic>Nat. Rev. Cardiol.</italic><bold>20</bold>, 145&#x02013;167 (2023).<pub-id pub-id-type="pmid">36109633</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name><surname>Lazzerini</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>63</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0098-z</pub-id><pub-id pub-id-type="pmid">30552387</pub-id>
</element-citation><mixed-citation id="mc-CR206" publication-type="journal">Lazzerini, P. E. et al. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. <italic>Nat. Rev. Immunol.</italic><bold>19</bold>, 63&#x02013;64 (2019).<pub-id pub-id-type="pmid">30552387</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>GQ</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Boutjdir</surname><given-names>M</given-names></name></person-group><article-title>Direct inhibition of expressed cardiac L- and T-type calcium channels by IgG from mothers whose children have congenital heart block</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>1599</fpage><lpage>1604</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.103.11.1599</pub-id><pub-id pub-id-type="pmid">11257091</pub-id>
</element-citation><mixed-citation id="mc-CR207" publication-type="journal">Xiao, G. Q., Hu, K. &#x00026; Boutjdir, M. Direct inhibition of expressed cardiac L- and T-type calcium channels by IgG from mothers whose children have congenital heart block. <italic>Circulation</italic><bold>103</bold>, 1599&#x02013;1604 (2001).<pub-id pub-id-type="pmid">11257091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name><surname>Karnabi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of &#x003b1;1D L-type Ca channel</article-title><source>J. Autoimmun.</source><year>2010</year><volume>34</volume><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2009.06.005</pub-id><pub-id pub-id-type="pmid">19640679</pub-id>
</element-citation><mixed-citation id="mc-CR208" publication-type="journal">Karnabi, E. et al. Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of &#x003b1;1D L-type Ca channel. <italic>J. Autoimmun.</italic><bold>34</bold>, 80&#x02013;86 (2010).<pub-id pub-id-type="pmid">19640679</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name><surname>Lazzerini</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Anti-Ro/SSA antibodies blocking calcium channels as a potentially reversible cause of atrioventricular block in adults</article-title><source>JACC Clin. Electrophysiol.</source><year>2023</year><volume>9</volume><fpage>1631</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1016/j.jacep.2023.03.007</pub-id><pub-id pub-id-type="pmid">37227349</pub-id>
</element-citation><mixed-citation id="mc-CR209" publication-type="journal">Lazzerini, P. E. et al. Anti-Ro/SSA antibodies blocking calcium channels as a potentially reversible cause of atrioventricular block in adults. <italic>JACC Clin. Electrophysiol.</italic><bold>9</bold>, 1631&#x02013;1648 (2023).<pub-id pub-id-type="pmid">37227349</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Noninvasive fetal electrocardiography in the diagnosis of long QT syndrome: a case series</article-title><source>Fetal Diagn. Ther.</source><year>2020</year><volume>47</volume><fpage>711</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1159/000508043</pub-id><pub-id pub-id-type="pmid">32615554</pub-id>
</element-citation><mixed-citation id="mc-CR210" publication-type="journal">Sethi, N. et al. Noninvasive fetal electrocardiography in the diagnosis of long QT syndrome: a case series. <italic>Fetal Diagn. Ther.</italic><bold>47</bold>, 711&#x02013;716 (2020).<pub-id pub-id-type="pmid">32615554</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>Y</given-names></name><name><surname>Casadei</surname><given-names>B</given-names></name><name><surname>Mar&#x000ed;n-Garc&#x000ed;a</surname><given-names>J</given-names></name></person-group><article-title>Pathogenesis of the novel autoimmune-associated long-QT syndrome</article-title><source>Circulation</source><year>2015</year><volume>132</volume><fpage>230</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.009800</pub-id><pub-id pub-id-type="pmid">25995318</pub-id>
</element-citation><mixed-citation id="mc-CR211" publication-type="journal">Yue, Y., Casadei, B. &#x00026; Mar&#x000ed;n-Garc&#x000ed;a, J. Pathogenesis of the novel autoimmune-associated long-QT syndrome. <italic>Circulation</italic><bold>132</bold>, 230&#x02013;240 (2015).<pub-id pub-id-type="pmid">25995318</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name><surname>Lazzerini</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Arrhythmogenicity of anti-Ro/SSA antibodies in patients with torsades de pointes</article-title><source>Circ. Arrhythm. Electrophysiol.</source><year>2016</year><volume>9</volume><fpage>e003419</fpage><pub-id pub-id-type="doi">10.1161/CIRCEP.115.003419</pub-id><pub-id pub-id-type="pmid">27030700</pub-id>
</element-citation><mixed-citation id="mc-CR212" publication-type="journal">Lazzerini, P. E., et al. Arrhythmogenicity of anti-Ro/SSA antibodies in patients with torsades de pointes. <italic>Circ. Arrhythm. Electrophysiol.</italic><bold>9</bold>, e003419 (2016).<pub-id pub-id-type="pmid">27030700</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cardiac involvements in myasthenia gravis associated with anti-KV1.4 antibodies</article-title><source>Eur. J. Neurol.</source><year>2014</year><volume>21</volume><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1111/ene.12234</pub-id><pub-id pub-id-type="pmid">23829303</pub-id>
</element-citation><mixed-citation id="mc-CR213" publication-type="journal">Suzuki, S. et al. Cardiac involvements in myasthenia gravis associated with anti-KV1.4 antibodies. <italic>Eur. J. Neurol.</italic><bold>21</bold>, 223&#x02013;230 (2014).<pub-id pub-id-type="pmid">23829303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Anti-KCNQ1 K channel autoantibodies increase IKs current and are associated with QT interval shortening in dilated cardiomyopathy</article-title><source>Cardiovasc. Res.</source><year>2013</year><volume>98</volume><fpage>496</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt046</pub-id><pub-id pub-id-type="pmid">23447643</pub-id>
</element-citation><mixed-citation id="mc-CR214" publication-type="journal">Li, J. et al. Anti-KCNQ1 K channel autoantibodies increase IKs current and are associated with QT interval shortening in dilated cardiomyopathy. <italic>Cardiovasc. Res.</italic><bold>98</bold>, 496&#x02013;503 (2013).<pub-id pub-id-type="pmid">23447643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>A</given-names></name><name><surname>Kontorovich</surname><given-names>AR</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Dec</surname><given-names>GW</given-names></name></person-group><article-title>Viral myocarditis-diagnosis, treatment options, and current controversies</article-title><source>Nat. Rev. Cardiol.</source><year>2015</year><volume>12</volume><fpage>670</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2015.108</pub-id><pub-id pub-id-type="pmid">26194549</pub-id>
</element-citation><mixed-citation id="mc-CR215" publication-type="journal">Pollack, A., Kontorovich, A. R., Fuster, V. &#x00026; Dec, G. W. Viral myocarditis-diagnosis, treatment options, and current controversies. <italic>Nat. Rev. Cardiol.</italic><bold>12</bold>, 670&#x02013;680 (2015).<pub-id pub-id-type="pmid">26194549</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsch&#x000f6;pe</surname><given-names>C</given-names></name><etal/></person-group><article-title>Myocarditis and inflammatory cardiomyopathy: current evidence and future directions</article-title><source>Nat. Rev. Cardiol.</source><year>2021</year><volume>18</volume><fpage>169</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1038/s41569-020-00435-x</pub-id><pub-id pub-id-type="pmid">33046850</pub-id>
</element-citation><mixed-citation id="mc-CR216" publication-type="journal">Tsch&#x000f6;pe, C. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. <italic>Nat. Rev. Cardiol.</italic><bold>18</bold>, 169&#x02013;193 (2021).<pub-id pub-id-type="pmid">33046850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name><surname>Koc</surname><given-names>A</given-names></name><name><surname>Cagavi</surname><given-names>E</given-names></name></person-group><article-title>Cardiac immunology: a new era for immune cells in the heart</article-title><source>Adv. Exp. Med. Biol.</source><year>2021</year><volume>1312</volume><fpage>75</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/5584_2020_576</pub-id><pub-id pub-id-type="pmid">32910424</pub-id>
</element-citation><mixed-citation id="mc-CR217" publication-type="journal">Koc, A. &#x00026; Cagavi, E. Cardiac immunology: a new era for immune cells in the heart. <italic>Adv. Exp. Med. Biol.</italic><bold>1312</bold>, 75&#x02013;95 (2021).<pub-id pub-id-type="pmid">32910424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>M</given-names></name><etal/></person-group><article-title>TRIM18 is a critical regulator of viral myocarditis and organ inflammation</article-title><source>J. Biomed. Sci.</source><year>2022</year><volume>29</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/s12929-022-00840-z</pub-id><pub-id pub-id-type="pmid">35909127</pub-id>
</element-citation><mixed-citation id="mc-CR218" publication-type="journal">Fang, M. et al. TRIM18 is a critical regulator of viral myocarditis and organ inflammation. <italic>J. Biomed. Sci.</italic><bold>29</bold>, 55 (2022).<pub-id pub-id-type="pmid">35909127</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Loss of TRIM29 mitigates viral myocarditis by attenuating PERK-driven ER stress response in male mice</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>3481</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-44745-x</pub-id><pub-id pub-id-type="pmid">38664417</pub-id>
</element-citation><mixed-citation id="mc-CR219" publication-type="journal">Wang, J., et al. Loss of TRIM29 mitigates viral myocarditis by attenuating PERK-driven ER stress response in male mice. <italic>Nat. Commun.</italic><bold>15</bold>, 3481 (2024).<pub-id pub-id-type="pmid">38664417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name><surname>Pappritz</surname><given-names>K</given-names></name><etal/></person-group><article-title>Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis</article-title><source>FASEB J.</source><year>2018</year><volume>32</volume><fpage>6066</fpage><lpage>6078</lpage><pub-id pub-id-type="doi">10.1096/fj.201701408R</pub-id></element-citation><mixed-citation id="mc-CR220" publication-type="journal">Pappritz, K. et al. Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis. <italic>FASEB J.</italic><bold>32</bold>, 6066&#x02013;6078 (2018).</mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name><surname>Dubin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>10391</fpage><pub-id pub-id-type="doi">10.1038/ncomms10391</pub-id><pub-id pub-id-type="pmid">26837003</pub-id>
</element-citation><mixed-citation id="mc-CR221" publication-type="journal">Dubin, K., et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. <italic>Nat. Commun.</italic><bold>7</bold>, 10391 (2016).<pub-id pub-id-type="pmid">26837003</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name><surname>Kindermann</surname><given-names>I</given-names></name><etal/></person-group><article-title>Update on myocarditis</article-title><source>J. Am. Coll. Cardiol.</source><year>2012</year><volume>59</volume><fpage>779</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2011.09.074</pub-id><pub-id pub-id-type="pmid">22361396</pub-id>
</element-citation><mixed-citation id="mc-CR222" publication-type="journal">Kindermann, I. et al. Update on myocarditis. <italic>J. Am. Coll. Cardiol.</italic><bold>59</bold>, 779&#x02013;792 (2012).<pub-id pub-id-type="pmid">22361396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name><surname>Sury</surname><given-names>K</given-names></name><name><surname>Perazella</surname><given-names>MA</given-names></name><name><surname>Shirali</surname><given-names>AC</given-names></name></person-group><article-title>Cardiorenal complications of immune checkpoint inhibitors</article-title><source>Nat. Rev. Nephrol.</source><year>2018</year><volume>14</volume><fpage>571</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1038/s41581-018-0035-1</pub-id><pub-id pub-id-type="pmid">30013100</pub-id>
</element-citation><mixed-citation id="mc-CR223" publication-type="journal">Sury, K., Perazella, M. A. &#x00026; Shirali, A. C. Cardiorenal complications of immune checkpoint inhibitors. <italic>Nat. Rev. Nephrol.</italic><bold>14</bold>, 571&#x02013;588 (2018).<pub-id pub-id-type="pmid">30013100</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors</article-title><source>BMC Med.</source><year>2021</year><volume>19</volume><fpage>140</fpage><pub-id pub-id-type="doi">10.1186/s12916-021-02006-4</pub-id><pub-id pub-id-type="pmid">34112147</pub-id>
</element-citation><mixed-citation id="mc-CR224" publication-type="journal">Wang, S. et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. <italic>BMC Med.</italic><bold>19</bold>, 140 (2021).<pub-id pub-id-type="pmid">34112147</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name><surname>Kantarjian</surname><given-names>H</given-names></name><etal/></person-group><article-title>Blinatumomab versus chemotherapy for Advanced Acute Lymphoblastic Leukemia</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>376</volume><fpage>836</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1609783</pub-id><pub-id pub-id-type="pmid">28249141</pub-id>
</element-citation><mixed-citation id="mc-CR225" publication-type="journal">Kantarjian, H. et al. Blinatumomab versus chemotherapy for Advanced Acute Lymphoblastic Leukemia. <italic>N. Engl. J. Med.</italic><bold>376</bold>, 836&#x02013;847 (2017).<pub-id pub-id-type="pmid">28249141</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name><surname>Grupp</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Chimeric antigen receptor-modified T cells for acute lymphoid leukemia</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>1509</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1215134</pub-id><pub-id pub-id-type="pmid">23527958</pub-id>
</element-citation><mixed-citation id="mc-CR226" publication-type="journal">Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. <italic>N. Engl. J. Med.</italic><bold>368</bold>, 1509&#x02013;1518 (2013).<pub-id pub-id-type="pmid">23527958</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells</article-title><source>Sci. Transl. Med.</source><year>2013</year><volume>5</volume><fpage>ra103</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3006034</pub-id></element-citation><mixed-citation id="mc-CR227" publication-type="journal">Cameron, B. J. et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. <italic>Sci. Transl. Med.</italic><bold>5</bold>, ra103 (2013).</mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228.</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name><surname>Minotti</surname><given-names>G</given-names></name><name><surname>Menna</surname><given-names>P</given-names></name><name><surname>Salvatorelli</surname><given-names>E</given-names></name><name><surname>Cairo</surname><given-names>G</given-names></name><name><surname>Gianni</surname><given-names>L</given-names></name></person-group><article-title>Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity</article-title><source>Pharm. Rev.</source><year>2004</year><volume>56</volume><fpage>185</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1124/pr.56.2.6</pub-id><pub-id pub-id-type="pmid">15169927</pub-id>
</element-citation><mixed-citation id="mc-CR228" publication-type="journal">Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. &#x00026; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. <italic>Pharm. Rev.</italic><bold>56</bold>, 185&#x02013;229 (2004).<pub-id pub-id-type="pmid">15169927</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229.</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhagat</surname><given-names>A</given-names></name><name><surname>Shrestha</surname><given-names>P</given-names></name><name><surname>Kleinerman</surname><given-names>ES</given-names></name></person-group><article-title>The innate immunesystem in cardiovascular diseases and Its role in doxorubicin-induced cardiotoxicity</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><fpage>14649</fpage><pub-id pub-id-type="doi">10.3390/ijms232314649</pub-id><pub-id pub-id-type="pmid">36498974</pub-id>
</element-citation><mixed-citation id="mc-CR229" publication-type="journal">Bhagat, A., Shrestha, P. &#x00026; Kleinerman, E. S. The innate immunesystem in cardiovascular diseases and Its role in doxorubicin-induced cardiotoxicity. <italic>Int. J. Mol. Sci.</italic><bold>23</bold>, 14649 (2022).<pub-id pub-id-type="pmid">36498974</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230.</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name><surname>Bayer</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction</article-title><source>Nat. Cardiovasc. Res.</source><year>2024</year><volume>3</volume><fpage>970</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1038/s44161-024-00507-y</pub-id><pub-id pub-id-type="pmid">39196030</pub-id>
</element-citation><mixed-citation id="mc-CR230" publication-type="journal">Bayer, A. L. et al. Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction. <italic>Nat. Cardiovasc. Res.</italic><bold>3</bold>, 970&#x02013;986 (2024).<pub-id pub-id-type="pmid">39196030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231.</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Triptolide induces p53-dependent cardiotoxicity through mitochondrial membrane permeabilization in cardiomyocytes</article-title><source>Toxicol. Appl. Pharmacol.</source><year>2018</year><volume>355</volume><fpage>269</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2018.07.011</pub-id><pub-id pub-id-type="pmid">30009776</pub-id>
</element-citation><mixed-citation id="mc-CR231" publication-type="journal">Xi, Y. et al. Triptolide induces p53-dependent cardiotoxicity through mitochondrial membrane permeabilization in cardiomyocytes. <italic>Toxicol. Appl. Pharmacol.</italic><bold>355</bold>, 269&#x02013;285 (2018).<pub-id pub-id-type="pmid">30009776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232.</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SR</given-names></name><etal/></person-group><article-title>MicroRNA expression, targeting, release dynamics and early-warning biomarkers in acute cardiotoxicity induced by triptolide in rats</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>111</volume><fpage>1467</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.109</pub-id><pub-id pub-id-type="pmid">30841462</pub-id>
</element-citation><mixed-citation id="mc-CR232" publication-type="journal">Wang, S. R. et al. MicroRNA expression, targeting, release dynamics and early-warning biomarkers in acute cardiotoxicity induced by triptolide in rats. <italic>Biomed. Pharmacother.</italic><bold>111</bold>, 1467&#x02013;1477 (2019).<pub-id pub-id-type="pmid">30841462</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233.</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name><surname>Dent</surname><given-names>SF</given-names></name><name><surname>Morse</surname><given-names>A</given-names></name><name><surname>Burnette</surname><given-names>S</given-names></name><name><surname>Guha</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>H</given-names></name></person-group><article-title>Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer</article-title><source>Curr. Oncol. Rep.</source><year>2021</year><volume>23</volume><fpage>128</fpage><pub-id pub-id-type="doi">10.1007/s11912-021-01114-x</pub-id><pub-id pub-id-type="pmid">34453232</pub-id>
</element-citation><mixed-citation id="mc-CR233" publication-type="journal">Dent, S. F., Morse, A., Burnette, S., Guha, A. &#x00026; Moore, H. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. <italic>Curr. Oncol. Rep.</italic><bold>23</bold>, 128 (2021).<pub-id pub-id-type="pmid">34453232</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234.</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name><surname>Mahalingaiah</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates</article-title><source>Pharm. Ther.</source><year>2019</year><volume>200</volume><fpage>110</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.04.008</pub-id></element-citation><mixed-citation id="mc-CR234" publication-type="journal">Mahalingaiah, P. K. et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. <italic>Pharm. Ther.</italic><bold>200</bold>, 110&#x02013;125 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235.</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>RJ</given-names></name><name><surname>Chien</surname><given-names>J</given-names></name></person-group><article-title>Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers</article-title><source>J. Pharm. Sci.</source><year>2014</year><volume>103</volume><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1002/jps.23761</pub-id><pub-id pub-id-type="pmid">24186148</pub-id>
</element-citation><mixed-citation id="mc-CR235" publication-type="journal">Ho, R. J. &#x00026; Chien, J. Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers. <italic>J. Pharm. Sci.</italic><bold>103</bold>, 71&#x02013;77 (2014).<pub-id pub-id-type="pmid">24186148</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236.</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>GM</given-names></name><name><surname>Reiss</surname><given-names>P</given-names></name></person-group><article-title>Abacavir and cardiovascular risk</article-title><source>Curr. Opin. Infect. Dis.</source><year>2010</year><volume>23</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e328334fe84</pub-id><pub-id pub-id-type="pmid">19996748</pub-id>
</element-citation><mixed-citation id="mc-CR236" publication-type="journal">Behrens, G. M. &#x00026; Reiss, P. Abacavir and cardiovascular risk. <italic>Curr. Opin. Infect. Dis.</italic><bold>23</bold>, 9&#x02013;14 (2010).<pub-id pub-id-type="pmid">19996748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237.</label><citation-alternatives><element-citation id="ec-CR237" publication-type="journal"><person-group person-group-type="author"><name><surname>Fresse</surname><given-names>A</given-names></name><etal/></person-group><article-title>Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem</article-title><source>Int. J. Cardiol.</source><year>2021</year><volume>324</volume><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2020.10.028</pub-id><pub-id pub-id-type="pmid">33075384</pub-id>
</element-citation><mixed-citation id="mc-CR237" publication-type="journal">Fresse, A. et al. Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem. <italic>Int. J. Cardiol.</italic><bold>324</bold>, 255&#x02013;260 (2021).<pub-id pub-id-type="pmid">33075384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR238"><label>238.</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name><surname>Marzolini</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e01177</fpage><lpage>01120</lpage><pub-id pub-id-type="doi">10.1128/AAC.01177-20</pub-id><pub-id pub-id-type="pmid">32641296</pub-id>
</element-citation><mixed-citation id="mc-CR238" publication-type="journal">Marzolini, C. et al. Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations. <italic>Antimicrob. Agents Chemother.</italic><bold>64</bold>, e01177&#x02013;01120 (2020).<pub-id pub-id-type="pmid">32641296</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239.</label><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name><surname>Durrington</surname><given-names>C</given-names></name><etal/></person-group><article-title>Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry</article-title><source>Eur. Respir. J.</source><year>2024</year><volume>63</volume><fpage>2300846</fpage><pub-id pub-id-type="doi">10.1183/13993003.00846-2023</pub-id><pub-id pub-id-type="pmid">38302154</pub-id>
</element-citation><mixed-citation id="mc-CR239" publication-type="journal">Durrington, C. et al. Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry. <italic>Eur. Respir. J.</italic><bold>63</bold>, 2300846 (2024).<pub-id pub-id-type="pmid">38302154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR240"><label>240.</label><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Complement-coagulation cross-talk:factor H-mediated regulation of the complement classical pathway activation by fibrin clots</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1368852</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1368852</pub-id><pub-id pub-id-type="pmid">38933264</pub-id>
</element-citation><mixed-citation id="mc-CR240" publication-type="journal">Kang, Y. H. et al. Complement-coagulation cross-talk:factor H-mediated regulation of the complement classical pathway activation by fibrin clots. <italic>Front. Immunol.</italic><bold>15</bold>, 1368852 (2024).<pub-id pub-id-type="pmid">38933264</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR241"><label>241.</label><citation-alternatives><element-citation id="ec-CR241" publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>K</given-names></name><name><surname>Massberg</surname><given-names>S</given-names></name></person-group><article-title>Interplay between inflammation and thrombosis in cardiovascular pathology</article-title><source>Nat. Rev. Cardiol.</source><year>2021</year><volume>18</volume><fpage>666</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/s41569-021-00552-1</pub-id><pub-id pub-id-type="pmid">33958774</pub-id>
</element-citation><mixed-citation id="mc-CR241" publication-type="journal">Stark, K. &#x00026; Massberg, S. Interplay between inflammation and thrombosis in cardiovascular pathology. <italic>Nat. Rev. Cardiol.</italic><bold>18</bold>, 666&#x02013;682 (2021).<pub-id pub-id-type="pmid">33958774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR242"><label>242.</label><citation-alternatives><element-citation id="ec-CR242" publication-type="journal"><person-group person-group-type="author"><name><surname>Engelmann</surname><given-names>B</given-names></name><name><surname>Massberg</surname><given-names>S</given-names></name></person-group><article-title>Thrombosis as an intravascular effector of innate immunity</article-title><source>Nat. Rev. Immunol.</source><year>2013</year><volume>13</volume><fpage>34</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1038/nri3345</pub-id><pub-id pub-id-type="pmid">23222502</pub-id>
</element-citation><mixed-citation id="mc-CR242" publication-type="journal">Engelmann, B. &#x00026; Massberg, S. Thrombosis as an intravascular effector of innate immunity. <italic>Nat. Rev. Immunol.</italic><bold>13</bold>, 34&#x02013;45 (2013).<pub-id pub-id-type="pmid">23222502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR243"><label>243.</label><citation-alternatives><element-citation id="ec-CR243" publication-type="journal"><person-group person-group-type="author"><name><surname>Renne</surname><given-names>T</given-names></name><name><surname>Stavrou</surname><given-names>EX</given-names></name></person-group><article-title>Roles of factor XII in innate immunity</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2011</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02011</pub-id><pub-id pub-id-type="pmid">31507606</pub-id>
</element-citation><mixed-citation id="mc-CR243" publication-type="journal">Renne, T. &#x00026; Stavrou, E. X. Roles of factor XII in innate immunity. <italic>Front. Immunol.</italic><bold>10</bold>, 2011 (2019).<pub-id pub-id-type="pmid">31507606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR244"><label>244.</label><citation-alternatives><element-citation id="ec-CR244" publication-type="journal"><person-group person-group-type="author"><name><surname>Kale</surname><given-names>S</given-names></name><etal/></person-group><article-title>The effects of age on inflammatory and coagulation-fibrinolysis response in patients hospitalized for pneumonia</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e13852</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0013852</pub-id><pub-id pub-id-type="pmid">21085465</pub-id>
</element-citation><mixed-citation id="mc-CR244" publication-type="journal">Kale, S. et al. The effects of age on inflammatory and coagulation-fibrinolysis response in patients hospitalized for pneumonia. <italic>PLoS ONE</italic><bold>5</bold>, e13852 (2010).<pub-id pub-id-type="pmid">21085465</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR245"><label>245.</label><citation-alternatives><element-citation id="ec-CR245" publication-type="journal"><person-group person-group-type="author"><name><surname>Michels</surname><given-names>EHA</given-names></name><etal/></person-group><article-title>Association between age and the host response in critically ill patients with sepsis</article-title><source>Crit. Care</source><year>2022</year><volume>26</volume><fpage>385</fpage><pub-id pub-id-type="doi">10.1186/s13054-022-04266-9</pub-id><pub-id pub-id-type="pmid">36514130</pub-id>
</element-citation><mixed-citation id="mc-CR245" publication-type="journal">Michels, E. H. A., et al. Association between age and the host response in critically ill patients with sepsis. <italic>Crit. Care</italic><bold>26</bold>, 385 (2022).<pub-id pub-id-type="pmid">36514130</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR246"><label>246.</label><citation-alternatives><element-citation id="ec-CR246" publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>SP</given-names></name></person-group><article-title>Arterial thrombosis-insidious, unpredictable and deadly</article-title><source>Nat. Med.</source><year>2011</year><volume>17</volume><fpage>1423</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1038/nm.2515</pub-id><pub-id pub-id-type="pmid">22064432</pub-id>
</element-citation><mixed-citation id="mc-CR246" publication-type="journal">Jackson, S. P. Arterial thrombosis-insidious, unpredictable and deadly. <italic>Nat. Med.</italic><bold>17</bold>, 1423&#x02013;1436 (2011).<pub-id pub-id-type="pmid">22064432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR247"><label>247.</label><citation-alternatives><element-citation id="ec-CR247" publication-type="journal"><person-group person-group-type="author"><name><surname>Massberg</surname><given-names>S</given-names></name><etal/></person-group><article-title>A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation</article-title><source>J. Exp. Med.</source><year>2002</year><volume>196</volume><fpage>887</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1084/jem.20012044</pub-id><pub-id pub-id-type="pmid">12370251</pub-id>
</element-citation><mixed-citation id="mc-CR247" publication-type="journal">Massberg, S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. <italic>J. Exp. Med.</italic><bold>196</bold>, 887&#x02013;896 (2002).<pub-id pub-id-type="pmid">12370251</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR248"><label>248.</label><citation-alternatives><element-citation id="ec-CR248" publication-type="journal"><person-group person-group-type="author"><name><surname>Massberg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>1180</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.539221</pub-id><pub-id pub-id-type="pmid">16103235</pub-id>
</element-citation><mixed-citation id="mc-CR248" publication-type="journal">Massberg, S. et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. <italic>Circulation</italic><bold>112</bold>, 1180&#x02013;1188 (2005).<pub-id pub-id-type="pmid">16103235</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR249"><label>249.</label><citation-alternatives><element-citation id="ec-CR249" publication-type="journal"><person-group person-group-type="author"><name><surname>Gerdes</surname><given-names>N</given-names></name><etal/></person-group><article-title>Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2016</year><volume>36</volume><fpage>482</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.115.307074</pub-id><pub-id pub-id-type="pmid">26821950</pub-id>
</element-citation><mixed-citation id="mc-CR249" publication-type="journal">Gerdes, N. et al. Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>36</bold>, 482&#x02013;490 (2016).<pub-id pub-id-type="pmid">26821950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR250"><label>250.</label><citation-alternatives><element-citation id="ec-CR250" publication-type="journal"><person-group person-group-type="author"><name><surname>Drechsler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>1837</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.961714</pub-id><pub-id pub-id-type="pmid">20956207</pub-id>
</element-citation><mixed-citation id="mc-CR250" publication-type="journal">Drechsler, M. et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. <italic>Circulation</italic><bold>122</bold>, 1837&#x02013;1845 (2010).<pub-id pub-id-type="pmid">20956207</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR251"><label>251.</label><citation-alternatives><element-citation id="ec-CR251" publication-type="journal"><person-group person-group-type="author"><name><surname>Koenen</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice</article-title><source>Nat. Med.</source><year>2009</year><volume>15</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nm.1898</pub-id><pub-id pub-id-type="pmid">19122657</pub-id>
</element-citation><mixed-citation id="mc-CR251" publication-type="journal">Koenen, R. R. et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. <italic>Nat. Med.</italic><bold>15</bold>, 97&#x02013;103 (2009).<pub-id pub-id-type="pmid">19122657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR252"><label>252.</label><citation-alternatives><element-citation id="ec-CR252" publication-type="journal"><person-group person-group-type="author"><name><surname>Massberg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo</article-title><source>J. Exp. Med.</source><year>2006</year><volume>203</volume><fpage>1221</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1084/jem.20051772</pub-id><pub-id pub-id-type="pmid">16618794</pub-id>
</element-citation><mixed-citation id="mc-CR252" publication-type="journal">Massberg, S. et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. <italic>J. Exp. Med.</italic><bold>203</bold>, 1221&#x02013;1233 (2006).<pub-id pub-id-type="pmid">16618794</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR253"><label>253.</label><citation-alternatives><element-citation id="ec-CR253" publication-type="journal"><person-group person-group-type="author"><name><surname>Gaertner</surname><given-names>F</given-names></name><etal/></person-group><article-title>Migrating platelets are mechano-scavengers that collect and bundle bacteria</article-title><source>Cell</source><year>2017</year><volume>171</volume><fpage>1368</fpage><lpage>1382.e1323</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.001</pub-id><pub-id pub-id-type="pmid">29195076</pub-id>
</element-citation><mixed-citation id="mc-CR253" publication-type="journal">Gaertner, F. et al. Migrating platelets are mechano-scavengers that collect and bundle bacteria. <italic>Cell</italic><bold>171</bold>, 1368&#x02013;1382.e1323 (2017).<pub-id pub-id-type="pmid">29195076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR254"><label>254.</label><citation-alternatives><element-citation id="ec-CR254" publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Neutrophil extracellular traps in COVID-19</article-title><source>JCI Insight</source><year>2020</year><volume>5</volume><fpage>e138999</fpage><pub-id pub-id-type="pmid">32329756</pub-id>
</element-citation><mixed-citation id="mc-CR254" publication-type="journal">Zuo, Y. et al. Neutrophil extracellular traps in COVID-19. <italic>JCI Insight</italic><bold>5</bold>, e138999 (2020).<pub-id pub-id-type="pmid">32329756</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR255"><label>255.</label><citation-alternatives><element-citation id="ec-CR255" publication-type="journal"><person-group person-group-type="author"><name><surname>Martinod</surname><given-names>K</given-names></name><etal/></person-group><article-title>Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>8674</fpage><lpage>8679</lpage><pub-id pub-id-type="doi">10.1073/pnas.1301059110</pub-id><pub-id pub-id-type="pmid">23650392</pub-id>
</element-citation><mixed-citation id="mc-CR255" publication-type="journal">Martinod, K. et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>110</bold>, 8674&#x02013;8679 (2013).<pub-id pub-id-type="pmid">23650392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR256"><label>256.</label><citation-alternatives><element-citation id="ec-CR256" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><etal/></person-group><article-title>PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps</article-title><source>J. Exp. Med.</source><year>2010</year><volume>207</volume><fpage>1853</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.1084/jem.20100239</pub-id><pub-id pub-id-type="pmid">20733033</pub-id>
</element-citation><mixed-citation id="mc-CR256" publication-type="journal">Li, P. et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. <italic>J. Exp. Med.</italic><bold>207</bold>, 1853&#x02013;1862 (2010).<pub-id pub-id-type="pmid">20733033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR257"><label>257.</label><citation-alternatives><element-citation id="ec-CR257" publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>K</given-names></name><etal/></person-group><article-title>Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice</article-title><source>Blood</source><year>2016</year><volume>128</volume><fpage>2435</fpage><lpage>2449</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-04-710632</pub-id><pub-id pub-id-type="pmid">27574188</pub-id>
</element-citation><mixed-citation id="mc-CR257" publication-type="journal">Stark, K. et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. <italic>Blood</italic><bold>128</bold>, 2435&#x02013;2449 (2016).<pub-id pub-id-type="pmid">27574188</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR258"><label>258.</label><citation-alternatives><element-citation id="ec-CR258" publication-type="journal"><person-group person-group-type="author"><name><surname>Jaen</surname><given-names>RI</given-names></name><etal/></person-group><article-title>Innate immune receptors, key actors in cardiovascular diseases</article-title><source>JACC Basic Transl. Sci.</source><year>2020</year><volume>5</volume><fpage>735</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.jacbts.2020.03.015</pub-id><pub-id pub-id-type="pmid">32760860</pub-id>
</element-citation><mixed-citation id="mc-CR258" publication-type="journal">Jaen, R. I. et al. Innate immune receptors, key actors in cardiovascular diseases. <italic>JACC Basic Transl. Sci.</italic><bold>5</bold>, 735&#x02013;749 (2020).<pub-id pub-id-type="pmid">32760860</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR259"><label>259.</label><citation-alternatives><element-citation id="ec-CR259" publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Ruiz</surname><given-names>I</given-names></name></person-group><article-title>Immune system and cardiovascular disease</article-title><source>Nat. Rev. Cardiol.</source><year>2016</year><volume>13</volume><fpage>503</fpage><pub-id pub-id-type="doi">10.1038/nrcardio.2016.127</pub-id><pub-id pub-id-type="pmid">27516069</pub-id>
</element-citation><mixed-citation id="mc-CR259" publication-type="journal">Fernandez-Ruiz, I. Immune system and cardiovascular disease. <italic>Nat. Rev. Cardiol.</italic><bold>13</bold>, 503 (2016).<pub-id pub-id-type="pmid">27516069</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR260"><label>260.</label><citation-alternatives><element-citation id="ec-CR260" publication-type="journal"><person-group person-group-type="author"><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Preston-Hurlburt</surname><given-names>P</given-names></name><name><surname>Janeway</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group><article-title>A human homologue of the Drosophila Toll protein signals activation of adaptive immunity</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>394</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1038/41131</pub-id><pub-id pub-id-type="pmid">9237759</pub-id>
</element-citation><mixed-citation id="mc-CR260" publication-type="journal">Medzhitov, R., Preston-Hurlburt, P. &#x00026; Janeway, C. A. Jr A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. <italic>Nature</italic><bold>388</bold>, 394&#x02013;397 (1997).<pub-id pub-id-type="pmid">9237759</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR261"><label>261.</label><citation-alternatives><element-citation id="ec-CR261" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name></person-group><article-title>Innate immune responses and pulmonary diseases</article-title><source>Adv. Exp. Med. Biol.</source><year>2021</year><volume>1304</volume><fpage>53</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-68748-9_4</pub-id><pub-id pub-id-type="pmid">34019263</pub-id>
</element-citation><mixed-citation id="mc-CR261" publication-type="journal">Liu, T., Liu, S. &#x00026; Zhou, X. Innate immune responses and pulmonary diseases. <italic>Adv. Exp. Med. Biol.</italic><bold>1304</bold>, 53&#x02013;71 (2021).<pub-id pub-id-type="pmid">34019263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR262"><label>262.</label><citation-alternatives><element-citation id="ec-CR262" publication-type="journal"><person-group person-group-type="author"><name><surname>Ionita</surname><given-names>MG</given-names></name><name><surname>Arslan</surname><given-names>F</given-names></name><name><surname>de Kleijn</surname><given-names>DP</given-names></name><name><surname>Pasterkamp</surname><given-names>G</given-names></name></person-group><article-title>Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease</article-title><source>J. Innate Immun.</source><year>2010</year><volume>2</volume><fpage>307</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1159/000314270</pub-id><pub-id pub-id-type="pmid">20431283</pub-id>
</element-citation><mixed-citation id="mc-CR262" publication-type="journal">Ionita, M. G., Arslan, F., de Kleijn, D. P. &#x00026; Pasterkamp, G. Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. <italic>J. Innate Immun.</italic><bold>2</bold>, 307&#x02013;315 (2010).<pub-id pub-id-type="pmid">20431283</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR263"><label>263.</label><citation-alternatives><element-citation id="ec-CR263" publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>D</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group><article-title>Oxidized low-density lipoprotein and atherosclerosis</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2010</year><volume>30</volume><fpage>2311</fpage><lpage>2316</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.108.179697</pub-id><pub-id pub-id-type="pmid">21084697</pub-id>
</element-citation><mixed-citation id="mc-CR263" publication-type="journal">Steinberg, D. &#x00026; Witztum, J. L. Oxidized low-density lipoprotein and atherosclerosis. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>30</bold>, 2311&#x02013;2316 (2010).<pub-id pub-id-type="pmid">21084697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR264"><label>264.</label><citation-alternatives><element-citation id="ec-CR264" publication-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name></person-group><article-title>Pathogen recognition and innate immunity</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>783</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.015</pub-id><pub-id pub-id-type="pmid">16497588</pub-id>
</element-citation><mixed-citation id="mc-CR264" publication-type="journal">Akira, S., Uematsu, S. &#x00026; Takeuchi, O. Pathogen recognition and innate immunity. <italic>Cell</italic><bold>124</bold>, 783&#x02013;801 (2006).<pub-id pub-id-type="pmid">16497588</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR265"><label>265.</label><citation-alternatives><element-citation id="ec-CR265" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Lo</surname><given-names>YC</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><article-title>Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling</article-title><source>Nature</source><year>2010</year><volume>465</volume><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1038/nature09121</pub-id><pub-id pub-id-type="pmid">20485341</pub-id>
</element-citation><mixed-citation id="mc-CR265" publication-type="journal">Lin, S. C., Lo, Y. C. &#x00026; Wu, H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. <italic>Nature</italic><bold>465</bold>, 885&#x02013;890 (2010).<pub-id pub-id-type="pmid">20485341</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR266"><label>266.</label><citation-alternatives><element-citation id="ec-CR266" publication-type="journal"><person-group person-group-type="author"><name><surname>Motshwene</surname><given-names>PG</given-names></name><etal/></person-group><article-title>An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>25404</fpage><lpage>25411</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.022392</pub-id><pub-id pub-id-type="pmid">19592493</pub-id>
</element-citation><mixed-citation id="mc-CR266" publication-type="journal">Motshwene, P. G. et al. An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. <italic>J. Biol. Chem.</italic><bold>284</bold>, 25404&#x02013;25411 (2009).<pub-id pub-id-type="pmid">19592493</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR267"><label>267.</label><citation-alternatives><element-citation id="ec-CR267" publication-type="journal"><person-group person-group-type="author"><name><surname>Kollewe</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>5227</fpage><lpage>5236</lpage><pub-id pub-id-type="doi">10.1074/jbc.M309251200</pub-id><pub-id pub-id-type="pmid">14625308</pub-id>
</element-citation><mixed-citation id="mc-CR267" publication-type="journal">Kollewe, C. et al. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. <italic>J. Biol. Chem.</italic><bold>279</bold>, 5227&#x02013;5236 (2004).<pub-id pub-id-type="pmid">14625308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR268"><label>268.</label><citation-alternatives><element-citation id="ec-CR268" publication-type="journal"><person-group person-group-type="author"><name><surname>Verstak</surname><given-names>B</given-names></name><etal/></person-group><article-title>The TLR signaling adaptor TRAM interacts with TRAF6 to mediate activation of the inflammatory response by TLR4</article-title><source>J. Leukoc. Biol.</source><year>2014</year><volume>96</volume><fpage>427</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1189/jlb.2A0913-487R</pub-id><pub-id pub-id-type="pmid">24812060</pub-id>
</element-citation><mixed-citation id="mc-CR268" publication-type="journal">Verstak, B. et al. The TLR signaling adaptor TRAM interacts with TRAF6 to mediate activation of the inflammatory response by TLR4. <italic>J. Leukoc. Biol.</italic><bold>96</bold>, 427&#x02013;436 (2014).<pub-id pub-id-type="pmid">24812060</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR269"><label>269.</label><citation-alternatives><element-citation id="ec-CR269" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Oligomerization-primed coiled-coil domain interaction with Ubc13 confers processivity to TRAF6 ubiquitin ligase activity</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>814</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01290-0</pub-id><pub-id pub-id-type="pmid">28993672</pub-id>
</element-citation><mixed-citation id="mc-CR269" publication-type="journal">Hu, L., et al. Oligomerization-primed coiled-coil domain interaction with Ubc13 confers processivity to TRAF6 ubiquitin ligase activity. <italic>Nat. Commun.</italic><bold>8</bold>, 814 (2017).<pub-id pub-id-type="pmid">28993672</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR270"><label>270.</label><citation-alternatives><element-citation id="ec-CR270" publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Kagan</surname><given-names>JC</given-names></name></person-group><article-title>Toll-like receptors and the control of immunity</article-title><source>Cell</source><year>2020</year><volume>180</volume><fpage>1044</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.041</pub-id><pub-id pub-id-type="pmid">32164908</pub-id>
</element-citation><mixed-citation id="mc-CR270" publication-type="journal">Fitzgerald, K. A. &#x00026; Kagan, J. C. Toll-like receptors and the control of immunity. <italic>Cell</italic><bold>180</bold>, 1044&#x02013;1066 (2020).<pub-id pub-id-type="pmid">32164908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR271"><label>271.</label><citation-alternatives><element-citation id="ec-CR271" publication-type="journal"><person-group person-group-type="author"><name><surname>McWhirter</surname><given-names>SM</given-names></name><etal/></person-group><article-title>IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1073/pnas.2237236100</pub-id><pub-id pub-id-type="pmid">14679297</pub-id>
</element-citation><mixed-citation id="mc-CR271" publication-type="journal">McWhirter, S. M. et al. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>101</bold>, 233&#x02013;238 (2004).<pub-id pub-id-type="pmid">14679297</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR272"><label>272.</label><citation-alternatives><element-citation id="ec-CR272" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><etal/></person-group><article-title>Triggering the interferon antiviral response through an IKK-related pathway</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>1148</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1126/science.1081315</pub-id><pub-id pub-id-type="pmid">12702806</pub-id>
</element-citation><mixed-citation id="mc-CR272" publication-type="journal">Sharma, S. et al. Triggering the interferon antiviral response through an IKK-related pathway. <italic>Science</italic><bold>300</bold>, 1148&#x02013;1151 (2003).<pub-id pub-id-type="pmid">12702806</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR273"><label>273.</label><citation-alternatives><element-citation id="ec-CR273" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signalling and airway inflammation</article-title><source>Eur. Respir. J.</source><year>2024</year><volume>63</volume><fpage>2301232</fpage><pub-id pub-id-type="doi">10.1183/13993003.01232-2023</pub-id><pub-id pub-id-type="pmid">38514093</pub-id>
</element-citation><mixed-citation id="mc-CR273" publication-type="journal">Liu, T. et al. Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signalling and airway inflammation. <italic>Eur. Respir. J.</italic><bold>63</bold>, 2301232 (2024).<pub-id pub-id-type="pmid">38514093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR274"><label>274.</label><citation-alternatives><element-citation id="ec-CR274" publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>M</given-names></name><name><surname>Naito</surname><given-names>S</given-names></name></person-group><article-title>Tissue-specific mRNA expression profiles of human toll-like receptors and related genes</article-title><source>Biol. Pharmacol. Bull.</source><year>2005</year><volume>28</volume><fpage>886</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1248/bpb.28.886</pub-id></element-citation><mixed-citation id="mc-CR274" publication-type="journal">Nishimura, M. &#x00026; Naito, S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. <italic>Biol. Pharmacol. Bull.</italic><bold>28</bold>, 886&#x02013;892 (2005).</mixed-citation></citation-alternatives></ref><ref id="CR275"><label>275.</label><citation-alternatives><element-citation id="ec-CR275" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction</article-title><source>J. Cell Mol. Med.</source><year>2015</year><volume>19</volume><fpage>2728</fpage><lpage>2740</lpage><pub-id pub-id-type="doi">10.1111/jcmm.12659</pub-id><pub-id pub-id-type="pmid">26290459</pub-id>
</element-citation><mixed-citation id="mc-CR275" publication-type="journal">Liu, L. et al. Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. <italic>J. Cell Mol. Med.</italic><bold>19</bold>, 2728&#x02013;2740 (2015).<pub-id pub-id-type="pmid">26290459</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR276"><label>276.</label><citation-alternatives><element-citation id="ec-CR276" publication-type="journal"><person-group person-group-type="author"><name><surname>Oyama</surname><given-names>J</given-names></name><etal/></person-group><article-title>Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>784</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000112575.66565.84</pub-id><pub-id pub-id-type="pmid">14970116</pub-id>
</element-citation><mixed-citation id="mc-CR276" publication-type="journal">Oyama, J. et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. <italic>Circulation</italic><bold>109</bold>, 784&#x02013;789 (2004).<pub-id pub-id-type="pmid">14970116</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR277"><label>277.</label><citation-alternatives><element-citation id="ec-CR277" publication-type="journal"><person-group person-group-type="author"><name><surname>Shimamoto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>I270</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.000901</pub-id><pub-id pub-id-type="pmid">16820585</pub-id>
</element-citation><mixed-citation id="mc-CR277" publication-type="journal">Shimamoto, A. et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. <italic>Circulation</italic><bold>114</bold>, I270&#x02013;274 (2006).<pub-id pub-id-type="pmid">16820585</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR278"><label>278.</label><citation-alternatives><element-citation id="ec-CR278" publication-type="journal"><person-group person-group-type="author"><name><surname>Shishido</surname><given-names>T</given-names></name><etal/></person-group><article-title>Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>2905</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000101921.93016.1C</pub-id><pub-id pub-id-type="pmid">14656915</pub-id>
</element-citation><mixed-citation id="mc-CR278" publication-type="journal">Shishido, T. et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. <italic>Circulation</italic><bold>108</bold>, 2905&#x02013;2910 (2003).<pub-id pub-id-type="pmid">14656915</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR279"><label>279.</label><citation-alternatives><element-citation id="ec-CR279" publication-type="journal"><person-group person-group-type="author"><name><surname>Frantz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium</article-title><source>J. Clin. Investig.</source><year>1999</year><volume>104</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1172/JCI6709</pub-id><pub-id pub-id-type="pmid">10430608</pub-id>
</element-citation><mixed-citation id="mc-CR279" publication-type="journal">Frantz, S. et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. <italic>J. Clin. Investig.</italic><bold>104</bold>, 271&#x02013;280 (1999).<pub-id pub-id-type="pmid">10430608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR280"><label>280.</label><citation-alternatives><element-citation id="ec-CR280" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Bacillus Calmette-Gu&#x000e9;rin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenvironment</article-title><source>J. Immunol.</source><year>2008</year><volume>180</volume><fpage>7349</fpage><lpage>7357</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.11.7349</pub-id><pub-id pub-id-type="pmid">18490734</pub-id>
</element-citation><mixed-citation id="mc-CR280" publication-type="journal">Liu, Y. Y. et al. Bacillus Calmette-Gu&#x000e9;rin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenvironment. <italic>J. Immunol.</italic><bold>180</bold>, 7349&#x02013;7357 (2008).<pub-id pub-id-type="pmid">18490734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR281"><label>281.</label><citation-alternatives><element-citation id="ec-CR281" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><article-title>Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics</article-title><source>Front. Physiol.</source><year>2017</year><volume>8</volume><fpage>508</fpage><pub-id pub-id-type="doi">10.3389/fphys.2017.00508</pub-id><pub-id pub-id-type="pmid">28769820</pub-id>
</element-citation><mixed-citation id="mc-CR281" publication-type="journal">Gao, W., Xiong, Y., Li, Q. &#x00026; Yang, H. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. <italic>Front. Physiol.</italic><bold>8</bold>, 508 (2017).<pub-id pub-id-type="pmid">28769820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR282"><label>282.</label><citation-alternatives><element-citation id="ec-CR282" publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>FC</given-names></name><etal/></person-group><article-title>TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension</article-title><source>Eur. Respir. J.</source><year>2023</year><volume>62</volume><fpage>2300204</fpage><pub-id pub-id-type="doi">10.1183/13993003.00204-2023</pub-id><pub-id pub-id-type="pmid">37290790</pub-id>
</element-citation><mixed-citation id="mc-CR282" publication-type="journal">Yeh, F. C. et al. TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension. <italic>Eur. Respir. J.</italic><bold>62</bold>, 2300204 (2023).<pub-id pub-id-type="pmid">37290790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR283"><label>283.</label><citation-alternatives><element-citation id="ec-CR283" publication-type="journal"><person-group person-group-type="author"><name><surname>Levitan</surname><given-names>I</given-names></name><name><surname>Volkov</surname><given-names>S</given-names></name><name><surname>Subbaiah</surname><given-names>PV</given-names></name></person-group><article-title>Oxidized LDL: diversity, patterns of recognition, and pathophysiology</article-title><source>Antioxid. Redox Signal.</source><year>2010</year><volume>13</volume><fpage>39</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1089/ars.2009.2733</pub-id><pub-id pub-id-type="pmid">19888833</pub-id>
</element-citation><mixed-citation id="mc-CR283" publication-type="journal">Levitan, I., Volkov, S. &#x00026; Subbaiah, P. V. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. <italic>Antioxid. Redox Signal.</italic><bold>13</bold>, 39&#x02013;75 (2010).<pub-id pub-id-type="pmid">19888833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR284"><label>284.</label><citation-alternatives><element-citation id="ec-CR284" publication-type="journal"><person-group person-group-type="author"><name><surname>Edfeldt</surname><given-names>K</given-names></name><name><surname>Swedenborg</surname><given-names>J</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name><name><surname>Yan</surname><given-names>ZQ</given-names></name></person-group><article-title>Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation</article-title><source>Circulation</source><year>2002</year><volume>105</volume><fpage>1158</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1161/circ.105.10.1158</pub-id><pub-id pub-id-type="pmid">11889007</pub-id>
</element-citation><mixed-citation id="mc-CR284" publication-type="journal">Edfeldt, K., Swedenborg, J., Hansson, G. K. &#x00026; Yan, Z. Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. <italic>Circulation</italic><bold>105</bold>, 1158&#x02013;1161 (2002).<pub-id pub-id-type="pmid">11889007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR285"><label>285.</label><citation-alternatives><element-citation id="ec-CR285" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>RK</given-names></name><etal/></person-group><article-title>TLR4 (Toll-Like Receptor 4)-dependent signaling drives extracellular catabolism of LDL (Low-Density Lipoprotein) aggregates</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2020</year><volume>40</volume><fpage>86</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.119.313200</pub-id><pub-id pub-id-type="pmid">31597445</pub-id>
</element-citation><mixed-citation id="mc-CR285" publication-type="journal">Singh, R. K. et al. TLR4 (Toll-Like Receptor 4)-dependent signaling drives extracellular catabolism of LDL (Low-Density Lipoprotein) aggregates. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>40</bold>, 86&#x02013;102 (2020).<pub-id pub-id-type="pmid">31597445</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR286"><label>286.</label><citation-alternatives><element-citation id="ec-CR286" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GL</given-names></name><etal/></person-group><article-title>TLR2 promotes vascular smooth muscle cell chondrogenic differentiation and consequent calcification via the concerted actions of 0steoprotegerin suppression and IL-6-mediated RANKL induction</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2019</year><volume>39</volume><fpage>432</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311874</pub-id><pub-id pub-id-type="pmid">30626205</pub-id>
</element-citation><mixed-citation id="mc-CR286" publication-type="journal">Lee, G. L. et al. TLR2 promotes vascular smooth muscle cell chondrogenic differentiation and consequent calcification via the concerted actions of 0steoprotegerin suppression and IL-6-mediated RANKL induction. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>39</bold>, 432&#x02013;445 (2019).<pub-id pub-id-type="pmid">30626205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR287"><label>287.</label><citation-alternatives><element-citation id="ec-CR287" publication-type="journal"><person-group person-group-type="author"><name><surname>Sundaram</surname><given-names>B</given-names></name><name><surname>Tweedell</surname><given-names>RE</given-names></name><name><surname>Prasanth Kumar</surname><given-names>S</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><article-title>The NLR family of innate immune and cell death sensors</article-title><source>Immunity</source><year>2024</year><volume>57</volume><fpage>674</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.03.012</pub-id><pub-id pub-id-type="pmid">38599165</pub-id>
</element-citation><mixed-citation id="mc-CR287" publication-type="journal">Sundaram, B., Tweedell, R. E., Prasanth Kumar, S. &#x00026; Kanneganti, T. D. The NLR family of innate immune and cell death sensors. <italic>Immunity</italic><bold>57</bold>, 674&#x02013;699 (2024).<pub-id pub-id-type="pmid">38599165</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR288"><label>288.</label><citation-alternatives><element-citation id="ec-CR288" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>USP19 suppresses inflammation and promotes M2-like macrophage polarization by manipulating NLRP3 function via autophagy</article-title><source>Cell Mol. Immunol.</source><year>2021</year><volume>18</volume><fpage>2431</fpage><lpage>2442</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-00567-7</pub-id><pub-id pub-id-type="pmid">33097834</pub-id>
</element-citation><mixed-citation id="mc-CR288" publication-type="journal">Liu, T. et al. USP19 suppresses inflammation and promotes M2-like macrophage polarization by manipulating NLRP3 function via autophagy. <italic>Cell Mol. Immunol.</italic><bold>18</bold>, 2431&#x02013;2442 (2021).<pub-id pub-id-type="pmid">33097834</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR289"><label>289.</label><citation-alternatives><element-citation id="ec-CR289" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>NOD-like receptor family, pyrin domain containing 3 (NLRP3) contributes to inflammation, pyroptosis, and mucin production in human airway epithelium on rhinovirus infection</article-title><source>J. Allergy Clin. Immunol.</source><year>2019</year><volume>144</volume><fpage>777</fpage><lpage>787.e9</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.05.006</pub-id><pub-id pub-id-type="pmid">31102698</pub-id>
</element-citation><mixed-citation id="mc-CR289" publication-type="journal">Liu, T. et al. NOD-like receptor family, pyrin domain containing 3 (NLRP3) contributes to inflammation, pyroptosis, and mucin production in human airway epithelium on rhinovirus infection. <italic>J. Allergy Clin. Immunol.</italic><bold>144</bold>, 777&#x02013;787.e9 (2019).<pub-id pub-id-type="pmid">31102698</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR290"><label>290.</label><citation-alternatives><element-citation id="ec-CR290" publication-type="journal"><person-group person-group-type="author"><name><surname>Sundaram</surname><given-names>B</given-names></name><etal/></person-group><article-title>NLRC5 senses NAD(+) depletion, forming a PANoptosome and driving PANoptosis and inflammation</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>4061</fpage><lpage>4077.E17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.05.034</pub-id><pub-id pub-id-type="pmid">38878777</pub-id>
</element-citation><mixed-citation id="mc-CR290" publication-type="journal">Sundaram, B. et al. NLRC5 senses NAD(+) depletion, forming a PANoptosome and driving PANoptosis and inflammation. <italic>Cell</italic><bold>187</bold>, 4061&#x02013;4077.E17 (2024).<pub-id pub-id-type="pmid">38878777</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR291"><label>291.</label><citation-alternatives><element-citation id="ec-CR291" publication-type="journal"><person-group person-group-type="author"><name><surname>Sundaram</surname><given-names>B</given-names></name><etal/></person-group><article-title>NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs</article-title><source>Cell</source><year>2023</year><volume>186</volume><fpage>2783</fpage><lpage>2801.e20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.05.005</pub-id><pub-id pub-id-type="pmid">37267949</pub-id>
</element-citation><mixed-citation id="mc-CR291" publication-type="journal">Sundaram, B. et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. <italic>Cell</italic><bold>186</bold>, 2783&#x02013;2801.e20 (2023).<pub-id pub-id-type="pmid">37267949</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR292"><label>292.</label><citation-alternatives><element-citation id="ec-CR292" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>N</given-names></name><etal/></person-group><article-title>Endosomes are specialized platforms for bacterial sensing and NOD2 signalling</article-title><source>Nature</source><year>2014</year><volume>509</volume><fpage>240</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1038/nature13133</pub-id><pub-id pub-id-type="pmid">24695226</pub-id>
</element-citation><mixed-citation id="mc-CR292" publication-type="journal">Nakamura, N. et al. Endosomes are specialized platforms for bacterial sensing and NOD2 signalling. <italic>Nature</italic><bold>509</bold>, 240&#x02013;244 (2014).<pub-id pub-id-type="pmid">24695226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR293"><label>293.</label><citation-alternatives><element-citation id="ec-CR293" publication-type="journal"><person-group person-group-type="author"><name><surname>Girardin</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>1584</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1126/science.1084677</pub-id><pub-id pub-id-type="pmid">12791997</pub-id>
</element-citation><mixed-citation id="mc-CR293" publication-type="journal">Girardin, S. E. et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. <italic>Science</italic><bold>300</bold>, 1584&#x02013;1587 (2003).<pub-id pub-id-type="pmid">12791997</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR294"><label>294.</label><citation-alternatives><element-citation id="ec-CR294" publication-type="journal"><person-group person-group-type="author"><name><surname>Girardin</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>8869</fpage><lpage>8872</lpage><pub-id pub-id-type="doi">10.1074/jbc.C200651200</pub-id><pub-id pub-id-type="pmid">12527755</pub-id>
</element-citation><mixed-citation id="mc-CR294" publication-type="journal">Girardin, S. E. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. <italic>J. Biol. Chem.</italic><bold>278</bold>, 8869&#x02013;8872 (2003).<pub-id pub-id-type="pmid">12527755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR295"><label>295.</label><citation-alternatives><element-citation id="ec-CR295" publication-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>R</given-names></name><name><surname>Warner</surname><given-names>N</given-names></name><name><surname>Inohara</surname><given-names>N</given-names></name><name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>G</given-names></name></person-group><article-title>NOD1 and NOD2: signaling, host defense, and inflammatory disease</article-title><source>Immunity</source><year>2014</year><volume>41</volume><fpage>898</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.12.010</pub-id><pub-id pub-id-type="pmid">25526305</pub-id>
</element-citation><mixed-citation id="mc-CR295" publication-type="journal">Caruso, R., Warner, N., Inohara, N. &#x00026; N&#x000fa;&#x000f1;ez, G. NOD1 and NOD2: signaling, host defense, and inflammatory disease. <italic>Immunity</italic><bold>41</bold>, 898&#x02013;908 (2014).<pub-id pub-id-type="pmid">25526305</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR296"><label>296.</label><citation-alternatives><element-citation id="ec-CR296" publication-type="journal"><person-group person-group-type="author"><name><surname>Inohara</surname><given-names>N</given-names></name><etal/></person-group><article-title>Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>14560</fpage><lpage>14567</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.21.14560</pub-id><pub-id pub-id-type="pmid">10329646</pub-id>
</element-citation><mixed-citation id="mc-CR296" publication-type="journal">Inohara, N. et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. <italic>J. Biol. Chem.</italic><bold>274</bold>, 14560&#x02013;14567 (1999).<pub-id pub-id-type="pmid">10329646</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR297"><label>297.</label><citation-alternatives><element-citation id="ec-CR297" publication-type="journal"><person-group person-group-type="author"><name><surname>Ogura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>4812</fpage><lpage>4818</lpage><pub-id pub-id-type="doi">10.1074/jbc.M008072200</pub-id><pub-id pub-id-type="pmid">11087742</pub-id>
</element-citation><mixed-citation id="mc-CR297" publication-type="journal">Ogura, Y. et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. <italic>J. Biol. Chem.</italic><bold>276</bold>, 4812&#x02013;4818 (2001).<pub-id pub-id-type="pmid">11087742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR298"><label>298.</label><citation-alternatives><element-citation id="ec-CR298" publication-type="journal"><person-group person-group-type="author"><name><surname>Sorbara</surname><given-names>MT</given-names></name><etal/></person-group><article-title>The protein ATG16L1 suppresses inflammatory cytokines induced by the intracellular sensors Nod1 and Nod2 in an autophagy-independent manner</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>858</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.10.013</pub-id><pub-id pub-id-type="pmid">24238340</pub-id>
</element-citation><mixed-citation id="mc-CR298" publication-type="journal">Sorbara, M. T. et al. The protein ATG16L1 suppresses inflammatory cytokines induced by the intracellular sensors Nod1 and Nod2 in an autophagy-independent manner. <italic>Immunity</italic><bold>39</bold>, 858&#x02013;873 (2013).<pub-id pub-id-type="pmid">24238340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR299"><label>299.</label><citation-alternatives><element-citation id="ec-CR299" publication-type="journal"><person-group person-group-type="author"><name><surname>Yeretssian</surname><given-names>G</given-names></name><etal/></person-group><article-title>Non-apoptotic role of BID in inflammation and innate immunity</article-title><source>Nature</source><year>2011</year><volume>474</volume><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/nature09982</pub-id><pub-id pub-id-type="pmid">21552281</pub-id>
</element-citation><mixed-citation id="mc-CR299" publication-type="journal">Yeretssian, G. et al. Non-apoptotic role of BID in inflammation and innate immunity. <italic>Nature</italic><bold>474</bold>, 96&#x02013;99 (2011).<pub-id pub-id-type="pmid">21552281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR300"><label>300.</label><citation-alternatives><element-citation id="ec-CR300" publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Simon</surname><given-names>D</given-names></name><etal/></person-group><article-title>Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma</article-title><source>Eur. Respir. J.</source><year>2024</year><volume>64</volume><fpage>2302288</fpage><pub-id pub-id-type="doi">10.1183/13993003.02288-2023</pub-id><pub-id pub-id-type="pmid">39117431</pub-id>
</element-citation><mixed-citation id="mc-CR300" publication-type="journal">Alvarez-Simon, D. et al. Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma. <italic>Eur. Respir. J.</italic><bold>64</bold>, 2302288 (2024).<pub-id pub-id-type="pmid">39117431</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR301"><label>301.</label><citation-alternatives><element-citation id="ec-CR301" publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><etal/></person-group><article-title>NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway</article-title><source>J. Clin. Investig.</source><year>2010</year><volume>120</volume><fpage>1645</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1172/JCI39481</pub-id><pub-id pub-id-type="pmid">20389019</pub-id>
</element-citation><mixed-citation id="mc-CR301" publication-type="journal">Watanabe, T. et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. <italic>J. Clin. Investig.</italic><bold>120</bold>, 1645&#x02013;1662 (2010).<pub-id pub-id-type="pmid">20389019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR302"><label>302.</label><citation-alternatives><element-citation id="ec-CR302" publication-type="journal"><person-group person-group-type="author"><name><surname>Bauernfeind</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>787</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901363</pub-id><pub-id pub-id-type="pmid">19570822</pub-id>
</element-citation><mixed-citation id="mc-CR302" publication-type="journal">Bauernfeind, F. G. et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. <italic>J. Immunol.</italic><bold>183</bold>, 787&#x02013;791 (2009).<pub-id pub-id-type="pmid">19570822</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR303"><label>303.</label><citation-alternatives><element-citation id="ec-CR303" publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cutting edge: TRAF6 mediates TLR/IL-1R signaling-induced nontranscriptional priming of the NLRP3 inflammasome</article-title><source>J. Immunol.</source><year>2017</year><volume>199</volume><fpage>1561</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700175</pub-id><pub-id pub-id-type="pmid">28739881</pub-id>
</element-citation><mixed-citation id="mc-CR303" publication-type="journal">Xing, Y. et al. Cutting edge: TRAF6 mediates TLR/IL-1R signaling-induced nontranscriptional priming of the NLRP3 inflammasome. <italic>J. Immunol.</italic><bold>199</bold>, 1561&#x02013;1566 (2017).<pub-id pub-id-type="pmid">28739881</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR304"><label>304.</label><citation-alternatives><element-citation id="ec-CR304" publication-type="journal"><person-group person-group-type="author"><name><surname>Juliana</surname><given-names>C</given-names></name><etal/></person-group><article-title>Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>36617</fpage><lpage>36622</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.407130</pub-id><pub-id pub-id-type="pmid">22948162</pub-id>
</element-citation><mixed-citation id="mc-CR304" publication-type="journal">Juliana, C. et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. <italic>J. Biol. Chem.</italic><bold>287</bold>, 36617&#x02013;36622 (2012).<pub-id pub-id-type="pmid">22948162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR305"><label>305.</label><citation-alternatives><element-citation id="ec-CR305" publication-type="journal"><person-group person-group-type="author"><name><surname>Py</surname><given-names>BF</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Vakifahmetoglu-Norberg</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name></person-group><article-title>Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity</article-title><source>Mol. Cell</source><year>2013</year><volume>49</volume><fpage>331</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.11.009</pub-id><pub-id pub-id-type="pmid">23246432</pub-id>
</element-citation><mixed-citation id="mc-CR305" publication-type="journal">Py, B. F., Kim, M. S., Vakifahmetoglu-Norberg, H. &#x00026; Yuan, J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. <italic>Mol. Cell</italic><bold>49</bold>, 331&#x02013;338 (2013).<pub-id pub-id-type="pmid">23246432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR306"><label>306.</label><citation-alternatives><element-citation id="ec-CR306" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><etal/></person-group><article-title>The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13727</fpage><pub-id pub-id-type="doi">10.1038/ncomms13727</pub-id><pub-id pub-id-type="pmid">27929086</pub-id>
</element-citation><mixed-citation id="mc-CR306" publication-type="journal">Song, H., et al. The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3. <italic>Nat. Commun.</italic><bold>7</bold>, 13727 (2016).<pub-id pub-id-type="pmid">27929086</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR307"><label>307.</label><citation-alternatives><element-citation id="ec-CR307" publication-type="journal"><person-group person-group-type="author"><name><surname>Masumoto</surname><given-names>J</given-names></name><etal/></person-group><article-title>ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>33835</fpage><lpage>33838</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.48.33835</pub-id><pub-id pub-id-type="pmid">10567338</pub-id>
</element-citation><mixed-citation id="mc-CR307" publication-type="journal">Masumoto, J. et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. <italic>J. Biol. Chem.</italic><bold>274</bold>, 33835&#x02013;33838 (1999).<pub-id pub-id-type="pmid">10567338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR308"><label>308.</label><citation-alternatives><element-citation id="ec-CR308" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Junior</surname><given-names>ES</given-names></name><name><surname>Morandini</surname><given-names>AC</given-names></name></person-group><article-title>Gasdermin: a new player to the inflammasome game</article-title><source>Biomed. J.</source><year>2017</year><volume>40</volume><fpage>313</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.bj.2017.10.002</pub-id><pub-id pub-id-type="pmid">29433834</pub-id>
</element-citation><mixed-citation id="mc-CR308" publication-type="journal">Ramos-Junior, E. S. &#x00026; Morandini, A. C. Gasdermin: a new player to the inflammasome game. <italic>Biomed. J.</italic><bold>40</bold>, 313&#x02013;316 (2017).<pub-id pub-id-type="pmid">29433834</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR309"><label>309.</label><citation-alternatives><element-citation id="ec-CR309" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux</article-title><source>Nature</source><year>2016</year><volume>530</volume><fpage>354</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nature16959</pub-id><pub-id pub-id-type="pmid">26814970</pub-id>
</element-citation><mixed-citation id="mc-CR309" publication-type="journal">He, Y. et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. <italic>Nature</italic><bold>530</bold>, 354&#x02013;357 (2016).<pub-id pub-id-type="pmid">26814970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR310"><label>310.</label><citation-alternatives><element-citation id="ec-CR310" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><etal/></person-group><article-title>NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component</article-title><source>Nat. Immunol.</source><year>2016</year><volume>17</volume><fpage>250</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/ni.3333</pub-id><pub-id pub-id-type="pmid">26642356</pub-id>
</element-citation><mixed-citation id="mc-CR310" publication-type="journal">Shi, H. et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. <italic>Nat. Immunol.</italic><bold>17</bold>, 250&#x02013;258 (2016).<pub-id pub-id-type="pmid">26642356</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR311"><label>311.</label><citation-alternatives><element-citation id="ec-CR311" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group><article-title>Excessive deubiquitination of NLRP3-R779C variant contributes to very-early-onset inflammatory bowel disease development</article-title><source>J. Allergy Clin. Immunol.</source><year>2021</year><volume>147</volume><fpage>267</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2020.09.003</pub-id><pub-id pub-id-type="pmid">32941940</pub-id>
</element-citation><mixed-citation id="mc-CR311" publication-type="journal">Zhou, L. et al. Excessive deubiquitination of NLRP3-R779C variant contributes to very-early-onset inflammatory bowel disease development. <italic>J. Allergy Clin. Immunol.</italic><bold>147</bold>, 267&#x02013;279 (2021).<pub-id pub-id-type="pmid">32941940</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR312"><label>312.</label><citation-alternatives><element-citation id="ec-CR312" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Woodruff</surname><given-names>PG</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name></person-group><article-title>Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies</article-title><source>Eur. Respir. J.</source><year>2024</year><volume>64</volume><fpage>2300826</fpage><pub-id pub-id-type="doi">10.1183/13993003.00826-2023</pub-id><pub-id pub-id-type="pmid">38697650</pub-id>
</element-citation><mixed-citation id="mc-CR312" publication-type="journal">Liu, T., Woodruff, P. G. &#x00026; Zhou, X. Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies. <italic>Eur. Respir. J.</italic><bold>64</bold>, 2300826 (2024).<pub-id pub-id-type="pmid">38697650</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR313"><label>313.</label><citation-alternatives><element-citation id="ec-CR313" publication-type="journal"><person-group person-group-type="author"><name><surname>Perea</surname><given-names>L</given-names></name><etal/></person-group><article-title>Airway IL-1&#x003b2; is related to disease severity and mucociliary function in bronchiectasis</article-title><source>Eur. Respir. J.</source><year>2024</year><volume>64</volume><fpage>2301966</fpage><pub-id pub-id-type="doi">10.1183/13993003.01966-2023</pub-id><pub-id pub-id-type="pmid">38811046</pub-id>
</element-citation><mixed-citation id="mc-CR313" publication-type="journal">Perea, L. et al. Airway IL-1&#x003b2; is related to disease severity and mucociliary function in bronchiectasis. <italic>Eur. Respir. J.</italic><bold>64</bold>, 2301966 (2024).<pub-id pub-id-type="pmid">38811046</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR314"><label>314.</label><citation-alternatives><element-citation id="ec-CR314" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CH</given-names></name><etal/></person-group><article-title>NLR network mediates immunity to diverse plant pathogens</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>8113</fpage><lpage>8118</lpage><pub-id pub-id-type="doi">10.1073/pnas.1702041114</pub-id><pub-id pub-id-type="pmid">28698366</pub-id>
</element-citation><mixed-citation id="mc-CR314" publication-type="journal">Wu, C. H. et al. NLR network mediates immunity to diverse plant pathogens. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>114</bold>, 8113&#x02013;8118 (2017).<pub-id pub-id-type="pmid">28698366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR315"><label>315.</label><citation-alternatives><element-citation id="ec-CR315" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuriakose</surname><given-names>T</given-names></name><etal/></person-group><article-title>ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways</article-title><source>Sci. Immunol.</source><year>2016</year><volume>1</volume><fpage>aag2045</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aag2045</pub-id><pub-id pub-id-type="pmid">27917412</pub-id>
</element-citation><mixed-citation id="mc-CR315" publication-type="journal">Kuriakose, T. et al. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. <italic>Sci. Immunol.</italic><bold>1</bold>, aag2045 (2016).<pub-id pub-id-type="pmid">27917412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR316"><label>316.</label><citation-alternatives><element-citation id="ec-CR316" publication-type="journal"><person-group person-group-type="author"><name><surname>Christgen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis)</article-title><source>Front. Cell Infect. Microbiol</source><year>2020</year><volume>10</volume><fpage>237</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2020.00237</pub-id><pub-id pub-id-type="pmid">32547960</pub-id>
</element-citation><mixed-citation id="mc-CR316" publication-type="journal">Christgen, S. et al. Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis). <italic>Front. Cell Infect. Microbiol</italic><bold>10</bold>, 237 (2020).<pub-id pub-id-type="pmid">32547960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR317"><label>317.</label><citation-alternatives><element-citation id="ec-CR317" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Activation of NOD1 by DAP contributes to myocardial ischemia/reperfusion injury via multiple signaling pathways</article-title><source>Apoptosis</source><year>2015</year><volume>20</volume><fpage>512</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1007/s10495-015-1089-1</pub-id><pub-id pub-id-type="pmid">25608996</pub-id>
</element-citation><mixed-citation id="mc-CR317" publication-type="journal">Yang, H. et al. Activation of NOD1 by DAP contributes to myocardial ischemia/reperfusion injury via multiple signaling pathways. <italic>Apoptosis</italic><bold>20</bold>, 512&#x02013;522 (2015).<pub-id pub-id-type="pmid">25608996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR318"><label>318.</label><citation-alternatives><element-citation id="ec-CR318" publication-type="journal"><person-group person-group-type="author"><name><surname>Val-Blasco</surname><given-names>A</given-names></name><etal/></person-group><article-title>NOD1 activation in cardiac fibroblasts induces myocardial fibrosis in a murine model of type 2 diabetes</article-title><source>Biochem. J.</source><year>2017</year><volume>474</volume><fpage>399</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1042/BCJ20160556</pub-id><pub-id pub-id-type="pmid">27803247</pub-id>
</element-citation><mixed-citation id="mc-CR318" publication-type="journal">Val-Blasco, A. et al. NOD1 activation in cardiac fibroblasts induces myocardial fibrosis in a murine model of type 2 diabetes. <italic>Biochem. J.</italic><bold>474</bold>, 399&#x02013;410 (2017).<pub-id pub-id-type="pmid">27803247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR319"><label>319.</label><citation-alternatives><element-citation id="ec-CR319" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Silencing of NOD2 protects against diabetic cardiomyopathy in a murine diabetes model</article-title><source>Int. J. Mol. Med.</source><year>2018</year><volume>42</volume><fpage>3017</fpage><lpage>3026</lpage><pub-id pub-id-type="pmid">30221681</pub-id>
</element-citation><mixed-citation id="mc-CR319" publication-type="journal">Shen, L. et al. Silencing of NOD2 protects against diabetic cardiomyopathy in a murine diabetes model. <italic>Int. J. Mol. Med.</italic><bold>42</bold>, 3017&#x02013;3026 (2018).<pub-id pub-id-type="pmid">30221681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR320"><label>320.</label><citation-alternatives><element-citation id="ec-CR320" publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>J</given-names></name><etal/></person-group><article-title>NOD2 deletion promotes cardiac hypertrophy and fibrosis induced by pressure overload</article-title><source>Lab Investig.</source><year>2013</year><volume>93</volume><fpage>1128</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2013.99</pub-id><pub-id pub-id-type="pmid">23958879</pub-id>
</element-citation><mixed-citation id="mc-CR320" publication-type="journal">Zong, J. et al. NOD2 deletion promotes cardiac hypertrophy and fibrosis induced by pressure overload. <italic>Lab Investig.</italic><bold>93</bold>, 1128&#x02013;1136 (2013).<pub-id pub-id-type="pmid">23958879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR321"><label>321.</label><citation-alternatives><element-citation id="ec-CR321" publication-type="journal"><person-group person-group-type="author"><name><surname>Kanno</surname><given-names>S</given-names></name><etal/></person-group><article-title>Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe-/- mice</article-title><source>J. Immunol.</source><year>2015</year><volume>194</volume><fpage>773</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302841</pub-id><pub-id pub-id-type="pmid">25488987</pub-id>
</element-citation><mixed-citation id="mc-CR321" publication-type="journal">Kanno, S. et al. Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe-/- mice. <italic>J. Immunol.</italic><bold>194</bold>, 773&#x02013;780 (2015).<pub-id pub-id-type="pmid">25488987</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR322"><label>322.</label><citation-alternatives><element-citation id="ec-CR322" publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Innate immune receptor NOD2 promotes vascular inflammation and formation of lipid-rich necrotic cores in hypercholesterolemic mice</article-title><source>Eur. J. Immunol.</source><year>2014</year><volume>44</volume><fpage>3081</fpage><lpage>3092</lpage><pub-id pub-id-type="doi">10.1002/eji.201444755</pub-id><pub-id pub-id-type="pmid">25042478</pub-id>
</element-citation><mixed-citation id="mc-CR322" publication-type="journal">Johansson, M. E. et al. Innate immune receptor NOD2 promotes vascular inflammation and formation of lipid-rich necrotic cores in hypercholesterolemic mice. <italic>Eur. J. Immunol.</italic><bold>44</bold>, 3081&#x02013;3092 (2014).<pub-id pub-id-type="pmid">25042478</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR323"><label>323.</label><citation-alternatives><element-citation id="ec-CR323" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Pivotal role of NOD2 in inflammatory processes affecting atherosclerosis and periodontal bone loss</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>E5059</fpage><lpage>E5068</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320862110</pub-id><pub-id pub-id-type="pmid">24324141</pub-id>
</element-citation><mixed-citation id="mc-CR323" publication-type="journal">Yuan, H. et al. Pivotal role of NOD2 in inflammatory processes affecting atherosclerosis and periodontal bone loss. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>110</bold>, E5059&#x02013;E5068 (2013).<pub-id pub-id-type="pmid">24324141</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR324"><label>324.</label><citation-alternatives><element-citation id="ec-CR324" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HQ</given-names></name><etal/></person-group><article-title>NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2013</year><volume>33</volume><fpage>2193</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.113.301715</pub-id><pub-id pub-id-type="pmid">23868940</pub-id>
</element-citation><mixed-citation id="mc-CR324" publication-type="journal">Liu, H. Q. et al. NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>33</bold>, 2193&#x02013;2201 (2013).<pub-id pub-id-type="pmid">23868940</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR325"><label>325.</label><citation-alternatives><element-citation id="ec-CR325" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><etal/></person-group><article-title>A novel crosstalk between TLR4- and NOD2-mediated signaling in the regulation of intestinal inflammation</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>12018</fpage><pub-id pub-id-type="doi">10.1038/srep12018</pub-id><pub-id pub-id-type="pmid">26153766</pub-id>
</element-citation><mixed-citation id="mc-CR325" publication-type="journal">Kim, H. et al. A novel crosstalk between TLR4- and NOD2-mediated signaling in the regulation of intestinal inflammation. <italic>Sci. Rep.</italic><bold>5</bold>, 12018 (2015).<pub-id pub-id-type="pmid">26153766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR326"><label>326.</label><citation-alternatives><element-citation id="ec-CR326" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name></person-group><article-title>Role of nucleotide-binding and oligomerization domain 2 protein (NOD2) in the development of atherosclerosis</article-title><source>Korean J. Physiol. Pharmacol.</source><year>2015</year><volume>19</volume><fpage>479</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.4196/kjpp.2015.19.6.479</pub-id><pub-id pub-id-type="pmid">26557013</pub-id>
</element-citation><mixed-citation id="mc-CR326" publication-type="journal">Kim, H. J. Role of nucleotide-binding and oligomerization domain 2 protein (NOD2) in the development of atherosclerosis. <italic>Korean J. Physiol. Pharmacol.</italic><bold>19</bold>, 479&#x02013;484 (2015).<pub-id pub-id-type="pmid">26557013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR327"><label>327.</label><citation-alternatives><element-citation id="ec-CR327" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury</article-title><source>Basic Res. Cardiol.</source><year>2014</year><volume>109</volume><fpage>415</fpage><pub-id pub-id-type="doi">10.1007/s00395-014-0415-z</pub-id><pub-id pub-id-type="pmid">25015733</pub-id>
</element-citation><mixed-citation id="mc-CR327" publication-type="journal">Liu, Y. et al. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. <italic>Basic Res. Cardiol.</italic><bold>109</bold>, 415 (2014).<pub-id pub-id-type="pmid">25015733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR328"><label>328.</label><citation-alternatives><element-citation id="ec-CR328" publication-type="journal"><person-group person-group-type="author"><name><surname>van Hout</surname><given-names>GP</given-names></name><etal/></person-group><article-title>The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction</article-title><source>Eur. Heart J.</source><year>2017</year><volume>38</volume><fpage>828</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">27432019</pub-id>
</element-citation><mixed-citation id="mc-CR328" publication-type="journal">van Hout, G. P. et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. <italic>Eur. Heart J.</italic><bold>38</bold>, 828&#x02013;836 (2017).<pub-id pub-id-type="pmid">27432019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR329"><label>329.</label><citation-alternatives><element-citation id="ec-CR329" publication-type="journal"><person-group person-group-type="author"><name><surname>Toldo</surname><given-names>S</given-names></name><name><surname>Abbate</surname><given-names>A</given-names></name></person-group><article-title>The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases</article-title><source>Nat. Rev. Cardiol.</source><year>2024</year><volume>21</volume><fpage>219</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1038/s41569-023-00946-3</pub-id><pub-id pub-id-type="pmid">37923829</pub-id>
</element-citation><mixed-citation id="mc-CR329" publication-type="journal">Toldo, S. &#x00026; Abbate, A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. <italic>Nat. Rev. Cardiol.</italic><bold>21</bold>, 219&#x02013;237 (2024).<pub-id pub-id-type="pmid">37923829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR330"><label>330.</label><citation-alternatives><element-citation id="ec-CR330" publication-type="journal"><person-group person-group-type="author"><name><surname>Kawaguchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury</article-title><source>Circulation</source><year>2011</year><volume>123</volume><fpage>594</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.982777</pub-id><pub-id pub-id-type="pmid">21282498</pub-id>
</element-citation><mixed-citation id="mc-CR330" publication-type="journal">Kawaguchi, M. et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. <italic>Circulation</italic><bold>123</bold>, 594&#x02013;604 (2011).<pub-id pub-id-type="pmid">21282498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR331"><label>331.</label><citation-alternatives><element-citation id="ec-CR331" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>TAK1 Activation by NLRP3 Deficiency Confers Cardioprotection Against Pressure Overload-Induced Cardiomyocyte Pyroptosis and Hypertrophy</article-title><source>JACC Basic Transl. Sci.</source><year>2023</year><volume>8</volume><fpage>1555</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1016/j.jacbts.2023.05.008</pub-id><pub-id pub-id-type="pmid">38205342</pub-id>
</element-citation><mixed-citation id="mc-CR331" publication-type="journal">Li, X. et al. TAK1 Activation by NLRP3 Deficiency Confers Cardioprotection Against Pressure Overload-Induced Cardiomyocyte Pyroptosis and Hypertrophy. <italic>JACC Basic Transl. Sci.</italic><bold>8</bold>, 1555&#x02013;1573 (2023).<pub-id pub-id-type="pmid">38205342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR332"><label>332.</label><citation-alternatives><element-citation id="ec-CR332" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Landscape of RNA-binding proteins in diagnostic utility, immune cell infiltration and PANoptosis features of heart failure</article-title><source>Front. Genet</source><year>2022</year><volume>13</volume><fpage>1004163</fpage><pub-id pub-id-type="doi">10.3389/fgene.2022.1004163</pub-id><pub-id pub-id-type="pmid">36313471</pub-id>
</element-citation><mixed-citation id="mc-CR332" publication-type="journal">Li, J. et al. Landscape of RNA-binding proteins in diagnostic utility, immune cell infiltration and PANoptosis features of heart failure. <italic>Front. Genet</italic><bold>13</bold>, 1004163 (2022).<pub-id pub-id-type="pmid">36313471</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR333"><label>333.</label><citation-alternatives><element-citation id="ec-CR333" publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>FUNDC1 protects against doxorubicin-induced cardiomyocyte PANoptosis through stabilizing mtDNA via interaction with TUFM</article-title><source>Cell Death Dis.</source><year>2022</year><volume>13</volume><fpage>1020</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-05460-x</pub-id><pub-id pub-id-type="pmid">36470869</pub-id>
</element-citation><mixed-citation id="mc-CR333" publication-type="journal">Bi, Y., et al. FUNDC1 protects against doxorubicin-induced cardiomyocyte PANoptosis through stabilizing mtDNA via interaction with TUFM. <italic>Cell Death Dis.</italic><bold>13</bold>, 1020 (2022).<pub-id pub-id-type="pmid">36470869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR334"><label>334.</label><citation-alternatives><element-citation id="ec-CR334" publication-type="journal"><person-group person-group-type="author"><name><surname>Duewell</surname><given-names>P</given-names></name><etal/></person-group><article-title>NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals</article-title><source>Nature</source><year>2010</year><volume>464</volume><fpage>1357</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1038/nature08938</pub-id><pub-id pub-id-type="pmid">20428172</pub-id>
</element-citation><mixed-citation id="mc-CR334" publication-type="journal">Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. <italic>Nature</italic><bold>464</bold>, 1357&#x02013;1361 (2010).<pub-id pub-id-type="pmid">20428172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR335"><label>335.</label><citation-alternatives><element-citation id="ec-CR335" publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>R</given-names></name><etal/></person-group><article-title>MicroRNA-155 promotes the ox-LDL-induced activation of NLRP3 inflammasomes via the ERK1/2 pathway in THP-1 macrophages and aggravates atherosclerosis in ApoE-/- mice</article-title><source>Ann. Palliat. Med.</source><year>2019</year><volume>8</volume><fpage>676</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.21037/apm.2019.10.11</pub-id><pub-id pub-id-type="pmid">31865729</pub-id>
</element-citation><mixed-citation id="mc-CR335" publication-type="journal">Yin, R. et al. MicroRNA-155 promotes the ox-LDL-induced activation of NLRP3 inflammasomes via the ERK1/2 pathway in THP-1 macrophages and aggravates atherosclerosis in ApoE-/- mice. <italic>Ann. Palliat. Med.</italic><bold>8</bold>, 676&#x02013;689 (2019).<pub-id pub-id-type="pmid">31865729</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR336"><label>336.</label><citation-alternatives><element-citation id="ec-CR336" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Humanin ameliorates free fatty acid-induced endothelial inflammation by suppressing the NLRP3 inflammasome</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>22039</fpage><lpage>22045</lpage><pub-id pub-id-type="doi">10.1021/acsomega.0c01778</pub-id><pub-id pub-id-type="pmid">32923762</pub-id>
</element-citation><mixed-citation id="mc-CR336" publication-type="journal">Li, W. et al. Humanin ameliorates free fatty acid-induced endothelial inflammation by suppressing the NLRP3 inflammasome. <italic>ACS Omega</italic><bold>5</bold>, 22039&#x02013;22045 (2020).<pub-id pub-id-type="pmid">32923762</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR337"><label>337.</label><citation-alternatives><element-citation id="ec-CR337" publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>circACTA2 inhibits NLRP3 inflammasome-mediated inflammation via interacting with NF-&#x003ba;B in vascular smooth muscle cells</article-title><source>Cell Mol. Life Sci.</source><year>2023</year><volume>80</volume><fpage>229</fpage><pub-id pub-id-type="doi">10.1007/s00018-023-04840-6</pub-id><pub-id pub-id-type="pmid">37498354</pub-id>
</element-citation><mixed-citation id="mc-CR337" publication-type="journal">Bai, Y. et al. circACTA2 inhibits NLRP3 inflammasome-mediated inflammation via interacting with NF-&#x003ba;B in vascular smooth muscle cells. <italic>Cell Mol. Life Sci.</italic><bold>80</bold>, 229 (2023).<pub-id pub-id-type="pmid">37498354</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR338"><label>338.</label><citation-alternatives><element-citation id="ec-CR338" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Endothelial nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome regulation in atherosclerosis</article-title><source>Cardiovasc. Res.</source><year>2024</year><volume>120</volume><fpage>883</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvae071</pub-id><pub-id pub-id-type="pmid">38626254</pub-id>
</element-citation><mixed-citation id="mc-CR338" publication-type="journal">Guo, S. et al. Endothelial nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome regulation in atherosclerosis. <italic>Cardiovasc. Res.</italic><bold>120</bold>, 883&#x02013;898 (2024).<pub-id pub-id-type="pmid">38626254</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR339"><label>339.</label><citation-alternatives><element-citation id="ec-CR339" publication-type="journal"><person-group person-group-type="author"><name><surname>Batool</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name></person-group><article-title>Structural insights into the distinctive RNA recognition and therapeutic potentials of RIG-I-like receptors</article-title><source>Med. Res. Rev.</source><year>2022</year><volume>42</volume><fpage>399</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1002/med.21845</pub-id><pub-id pub-id-type="pmid">34287999</pub-id>
</element-citation><mixed-citation id="mc-CR339" publication-type="journal">Batool, M., Kim, M. S. &#x00026; Choi, S. Structural insights into the distinctive RNA recognition and therapeutic potentials of RIG-I-like receptors. <italic>Med. Res. Rev.</italic><bold>42</bold>, 399&#x02013;425 (2022).<pub-id pub-id-type="pmid">34287999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR340"><label>340.</label><citation-alternatives><element-citation id="ec-CR340" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrage</surname><given-names>F</given-names></name><etal/></person-group><article-title>Structure and dynamics of the second CARD of human RIG-I provide mechanistic insights into regulation of RIG-I activation</article-title><source>Structure</source><year>2012</year><volume>20</volume><fpage>2048</fpage><lpage>2061</lpage><pub-id pub-id-type="doi">10.1016/j.str.2012.09.003</pub-id><pub-id pub-id-type="pmid">23063562</pub-id>
</element-citation><mixed-citation id="mc-CR340" publication-type="journal">Ferrage, F. et al. Structure and dynamics of the second CARD of human RIG-I provide mechanistic insights into regulation of RIG-I activation. <italic>Structure</italic><bold>20</bold>, 2048&#x02013;2061 (2012).<pub-id pub-id-type="pmid">23063562</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR341"><label>341.</label><citation-alternatives><element-citation id="ec-CR341" publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>T</given-names></name><etal/></person-group><article-title>LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>1512</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912986107</pub-id><pub-id pub-id-type="pmid">20080593</pub-id>
</element-citation><mixed-citation id="mc-CR341" publication-type="journal">Satoh, T. et al. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>107</bold>, 1512&#x02013;1517 (2010).<pub-id pub-id-type="pmid">20080593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR342"><label>342.</label><citation-alternatives><element-citation id="ec-CR342" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><etal/></person-group><article-title>PARP9 is overexpressed in human breast cancer and promotes cancer cell migration</article-title><source>Oncol. Lett.</source><year>2018</year><volume>16</volume><fpage>4073</fpage><lpage>4077</lpage><pub-id pub-id-type="pmid">30128030</pub-id>
</element-citation><mixed-citation id="mc-CR342" publication-type="journal">Tang, X. et al. PARP9 is overexpressed in human breast cancer and promotes cancer cell migration. <italic>Oncol. Lett.</italic><bold>16</bold>, 4073&#x02013;4077 (2018).<pub-id pub-id-type="pmid">30128030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR343"><label>343.</label><citation-alternatives><element-citation id="ec-CR343" publication-type="journal"><person-group person-group-type="author"><name><surname>Camicia</surname><given-names>R</given-names></name><etal/></person-group><article-title>BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNgamma-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma</article-title><source>J. Cell Sci.</source><year>2013</year><volume>126</volume><fpage>1969</fpage><lpage>1980</lpage><pub-id pub-id-type="pmid">23487038</pub-id>
</element-citation><mixed-citation id="mc-CR343" publication-type="journal">Camicia, R. et al. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNgamma-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma. <italic>J. Cell Sci.</italic><bold>126</bold>, 1969&#x02013;1980 (2013).<pub-id pub-id-type="pmid">23487038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR344"><label>344.</label><citation-alternatives><element-citation id="ec-CR344" publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>H</given-names></name><etal/></person-group><article-title>PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>12849</fpage><pub-id pub-id-type="doi">10.1038/ncomms12849</pub-id><pub-id pub-id-type="pmid">27796300</pub-id>
</element-citation><mixed-citation id="mc-CR344" publication-type="journal">Iwata, H. et al. PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. <italic>Nat. Commun.</italic><bold>7</bold>, 12849 (2016).<pub-id pub-id-type="pmid">27796300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR345"><label>345.</label><citation-alternatives><element-citation id="ec-CR345" publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>J</given-names></name><etal/></person-group><article-title>Identification of poly(ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>2681</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-23003-4</pub-id><pub-id pub-id-type="pmid">33976210</pub-id>
</element-citation><mixed-citation id="mc-CR345" publication-type="journal">Xing, J., et al. Identification of poly(ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells. <italic>Nat. Commun.</italic><bold>12</bold>, 2681 (2021).<pub-id pub-id-type="pmid">33976210</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR346"><label>346.</label><citation-alternatives><element-citation id="ec-CR346" publication-type="journal"><person-group person-group-type="author"><name><surname>Hornung</surname><given-names>V</given-names></name><etal/></person-group><article-title>5&#x02019;-Triphosphate RNA is the ligand for RIG-I</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>994</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1126/science.1132505</pub-id><pub-id pub-id-type="pmid">17038590</pub-id>
</element-citation><mixed-citation id="mc-CR346" publication-type="journal">Hornung, V. et al. 5&#x02019;-Triphosphate RNA is the ligand for RIG-I. <italic>Science</italic><bold>314</bold>, 994&#x02013;997 (2006).<pub-id pub-id-type="pmid">17038590</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR347"><label>347.</label><citation-alternatives><element-citation id="ec-CR347" publication-type="journal"><person-group person-group-type="author"><name><surname>Myong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cytosolic viral sensor RIG-I is a 5&#x02019;-triphosphate-dependent translocase on double-stranded RNA</article-title><source>Science</source><year>2009</year><volume>323</volume><fpage>1070</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1126/science.1168352</pub-id><pub-id pub-id-type="pmid">19119185</pub-id>
</element-citation><mixed-citation id="mc-CR347" publication-type="journal">Myong, S. et al. Cytosolic viral sensor RIG-I is a 5&#x02019;-triphosphate-dependent translocase on double-stranded RNA. <italic>Science</italic><bold>323</bold>, 1070&#x02013;1074 (2009).<pub-id pub-id-type="pmid">19119185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR348"><label>348.</label><citation-alternatives><element-citation id="ec-CR348" publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><article-title>Signaling to NF-kappaB</article-title><source>Genes Dev.</source><year>2004</year><volume>18</volume><fpage>2195</fpage><lpage>2224</lpage><pub-id pub-id-type="doi">10.1101/gad.1228704</pub-id><pub-id pub-id-type="pmid">15371334</pub-id>
</element-citation><mixed-citation id="mc-CR348" publication-type="journal">Hayden, M. S. &#x00026; Ghosh, S. Signaling to NF-kappaB. <italic>Genes Dev.</italic><bold>18</bold>, 2195&#x02013;2224 (2004).<pub-id pub-id-type="pmid">15371334</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR349"><label>349.</label><citation-alternatives><element-citation id="ec-CR349" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>E</given-names></name><etal/></person-group><article-title>Mechanisms involved in controlling RNA virus-induced intestinal inflammation</article-title><source>Cell Mol. Life Sci.</source><year>2022</year><volume>79</volume><fpage>313</fpage><pub-id pub-id-type="doi">10.1007/s00018-022-04332-z</pub-id><pub-id pub-id-type="pmid">35604464</pub-id>
</element-citation><mixed-citation id="mc-CR349" publication-type="journal">Zhang, E. et al. Mechanisms involved in controlling RNA virus-induced intestinal inflammation. <italic>Cell Mol. Life Sci.</italic><bold>79</bold>, 313 (2022).<pub-id pub-id-type="pmid">35604464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR350"><label>350.</label><citation-alternatives><element-citation id="ec-CR350" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Valaperti</surname><given-names>A</given-names></name></person-group><article-title>Human cardiac fibroblasts produce pro-inflammatory cytokines upon TLRs and RLRs stimulation</article-title><source>Mol. Cell Biochem.</source><year>2021</year><volume>476</volume><fpage>3241</fpage><lpage>3252</lpage><pub-id pub-id-type="doi">10.1007/s11010-021-04157-7</pub-id><pub-id pub-id-type="pmid">33881711</pub-id>
</element-citation><mixed-citation id="mc-CR350" publication-type="journal">Li, Z., Nguyen, T. T. &#x00026; Valaperti, A. Human cardiac fibroblasts produce pro-inflammatory cytokines upon TLRs and RLRs stimulation. <italic>Mol. Cell Biochem.</italic><bold>476</bold>, 3241&#x02013;3252 (2021).<pub-id pub-id-type="pmid">33881711</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR351"><label>351.</label><citation-alternatives><element-citation id="ec-CR351" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>P</given-names></name><etal/></person-group><article-title>The function, role and process of DDX58 in heart failure and human cancers</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><fpage>911309</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.911309</pub-id><pub-id pub-id-type="pmid">35814394</pub-id>
</element-citation><mixed-citation id="mc-CR351" publication-type="journal">Yu, P. et al. The function, role and process of DDX58 in heart failure and human cancers. <italic>Front. Oncol.</italic><bold>12</bold>, 911309 (2022).<pub-id pub-id-type="pmid">35814394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR352"><label>352.</label><citation-alternatives><element-citation id="ec-CR352" publication-type="journal"><person-group person-group-type="author"><name><surname>Imaizumi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Expression of retinoic acid-inducible gene-I (RIG-I) in macrophages: possible involvement of RIG-I in atherosclerosis</article-title><source>J. Atheroscler. Thromb.</source><year>2007</year><volume>14</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.5551/jat.14.51</pub-id><pub-id pub-id-type="pmid">17485888</pub-id>
</element-citation><mixed-citation id="mc-CR352" publication-type="journal">Imaizumi, T. et al. Expression of retinoic acid-inducible gene-I (RIG-I) in macrophages: possible involvement of RIG-I in atherosclerosis. <italic>J. Atheroscler. Thromb.</italic><bold>14</bold>, 51&#x02013;55 (2007).<pub-id pub-id-type="pmid">17485888</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR353"><label>353.</label><citation-alternatives><element-citation id="ec-CR353" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>T</given-names></name><name><surname>Weng</surname><given-names>J</given-names></name></person-group><article-title>Endothelial cells as a key cell type for innate immunity: a focused review on RIG-I signaling pathway</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>951614</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.951614</pub-id><pub-id pub-id-type="pmid">35865527</pub-id>
</element-citation><mixed-citation id="mc-CR353" publication-type="journal">Xu, S., Jin, T. &#x00026; Weng, J. Endothelial cells as a key cell type for innate immunity: a focused review on RIG-I signaling pathway. <italic>Front. Immunol.</italic><bold>13</bold>, 951614 (2022).<pub-id pub-id-type="pmid">35865527</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR354"><label>354.</label><citation-alternatives><element-citation id="ec-CR354" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><etal/></person-group><article-title>PARP9 affects myocardial function through TGF-beta/Smad axis and pirfenidone</article-title><source>Biomol. Biomed.</source><year>2024</year><volume>24</volume><fpage>1199</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.17305/bb.2024.10246</pub-id><pub-id pub-id-type="pmid">39213416</pub-id>
</element-citation><mixed-citation id="mc-CR354" publication-type="journal">Chen, N. et al. PARP9 affects myocardial function through TGF-beta/Smad axis and pirfenidone. <italic>Biomol. Biomed.</italic><bold>24</bold>, 1199&#x02013;1215 (2024).<pub-id pub-id-type="pmid">39213416</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR355"><label>355.</label><citation-alternatives><element-citation id="ec-CR355" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2005</year><volume>312</volume><fpage>891</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.077164</pub-id><pub-id pub-id-type="pmid">15523000</pub-id>
</element-citation><mixed-citation id="mc-CR355" publication-type="journal">Xiao, C. Y. et al. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. <italic>J. Pharmacol. Exp. Ther.</italic><bold>312</bold>, 891&#x02013;898 (2005).<pub-id pub-id-type="pmid">15523000</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR356"><label>356.</label><citation-alternatives><element-citation id="ec-CR356" publication-type="journal"><person-group person-group-type="author"><name><surname>Halmosi</surname><given-names>R</given-names></name><etal/></person-group><article-title>PARP inhibition and postinfarction myocardial remodeling</article-title><source>Int. J. Cardiol.</source><year>2016</year><volume>217</volume><fpage>S52</fpage><lpage>S59</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.06.223</pub-id><pub-id pub-id-type="pmid">27392900</pub-id>
</element-citation><mixed-citation id="mc-CR356" publication-type="journal">Halmosi, R. et al. PARP inhibition and postinfarction myocardial remodeling. <italic>Int. J. Cardiol.</italic><bold>217</bold>, S52&#x02013;S59 (2016).<pub-id pub-id-type="pmid">27392900</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR357"><label>357.</label><citation-alternatives><element-citation id="ec-CR357" publication-type="journal"><person-group person-group-type="author"><name><surname>Erbel</surname><given-names>C</given-names></name><etal/></person-group><article-title>PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels</article-title><source>Eur. J. Med. Res.</source><year>2011</year><volume>16</volume><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1186/2047-783X-16-8-367</pub-id><pub-id pub-id-type="pmid">21813379</pub-id>
</element-citation><mixed-citation id="mc-CR357" publication-type="journal">Erbel, C. et al. PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels. <italic>Eur. J. Med. Res.</italic><bold>16</bold>, 367&#x02013;374 (2011).<pub-id pub-id-type="pmid">21813379</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR358"><label>358.</label><citation-alternatives><element-citation id="ec-CR358" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name></person-group><article-title>cGAS-STING signaling</article-title><source>Curr. Biol.</source><year>2022</year><volume>32</volume><fpage>R730</fpage><lpage>r734</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2022.05.027</pub-id><pub-id pub-id-type="pmid">35820380</pub-id>
</element-citation><mixed-citation id="mc-CR358" publication-type="journal">Sun, Z. &#x00026; Hornung, V. cGAS-STING signaling. <italic>Curr. Biol.</italic><bold>32</bold>, R730&#x02013;r734 (2022).<pub-id pub-id-type="pmid">35820380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR359"><label>359.</label><citation-alternatives><element-citation id="ec-CR359" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>MM</given-names></name><name><surname>Shu</surname><given-names>HB</given-names></name></person-group><article-title>Mitochondrial DNA-triggered innate immune response: mechanisms and diseases</article-title><source>Cell Mol. Immunol.</source><year>2023</year><volume>20</volume><fpage>1403</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-01086-x</pub-id><pub-id pub-id-type="pmid">37932533</pub-id>
</element-citation><mixed-citation id="mc-CR359" publication-type="journal">Hu, M. M. &#x00026; Shu, H. B. Mitochondrial DNA-triggered innate immune response: mechanisms and diseases. <italic>Cell Mol. Immunol.</italic><bold>20</bold>, 1403&#x02013;1412 (2023).<pub-id pub-id-type="pmid">37932533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR360"><label>360.</label><citation-alternatives><element-citation id="ec-CR360" publication-type="journal"><person-group person-group-type="author"><name><surname>Decout</surname><given-names>A</given-names></name><name><surname>Katz</surname><given-names>JD</given-names></name><name><surname>Venkatraman</surname><given-names>S</given-names></name><name><surname>Ablasser</surname><given-names>A</given-names></name></person-group><article-title>The cGAS-STING pathway as a therapeutic target in inflammatory diseases</article-title><source>Nat. Rev. Immunol.</source><year>2021</year><volume>21</volume><fpage>548</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00524-z</pub-id><pub-id pub-id-type="pmid">33833439</pub-id>
</element-citation><mixed-citation id="mc-CR360" publication-type="journal">Decout, A., Katz, J. D., Venkatraman, S. &#x00026; Ablasser, A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. <italic>Nat. Rev. Immunol.</italic><bold>21</bold>, 548&#x02013;569 (2021).<pub-id pub-id-type="pmid">33833439</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR361"><label>361.</label><citation-alternatives><element-citation id="ec-CR361" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ZD</given-names></name><etal/></person-group><article-title>Disulfiram ameliorates STING/MITA-dependent inflammation and autoimmunity by targeting RNF115</article-title><source>Cell Mol. Immunol.</source><year>2024</year><volume>21</volume><fpage>275</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/s41423-024-01131-3</pub-id><pub-id pub-id-type="pmid">38267694</pub-id>
</element-citation><mixed-citation id="mc-CR361" publication-type="journal">Zhang, Z. D. et al. Disulfiram ameliorates STING/MITA-dependent inflammation and autoimmunity by targeting RNF115. <italic>Cell Mol. Immunol.</italic><bold>21</bold>, 275&#x02013;291 (2024).<pub-id pub-id-type="pmid">38267694</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR362"><label>362.</label><citation-alternatives><element-citation id="ec-CR362" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>The asthma risk gene, GSDMB, promotes mitochondrial DNA-induced ISGs expression</article-title><source>J. Respir. Biol. Transl. Med.</source><year>2024</year><volume>1</volume><fpage>10005</fpage><pub-id pub-id-type="pmid">38737375</pub-id>
</element-citation><mixed-citation id="mc-CR362" publication-type="journal">Liu, T. et al. The asthma risk gene, GSDMB, promotes mitochondrial DNA-induced ISGs expression. <italic>J. Respir. Biol. Transl. Med.</italic><bold>1</bold>, 10005 (2024).<pub-id pub-id-type="pmid">38737375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR363"><label>363.</label><citation-alternatives><element-citation id="ec-CR363" publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP</article-title><source>Nature</source><year>2019</year><volume>567</volume><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0998-5</pub-id><pub-id pub-id-type="pmid">30842659</pub-id>
</element-citation><mixed-citation id="mc-CR363" publication-type="journal">Shang, G. et al. Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP. <italic>Nature</italic><bold>567</bold>, 389&#x02013;393 (2019).<pub-id pub-id-type="pmid">30842659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR364"><label>364.</label><citation-alternatives><element-citation id="ec-CR364" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells</article-title><source>Nat. Immunol.</source><year>2011</year><volume>12</volume><fpage>959</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1038/ni.2091</pub-id><pub-id pub-id-type="pmid">21892174</pub-id>
</element-citation><mixed-citation id="mc-CR364" publication-type="journal">Zhang, Z. et al. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. <italic>Nat. Immunol.</italic><bold>12</bold>, 959&#x02013;965 (2011).<pub-id pub-id-type="pmid">21892174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR365"><label>365.</label><citation-alternatives><element-citation id="ec-CR365" publication-type="journal"><person-group person-group-type="author"><name><surname>Parvatiyar</surname><given-names>K</given-names></name><etal/></person-group><article-title>The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response</article-title><source>Nat. Immunol.</source><year>2012</year><volume>13</volume><fpage>1155</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1038/ni.2460</pub-id><pub-id pub-id-type="pmid">23142775</pub-id>
</element-citation><mixed-citation id="mc-CR365" publication-type="journal">Parvatiyar, K. et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. <italic>Nat. Immunol.</italic><bold>13</bold>, 1155&#x02013;1161 (2012).<pub-id pub-id-type="pmid">23142775</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR366"><label>366.</label><citation-alternatives><element-citation id="ec-CR366" publication-type="journal"><person-group person-group-type="author"><name><surname>Motani</surname><given-names>K</given-names></name><etal/></person-group><article-title>The Golgi-resident protein ACBD3 concentrates STING at ER-Golgi contact sites to drive export from the ER</article-title><source>Cell Rep.</source><year>2022</year><volume>41</volume><fpage>111868</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111868</pub-id><pub-id pub-id-type="pmid">36543137</pub-id>
</element-citation><mixed-citation id="mc-CR366" publication-type="journal">Motani, K., et al. The Golgi-resident protein ACBD3 concentrates STING at ER-Golgi contact sites to drive export from the ER. <italic>Cell Rep.</italic><bold>41</bold>, 111868 (2022).<pub-id pub-id-type="pmid">36543137</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR367"><label>367.</label><citation-alternatives><element-citation id="ec-CR367" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>Targeting STING in dendritic cells alleviates psoriatic inflammation by suppressing IL-17A production</article-title><source>Cell Mol. Immunol.</source><year>2024</year><volume>21</volume><fpage>738</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1038/s41423-024-01160-y</pub-id><pub-id pub-id-type="pmid">38806624</pub-id>
</element-citation><mixed-citation id="mc-CR367" publication-type="journal">Sun, X. et al. Targeting STING in dendritic cells alleviates psoriatic inflammation by suppressing IL-17A production. <italic>Cell Mol. Immunol.</italic><bold>21</bold>, 738&#x02013;751 (2024).<pub-id pub-id-type="pmid">38806624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR368"><label>368.</label><citation-alternatives><element-citation id="ec-CR368" publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>H</given-names></name><name><surname>Barber</surname><given-names>GN</given-names></name></person-group><article-title>STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nature07317</pub-id><pub-id pub-id-type="pmid">18724357</pub-id>
</element-citation><mixed-citation id="mc-CR368" publication-type="journal">Ishikawa, H. &#x00026; Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. <italic>Nature</italic><bold>455</bold>, 674&#x02013;678 (2008).<pub-id pub-id-type="pmid">18724357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR369"><label>369.</label><citation-alternatives><element-citation id="ec-CR369" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><article-title>STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway</article-title><source>Sci. Signal</source><year>2012</year><volume>5</volume><fpage>ra20</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2002521</pub-id><pub-id pub-id-type="pmid">22394562</pub-id>
</element-citation><mixed-citation id="mc-CR369" publication-type="journal">Tanaka, Y. &#x00026; Chen, Z. J. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. <italic>Sci. Signal</italic><bold>5</bold>, ra20 (2012).<pub-id pub-id-type="pmid">22394562</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR370"><label>370.</label><citation-alternatives><element-citation id="ec-CR370" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Bruton&#x02019;s tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response</article-title><source>Cell Rep.</source><year>2015</year><volume>10</volume><fpage>1055</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.039</pub-id><pub-id pub-id-type="pmid">25704810</pub-id>
</element-citation><mixed-citation id="mc-CR370" publication-type="journal">Lee, K. G. et al. Bruton&#x02019;s tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response. <italic>Cell Rep.</italic><bold>10</bold>, 1055&#x02013;1065 (2015).<pub-id pub-id-type="pmid">25704810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR371"><label>371.</label><citation-alternatives><element-citation id="ec-CR371" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Cytosolic DNA sensing promotes macrophage transformation and governs myocardial ischemic injury</article-title><source>Circulation</source><year>2018</year><volume>137</volume><fpage>2613</fpage><lpage>2634</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.031046</pub-id><pub-id pub-id-type="pmid">29437120</pub-id>
</element-citation><mixed-citation id="mc-CR371" publication-type="journal">Cao, D. J. et al. Cytosolic DNA sensing promotes macrophage transformation and governs myocardial ischemic injury. <italic>Circulation</italic><bold>137</bold>, 2613&#x02013;2634 (2018).<pub-id pub-id-type="pmid">29437120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR372"><label>372.</label><citation-alternatives><element-citation id="ec-CR372" publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Plasmacytoid dendritic cells mediate myocardial ischemia/reperfusion injury by secreting type I interferons</article-title><source>J. Am. Heart Assoc.</source><year>2021</year><volume>10</volume><fpage>e020754</fpage><pub-id pub-id-type="doi">10.1161/JAHA.121.020754</pub-id><pub-id pub-id-type="pmid">34325534</pub-id>
</element-citation><mixed-citation id="mc-CR372" publication-type="journal">Lai, L., et al. Plasmacytoid dendritic cells mediate myocardial ischemia/reperfusion injury by secreting type I interferons. <italic>J. Am. Heart Assoc.</italic><bold>10</bold>, e020754 (2021).<pub-id pub-id-type="pmid">34325534</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR373"><label>373.</label><citation-alternatives><element-citation id="ec-CR373" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cytosolic DNA sensor cGAS plays an essential pathogenetic role in pressure overload-induced heart failure</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2020</year><volume>318</volume><fpage>H1525</fpage><lpage>h1537</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00097.2020</pub-id><pub-id pub-id-type="pmid">32383996</pub-id>
</element-citation><mixed-citation id="mc-CR373" publication-type="journal">Hu, D. et al. Cytosolic DNA sensor cGAS plays an essential pathogenetic role in pressure overload-induced heart failure. <italic>Am. J. Physiol. Heart Circ. Physiol.</italic><bold>318</bold>, H1525&#x02013;h1537 (2020).<pub-id pub-id-type="pmid">32383996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR374"><label>374.</label><citation-alternatives><element-citation id="ec-CR374" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W</given-names></name><etal/></person-group><article-title>Critical role of the cGAS-STING pathway in doxorubicin-induced cardiotoxicity</article-title><source>Circ. Res.</source><year>2023</year><volume>132</volume><fpage>e223</fpage><lpage>e242</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.321587</pub-id><pub-id pub-id-type="pmid">37154056</pub-id>
</element-citation><mixed-citation id="mc-CR374" publication-type="journal">Luo, W. et al. Critical role of the cGAS-STING pathway in doxorubicin-induced cardiotoxicity. <italic>Circ. Res.</italic><bold>132</bold>, e223&#x02013;e242 (2023).<pub-id pub-id-type="pmid">37154056</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR375"><label>375.</label><citation-alternatives><element-citation id="ec-CR375" publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Porphyromonas gingivalis accelerates inflammatory atherosclerosis in the innominate artery of ApoE deficient mice</article-title><source>Atherosclerosis</source><year>2011</year><volume>215</volume><fpage>52</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2010.12.009</pub-id><pub-id pub-id-type="pmid">21251656</pub-id>
</element-citation><mixed-citation id="mc-CR375" publication-type="journal">Hayashi, C. et al. Porphyromonas gingivalis accelerates inflammatory atherosclerosis in the innominate artery of ApoE deficient mice. <italic>Atherosclerosis</italic><bold>215</bold>, 52&#x02013;59 (2011).<pub-id pub-id-type="pmid">21251656</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR376"><label>376.</label><mixed-citation publication-type="other">Olejarz, W., &#x00141;acheta, D. &#x00026; Kubiak-Tomaszewska, G. Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability. <italic>Int. J. Mol. Sci</italic>. <bold>21</bold>, 3946 (2020).</mixed-citation></ref><ref id="CR377"><label>377.</label><citation-alternatives><element-citation id="ec-CR377" publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>PT</given-names></name><etal/></person-group><article-title>STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases</article-title><source>Eur. Heart J.</source><year>2021</year><volume>42</volume><fpage>4336</fpage><lpage>4348</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab249</pub-id><pub-id pub-id-type="pmid">34226923</pub-id>
</element-citation><mixed-citation id="mc-CR377" publication-type="journal">Pham, P. T. et al. STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases. <italic>Eur. Heart J.</italic><bold>42</bold>, 4336&#x02013;4348 (2021).<pub-id pub-id-type="pmid">34226923</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR378"><label>378.</label><citation-alternatives><element-citation id="ec-CR378" publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>D</given-names></name><etal/></person-group><article-title>Balasubramide derivative 3C attenuates atherosclerosis in apolipoprotein E-deficient mice: role of AMPK-STAT1-STING signaling pathway</article-title><source>Aging</source><year>2021</year><volume>13</volume><fpage>12160</fpage><lpage>12178</lpage><pub-id pub-id-type="doi">10.18632/aging.202929</pub-id><pub-id pub-id-type="pmid">33901014</pub-id>
</element-citation><mixed-citation id="mc-CR378" publication-type="journal">Cai, D. et al. Balasubramide derivative 3C attenuates atherosclerosis in apolipoprotein E-deficient mice: role of AMPK-STAT1-STING signaling pathway. <italic>Aging</italic><bold>13</bold>, 12160&#x02013;12178 (2021).<pub-id pub-id-type="pmid">33901014</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR379"><label>379.</label><citation-alternatives><element-citation id="ec-CR379" publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Karki</surname><given-names>R</given-names></name></person-group><article-title>DNA sensors in metabolic and cardiovascular diseases: Molecular mechanisms and therapeutic prospects</article-title><source>Immunol. Rev.</source><year>2024</year><volume>329</volume><fpage>e13382</fpage><pub-id pub-id-type="doi">10.1111/imr.13382</pub-id><pub-id pub-id-type="pmid">39158380</pub-id>
</element-citation><mixed-citation id="mc-CR379" publication-type="journal">Kwak, H., Lee, E. &#x00026; Karki, R. DNA sensors in metabolic and cardiovascular diseases: Molecular mechanisms and therapeutic prospects. <italic>Immunol. Rev.</italic><bold>329</bold>, e13382 (2024).<pub-id pub-id-type="pmid">39158380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR380"><label>380.</label><citation-alternatives><element-citation id="ec-CR380" publication-type="journal"><person-group person-group-type="author"><name><surname>Venkat</surname><given-names>V</given-names></name><etal/></person-group><article-title>Investigating genes associated with heart failure, atrial fibrillation, and other cardiovascular diseases, and predicting disease using machine learning techniques for translational research and precision medicine</article-title><source>Genomics</source><year>2023</year><volume>115</volume><fpage>110584</fpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2023.110584</pub-id><pub-id pub-id-type="pmid">36813091</pub-id>
</element-citation><mixed-citation id="mc-CR380" publication-type="journal">Venkat, V., et al. Investigating genes associated with heart failure, atrial fibrillation, and other cardiovascular diseases, and predicting disease using machine learning techniques for translational research and precision medicine. <italic>Genomics</italic><bold>115</bold>, 110584 (2023).<pub-id pub-id-type="pmid">36813091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR381"><label>381.</label><citation-alternatives><element-citation id="ec-CR381" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JR</given-names></name><etal/></person-group><article-title>MEF2A suppresses stress responses that trigger DDX41-dependent IFN production</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112805</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112805</pub-id><pub-id pub-id-type="pmid">37467105</pub-id>
</element-citation><mixed-citation id="mc-CR381" publication-type="journal">Smith, J. R., et al. MEF2A suppresses stress responses that trigger DDX41-dependent IFN production. <italic>Cell Rep.</italic><bold>42</bold>, 112805 (2023).<pub-id pub-id-type="pmid">37467105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR382"><label>382.</label><citation-alternatives><element-citation id="ec-CR382" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>TRIM11 suppresses AIM2 inflammasome by degrading AIM2 via p62-dependent selective autophagy</article-title><source>Cell Rep.</source><year>2016</year><volume>16</volume><fpage>1988</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.07.019</pub-id><pub-id pub-id-type="pmid">27498865</pub-id>
</element-citation><mixed-citation id="mc-CR382" publication-type="journal">Liu, T. et al. TRIM11 suppresses AIM2 inflammasome by degrading AIM2 via p62-dependent selective autophagy. <italic>Cell Rep.</italic><bold>16</bold>, 1988&#x02013;2002 (2016).<pub-id pub-id-type="pmid">27498865</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR383"><label>383.</label><citation-alternatives><element-citation id="ec-CR383" publication-type="journal"><person-group person-group-type="author"><name><surname>Baran</surname><given-names>M</given-names></name><etal/></person-group><article-title>PYHIN protein IFI207 regulates cytokine transcription and IRF7 and contributes to the establishment of K. pneumoniae infection</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112341</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112341</pub-id><pub-id pub-id-type="pmid">37018072</pub-id>
</element-citation><mixed-citation id="mc-CR383" publication-type="journal">Baran, M., et al. PYHIN protein IFI207 regulates cytokine transcription and IRF7 and contributes to the establishment of K. pneumoniae infection. <italic>Cell Rep.</italic><bold>42</bold>, 112341 (2023).<pub-id pub-id-type="pmid">37018072</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR384"><label>384.</label><citation-alternatives><element-citation id="ec-CR384" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T</given-names></name><etal/></person-group><article-title>TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation of AIM2</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>113231</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.113231</pub-id><pub-id pub-id-type="pmid">37804507</pub-id>
</element-citation><mixed-citation id="mc-CR384" publication-type="journal">Yu, T. et al. TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation of AIM2. <italic>Cell Rep.</italic><bold>42</bold>, 113231 (2023).<pub-id pub-id-type="pmid">37804507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR385"><label>385.</label><citation-alternatives><element-citation id="ec-CR385" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis</article-title><source>EMBO J.</source><year>2018</year><volume>37</volume><fpage>e99347</fpage><pub-id pub-id-type="doi">10.15252/embj.201899347</pub-id><pub-id pub-id-type="pmid">30065070</pub-id>
</element-citation><mixed-citation id="mc-CR385" publication-type="journal">Zheng, Y. et al. Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis. <italic>EMBO J.</italic><bold>37</bold>, e99347 (2018).<pub-id pub-id-type="pmid">30065070</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR386"><label>386.</label><citation-alternatives><element-citation id="ec-CR386" publication-type="journal"><person-group person-group-type="author"><name><surname>Hornung</surname><given-names>V</given-names></name><etal/></person-group><article-title>AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC</article-title><source>Nature</source><year>2009</year><volume>458</volume><fpage>514</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/nature07725</pub-id><pub-id pub-id-type="pmid">19158675</pub-id>
</element-citation><mixed-citation id="mc-CR386" publication-type="journal">Hornung, V. et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. <italic>Nature</italic><bold>458</bold>, 514&#x02013;518 (2009).<pub-id pub-id-type="pmid">19158675</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR387"><label>387.</label><citation-alternatives><element-citation id="ec-CR387" publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes-Alnemri</surname><given-names>T</given-names></name><etal/></person-group><article-title>AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA</article-title><source>Nature</source><year>2009</year><volume>458</volume><fpage>509</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1038/nature07710</pub-id><pub-id pub-id-type="pmid">19158676</pub-id>
</element-citation><mixed-citation id="mc-CR387" publication-type="journal">Fernandes-Alnemri, T. et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. <italic>Nature</italic><bold>458</bold>, 509&#x02013;513 (2009).<pub-id pub-id-type="pmid">19158676</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR388"><label>388.</label><citation-alternatives><element-citation id="ec-CR388" publication-type="journal"><person-group person-group-type="author"><name><surname>Kerur</surname><given-names>N</given-names></name><etal/></person-group><article-title>IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection</article-title><source>Cell Host Microbe</source><year>2011</year><volume>9</volume><fpage>363</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2011.04.008</pub-id><pub-id pub-id-type="pmid">21575908</pub-id>
</element-citation><mixed-citation id="mc-CR388" publication-type="journal">Kerur, N. et al. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. <italic>Cell Host Microbe</italic><bold>9</bold>, 363&#x02013;375 (2011).<pub-id pub-id-type="pmid">21575908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR389"><label>389.</label><citation-alternatives><element-citation id="ec-CR389" publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>TP</given-names></name><etal/></person-group><article-title>The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis</article-title><source>Nature</source><year>2021</year><volume>592</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03341-5</pub-id><pub-id pub-id-type="pmid">33731931</pub-id>
</element-citation><mixed-citation id="mc-CR389" publication-type="journal">Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. <italic>Nature</italic><bold>592</bold>, 296&#x02013;301 (2021).<pub-id pub-id-type="pmid">33731931</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR390"><label>390.</label><citation-alternatives><element-citation id="ec-CR390" publication-type="journal"><person-group person-group-type="author"><name><surname>On&#x000f3;di</surname><given-names>Z</given-names></name><etal/></person-group><article-title>AIM2-driven inflammasome activation in heart failure</article-title><source>Cardiovasc. Res.</source><year>2021</year><volume>117</volume><fpage>2639</fpage><lpage>2651</lpage><pub-id pub-id-type="pmid">34117866</pub-id>
</element-citation><mixed-citation id="mc-CR390" publication-type="journal">On&#x000f3;di, Z. et al. AIM2-driven inflammasome activation in heart failure. <italic>Cardiovasc. Res.</italic><bold>117</bold>, 2639&#x02013;2651 (2021).<pub-id pub-id-type="pmid">34117866</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR391"><label>391.</label><citation-alternatives><element-citation id="ec-CR391" publication-type="journal"><person-group person-group-type="author"><name><surname>Fahrl&#x000e4;nder</surname><given-names>H</given-names></name></person-group><article-title>[Salazosulfapyridine in pregnancy]</article-title><source>Dtsch Med. Wochenschr.</source><year>1978</year><volume>103</volume><fpage>1429</fpage><pub-id pub-id-type="pmid">28935</pub-id>
</element-citation><mixed-citation id="mc-CR391" publication-type="journal">Fahrl&#x000e4;nder, H. [Salazosulfapyridine in pregnancy]. <italic>Dtsch Med. Wochenschr.</italic><bold>103</bold>, 1429 (1978).<pub-id pub-id-type="pmid">28935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR392"><label>392.</label><citation-alternatives><element-citation id="ec-CR392" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>T</given-names></name><etal/></person-group><article-title>Ginsenoside Rd promotes cardiac repair after myocardial infarction by modulating monocytes/macrophages subsets conversion</article-title><source>Drug Des. Devel Ther.</source><year>2022</year><volume>16</volume><fpage>2767</fpage><lpage>2782</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S377624</pub-id><pub-id pub-id-type="pmid">36033133</pub-id>
</element-citation><mixed-citation id="mc-CR392" publication-type="journal">Zhao, T. et al. Ginsenoside Rd promotes cardiac repair after myocardial infarction by modulating monocytes/macrophages subsets conversion. <italic>Drug Des. Devel Ther.</italic><bold>16</bold>, 2767&#x02013;2782 (2022).<pub-id pub-id-type="pmid">36033133</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR393"><label>393.</label><citation-alternatives><element-citation id="ec-CR393" publication-type="journal"><person-group person-group-type="author"><name><surname>Soehnlein</surname><given-names>O</given-names></name><name><surname>Tall</surname><given-names>AR</given-names></name></person-group><article-title>AIMing 2 treat atherosclerosis</article-title><source>Nat. Rev. Cardiol.</source><year>2022</year><volume>19</volume><fpage>567</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1038/s41569-022-00755-0</pub-id><pub-id pub-id-type="pmid">35882998</pub-id>
</element-citation><mixed-citation id="mc-CR393" publication-type="journal">Soehnlein, O. &#x00026; Tall, A. R. AIMing 2 treat atherosclerosis. <italic>Nat. Rev. Cardiol.</italic><bold>19</bold>, 567&#x02013;568 (2022).<pub-id pub-id-type="pmid">35882998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR394"><label>394.</label><citation-alternatives><element-citation id="ec-CR394" publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;sebrink</surname><given-names>E</given-names></name><etal/></person-group><article-title>AIM2 stimulation impairs reendothelialization and promotes the development of atherosclerosis in mice</article-title><source>Front. Cardiovasc. Med.</source><year>2020</year><volume>7</volume><fpage>582482</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2020.582482</pub-id><pub-id pub-id-type="pmid">33263007</pub-id>
</element-citation><mixed-citation id="mc-CR394" publication-type="journal">L&#x000fc;sebrink, E., et al. AIM2 stimulation impairs reendothelialization and promotes the development of atherosclerosis in mice. <italic>Front. Cardiovasc. Med.</italic><bold>7</bold>, 582482 (2020).<pub-id pub-id-type="pmid">33263007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR395"><label>395.</label><citation-alternatives><element-citation id="ec-CR395" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>J</given-names></name><etal/></person-group><article-title>AIM2 regulates vascular smooth muscle cell migration in atherosclerosis</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2018</year><volume>497</volume><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.02.094</pub-id><pub-id pub-id-type="pmid">29448104</pub-id>
</element-citation><mixed-citation id="mc-CR395" publication-type="journal">Pan, J. et al. AIM2 regulates vascular smooth muscle cell migration in atherosclerosis. <italic>Biochem. Biophys. Res. Commun.</italic><bold>497</bold>, 401&#x02013;409 (2018).<pub-id pub-id-type="pmid">29448104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR396"><label>396.</label><citation-alternatives><element-citation id="ec-CR396" publication-type="journal"><person-group person-group-type="author"><name><surname>Paulin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Double-strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability</article-title><source>Circulation</source><year>2018</year><volume>138</volume><fpage>321</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.033098</pub-id><pub-id pub-id-type="pmid">30012706</pub-id>
</element-citation><mixed-citation id="mc-CR396" publication-type="journal">Paulin, N. et al. Double-strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability. <italic>Circulation</italic><bold>138</bold>, 321&#x02013;323 (2018).<pub-id pub-id-type="pmid">30012706</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR397"><label>397.</label><citation-alternatives><element-citation id="ec-CR397" publication-type="journal"><person-group person-group-type="author"><name><surname>Ugurlar</surname><given-names>D</given-names></name><etal/></person-group><article-title>Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>794</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1126/science.aao4988</pub-id><pub-id pub-id-type="pmid">29449492</pub-id>
</element-citation><mixed-citation id="mc-CR397" publication-type="journal">Ugurlar, D. et al. Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. <italic>Science</italic><bold>359</bold>, 794&#x02013;797 (2018).<pub-id pub-id-type="pmid">29449492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR398"><label>398.</label><citation-alternatives><element-citation id="ec-CR398" publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Leffler</surname><given-names>J</given-names></name><name><surname>Blom</surname><given-names>AM</given-names></name></person-group><article-title>Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>33733</fpage><lpage>33744</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.341339</pub-id><pub-id pub-id-type="pmid">22879587</pub-id>
</element-citation><mixed-citation id="mc-CR398" publication-type="journal">Martin, M., Leffler, J. &#x00026; Blom, A. M. Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells. <italic>J. Biol. Chem.</italic><bold>287</bold>, 33733&#x02013;33744 (2012).<pub-id pub-id-type="pmid">22879587</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR399"><label>399.</label><citation-alternatives><element-citation id="ec-CR399" publication-type="journal"><person-group person-group-type="author"><name><surname>Leffler</surname><given-names>J</given-names></name><etal/></person-group><article-title>Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>3766</fpage><lpage>3776</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.045427</pub-id><pub-id pub-id-type="pmid">19951950</pub-id>
</element-citation><mixed-citation id="mc-CR399" publication-type="journal">Leffler, J. et al. Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. <italic>J. Biol. Chem.</italic><bold>285</bold>, 3766&#x02013;3776 (2010).<pub-id pub-id-type="pmid">19951950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR400"><label>400.</label><citation-alternatives><element-citation id="ec-CR400" publication-type="journal"><person-group person-group-type="author"><name><surname>Mortensen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Structural basis for the function of complement component C4 within the classical and lectin pathways of complement</article-title><source>J. Immunol.</source><year>2015</year><volume>194</volume><fpage>5488</fpage><lpage>5496</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500087</pub-id><pub-id pub-id-type="pmid">25911760</pub-id>
</element-citation><mixed-citation id="mc-CR400" publication-type="journal">Mortensen, S. et al. Structural basis for the function of complement component C4 within the classical and lectin pathways of complement. <italic>J. Immunol.</italic><bold>194</bold>, 5488&#x02013;5496 (2015).<pub-id pub-id-type="pmid">25911760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR401"><label>401.</label><citation-alternatives><element-citation id="ec-CR401" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>11900</fpage><lpage>11905</lpage><pub-id pub-id-type="doi">10.1073/pnas.1901841116</pub-id><pub-id pub-id-type="pmid">31147461</pub-id>
</element-citation><mixed-citation id="mc-CR401" publication-type="journal">Sharp, T. H. et al. Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>116</bold>, 11900&#x02013;11905 (2019).<pub-id pub-id-type="pmid">31147461</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR402"><label>402.</label><citation-alternatives><element-citation id="ec-CR402" publication-type="journal"><person-group person-group-type="author"><name><surname>Zarantonello</surname><given-names>A</given-names></name><name><surname>Revel</surname><given-names>M</given-names></name><name><surname>Grunenwald</surname><given-names>A</given-names></name><name><surname>Roumenina</surname><given-names>LT</given-names></name></person-group><article-title>C3-dependent effector functions of complement</article-title><source>Immunol. Rev.</source><year>2023</year><volume>313</volume><fpage>120</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1111/imr.13147</pub-id><pub-id pub-id-type="pmid">36271889</pub-id>
</element-citation><mixed-citation id="mc-CR402" publication-type="journal">Zarantonello, A., Revel, M., Grunenwald, A. &#x00026; Roumenina, L. T. C3-dependent effector functions of complement. <italic>Immunol. Rev.</italic><bold>313</bold>, 120&#x02013;138 (2023).<pub-id pub-id-type="pmid">36271889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR403"><label>403.</label><citation-alternatives><element-citation id="ec-CR403" publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>M</given-names></name><name><surname>Farrar</surname><given-names>CA</given-names></name><name><surname>Sacks</surname><given-names>SH</given-names></name></person-group><article-title>Structural and functional diversity of collectins and ficolins and their relationship to disease</article-title><source>Semin. Immunopathol.</source><year>2018</year><volume>40</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s00281-017-0642-0</pub-id><pub-id pub-id-type="pmid">28894916</pub-id>
</element-citation><mixed-citation id="mc-CR403" publication-type="journal">Howard, M., Farrar, C. A. &#x00026; Sacks, S. H. Structural and functional diversity of collectins and ficolins and their relationship to disease. <italic>Semin. Immunopathol.</italic><bold>40</bold>, 75&#x02013;85 (2018).<pub-id pub-id-type="pmid">28894916</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR404"><label>404.</label><citation-alternatives><element-citation id="ec-CR404" publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Endo</surname><given-names>Y</given-names></name></person-group><article-title>The lectin-complement pathway-its role in innate immunity and evolution</article-title><source>Immunol. Rev.</source><year>2004</year><volume>198</volume><fpage>185</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.0123.x</pub-id><pub-id pub-id-type="pmid">15199963</pub-id>
</element-citation><mixed-citation id="mc-CR404" publication-type="journal">Fujita, T., Matsushita, M. &#x00026; Endo, Y. The lectin-complement pathway-its role in innate immunity and evolution. <italic>Immunol. Rev.</italic><bold>198</bold>, 185&#x02013;202 (2004).<pub-id pub-id-type="pmid">15199963</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR405"><label>405.</label><citation-alternatives><element-citation id="ec-CR405" publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>T</given-names></name></person-group><article-title>Evolution of the lectin-complement pathway and its role in innate immunity</article-title><source>Nat. Rev. Immunol.</source><year>2002</year><volume>2</volume><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1038/nri800</pub-id><pub-id pub-id-type="pmid">12033740</pub-id>
</element-citation><mixed-citation id="mc-CR405" publication-type="journal">Fujita, T. Evolution of the lectin-complement pathway and its role in innate immunity. <italic>Nat. Rev. Immunol.</italic><bold>2</bold>, 346&#x02013;353 (2002).<pub-id pub-id-type="pmid">12033740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR406"><label>406.</label><citation-alternatives><element-citation id="ec-CR406" publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Drickamer</surname><given-names>K</given-names></name><name><surname>Hendrickson</surname><given-names>WA</given-names></name></person-group><article-title>Structure of a C-type mannose-binding protein complexed with an oligosaccharide</article-title><source>Nature</source><year>1992</year><volume>360</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1038/360127a0</pub-id><pub-id pub-id-type="pmid">1436090</pub-id>
</element-citation><mixed-citation id="mc-CR406" publication-type="journal">Weis, W. I., Drickamer, K. &#x00026; Hendrickson, W. A. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. <italic>Nature</italic><bold>360</bold>, 127&#x02013;134 (1992).<pub-id pub-id-type="pmid">1436090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR407"><label>407.</label><citation-alternatives><element-citation id="ec-CR407" publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity</article-title><source>J. Immunol.</source><year>2010</year><volume>185</volume><fpage>6096</fpage><lpage>6104</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002185</pub-id><pub-id pub-id-type="pmid">20956340</pub-id>
</element-citation><mixed-citation id="mc-CR407" publication-type="journal">Hansen, S. et al. Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity. <italic>J. Immunol.</italic><bold>185</bold>, 6096&#x02013;6104 (2010).<pub-id pub-id-type="pmid">20956340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR408"><label>408.</label><citation-alternatives><element-citation id="ec-CR408" publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Ficolin-2 recognizes DNA and participates in the clearance of dying host cells</article-title><source>Mol. Immunol.</source><year>2007</year><volume>44</volume><fpage>856</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2006.04.002</pub-id><pub-id pub-id-type="pmid">16730064</pub-id>
</element-citation><mixed-citation id="mc-CR408" publication-type="journal">Jensen, M. L. et al. Ficolin-2 recognizes DNA and participates in the clearance of dying host cells. <italic>Mol. Immunol.</italic><bold>44</bold>, 856&#x02013;865 (2007).<pub-id pub-id-type="pmid">16730064</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR409"><label>409.</label><citation-alternatives><element-citation id="ec-CR409" publication-type="journal"><person-group person-group-type="author"><name><surname>Choteau</surname><given-names>L</given-names></name><etal/></person-group><article-title>Role of mannose-binding lectin in intestinal homeostasis and fungal elimination</article-title><source>Mucosal Immunol.</source><year>2016</year><volume>9</volume><fpage>767</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1038/mi.2015.100</pub-id><pub-id pub-id-type="pmid">26442658</pub-id>
</element-citation><mixed-citation id="mc-CR409" publication-type="journal">Choteau, L. et al. Role of mannose-binding lectin in intestinal homeostasis and fungal elimination. <italic>Mucosal Immunol.</italic><bold>9</bold>, 767&#x02013;776 (2016).<pub-id pub-id-type="pmid">26442658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR410"><label>410.</label><citation-alternatives><element-citation id="ec-CR410" publication-type="journal"><person-group person-group-type="author"><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Janeway</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group><article-title>Decoding the patterns of self and nonself by the innate immune system</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>298</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1126/science.1068883</pub-id><pub-id pub-id-type="pmid">11951031</pub-id>
</element-citation><mixed-citation id="mc-CR410" publication-type="journal">Medzhitov, R. &#x00026; Janeway, C. A. Jr Decoding the patterns of self and nonself by the innate immune system. <italic>Science</italic><bold>296</bold>, 298&#x02013;300 (2002).<pub-id pub-id-type="pmid">11951031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR411"><label>411.</label><citation-alternatives><element-citation id="ec-CR411" publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>MW</given-names></name></person-group><article-title>Mannose-binding lectin: the pluripotent molecule of the innate immune system</article-title><source>Immunol. Today</source><year>1996</year><volume>17</volume><fpage>532</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/S0167-5699(96)80908-X</pub-id><pub-id pub-id-type="pmid">8961631</pub-id>
</element-citation><mixed-citation id="mc-CR411" publication-type="journal">Turner, M. W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. <italic>Immunol. Today</italic><bold>17</bold>, 532&#x02013;540 (1996).<pub-id pub-id-type="pmid">8961631</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR412"><label>412.</label><citation-alternatives><element-citation id="ec-CR412" publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>R</given-names></name></person-group><article-title>Structural and functional aspects of complement activation by mannose-binding protein</article-title><source>Immunobiology</source><year>2002</year><volume>205</volume><fpage>433</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1078/0171-2985-00144</pub-id><pub-id pub-id-type="pmid">12396005</pub-id>
</element-citation><mixed-citation id="mc-CR412" publication-type="journal">Wallis, R. Structural and functional aspects of complement activation by mannose-binding protein. <italic>Immunobiology</italic><bold>205</bold>, 433&#x02013;445 (2002).<pub-id pub-id-type="pmid">12396005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR413"><label>413.</label><citation-alternatives><element-citation id="ec-CR413" publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>R</given-names></name></person-group><article-title>Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway</article-title><source>Immunobiology</source><year>2007</year><volume>212</volume><fpage>289</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2006.11.004</pub-id><pub-id pub-id-type="pmid">17544814</pub-id>
</element-citation><mixed-citation id="mc-CR413" publication-type="journal">Wallis, R. Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway. <italic>Immunobiology</italic><bold>212</bold>, 289&#x02013;299 (2007).<pub-id pub-id-type="pmid">17544814</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR414"><label>414.</label><citation-alternatives><element-citation id="ec-CR414" publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrus</surname><given-names>G</given-names></name><etal/></person-group><article-title>Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments</article-title><source>J. Immunol.</source><year>2003</year><volume>170</volume><fpage>1374</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.3.1374</pub-id><pub-id pub-id-type="pmid">12538697</pub-id>
</element-citation><mixed-citation id="mc-CR414" publication-type="journal">Ambrus, G. et al. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. <italic>J. Immunol.</italic><bold>170</bold>, 1374&#x02013;1382 (2003).<pub-id pub-id-type="pmid">12538697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR415"><label>415.</label><citation-alternatives><element-citation id="ec-CR415" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>T</given-names></name><etal/></person-group><article-title>Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation</article-title><source>Signal. Transduct. Target Ther.</source><year>2022</year><volume>7</volume><fpage>318</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-01133-5</pub-id><pub-id pub-id-type="pmid">36100602</pub-id>
</element-citation><mixed-citation id="mc-CR415" publication-type="journal">Gao, T. et al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. <italic>Signal. Transduct. Target Ther.</italic><bold>7</bold>, 318 (2022).<pub-id pub-id-type="pmid">36100602</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR416"><label>416.</label><citation-alternatives><element-citation id="ec-CR416" publication-type="journal"><person-group person-group-type="author"><name><surname>Hallstr&#x000f6;m</surname><given-names>T</given-names></name><name><surname>Riesbeck</surname><given-names>K</given-names></name></person-group><article-title>Haemophilus influenzae and the complement system</article-title><source>Trends Microbiol.</source><year>2010</year><volume>18</volume><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2010.03.007</pub-id><pub-id pub-id-type="pmid">20399102</pub-id>
</element-citation><mixed-citation id="mc-CR416" publication-type="journal">Hallstr&#x000f6;m, T. &#x00026; Riesbeck, K. Haemophilus influenzae and the complement system. <italic>Trends Microbiol.</italic><bold>18</bold>, 258&#x02013;265 (2010).<pub-id pub-id-type="pmid">20399102</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR417"><label>417.</label><citation-alternatives><element-citation id="ec-CR417" publication-type="journal"><person-group person-group-type="author"><name><surname>de Boer</surname><given-names>EC</given-names></name><etal/></person-group><article-title>The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation</article-title><source>Clin. Transl. Immunol.</source><year>2023</year><volume>12</volume><fpage>e1436</fpage><pub-id pub-id-type="doi">10.1002/cti2.1436</pub-id></element-citation><mixed-citation id="mc-CR417" publication-type="journal">de Boer, E. C. et al. The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation. <italic>Clin. Transl. Immunol.</italic><bold>12</bold>, e1436 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR418"><label>418.</label><citation-alternatives><element-citation id="ec-CR418" publication-type="journal"><person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group><article-title>Spontaneous reformation of the intramolecular thioester in complement protein C3 and low temperature capture of a conformational intermediate capable of reformation</article-title><source>J. Biol. Chem.</source><year>1992</year><volume>267</volume><fpage>8584</fpage><lpage>8590</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)42483-0</pub-id><pub-id pub-id-type="pmid">1569104</pub-id>
</element-citation><mixed-citation id="mc-CR418" publication-type="journal">Pangburn, M. K. Spontaneous reformation of the intramolecular thioester in complement protein C3 and low temperature capture of a conformational intermediate capable of reformation. <italic>J. Biol. Chem.</italic><bold>267</bold>, 8584&#x02013;8590 (1992).<pub-id pub-id-type="pmid">1569104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR419"><label>419.</label><citation-alternatives><element-citation id="ec-CR419" publication-type="journal"><person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>M&#x000fc;ller-Eberhard</surname><given-names>HJ</given-names></name></person-group><article-title>Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3</article-title><source>J. Exp. Med.</source><year>1981</year><volume>154</volume><fpage>856</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1084/jem.154.3.856</pub-id><pub-id pub-id-type="pmid">6912277</pub-id>
</element-citation><mixed-citation id="mc-CR419" publication-type="journal">Pangburn, M. K., Schreiber, R. D. &#x00026; M&#x000fc;ller-Eberhard, H. J. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. <italic>J. Exp. Med.</italic><bold>154</bold>, 856&#x02013;867 (1981).<pub-id pub-id-type="pmid">6912277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR420"><label>420.</label><citation-alternatives><element-citation id="ec-CR420" publication-type="journal"><person-group person-group-type="author"><name><surname>Michels</surname><given-names>M</given-names></name><name><surname>Volokhina</surname><given-names>EB</given-names></name><name><surname>van de Kar</surname><given-names>N</given-names></name><name><surname>van den Heuvel</surname><given-names>L</given-names></name></person-group><article-title>The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?</article-title><source>Pediatr. Nephrol.</source><year>2019</year><volume>34</volume><fpage>1349</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1007/s00467-018-4042-z</pub-id><pub-id pub-id-type="pmid">30141176</pub-id>
</element-citation><mixed-citation id="mc-CR420" publication-type="journal">Michels, M., Volokhina, E. B., van de Kar, N. &#x00026; van den Heuvel, L. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?. <italic>Pediatr. Nephrol.</italic><bold>34</bold>, 1349&#x02013;1367 (2019).<pub-id pub-id-type="pmid">30141176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR421"><label>421.</label><citation-alternatives><element-citation id="ec-CR421" publication-type="journal"><person-group person-group-type="author"><name><surname>Ricklin</surname><given-names>D</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name></person-group><article-title>Complement: a key system for immune surveillance and homeostasis</article-title><source>Nat. Immunol.</source><year>2010</year><volume>11</volume><fpage>785</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/ni.1923</pub-id><pub-id pub-id-type="pmid">20720586</pub-id>
</element-citation><mixed-citation id="mc-CR421" publication-type="journal">Ricklin, D., Hajishengallis, G., Yang, K. &#x00026; Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. <italic>Nat. Immunol.</italic><bold>11</bold>, 785&#x02013;797 (2010).<pub-id pub-id-type="pmid">20720586</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR422"><label>422.</label><citation-alternatives><element-citation id="ec-CR422" publication-type="journal"><person-group person-group-type="author"><name><surname>Verdeguer</surname><given-names>F</given-names></name><etal/></person-group><article-title>Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation</article-title><source>Cardiovasc. Res.</source><year>2007</year><volume>76</volume><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2007.06.028</pub-id><pub-id pub-id-type="pmid">17673191</pub-id>
</element-citation><mixed-citation id="mc-CR422" publication-type="journal">Verdeguer, F. et al. Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation. <italic>Cardiovasc. Res.</italic><bold>76</bold>, 340&#x02013;350 (2007).<pub-id pub-id-type="pmid">17673191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR423"><label>423.</label><citation-alternatives><element-citation id="ec-CR423" publication-type="journal"><person-group person-group-type="author"><name><surname>Schepers</surname><given-names>A</given-names></name><etal/></person-group><article-title>Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>2831</fpage><lpage>2838</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.619502</pub-id><pub-id pub-id-type="pmid">17145993</pub-id>
</element-citation><mixed-citation id="mc-CR423" publication-type="journal">Schepers, A. et al. Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. <italic>Circulation</italic><bold>114</bold>, 2831&#x02013;2838 (2006).<pub-id pub-id-type="pmid">17145993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR424"><label>424.</label><citation-alternatives><element-citation id="ec-CR424" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>15818</fpage><lpage>15826</lpage><pub-id pub-id-type="doi">10.1073/pnas.2006348117</pub-id><pub-id pub-id-type="pmid">32541024</pub-id>
</element-citation><mixed-citation id="mc-CR424" publication-type="journal">Wang, Y. et al. Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>117</bold>, 15818&#x02013;15826 (2020).<pub-id pub-id-type="pmid">32541024</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR425"><label>425.</label><citation-alternatives><element-citation id="ec-CR425" publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>JH</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name></person-group><article-title>The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats</article-title><source>J. Exp. Med.</source><year>1971</year><volume>133</volume><fpage>885</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1084/jem.133.4.885</pub-id><pub-id pub-id-type="pmid">4993831</pub-id>
</element-citation><mixed-citation id="mc-CR425" publication-type="journal">Hill, J. H. &#x00026; Ward, P. A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. <italic>J. Exp. Med.</italic><bold>133</bold>, 885&#x02013;900 (1971).<pub-id pub-id-type="pmid">4993831</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR426"><label>426.</label><citation-alternatives><element-citation id="ec-CR426" publication-type="journal"><person-group person-group-type="author"><name><surname>Nijmeijer</surname><given-names>R</given-names></name><etal/></person-group><article-title>C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion</article-title><source>Eur. J. Clin. Investig.</source><year>2004</year><volume>34</volume><fpage>803</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2004.01425.x</pub-id><pub-id pub-id-type="pmid">15606722</pub-id>
</element-citation><mixed-citation id="mc-CR426" publication-type="journal">Nijmeijer, R. et al. C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. <italic>Eur. J. Clin. Investig.</italic><bold>34</bold>, 803&#x02013;810 (2004).<pub-id pub-id-type="pmid">15606722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR427"><label>427.</label><citation-alternatives><element-citation id="ec-CR427" publication-type="journal"><person-group person-group-type="author"><name><surname>Yasojima</surname><given-names>K</given-names></name><name><surname>Schwab</surname><given-names>C</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><article-title>Human heart generates complement proteins that are upregulated and activated after myocardial infarction</article-title><source>Circ. Res.</source><year>1998</year><volume>83</volume><fpage>860</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1161/01.RES.83.8.860</pub-id><pub-id pub-id-type="pmid">9776733</pub-id>
</element-citation><mixed-citation id="mc-CR427" publication-type="journal">Yasojima, K., Schwab, C., McGeer, E. G. &#x00026; McGeer, P. L. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. <italic>Circ. Res.</italic><bold>83</bold>, 860&#x02013;869 (1998).<pub-id pub-id-type="pmid">9776733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR428"><label>428.</label><citation-alternatives><element-citation id="ec-CR428" publication-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>A</given-names></name><etal/></person-group><article-title>Complement C3c as a biomarker in heart failure</article-title><source>Mediat. Inflamm.</source><year>2013</year><volume>2013</volume><fpage>716902</fpage><pub-id pub-id-type="doi">10.1155/2013/716902</pub-id></element-citation><mixed-citation id="mc-CR428" publication-type="journal">Frey, A., et al. Complement C3c as a biomarker in heart failure. <italic>Mediat. Inflamm.</italic><bold>2013</bold>, 716902 (2013).</mixed-citation></citation-alternatives></ref><ref id="CR429"><label>429.</label><citation-alternatives><element-citation id="ec-CR429" publication-type="journal"><person-group person-group-type="author"><name><surname>Nityanand</surname><given-names>S</given-names></name><etal/></person-group><article-title>Circulating immune complexes and complement C4 null alleles in patients in patients operated on for premature atherosclerotic peripheral vascular disease</article-title><source>J. Clin. Immunol.</source><year>1999</year><volume>19</volume><fpage>406</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1023/A:1020506901117</pub-id><pub-id pub-id-type="pmid">10634214</pub-id>
</element-citation><mixed-citation id="mc-CR429" publication-type="journal">Nityanand, S. et al. Circulating immune complexes and complement C4 null alleles in patients in patients operated on for premature atherosclerotic peripheral vascular disease. <italic>J. Clin. Immunol.</italic><bold>19</bold>, 406&#x02013;413 (1999).<pub-id pub-id-type="pmid">10634214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR430"><label>430.</label><citation-alternatives><element-citation id="ec-CR430" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>VK</given-names></name><etal/></person-group><article-title>Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice</article-title><source>Am. J. Pathol.</source><year>2007</year><volume>170</volume><fpage>416</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.060406</pub-id><pub-id pub-id-type="pmid">17200212</pub-id>
</element-citation><mixed-citation id="mc-CR430" publication-type="journal">Bhatia, V. K. et al. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. <italic>Am. J. Pathol.</italic><bold>170</bold>, 416&#x02013;426 (2007).<pub-id pub-id-type="pmid">17200212</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR431"><label>431.</label><citation-alternatives><element-citation id="ec-CR431" publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>JE</given-names></name><name><surname>Montalto</surname><given-names>MC</given-names></name><name><surname>Stahl</surname><given-names>GL</given-names></name></person-group><article-title>Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury</article-title><source>Circulation</source><year>2001</year><volume>104</volume><fpage>1413</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1161/hc3601.095578</pub-id><pub-id pub-id-type="pmid">11560858</pub-id>
</element-citation><mixed-citation id="mc-CR431" publication-type="journal">Jordan, J. E., Montalto, M. C. &#x00026; Stahl, G. L. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. <italic>Circulation</italic><bold>104</bold>, 1413&#x02013;1418 (2001).<pub-id pub-id-type="pmid">11560858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR432"><label>432.</label><citation-alternatives><element-citation id="ec-CR432" publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury</article-title><source>J. Immunol.</source><year>2005</year><volume>175</volume><fpage>541</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.1.541</pub-id><pub-id pub-id-type="pmid">15972690</pub-id>
</element-citation><mixed-citation id="mc-CR432" publication-type="journal">Walsh, M. C. et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. <italic>J. Immunol.</italic><bold>175</bold>, 541&#x02013;546 (2005).<pub-id pub-id-type="pmid">15972690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR433"><label>433.</label><citation-alternatives><element-citation id="ec-CR433" publication-type="journal"><person-group person-group-type="author"><name><surname>Schwaeble</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>7523</fpage><lpage>7528</lpage><pub-id pub-id-type="doi">10.1073/pnas.1101748108</pub-id><pub-id pub-id-type="pmid">21502512</pub-id>
</element-citation><mixed-citation id="mc-CR433" publication-type="journal">Schwaeble, W. J. et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>108</bold>, 7523&#x02013;7528 (2011).<pub-id pub-id-type="pmid">21502512</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR434"><label>434.</label><citation-alternatives><element-citation id="ec-CR434" publication-type="journal"><person-group person-group-type="author"><name><surname>Markiewski</surname><given-names>MM</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name></person-group><article-title>The role of complement in inflammatory diseases from behind the scenes into the spotlight</article-title><source>Am. J. Pathol.</source><year>2007</year><volume>171</volume><fpage>715</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.070166</pub-id><pub-id pub-id-type="pmid">17640961</pub-id>
</element-citation><mixed-citation id="mc-CR434" publication-type="journal">Markiewski, M. M. &#x00026; Lambris, J. D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. <italic>Am. J. Pathol.</italic><bold>171</bold>, 715&#x02013;727 (2007).<pub-id pub-id-type="pmid">17640961</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR435"><label>435.</label><citation-alternatives><element-citation id="ec-CR435" publication-type="journal"><person-group person-group-type="author"><name><surname>Ritis</surname><given-names>K</given-names></name><etal/></person-group><article-title>A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways</article-title><source>J. Immunol.</source><year>2006</year><volume>177</volume><fpage>4794</fpage><lpage>4802</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.7.4794</pub-id><pub-id pub-id-type="pmid">16982920</pub-id>
</element-citation><mixed-citation id="mc-CR435" publication-type="journal">Ritis, K. et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. <italic>J. Immunol.</italic><bold>177</bold>, 4794&#x02013;4802 (2006).<pub-id pub-id-type="pmid">16982920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR436"><label>436.</label><citation-alternatives><element-citation id="ec-CR436" publication-type="journal"><person-group person-group-type="author"><name><surname>Delvaeye</surname><given-names>M</given-names></name><name><surname>Conway</surname><given-names>EM</given-names></name></person-group><article-title>Coagulation and innate immune responses: can we view them separately?</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>2367</fpage><lpage>2374</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-05-199208</pub-id><pub-id pub-id-type="pmid">19584396</pub-id>
</element-citation><mixed-citation id="mc-CR436" publication-type="journal">Delvaeye, M. &#x00026; Conway, E. M. Coagulation and innate immune responses: can we view them separately?. <italic>Blood</italic><bold>114</bold>, 2367&#x02013;2374 (2009).<pub-id pub-id-type="pmid">19584396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR437"><label>437.</label><citation-alternatives><element-citation id="ec-CR437" publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Farber</surname><given-names>DL</given-names></name></person-group><article-title>A guide to adaptive immune memory</article-title><source>Nat. Rev. Immunol.</source><year>2024</year><volume>24</volume><fpage>810</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1038/s41577-024-01040-6</pub-id><pub-id pub-id-type="pmid">38831162</pub-id>
</element-citation><mixed-citation id="mc-CR437" publication-type="journal">Lam, N., Lee, Y. &#x00026; Farber, D. L. A guide to adaptive immune memory. <italic>Nat. Rev. Immunol.</italic><bold>24</bold>, 810&#x02013;829 (2024).<pub-id pub-id-type="pmid">38831162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR438"><label>438.</label><citation-alternatives><element-citation id="ec-CR438" publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>H</given-names></name><name><surname>Pepper</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name></person-group><article-title>Principles and therapeutic applications of adaptive immunity</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>2052</fpage><lpage>2078</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.03.037</pub-id><pub-id pub-id-type="pmid">38670065</pub-id>
</element-citation><mixed-citation id="mc-CR438" publication-type="journal">Chi, H., Pepper, M. &#x00026; Thomas, P. G. Principles and therapeutic applications of adaptive immunity. <italic>Cell</italic><bold>187</bold>, 2052&#x02013;2078 (2024).<pub-id pub-id-type="pmid">38670065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR439"><label>439.</label><citation-alternatives><element-citation id="ec-CR439" publication-type="journal"><person-group person-group-type="author"><name><surname>Eiz-Vesper</surname><given-names>B</given-names></name><name><surname>Schmetzer</surname><given-names>HM</given-names></name></person-group><article-title>Antigen-presenting cells: potential of proven and new players in immune therapies</article-title><source>Transfus. Med. Hemother</source><year>2020</year><volume>47</volume><fpage>429</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1159/000512729</pub-id><pub-id pub-id-type="pmid">33442337</pub-id>
</element-citation><mixed-citation id="mc-CR439" publication-type="journal">Eiz-Vesper, B. &#x00026; Schmetzer, H. M. Antigen-presenting cells: potential of proven and new players in immune therapies. <italic>Transfus. Med. Hemother</italic><bold>47</bold>, 429&#x02013;431 (2020).<pub-id pub-id-type="pmid">33442337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR440"><label>440.</label><citation-alternatives><element-citation id="ec-CR440" publication-type="journal"><person-group person-group-type="author"><name><surname>Joffre</surname><given-names>OP</given-names></name><name><surname>Segura</surname><given-names>E</given-names></name><name><surname>Savina</surname><given-names>A</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name></person-group><article-title>Cross-presentation by dendritic cells</article-title><source>Nat. Rev. Immunol.</source><year>2012</year><volume>12</volume><fpage>557</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/nri3254</pub-id><pub-id pub-id-type="pmid">22790179</pub-id>
</element-citation><mixed-citation id="mc-CR440" publication-type="journal">Joffre, O. P., Segura, E., Savina, A. &#x00026; Amigorena, S. Cross-presentation by dendritic cells. <italic>Nat. Rev. Immunol.</italic><bold>12</bold>, 557&#x02013;569 (2012).<pub-id pub-id-type="pmid">22790179</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR441"><label>441.</label><citation-alternatives><element-citation id="ec-CR441" publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>JS</given-names></name><name><surname>Wearsch</surname><given-names>PA</given-names></name><name><surname>Cresswell</surname><given-names>P</given-names></name></person-group><article-title>Pathways of antigen processing</article-title><source>Annu. Rev. Immunol.</source><year>2013</year><volume>31</volume><fpage>443</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095910</pub-id><pub-id pub-id-type="pmid">23298205</pub-id>
</element-citation><mixed-citation id="mc-CR441" publication-type="journal">Blum, J. S., Wearsch, P. A. &#x00026; Cresswell, P. Pathways of antigen processing. <italic>Annu. Rev. Immunol.</italic><bold>31</bold>, 443&#x02013;473 (2013).<pub-id pub-id-type="pmid">23298205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR442"><label>442.</label><citation-alternatives><element-citation id="ec-CR442" publication-type="journal"><person-group person-group-type="author"><name><surname>Bonilla</surname><given-names>FA</given-names></name><name><surname>Oettgen</surname><given-names>HC</given-names></name></person-group><article-title>Adaptive immunity</article-title><source>J. Allergy Clin. Immunol.</source><year>2010</year><volume>125</volume><fpage>S33</fpage><lpage>S40</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.09.017</pub-id><pub-id pub-id-type="pmid">20061006</pub-id>
</element-citation><mixed-citation id="mc-CR442" publication-type="journal">Bonilla, F. A. &#x00026; Oettgen, H. C. Adaptive immunity. <italic>J. Allergy Clin. Immunol.</italic><bold>125</bold>, S33&#x02013;S40 (2010).<pub-id pub-id-type="pmid">20061006</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR443"><label>443.</label><citation-alternatives><element-citation id="ec-CR443" publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name></person-group><article-title>Immunity and inflammation in atherosclerosis</article-title><source>Circ. Res.</source><year>2019</year><volume>124</volume><fpage>315</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.313591</pub-id><pub-id pub-id-type="pmid">30653442</pub-id>
</element-citation><mixed-citation id="mc-CR443" publication-type="journal">Wolf, D. &#x00026; Ley, K. Immunity and inflammation in atherosclerosis. <italic>Circ. Res.</italic><bold>124</bold>, 315&#x02013;327 (2019).<pub-id pub-id-type="pmid">30653442</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR444"><label>444.</label><citation-alternatives><element-citation id="ec-CR444" publication-type="journal"><person-group person-group-type="author"><name><surname>Akinyemi</surname><given-names>DE</given-names></name><name><surname>Chevre</surname><given-names>R</given-names></name><name><surname>Soehnlein</surname><given-names>O</given-names></name></person-group><article-title>Neuro-immune crosstalk in hematopoiesis, inflammation, and repair</article-title><source>Trends Immunol.</source><year>2024</year><volume>45</volume><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/j.it.2024.06.005</pub-id><pub-id pub-id-type="pmid">39030115</pub-id>
</element-citation><mixed-citation id="mc-CR444" publication-type="journal">Akinyemi, D. E., Chevre, R. &#x00026; Soehnlein, O. Neuro-immune crosstalk in hematopoiesis, inflammation, and repair. <italic>Trends Immunol.</italic><bold>45</bold>, 597&#x02013;608 (2024).<pub-id pub-id-type="pmid">39030115</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR445"><label>445.</label><citation-alternatives><element-citation id="ec-CR445" publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>M</given-names></name><name><surname>Bleackley</surname><given-names>RC</given-names></name></person-group><article-title>Cytotoxic T lymphocytes: all roads lead to death</article-title><source>Nat. Rev. Immunol.</source><year>2002</year><volume>2</volume><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1038/nri819</pub-id><pub-id pub-id-type="pmid">12093006</pub-id>
</element-citation><mixed-citation id="mc-CR445" publication-type="journal">Barry, M. &#x00026; Bleackley, R. C. Cytotoxic T lymphocytes: all roads lead to death. <italic>Nat. Rev. Immunol.</italic><bold>2</bold>, 401&#x02013;409 (2002).<pub-id pub-id-type="pmid">12093006</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR446"><label>446.</label><citation-alternatives><element-citation id="ec-CR446" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name></person-group><article-title>T Helper Cell Differentiation, Heterogeneity, and Plasticity</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2018</year><volume>10</volume><fpage>a030338</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a030338</pub-id><pub-id pub-id-type="pmid">28847903</pub-id>
</element-citation><mixed-citation id="mc-CR446" publication-type="journal">Zhu, J. T Helper Cell Differentiation, Heterogeneity, and Plasticity. <italic>Cold Spring Harb. Perspect. Biol.</italic><bold>10</bold>, a030338 (2018).<pub-id pub-id-type="pmid">28847903</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR447"><label>447.</label><citation-alternatives><element-citation id="ec-CR447" publication-type="journal"><person-group person-group-type="author"><name><surname>Wigren</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Kolbus</surname><given-names>D</given-names></name></person-group><article-title>Lymphocytes in atherosclerosis</article-title><source>Clin. Chim. Acta</source><year>2012</year><volume>413</volume><fpage>1562</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2012.04.031</pub-id><pub-id pub-id-type="pmid">22565046</pub-id>
</element-citation><mixed-citation id="mc-CR447" publication-type="journal">Wigren, M., Nilsson, J. &#x00026; Kolbus, D. Lymphocytes in atherosclerosis. <italic>Clin. Chim. Acta</italic><bold>413</bold>, 1562&#x02013;1568 (2012).<pub-id pub-id-type="pmid">22565046</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR448"><label>448.</label><citation-alternatives><element-citation id="ec-CR448" publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>P</given-names></name><etal/></person-group><article-title>Inflammation and atherosclerosis: signaling pathways and therapeutic intervention</article-title><source>Signal. Transduct. Target Ther.</source><year>2022</year><volume>7</volume><fpage>131</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-00955-7</pub-id><pub-id pub-id-type="pmid">35459215</pub-id>
</element-citation><mixed-citation id="mc-CR448" publication-type="journal">Kong, P. et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. <italic>Signal. Transduct. Target Ther.</italic><bold>7</bold>, 131 (2022).<pub-id pub-id-type="pmid">35459215</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR449"><label>449.</label><citation-alternatives><element-citation id="ec-CR449" publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Al-Haidari</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Kazi</surname><given-names>JU</given-names></name></person-group><article-title>T cell receptor (TCR) signaling in health and disease</article-title><source>Signal Transduct. Target Ther.</source><year>2021</year><volume>6</volume><fpage>412</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00823-w</pub-id><pub-id pub-id-type="pmid">34897277</pub-id>
</element-citation><mixed-citation id="mc-CR449" publication-type="journal">Shah, K., Al-Haidari, A., Sun, J. &#x00026; Kazi, J. U. T cell receptor (TCR) signaling in health and disease. <italic>Signal Transduct. Target Ther.</italic><bold>6</bold>, 412 (2021).<pub-id pub-id-type="pmid">34897277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR450"><label>450.</label><citation-alternatives><element-citation id="ec-CR450" publication-type="journal"><person-group person-group-type="author"><name><surname>Wucherpfennig</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Structural biology of the T-cell receptor: insights into receptor assembly, ligand recognition, and initiation of signaling</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2010</year><volume>2</volume><fpage>a005140</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a005140</pub-id><pub-id pub-id-type="pmid">20452950</pub-id>
</element-citation><mixed-citation id="mc-CR450" publication-type="journal">Wucherpfennig, K. W. et al. Structural biology of the T-cell receptor: insights into receptor assembly, ligand recognition, and initiation of signaling. <italic>Cold Spring Harb. Perspect. Biol.</italic><bold>2</bold>, a005140 (2010).<pub-id pub-id-type="pmid">20452950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR451"><label>451.</label><citation-alternatives><element-citation id="ec-CR451" publication-type="journal"><person-group person-group-type="author"><name><surname>Liew</surname><given-names>FY</given-names></name></person-group><article-title>T(H)1 and T(H)2 cells: a historical perspective</article-title><source>Nat. Rev. Immunol.</source><year>2002</year><volume>2</volume><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nri705</pub-id><pub-id pub-id-type="pmid">11905838</pub-id>
</element-citation><mixed-citation id="mc-CR451" publication-type="journal">Liew, F. Y. T(H)1 and T(H)2 cells: a historical perspective. <italic>Nat. Rev. Immunol.</italic><bold>2</bold>, 55&#x02013;60 (2002).<pub-id pub-id-type="pmid">11905838</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR452"><label>452.</label><citation-alternatives><element-citation id="ec-CR452" publication-type="journal"><person-group person-group-type="author"><name><surname>Coffman</surname><given-names>RL</given-names></name></person-group><article-title>Origins of the T(H)1-T(H)2 model: a personal perspective</article-title><source>Nat. Immunol.</source><year>2006</year><volume>7</volume><fpage>539</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/ni0606-539</pub-id><pub-id pub-id-type="pmid">16715060</pub-id>
</element-citation><mixed-citation id="mc-CR452" publication-type="journal">Coffman, R. L. Origins of the T(H)1-T(H)2 model: a personal perspective. <italic>Nat. Immunol.</italic><bold>7</bold>, 539&#x02013;541 (2006).<pub-id pub-id-type="pmid">16715060</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR453"><label>453.</label><citation-alternatives><element-citation id="ec-CR453" publication-type="journal"><person-group person-group-type="author"><name><surname>Malissen</surname><given-names>B</given-names></name><name><surname>Gr&#x000e9;goire</surname><given-names>C</given-names></name><name><surname>Malissen</surname><given-names>M</given-names></name><name><surname>Roncagalli</surname><given-names>R</given-names></name></person-group><article-title>Integrative biology of T cell activation</article-title><source>Nat. Immunol.</source><year>2014</year><volume>15</volume><fpage>790</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/ni.2959</pub-id><pub-id pub-id-type="pmid">25137453</pub-id>
</element-citation><mixed-citation id="mc-CR453" publication-type="journal">Malissen, B., Gr&#x000e9;goire, C., Malissen, M. &#x00026; Roncagalli, R. Integrative biology of T cell activation. <italic>Nat. Immunol.</italic><bold>15</bold>, 790&#x02013;797 (2014).<pub-id pub-id-type="pmid">25137453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR454"><label>454.</label><citation-alternatives><element-citation id="ec-CR454" publication-type="journal"><person-group person-group-type="author"><name><surname>Cantor</surname><given-names>H</given-names></name><name><surname>Boyse</surname><given-names>EA</given-names></name></person-group><article-title>Functional subclasses of T-lymphocytes bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen</article-title><source>J. Exp. Med.</source><year>1975</year><volume>141</volume><fpage>1376</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1084/jem.141.6.1376</pub-id><pub-id pub-id-type="pmid">1092798</pub-id>
</element-citation><mixed-citation id="mc-CR454" publication-type="journal">Cantor, H. &#x00026; Boyse, E. A. Functional subclasses of T-lymphocytes bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen. <italic>J. Exp. Med.</italic><bold>141</bold>, 1376&#x02013;1389 (1975).<pub-id pub-id-type="pmid">1092798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR455"><label>455.</label><citation-alternatives><element-citation id="ec-CR455" publication-type="journal"><person-group person-group-type="author"><name><surname>Cerottini</surname><given-names>JC</given-names></name><name><surname>Nordin</surname><given-names>AA</given-names></name><name><surname>Brunner</surname><given-names>KT</given-names></name></person-group><article-title>Specific in vitro cytotoxicity of thymus-derived lymphocytes sensitized to alloantigens</article-title><source>Nature</source><year>1970</year><volume>228</volume><fpage>1308</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1038/2281308a0</pub-id><pub-id pub-id-type="pmid">4922690</pub-id>
</element-citation><mixed-citation id="mc-CR455" publication-type="journal">Cerottini, J. C., Nordin, A. A. &#x00026; Brunner, K. T. Specific in vitro cytotoxicity of thymus-derived lymphocytes sensitized to alloantigens. <italic>Nature</italic><bold>228</bold>, 1308&#x02013;1309 (1970).<pub-id pub-id-type="pmid">4922690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR456"><label>456.</label><citation-alternatives><element-citation id="ec-CR456" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Bevan</surname><given-names>MJ</given-names></name></person-group><article-title>CD8(+) T cells: foot soldiers of the immune system</article-title><source>Immunity</source><year>2011</year><volume>35</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.07.010</pub-id><pub-id pub-id-type="pmid">21867926</pub-id>
</element-citation><mixed-citation id="mc-CR456" publication-type="journal">Zhang, N. &#x00026; Bevan, M. J. CD8(+) T cells: foot soldiers of the immune system. <italic>Immunity</italic><bold>35</bold>, 161&#x02013;168 (2011).<pub-id pub-id-type="pmid">21867926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR457"><label>457.</label><citation-alternatives><element-citation id="ec-CR457" publication-type="journal"><person-group person-group-type="author"><name><surname>Yannelli</surname><given-names>JR</given-names></name><name><surname>Sullivan</surname><given-names>JA</given-names></name><name><surname>Mandell</surname><given-names>GL</given-names></name><name><surname>Engelhard</surname><given-names>VH</given-names></name></person-group><article-title>Reorientation and fusion of cytotoxic T lymphocyte granules after interaction with target cells as determined by high resolution cinemicrography</article-title><source>J. Immunol.</source><year>1986</year><volume>136</volume><fpage>377</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.136.2.377</pub-id><pub-id pub-id-type="pmid">3510248</pub-id>
</element-citation><mixed-citation id="mc-CR457" publication-type="journal">Yannelli, J. R., Sullivan, J. A., Mandell, G. L. &#x00026; Engelhard, V. H. Reorientation and fusion of cytotoxic T lymphocyte granules after interaction with target cells as determined by high resolution cinemicrography. <italic>J. Immunol.</italic><bold>136</bold>, 377&#x02013;382 (1986).<pub-id pub-id-type="pmid">3510248</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR458"><label>458.</label><citation-alternatives><element-citation id="ec-CR458" publication-type="journal"><person-group person-group-type="author"><name><surname>Trenn</surname><given-names>G</given-names></name><name><surname>Takayama</surname><given-names>H</given-names></name><name><surname>Sitkovsky</surname><given-names>MV</given-names></name></person-group><article-title>Exocytosis of cytolytic granules may not be required for target cell lysis by cytotoxic T-lymphocytes</article-title><source>Nature</source><year>1987</year><volume>330</volume><fpage>72</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/330072a0</pub-id><pub-id pub-id-type="pmid">3118213</pub-id>
</element-citation><mixed-citation id="mc-CR458" publication-type="journal">Trenn, G., Takayama, H. &#x00026; Sitkovsky, M. V. Exocytosis of cytolytic granules may not be required for target cell lysis by cytotoxic T-lymphocytes. <italic>Nature</italic><bold>330</bold>, 72&#x02013;74 (1987).<pub-id pub-id-type="pmid">3118213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR459"><label>459.</label><citation-alternatives><element-citation id="ec-CR459" publication-type="journal"><person-group person-group-type="author"><name><surname>Boag</surname><given-names>SE</given-names></name><etal/></person-group><article-title>T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>3063</fpage><lpage>3076</lpage><pub-id pub-id-type="doi">10.1172/JCI80055</pub-id><pub-id pub-id-type="pmid">26168217</pub-id>
</element-citation><mixed-citation id="mc-CR459" publication-type="journal">Boag, S. E. et al. T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients. <italic>J. Clin. Investig.</italic><bold>125</bold>, 3063&#x02013;3076 (2015).<pub-id pub-id-type="pmid">26168217</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR460"><label>460.</label><citation-alternatives><element-citation id="ec-CR460" publication-type="journal"><person-group person-group-type="author"><name><surname>Ilatovskaya</surname><given-names>DV</given-names></name><etal/></person-group><article-title>CD8(+) T-cells negatively regulate inflammation post-myocardial infarction</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2019</year><volume>317</volume><fpage>H581</fpage><lpage>h596</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00112.2019</pub-id><pub-id pub-id-type="pmid">31322426</pub-id>
</element-citation><mixed-citation id="mc-CR460" publication-type="journal">Ilatovskaya, D. V. et al. CD8(+) T-cells negatively regulate inflammation post-myocardial infarction. <italic>Am. J. Physiol. Heart Circ. Physiol.</italic><bold>317</bold>, H581&#x02013;h596 (2019).<pub-id pub-id-type="pmid">31322426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR461"><label>461.</label><citation-alternatives><element-citation id="ec-CR461" publication-type="journal"><person-group person-group-type="author"><name><surname>Branchetti</surname><given-names>E</given-names></name><etal/></person-group><article-title>Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm</article-title><source>Cardiovasc. Res.</source><year>2013</year><volume>100</volume><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt205</pub-id><pub-id pub-id-type="pmid">23985903</pub-id>
</element-citation><mixed-citation id="mc-CR461" publication-type="journal">Branchetti, E. et al. Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm. <italic>Cardiovasc. Res.</italic><bold>100</bold>, 316&#x02013;324 (2013).<pub-id pub-id-type="pmid">23985903</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR462"><label>462.</label><citation-alternatives><element-citation id="ec-CR462" publication-type="journal"><person-group person-group-type="author"><name><surname>Curato</surname><given-names>C</given-names></name><etal/></person-group><article-title>Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury</article-title><source>J. Immunol.</source><year>2010</year><volume>185</volume><fpage>6286</fpage><lpage>6293</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903681</pub-id><pub-id pub-id-type="pmid">20935205</pub-id>
</element-citation><mixed-citation id="mc-CR462" publication-type="journal">Curato, C. et al. Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury. <italic>J. Immunol.</italic><bold>185</bold>, 6286&#x02013;6293 (2010).<pub-id pub-id-type="pmid">20935205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR463"><label>463.</label><citation-alternatives><element-citation id="ec-CR463" publication-type="journal"><person-group person-group-type="author"><name><surname>Elhage</surname><given-names>R</given-names></name><etal/></person-group><article-title>Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice</article-title><source>Am. J. Pathol.</source><year>2004</year><volume>165</volume><fpage>2013</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63252-X</pub-id><pub-id pub-id-type="pmid">15579444</pub-id>
</element-citation><mixed-citation id="mc-CR463" publication-type="journal">Elhage, R. et al. Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. <italic>Am. J. Pathol.</italic><bold>165</bold>, 2013&#x02013;2018 (2004).<pub-id pub-id-type="pmid">15579444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR464"><label>464.</label><citation-alternatives><element-citation id="ec-CR464" publication-type="journal"><person-group person-group-type="author"><name><surname>Sage</surname><given-names>AP</given-names></name><etal/></person-group><article-title>X-box binding protein-1 dependent plasma cell responses limit the development of atherosclerosis</article-title><source>Circ. Res.</source><year>2017</year><volume>121</volume><fpage>270</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.310884</pub-id><pub-id pub-id-type="pmid">28620068</pub-id>
</element-citation><mixed-citation id="mc-CR464" publication-type="journal">Sage, A. P. et al. X-box binding protein-1 dependent plasma cell responses limit the development of atherosclerosis. <italic>Circ. Res.</italic><bold>121</bold>, 270&#x02013;281 (2017).<pub-id pub-id-type="pmid">28620068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR465"><label>465.</label><citation-alternatives><element-citation id="ec-CR465" publication-type="journal"><person-group person-group-type="author"><name><surname>Taleb</surname><given-names>S</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name><name><surname>Mallat</surname><given-names>Z</given-names></name></person-group><article-title>IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2015</year><volume>35</volume><fpage>258</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.303567</pub-id><pub-id pub-id-type="pmid">25234818</pub-id>
</element-citation><mixed-citation id="mc-CR465" publication-type="journal">Taleb, S., Tedgui, A. &#x00026; Mallat, Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>35</bold>, 258&#x02013;264 (2015).<pub-id pub-id-type="pmid">25234818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR466"><label>466.</label><citation-alternatives><element-citation id="ec-CR466" publication-type="journal"><person-group person-group-type="author"><name><surname>Weirather</surname><given-names>J</given-names></name><etal/></person-group><article-title>Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation</article-title><source>Circ. Res.</source><year>2014</year><volume>115</volume><fpage>55</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.303895</pub-id><pub-id pub-id-type="pmid">24786398</pub-id>
</element-citation><mixed-citation id="mc-CR466" publication-type="journal">Weirather, J. et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. <italic>Circ. Res.</italic><bold>115</bold>, 55&#x02013;67 (2014).<pub-id pub-id-type="pmid">24786398</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR467"><label>467.</label><citation-alternatives><element-citation id="ec-CR467" publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>U</given-names></name><etal/></person-group><article-title>Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice</article-title><source>Circulation</source><year>2012</year><volume>125</volume><fpage>1652</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.044164</pub-id><pub-id pub-id-type="pmid">22388323</pub-id>
</element-citation><mixed-citation id="mc-CR467" publication-type="journal">Hofmann, U. et al. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. <italic>Circulation</italic><bold>125</bold>, 1652&#x02013;1663 (2012).<pub-id pub-id-type="pmid">22388323</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR468"><label>468.</label><citation-alternatives><element-citation id="ec-CR468" publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>CD4+CD25+ regulatory T cells control innate immune reactivity after injury</article-title><source>J. Immunol.</source><year>2005</year><volume>174</volume><fpage>2957</fpage><lpage>2963</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.5.2957</pub-id><pub-id pub-id-type="pmid">15728508</pub-id>
</element-citation><mixed-citation id="mc-CR468" publication-type="journal">Murphy, T. J. et al. CD4+CD25+ regulatory T cells control innate immune reactivity after injury. <italic>J. Immunol.</italic><bold>174</bold>, 2957&#x02013;2963 (2005).<pub-id pub-id-type="pmid">15728508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR469"><label>469.</label><citation-alternatives><element-citation id="ec-CR469" publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>M</given-names></name><etal/></person-group><article-title>IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation</article-title><source>Basic Res. Cardiol.</source><year>2017</year><volume>112</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1007/s00395-017-0622-5</pub-id><pub-id pub-id-type="pmid">28439731</pub-id>
</element-citation><mixed-citation id="mc-CR469" publication-type="journal">Jung, M. et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. <italic>Basic Res. Cardiol.</italic><bold>112</bold>, 33 (2017).<pub-id pub-id-type="pmid">28439731</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR470"><label>470.</label><citation-alternatives><element-citation id="ec-CR470" publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeuchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction</article-title><source>Cardiovasc. Res.</source><year>2004</year><volume>64</volume><fpage>526</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2004.07.017</pub-id><pub-id pub-id-type="pmid">15537506</pub-id>
</element-citation><mixed-citation id="mc-CR470" publication-type="journal">Ikeuchi, M. et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. <italic>Cardiovasc. Res.</italic><bold>64</bold>, 526&#x02013;535 (2004).<pub-id pub-id-type="pmid">15537506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR471"><label>471.</label><citation-alternatives><element-citation id="ec-CR471" publication-type="journal"><person-group person-group-type="author"><name><surname>Akkaya</surname><given-names>M</given-names></name><name><surname>Kwak</surname><given-names>K</given-names></name><name><surname>Pierce</surname><given-names>SK</given-names></name></person-group><article-title>B cell memory: building two walls of protection against pathogens</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>229</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0244-2</pub-id><pub-id pub-id-type="pmid">31836872</pub-id>
</element-citation><mixed-citation id="mc-CR471" publication-type="journal">Akkaya, M., Kwak, K. &#x00026; Pierce, S. K. B cell memory: building two walls of protection against pathogens. <italic>Nat. Rev. Immunol.</italic><bold>20</bold>, 229&#x02013;238 (2020).<pub-id pub-id-type="pmid">31836872</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR472"><label>472.</label><citation-alternatives><element-citation id="ec-CR472" publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>K</given-names></name><name><surname>Akkaya</surname><given-names>M</given-names></name><name><surname>Pierce</surname><given-names>SK</given-names></name></person-group><article-title>B cell signaling in context</article-title><source>Nat. Immunol.</source><year>2019</year><volume>20</volume><fpage>963</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0427-9</pub-id><pub-id pub-id-type="pmid">31285625</pub-id>
</element-citation><mixed-citation id="mc-CR472" publication-type="journal">Kwak, K., Akkaya, M. &#x00026; Pierce, S. K. B cell signaling in context. <italic>Nat. Immunol.</italic><bold>20</bold>, 963&#x02013;969 (2019).<pub-id pub-id-type="pmid">31285625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR473"><label>473.</label><citation-alternatives><element-citation id="ec-CR473" publication-type="journal"><person-group person-group-type="author"><name><surname>Labeur-Iurman</surname><given-names>L</given-names></name><name><surname>Harker</surname><given-names>JA</given-names></name></person-group><article-title>Mechanisms of antibody mediated immunity - Distinct in early life</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2024</year><volume>172</volume><fpage>106588</fpage><pub-id pub-id-type="doi">10.1016/j.biocel.2024.106588</pub-id><pub-id pub-id-type="pmid">38768890</pub-id>
</element-citation><mixed-citation id="mc-CR473" publication-type="journal">Labeur-Iurman, L. &#x00026; Harker, J. A. Mechanisms of antibody mediated immunity - Distinct in early life. <italic>Int. J. Biochem. Cell Biol.</italic><bold>172</bold>, 106588 (2024).<pub-id pub-id-type="pmid">38768890</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR474"><label>474.</label><citation-alternatives><element-citation id="ec-CR474" publication-type="journal"><person-group person-group-type="author"><name><surname>Casadevall</surname><given-names>A</given-names></name><name><surname>Pirofski</surname><given-names>LA</given-names></name></person-group><article-title>A new synthesis for antibody-mediated immunity</article-title><source>Nat. Immunol.</source><year>2011</year><volume>13</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1038/ni.2184</pub-id><pub-id pub-id-type="pmid">22179281</pub-id>
</element-citation><mixed-citation id="mc-CR474" publication-type="journal">Casadevall, A. &#x00026; Pirofski, L. A. A new synthesis for antibody-mediated immunity. <italic>Nat. Immunol.</italic><bold>13</bold>, 21&#x02013;28 (2011).<pub-id pub-id-type="pmid">22179281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR475"><label>475.</label><citation-alternatives><element-citation id="ec-CR475" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoehn</surname><given-names>KB</given-names></name><name><surname>Fowler</surname><given-names>A</given-names></name><name><surname>Lunter</surname><given-names>G</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name></person-group><article-title>The diversity and molecular evolution of B-cell receptors during infection</article-title><source>Mol. Biol. Evol.</source><year>2016</year><volume>33</volume><fpage>1147</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1093/molbev/msw015</pub-id><pub-id pub-id-type="pmid">26802217</pub-id>
</element-citation><mixed-citation id="mc-CR475" publication-type="journal">Hoehn, K. B., Fowler, A., Lunter, G. &#x00026; Pybus, O. G. The diversity and molecular evolution of B-cell receptors during infection. <italic>Mol. Biol. Evol.</italic><bold>33</bold>, 1147&#x02013;1157 (2016).<pub-id pub-id-type="pmid">26802217</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR476"><label>476.</label><citation-alternatives><element-citation id="ec-CR476" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>R</given-names></name><etal/></person-group><article-title>Distinct metabolic requirements regulate B cell activation and germinal center responses</article-title><source>Nat. Immunol.</source><year>2023</year><volume>24</volume><fpage>1358</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01540-y</pub-id><pub-id pub-id-type="pmid">37365386</pub-id>
</element-citation><mixed-citation id="mc-CR476" publication-type="journal">Sharma, R. et al. Distinct metabolic requirements regulate B cell activation and germinal center responses. <italic>Nat. Immunol.</italic><bold>24</bold>, 1358&#x02013;1369 (2023).<pub-id pub-id-type="pmid">37365386</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR477"><label>477.</label><citation-alternatives><element-citation id="ec-CR477" publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e4;ggl&#x000f6;f</surname><given-names>T</given-names></name><etal/></person-group><article-title>Continuous germinal center invasion contributes to the diversity of the immune response</article-title><source>Cell</source><year>2023</year><volume>186</volume><fpage>147</fpage><lpage>161.e115</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.11.032</pub-id><pub-id pub-id-type="pmid">36565698</pub-id>
</element-citation><mixed-citation id="mc-CR477" publication-type="journal">H&#x000e4;ggl&#x000f6;f, T. et al. Continuous germinal center invasion contributes to the diversity of the immune response. <italic>Cell</italic><bold>186</bold>, 147&#x02013;161.e115 (2023).<pub-id pub-id-type="pmid">36565698</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR478"><label>478.</label><citation-alternatives><element-citation id="ec-CR478" publication-type="journal"><person-group person-group-type="author"><name><surname>Horckmans</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pericardial adipose tissue regulates granulopoiesis, fibrosis, and cardiac function after myocardial infarction</article-title><source>Circulation</source><year>2018</year><volume>137</volume><fpage>948</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.028833</pub-id><pub-id pub-id-type="pmid">29167227</pub-id>
</element-citation><mixed-citation id="mc-CR478" publication-type="journal">Horckmans, M. et al. Pericardial adipose tissue regulates granulopoiesis, fibrosis, and cardiac function after myocardial infarction. <italic>Circulation</italic><bold>137</bold>, 948&#x02013;960 (2018).<pub-id pub-id-type="pmid">29167227</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR479"><label>479.</label><citation-alternatives><element-citation id="ec-CR479" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group><article-title>IL-10-producing B cells are enriched in murine pericardial adipose tissues and ameliorate the outcome of acute myocardial infarction</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>21673</fpage><lpage>21684</lpage><pub-id pub-id-type="doi">10.1073/pnas.1911464116</pub-id><pub-id pub-id-type="pmid">31591231</pub-id>
</element-citation><mixed-citation id="mc-CR479" publication-type="journal">Wu, L. et al. IL-10-producing B cells are enriched in murine pericardial adipose tissues and ameliorate the outcome of acute myocardial infarction. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>116</bold>, 21673&#x02013;21684 (2019).<pub-id pub-id-type="pmid">31591231</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR480"><label>480.</label><citation-alternatives><element-citation id="ec-CR480" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>The hippo pathway: biology and pathophysiology</article-title><source>Annu. Rev. Biochem.</source><year>2019</year><volume>88</volume><fpage>577</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-013118-111829</pub-id><pub-id pub-id-type="pmid">30566373</pub-id>
</element-citation><mixed-citation id="mc-CR480" publication-type="journal">Ma, S., Meng, Z., Chen, R. &#x00026; Guan, K. L. The hippo pathway: biology and pathophysiology. <italic>Annu. Rev. Biochem.</italic><bold>88</bold>, 577&#x02013;604 (2019).<pub-id pub-id-type="pmid">30566373</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR481"><label>481.</label><citation-alternatives><element-citation id="ec-CR481" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>FX</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>Hippo pathway in organ size control, tissue homeostasis, and cancer</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>811</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.044</pub-id><pub-id pub-id-type="pmid">26544935</pub-id>
</element-citation><mixed-citation id="mc-CR481" publication-type="journal">Yu, F. X., Zhao, B. &#x00026; Guan, K. L. Hippo pathway in organ size control, tissue homeostasis, and cancer. <italic>Cell</italic><bold>163</bold>, 811&#x02013;828 (2015).<pub-id pub-id-type="pmid">26544935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR482"><label>482.</label><citation-alternatives><element-citation id="ec-CR482" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade</article-title><source>Nat. Cell Biol.</source><year>2017</year><volume>19</volume><fpage>362</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/ncb3496</pub-id><pub-id pub-id-type="pmid">28346439</pub-id>
</element-citation><mixed-citation id="mc-CR482" publication-type="journal">Zhang, Q. et al. Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade. <italic>Nat. Cell Biol.</italic><bold>19</bold>, 362&#x02013;374 (2017).<pub-id pub-id-type="pmid">28346439</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR483"><label>483.</label><citation-alternatives><element-citation id="ec-CR483" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKvarepsilon-mediated phosphorylation</article-title><source>Nat. Immunol.</source><year>2017</year><volume>18</volume><fpage>733</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1038/ni.3744</pub-id><pub-id pub-id-type="pmid">28481329</pub-id>
</element-citation><mixed-citation id="mc-CR483" publication-type="journal">Wang, S. et al. YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKvarepsilon-mediated phosphorylation. <italic>Nat. Immunol.</italic><bold>18</bold>, 733&#x02013;743 (2017).<pub-id pub-id-type="pmid">28481329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR484"><label>484.</label><citation-alternatives><element-citation id="ec-CR484" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Toll receptor-mediated hippo signaling controls innate immunity in drosophila</article-title><source>Cell</source><year>2016</year><volume>164</volume><fpage>406</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.12.029</pub-id><pub-id pub-id-type="pmid">26824654</pub-id>
</element-citation><mixed-citation id="mc-CR484" publication-type="journal">Liu, B. et al. Toll receptor-mediated hippo signaling controls innate immunity in drosophila. <italic>Cell</italic><bold>164</bold>, 406&#x02013;419 (2016).<pub-id pub-id-type="pmid">26824654</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR485"><label>485.</label><citation-alternatives><element-citation id="ec-CR485" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>X</given-names></name><etal/></person-group><article-title>Hippo/Mst signalling couples metabolic state and immune function of CD8alpha(+) dendritic cells</article-title><source>Nature</source><year>2018</year><volume>558</volume><fpage>141</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0177-0</pub-id><pub-id pub-id-type="pmid">29849151</pub-id>
</element-citation><mixed-citation id="mc-CR485" publication-type="journal">Du, X. et al. Hippo/Mst signalling couples metabolic state and immune function of CD8alpha(+) dendritic cells. <italic>Nature</italic><bold>558</bold>, 141&#x02013;145 (2018).<pub-id pub-id-type="pmid">29849151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR486"><label>486.</label><citation-alternatives><element-citation id="ec-CR486" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Hippo kinases Mst1 and Mst2 sense and amplify IL-2R-STAT5 signaling in regulatory T cells to establish stable regulatory activity</article-title><source>Immunity</source><year>2018</year><volume>49</volume><fpage>899</fpage><lpage>914.e6</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.10.010</pub-id><pub-id pub-id-type="pmid">30413360</pub-id>
</element-citation><mixed-citation id="mc-CR486" publication-type="journal">Shi, H. et al. Hippo kinases Mst1 and Mst2 sense and amplify IL-2R-STAT5 signaling in regulatory T cells to establish stable regulatory activity. <italic>Immunity</italic><bold>49</bold>, 899&#x02013;914.e6 (2018).<pub-id pub-id-type="pmid">30413360</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR487"><label>487.</label><citation-alternatives><element-citation id="ec-CR487" publication-type="journal"><person-group person-group-type="author"><name><surname>Odashima</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of endogenous Mst1 prevents apoptosis and cardiac dysfunction without affecting cardiac hypertrophy after myocardial infarction</article-title><source>Circ. Res.</source><year>2007</year><volume>100</volume><fpage>1344</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000265846.23485.7a</pub-id><pub-id pub-id-type="pmid">17395874</pub-id>
</element-citation><mixed-citation id="mc-CR487" publication-type="journal">Odashima, M. et al. Inhibition of endogenous Mst1 prevents apoptosis and cardiac dysfunction without affecting cardiac hypertrophy after myocardial infarction. <italic>Circ. Res.</italic><bold>100</bold>, 1344&#x02013;1352 (2007).<pub-id pub-id-type="pmid">17395874</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR488"><label>488.</label><citation-alternatives><element-citation id="ec-CR488" publication-type="journal"><person-group person-group-type="author"><name><surname>Del Re</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL</article-title><source>Mol. Cell</source><year>2014</year><volume>54</volume><fpage>639</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.04.007</pub-id><pub-id pub-id-type="pmid">24813943</pub-id>
</element-citation><mixed-citation id="mc-CR488" publication-type="journal">Del Re, D. P. et al. Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL. <italic>Mol. Cell</italic><bold>54</bold>, 639&#x02013;650 (2014).<pub-id pub-id-type="pmid">24813943</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR489"><label>489.</label><citation-alternatives><element-citation id="ec-CR489" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>YAP/TEAD1 complex is a default repressor of cardiac toll-like receptor genes</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><fpage>6649</fpage><pub-id pub-id-type="doi">10.3390/ijms22136649</pub-id><pub-id pub-id-type="pmid">34206257</pub-id>
</element-citation><mixed-citation id="mc-CR489" publication-type="journal">Gao, Y. et al. YAP/TEAD1 complex is a default repressor of cardiac toll-like receptor genes. <italic>Int. J. Mol. Sci.</italic><bold>22</bold>, 6649 (2021).<pub-id pub-id-type="pmid">34206257</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR490"><label>490.</label><citation-alternatives><element-citation id="ec-CR490" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>TLR3 mediates repair and regeneration of damaged neonatal heart through glycolysis dependent YAP1 regulated miR-152 expression</article-title><source>Cell Death Differ.</source><year>2018</year><volume>25</volume><fpage>966</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1038/s41418-017-0036-9</pub-id><pub-id pub-id-type="pmid">29358670</pub-id>
</element-citation><mixed-citation id="mc-CR490" publication-type="journal">Wang, X. et al. TLR3 mediates repair and regeneration of damaged neonatal heart through glycolysis dependent YAP1 regulated miR-152 expression. <italic>Cell Death Differ.</italic><bold>25</bold>, 966&#x02013;982 (2018).<pub-id pub-id-type="pmid">29358670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR491"><label>491.</label><citation-alternatives><element-citation id="ec-CR491" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model</article-title><source>Circ. Res.</source><year>2014</year><volume>115</volume><fpage>354</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.303632</pub-id><pub-id pub-id-type="pmid">24833660</pub-id>
</element-citation><mixed-citation id="mc-CR491" publication-type="journal">Lin, Z. et al. Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. <italic>Circ. Res.</italic><bold>115</bold>, 354&#x02013;363 (2014).<pub-id pub-id-type="pmid">24833660</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR492"><label>492.</label><citation-alternatives><element-citation id="ec-CR492" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model</article-title><source>Life Sci. Alliance</source><year>2020</year><volume>3</volume><fpage>e201900424</fpage><pub-id pub-id-type="doi">10.26508/lsa.201900424</pub-id><pub-id pub-id-type="pmid">31843959</pub-id>
</element-citation><mixed-citation id="mc-CR492" publication-type="journal">Chen, J. et al. aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model. <italic>Life Sci. Alliance</italic><bold>3</bold>, e201900424 (2020).<pub-id pub-id-type="pmid">31843959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR493"><label>493.</label><citation-alternatives><element-citation id="ec-CR493" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><etal/></person-group><article-title>The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy</article-title><source>Basic Res. Cardiol.</source><year>2014</year><volume>109</volume><fpage>435</fpage><pub-id pub-id-type="doi">10.1007/s00395-014-0435-8</pub-id><pub-id pub-id-type="pmid">25168380</pub-id>
</element-citation><mixed-citation id="mc-CR493" publication-type="journal">Wang, P. et al. The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy. <italic>Basic Res. Cardiol.</italic><bold>109</bold>, 435 (2014).<pub-id pub-id-type="pmid">25168380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR494"><label>494.</label><citation-alternatives><element-citation id="ec-CR494" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Mst1 knockdown alleviates cardiac lipotoxicity and inhibits the development of diabetic cardiomyopathy in db/db mice</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><year>2020</year><volume>1866</volume><fpage>165806</fpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165806</pub-id><pub-id pub-id-type="pmid">32320827</pub-id>
</element-citation><mixed-citation id="mc-CR494" publication-type="journal">Xiong, Z. et al. Mst1 knockdown alleviates cardiac lipotoxicity and inhibits the development of diabetic cardiomyopathy in db/db mice. <italic>Biochim. Biophys. Acta Mol. Basis Dis.</italic><bold>1866</bold>, 165806 (2020).<pub-id pub-id-type="pmid">32320827</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR495"><label>495.</label><citation-alternatives><element-citation id="ec-CR495" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>11525</fpage><lpage>11530</lpage><pub-id pub-id-type="doi">10.1073/pnas.1613121113</pub-id><pub-id pub-id-type="pmid">27671657</pub-id>
</element-citation><mixed-citation id="mc-CR495" publication-type="journal">Wang, K. C. et al. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>113</bold>, 11525&#x02013;11530 (2016).<pub-id pub-id-type="pmid">27671657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR496"><label>496.</label><citation-alternatives><element-citation id="ec-CR496" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow</article-title><source>Nature</source><year>2016</year><volume>540</volume><fpage>579</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/nature20602</pub-id><pub-id pub-id-type="pmid">27926730</pub-id>
</element-citation><mixed-citation id="mc-CR496" publication-type="journal">Wang, L. et al. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. <italic>Nature</italic><bold>540</bold>, 579&#x02013;582 (2016).<pub-id pub-id-type="pmid">27926730</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR497"><label>497.</label><citation-alternatives><element-citation id="ec-CR497" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Activation of yes-associated protein/PDZ-binding motif pathway contributes to endothelial dysfunction and vascular inflammation in angiotensinII hypertension</article-title><source>Front. Physiol.</source><year>2021</year><volume>12</volume><fpage>732084</fpage><pub-id pub-id-type="doi">10.3389/fphys.2021.732084</pub-id><pub-id pub-id-type="pmid">34650444</pub-id>
</element-citation><mixed-citation id="mc-CR497" publication-type="journal">Xu, Q. et al. Activation of yes-associated protein/PDZ-binding motif pathway contributes to endothelial dysfunction and vascular inflammation in angiotensinII hypertension. <italic>Front. Physiol.</italic><bold>12</bold>, 732084 (2021).<pub-id pub-id-type="pmid">34650444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR498"><label>498.</label><citation-alternatives><element-citation id="ec-CR498" publication-type="journal"><person-group person-group-type="author"><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><article-title>The complex world of WNT receptor signalling</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2012</year><volume>13</volume><fpage>767</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1038/nrm3470</pub-id><pub-id pub-id-type="pmid">23151663</pub-id>
</element-citation><mixed-citation id="mc-CR498" publication-type="journal">Niehrs, C. The complex world of WNT receptor signalling. <italic>Nat. Rev. Mol. Cell Biol.</italic><bold>13</bold>, 767&#x02013;779 (2012).<pub-id pub-id-type="pmid">23151663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR499"><label>499.</label><citation-alternatives><element-citation id="ec-CR499" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Wnt/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities</article-title><source>Signal. Transduct. Target Ther.</source><year>2022</year><volume>7</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00762-6</pub-id><pub-id pub-id-type="pmid">34980884</pub-id>
</element-citation><mixed-citation id="mc-CR499" publication-type="journal">Liu, J. et al. Wnt/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities. <italic>Signal. Transduct. Target Ther.</italic><bold>7</bold>, 3 (2022).<pub-id pub-id-type="pmid">34980884</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR500"><label>500.</label><citation-alternatives><element-citation id="ec-CR500" publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities</article-title><source>Cell</source><year>2017</year><volume>169</volume><fpage>985</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id><pub-id pub-id-type="pmid">28575679</pub-id>
</element-citation><mixed-citation id="mc-CR500" publication-type="journal">Nusse, R. &#x00026; Clevers, H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. <italic>Cell</italic><bold>169</bold>, 985&#x02013;999 (2017).<pub-id pub-id-type="pmid">28575679</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR501"><label>501.</label><citation-alternatives><element-citation id="ec-CR501" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Hottiger</surname><given-names>MO</given-names></name></person-group><article-title>Crosstalk between Wnt/beta-catenin and NF-kappaB signaling pathway during inflammation</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><fpage>378</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00378</pub-id><pub-id pub-id-type="pmid">27713747</pub-id>
</element-citation><mixed-citation id="mc-CR501" publication-type="journal">Ma, B. &#x00026; Hottiger, M. O. Crosstalk between Wnt/beta-catenin and NF-kappaB signaling pathway during inflammation. <italic>Front. Immunol.</italic><bold>7</bold>, 378 (2016).<pub-id pub-id-type="pmid">27713747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR502"><label>502.</label><citation-alternatives><element-citation id="ec-CR502" publication-type="journal"><person-group person-group-type="author"><name><surname>Trinath</surname><given-names>J</given-names></name><etal/></person-group><article-title>The WNT signaling pathway contributes to dectin-1-dependent inhibition of Toll-like receptor-induced inflammatory signature</article-title><source>Mol. Cell Biol.</source><year>2014</year><volume>34</volume><fpage>4301</fpage><lpage>4314</lpage><pub-id pub-id-type="doi">10.1128/MCB.00641-14</pub-id><pub-id pub-id-type="pmid">25246634</pub-id>
</element-citation><mixed-citation id="mc-CR502" publication-type="journal">Trinath, J. et al. The WNT signaling pathway contributes to dectin-1-dependent inhibition of Toll-like receptor-induced inflammatory signature. <italic>Mol. Cell Biol.</italic><bold>34</bold>, 4301&#x02013;4314 (2014).<pub-id pub-id-type="pmid">25246634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR503"><label>503.</label><citation-alternatives><element-citation id="ec-CR503" publication-type="journal"><person-group person-group-type="author"><name><surname>Aisagbonhi</surname><given-names>O</given-names></name><etal/></person-group><article-title>Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition</article-title><source>Dis. Model Mech.</source><year>2011</year><volume>4</volume><fpage>469</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1242/dmm.006510</pub-id><pub-id pub-id-type="pmid">21324930</pub-id>
</element-citation><mixed-citation id="mc-CR503" publication-type="journal">Aisagbonhi, O. et al. Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition. <italic>Dis. Model Mech.</italic><bold>4</bold>, 469&#x02013;483 (2011).<pub-id pub-id-type="pmid">21324930</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR504"><label>504.</label><citation-alternatives><element-citation id="ec-CR504" publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>J</given-names></name><etal/></person-group><article-title>Blockade to pathological remodeling of infarcted heart tissue using a porcupine antagonist</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>1649</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1073/pnas.1621346114</pub-id><pub-id pub-id-type="pmid">28143939</pub-id>
</element-citation><mixed-citation id="mc-CR504" publication-type="journal">Moon, J. et al. Blockade to pathological remodeling of infarcted heart tissue using a porcupine antagonist. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>114</bold>, 1649&#x02013;1654 (2017).<pub-id pub-id-type="pmid">28143939</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR505"><label>505.</label><citation-alternatives><element-citation id="ec-CR505" publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenthal</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>965</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-12-5046</pub-id><pub-id pub-id-type="pmid">16601243</pub-id>
</element-citation><mixed-citation id="mc-CR505" publication-type="journal">Blumenthal, A. et al. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. <italic>Blood</italic><bold>108</bold>, 965&#x02013;973 (2006).<pub-id pub-id-type="pmid">16601243</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR506"><label>506.</label><citation-alternatives><element-citation id="ec-CR506" publication-type="journal"><person-group person-group-type="author"><name><surname>Barandon</surname><given-names>L</given-names></name><etal/></person-group><article-title>Secreted frizzled-related protein-1 improves postinfarction scar formation through a modulation of inflammatory response</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2011</year><volume>31</volume><fpage>e80</fpage><lpage>e87</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.111.232280</pub-id><pub-id pub-id-type="pmid">21836067</pub-id>
</element-citation><mixed-citation id="mc-CR506" publication-type="journal">Barandon, L. et al. Secreted frizzled-related protein-1 improves postinfarction scar formation through a modulation of inflammatory response. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>31</bold>, e80&#x02013;e87 (2011).<pub-id pub-id-type="pmid">21836067</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR507"><label>507.</label><citation-alternatives><element-citation id="ec-CR507" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JC</given-names></name><etal/></person-group><article-title>beta-Catenin overexpression causes an increase in inflammatory cytokines and NF-kappaB activation in cardiomyocytes</article-title><source>Cell Mol. Biol.</source><year>2016</year><volume>63</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.14715/cmb/2017.63.1.4</pub-id><pub-id pub-id-type="pmid">28234620</pub-id>
</element-citation><mixed-citation id="mc-CR507" publication-type="journal">Lin, J. C. et al. beta-Catenin overexpression causes an increase in inflammatory cytokines and NF-kappaB activation in cardiomyocytes. <italic>Cell Mol. Biol.</italic><bold>63</bold>, 17&#x02013;22 (2016).<pub-id pub-id-type="pmid">28234620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR508"><label>508.</label><citation-alternatives><element-citation id="ec-CR508" publication-type="journal"><person-group person-group-type="author"><name><surname>van de Schans</surname><given-names>VA</given-names></name><etal/></person-group><article-title>Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy</article-title><source>Hypertension</source><year>2007</year><volume>49</volume><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000255946.55091.24</pub-id><pub-id pub-id-type="pmid">17210832</pub-id>
</element-citation><mixed-citation id="mc-CR508" publication-type="journal">van de Schans, V. A. et al. Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy. <italic>Hypertension</italic><bold>49</bold>, 473&#x02013;480 (2007).<pub-id pub-id-type="pmid">17210832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR509"><label>509.</label><citation-alternatives><element-citation id="ec-CR509" publication-type="journal"><person-group person-group-type="author"><name><surname>Awan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Wnt5a promotes lysosomal cholesterol egress and protects against atherosclerosis</article-title><source>Circ. Res.</source><year>2022</year><volume>130</volume><fpage>184</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318881</pub-id><pub-id pub-id-type="pmid">34886684</pub-id>
</element-citation><mixed-citation id="mc-CR509" publication-type="journal">Awan, S. et al. Wnt5a promotes lysosomal cholesterol egress and protects against atherosclerosis. <italic>Circ. Res.</italic><bold>130</bold>, 184&#x02013;199 (2022).<pub-id pub-id-type="pmid">34886684</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR510"><label>510.</label><citation-alternatives><element-citation id="ec-CR510" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>PM</given-names></name><name><surname>Malgor</surname><given-names>R</given-names></name></person-group><article-title>Wnt5a: a player in the pathogenesis of atherosclerosis and other inflammatory disorders</article-title><source>Atherosclerosis</source><year>2014</year><volume>237</volume><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.08.027</pub-id><pub-id pub-id-type="pmid">25240110</pub-id>
</element-citation><mixed-citation id="mc-CR510" publication-type="journal">Bhatt, P. M. &#x00026; Malgor, R. Wnt5a: a player in the pathogenesis of atherosclerosis and other inflammatory disorders. <italic>Atherosclerosis</italic><bold>237</bold>, 155&#x02013;162 (2014).<pub-id pub-id-type="pmid">25240110</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR511"><label>511.</label><citation-alternatives><element-citation id="ec-CR511" publication-type="journal"><person-group person-group-type="author"><name><surname>Schaale</surname><given-names>K</given-names></name><etal/></person-group><article-title>Wnt signaling in macrophages: augmenting and inhibiting mycobacteria-induced inflammatory responses</article-title><source>Eur. J. Cell Biol.</source><year>2011</year><volume>90</volume><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1016/j.ejcb.2010.11.004</pub-id><pub-id pub-id-type="pmid">21185106</pub-id>
</element-citation><mixed-citation id="mc-CR511" publication-type="journal">Schaale, K. et al. Wnt signaling in macrophages: augmenting and inhibiting mycobacteria-induced inflammatory responses. <italic>Eur. J. Cell Biol.</italic><bold>90</bold>, 553&#x02013;559 (2011).<pub-id pub-id-type="pmid">21185106</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR512"><label>512.</label><citation-alternatives><element-citation id="ec-CR512" publication-type="journal"><person-group person-group-type="author"><name><surname>Borrell-Pages</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>JC</given-names></name><name><surname>Juan-Babot</surname><given-names>O</given-names></name><name><surname>Badimon</surname><given-names>L</given-names></name></person-group><article-title>Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages</article-title><source>Eur. Heart J.</source><year>2011</year><volume>32</volume><fpage>2841</fpage><lpage>2850</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr062</pub-id><pub-id pub-id-type="pmid">21398644</pub-id>
</element-citation><mixed-citation id="mc-CR512" publication-type="journal">Borrell-Pages, M., Romero, J. C., Juan-Babot, O. &#x00026; Badimon, L. Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages. <italic>Eur. Heart J.</italic><bold>32</bold>, 2841&#x02013;2850 (2011).<pub-id pub-id-type="pmid">21398644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR513"><label>513.</label><citation-alternatives><element-citation id="ec-CR513" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Myeloid beta-catenin deficiency exacerbates atherosclerosis in low-density lipoprotein receptor-deficient mice</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2018</year><volume>38</volume><fpage>1468</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311059</pub-id><pub-id pub-id-type="pmid">29724817</pub-id>
</element-citation><mixed-citation id="mc-CR513" publication-type="journal">Wang, F. et al. Myeloid beta-catenin deficiency exacerbates atherosclerosis in low-density lipoprotein receptor-deficient mice. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>38</bold>, 1468&#x02013;1478 (2018).<pub-id pub-id-type="pmid">29724817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR514"><label>514.</label><citation-alternatives><element-citation id="ec-CR514" publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>DM</given-names></name><etal/></person-group><article-title>JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</article-title><source>Nat. Rev. Drug Discov.</source><year>2017</year><volume>16</volume><fpage>843</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.201</pub-id><pub-id pub-id-type="pmid">29104284</pub-id>
</element-citation><mixed-citation id="mc-CR514" publication-type="journal">Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. <italic>Nat. Rev. Drug Discov.</italic><bold>16</bold>, 843&#x02013;862 (2017).<pub-id pub-id-type="pmid">29104284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR515"><label>515.</label><citation-alternatives><element-citation id="ec-CR515" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Shea</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Janus kinase inhibitors in autoimmune diseases</article-title><source>Ann. Rheum. Dis.</source><year>2013</year><volume>72</volume><fpage>ii111</fpage><lpage>ii115</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202576</pub-id><pub-id pub-id-type="pmid">23532440</pub-id>
</element-citation><mixed-citation id="mc-CR515" publication-type="journal">O&#x02019;Shea, J. J. et al. Janus kinase inhibitors in autoimmune diseases. <italic>Ann. Rheum. Dis.</italic><bold>72</bold>, ii111&#x02013;ii115 (2013).<pub-id pub-id-type="pmid">23532440</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR516"><label>516.</label><citation-alternatives><element-citation id="ec-CR516" publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Mechanism of activation of protein kinase JAK2 by the growth hormone receptor</article-title><source>Science</source><year>2014</year><volume>344</volume><fpage>1249783</fpage><pub-id pub-id-type="doi">10.1126/science.1249783</pub-id><pub-id pub-id-type="pmid">24833397</pub-id>
</element-citation><mixed-citation id="mc-CR516" publication-type="journal">Brooks, A. J. et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. <italic>Science</italic><bold>344</bold>, 1249783 (2014).<pub-id pub-id-type="pmid">24833397</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR517"><label>517.</label><citation-alternatives><element-citation id="ec-CR517" publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>DM</given-names></name><name><surname>Bonelli</surname><given-names>M</given-names></name><name><surname>Gadina</surname><given-names>M</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>JJ</given-names></name></person-group><article-title>Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</article-title><source>Nat. Rev. Rheumatol.</source><year>2016</year><volume>12</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2015.167</pub-id><pub-id pub-id-type="pmid">26633291</pub-id>
</element-citation><mixed-citation id="mc-CR517" publication-type="journal">Schwartz, D. M., Bonelli, M., Gadina, M. &#x00026; O&#x02019;Shea, J. J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. <italic>Nat. Rev. Rheumatol.</italic><bold>12</bold>, 25&#x02013;36 (2016).<pub-id pub-id-type="pmid">26633291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR518"><label>518.</label><citation-alternatives><element-citation id="ec-CR518" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Shea</surname><given-names>JJ</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name></person-group><article-title>JAKs and STATs in immunity, immunodeficiency, and cancer</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1202117</pub-id><pub-id pub-id-type="pmid">23301733</pub-id>
</element-citation><mixed-citation id="mc-CR518" publication-type="journal">O&#x02019;Shea, J. J., Holland, S. M. &#x00026; Staudt, L. M. JAKs and STATs in immunity, immunodeficiency, and cancer. <italic>N. Engl. J. Med.</italic><bold>368</bold>, 161&#x02013;170 (2013).<pub-id pub-id-type="pmid">23301733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR519"><label>519.</label><citation-alternatives><element-citation id="ec-CR519" publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>S</given-names></name><etal/></person-group><article-title>JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects</article-title><source>Drugs</source><year>2017</year><volume>77</volume><fpage>521</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0701-9</pub-id><pub-id pub-id-type="pmid">28255960</pub-id>
</element-citation><mixed-citation id="mc-CR519" publication-type="journal">Banerjee, S. et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. <italic>Drugs</italic><bold>77</bold>, 521&#x02013;546 (2017).<pub-id pub-id-type="pmid">28255960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR520"><label>520.</label><citation-alternatives><element-citation id="ec-CR520" publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>J</given-names></name><etal/></person-group><article-title>Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury</article-title><source>FASEB J.</source><year>2006</year><volume>20</volume><fpage>2115</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1096/fj.06-6188fje</pub-id><pub-id pub-id-type="pmid">16935931</pub-id>
</element-citation><mixed-citation id="mc-CR520" publication-type="journal">McCormick, J. et al. Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. <italic>FASEB J.</italic><bold>20</bold>, 2115&#x02013;2117 (2006).<pub-id pub-id-type="pmid">16935931</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR521"><label>521.</label><citation-alternatives><element-citation id="ec-CR521" publication-type="journal"><person-group person-group-type="author"><name><surname>Negoro</surname><given-names>S</given-names></name><etal/></person-group><article-title>Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction</article-title><source>Cardiovasc. Res.</source><year>2000</year><volume>47</volume><fpage>797</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(00)00138-3</pub-id><pub-id pub-id-type="pmid">10974228</pub-id>
</element-citation><mixed-citation id="mc-CR521" publication-type="journal">Negoro, S. et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. <italic>Cardiovasc. Res.</italic><bold>47</bold>, 797&#x02013;805 (2000).<pub-id pub-id-type="pmid">10974228</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR522"><label>522.</label><citation-alternatives><element-citation id="ec-CR522" publication-type="journal"><person-group person-group-type="author"><name><surname>Kunisada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>315</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.1.315</pub-id><pub-id pub-id-type="pmid">10618415</pub-id>
</element-citation><mixed-citation id="mc-CR522" publication-type="journal">Kunisada, K. et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>97</bold>, 315&#x02013;319 (2000).<pub-id pub-id-type="pmid">10618415</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR523"><label>523.</label><citation-alternatives><element-citation id="ec-CR523" publication-type="journal"><person-group person-group-type="author"><name><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name><etal/></person-group><article-title>Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury</article-title><source>Circ. Res.</source><year>2004</year><volume>95</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000134921.50377.61</pub-id><pub-id pub-id-type="pmid">15192020</pub-id>
</element-citation><mixed-citation id="mc-CR523" publication-type="journal">Hilfiker-Kleiner, D. et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. <italic>Circ. Res.</italic><bold>95</bold>, 187&#x02013;195 (2004).<pub-id pub-id-type="pmid">15192020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR524"><label>524.</label><citation-alternatives><element-citation id="ec-CR524" publication-type="journal"><person-group person-group-type="author"><name><surname>Dawn</surname><given-names>B</given-names></name><etal/></person-group><article-title>IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2</article-title><source>Cardiovasc. Res.</source><year>2004</year><volume>64</volume><fpage>61</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2004.05.011</pub-id><pub-id pub-id-type="pmid">15364614</pub-id>
</element-citation><mixed-citation id="mc-CR524" publication-type="journal">Dawn, B. et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. <italic>Cardiovasc. Res.</italic><bold>64</bold>, 61&#x02013;71 (2004).<pub-id pub-id-type="pmid">15364614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR525"><label>525.</label><citation-alternatives><element-citation id="ec-CR525" publication-type="journal"><person-group person-group-type="author"><name><surname>Xuan</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits</article-title><source>Circ. Res.</source><year>1999</year><volume>84</volume><fpage>1095</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1161/01.RES.84.9.1095</pub-id><pub-id pub-id-type="pmid">10325247</pub-id>
</element-citation><mixed-citation id="mc-CR525" publication-type="journal">Xuan, Y. T. et al. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. <italic>Circ. Res.</italic><bold>84</bold>, 1095&#x02013;1109 (1999).<pub-id pub-id-type="pmid">10325247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR526"><label>526.</label><citation-alternatives><element-citation id="ec-CR526" publication-type="journal"><person-group person-group-type="author"><name><surname>Dotan</surname><given-names>I</given-names></name><etal/></person-group><article-title>Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux</article-title><source>Commun. Biol.</source><year>2022</year><volume>5</volume><fpage>132</fpage><pub-id pub-id-type="doi">10.1038/s42003-022-03078-5</pub-id><pub-id pub-id-type="pmid">35169231</pub-id>
</element-citation><mixed-citation id="mc-CR526" publication-type="journal">Dotan, I. et al. Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux. <italic>Commun. Biol.</italic><bold>5</bold>, 132 (2022).<pub-id pub-id-type="pmid">35169231</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR527"><label>527.</label><citation-alternatives><element-citation id="ec-CR527" publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>STAT3/NF&#x02011;kappaB decoy oligodeoxynucleotides inhibit atherosclerosis through regulation of the STAT/NF&#x02011;kappaB signaling pathway in a mouse model of atherosclerosis</article-title><source>Int. J. Mol. Med.</source><year>2023</year><volume>51</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.3892/ijmm.2023.5240</pub-id><pub-id pub-id-type="pmid">37026512</pub-id>
</element-citation><mixed-citation id="mc-CR527" publication-type="journal">An, H. J. et al. STAT3/NF&#x02011;kappaB decoy oligodeoxynucleotides inhibit atherosclerosis through regulation of the STAT/NF&#x02011;kappaB signaling pathway in a mouse model of atherosclerosis. <italic>Int. J. Mol. Med.</italic><bold>51</bold>, 37 (2023).<pub-id pub-id-type="pmid">37026512</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR528"><label>528.</label><citation-alternatives><element-citation id="ec-CR528" publication-type="journal"><person-group person-group-type="author"><name><surname>Dor</surname><given-names>Y</given-names></name><name><surname>Cedar</surname><given-names>H</given-names></name></person-group><article-title>Principles of DNA methylation and their implications for biology and medicine</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>777</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31268-6</pub-id><pub-id pub-id-type="pmid">30100054</pub-id>
</element-citation><mixed-citation id="mc-CR528" publication-type="journal">Dor, Y. &#x00026; Cedar, H. Principles of DNA methylation and their implications for biology and medicine. <italic>Lancet</italic><bold>392</bold>, 777&#x02013;786 (2018).<pub-id pub-id-type="pmid">30100054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR529"><label>529.</label><citation-alternatives><element-citation id="ec-CR529" publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>LD</given-names></name><name><surname>Le</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name></person-group><article-title>DNA methylation and its basic function</article-title><source>Neuropsychopharmacology</source><year>2013</year><volume>38</volume><fpage>23</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/npp.2012.112</pub-id><pub-id pub-id-type="pmid">22781841</pub-id>
</element-citation><mixed-citation id="mc-CR529" publication-type="journal">Moore, L. D., Le, T. &#x00026; Fan, G. DNA methylation and its basic function. <italic>Neuropsychopharmacology</italic><bold>38</bold>, 23&#x02013;38 (2013).<pub-id pub-id-type="pmid">22781841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR530"><label>530.</label><citation-alternatives><element-citation id="ec-CR530" publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Enhanced CD19 activity in B cells contributes to immunodeficiency in mice deficient in the ICF syndrome gene Zbtb24</article-title><source>Cell Mol. Immunol.</source><year>2023</year><volume>20</volume><fpage>1487</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-01106-w</pub-id><pub-id pub-id-type="pmid">37990035</pub-id>
</element-citation><mixed-citation id="mc-CR530" publication-type="journal">Ying, Z. et al. Enhanced CD19 activity in B cells contributes to immunodeficiency in mice deficient in the ICF syndrome gene Zbtb24. <italic>Cell Mol. Immunol.</italic><bold>20</bold>, 1487&#x02013;1498 (2023).<pub-id pub-id-type="pmid">37990035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR531"><label>531.</label><citation-alternatives><element-citation id="ec-CR531" publication-type="journal"><person-group person-group-type="author"><name><surname>Cardenas</surname><given-names>A</given-names></name><name><surname>Fadadu</surname><given-names>R</given-names></name><name><surname>Bunyavanich</surname><given-names>S</given-names></name></person-group><article-title>Climate change and epigenetic biomarkers in allergic and airway diseases</article-title><source>J. Allergy Clin. Immunol.</source><year>2023</year><volume>152</volume><fpage>1060</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2023.09.011</pub-id><pub-id pub-id-type="pmid">37741554</pub-id>
</element-citation><mixed-citation id="mc-CR531" publication-type="journal">Cardenas, A., Fadadu, R. &#x00026; Bunyavanich, S. Climate change and epigenetic biomarkers in allergic and airway diseases. <italic>J. Allergy Clin. Immunol.</italic><bold>152</bold>, 1060&#x02013;1072 (2023).<pub-id pub-id-type="pmid">37741554</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR532"><label>532.</label><citation-alternatives><element-citation id="ec-CR532" publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Garcia</surname><given-names>J</given-names></name><name><surname>Cardenas</surname><given-names>A</given-names></name><name><surname>Lorenzo-Diaz</surname><given-names>F</given-names></name><name><surname>Pino-Yanes</surname><given-names>M</given-names></name></person-group><article-title>Precision medicine for asthma treatment: Unlocking the potential of the epigenome and microbiome</article-title><source>J. Allergy Clin. Immunol.</source><year>2024</year><volume>S0091-6749</volume><fpage>00634</fpage><lpage>1</lpage></element-citation><mixed-citation id="mc-CR532" publication-type="journal">Perez-Garcia, J., Cardenas, A., Lorenzo-Diaz, F. &#x00026; Pino-Yanes, M. Precision medicine for asthma treatment: Unlocking the potential of the epigenome and microbiome. <italic>J. Allergy Clin. Immunol.</italic><bold>S0091-6749</bold>, 00634&#x02013;1 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR533"><label>533.</label><citation-alternatives><element-citation id="ec-CR533" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association of cardiovascular health through young adulthood with genome-wide DNA methylation patterns in midlife: the CARDIA study</article-title><source>Circulation</source><year>2022</year><volume>146</volume><fpage>94</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.055484</pub-id><pub-id pub-id-type="pmid">35652342</pub-id>
</element-citation><mixed-citation id="mc-CR533" publication-type="journal">Zheng, Y. et al. Association of cardiovascular health through young adulthood with genome-wide DNA methylation patterns in midlife: the CARDIA study. <italic>Circulation</italic><bold>146</bold>, 94&#x02013;109 (2022).<pub-id pub-id-type="pmid">35652342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR534"><label>534.</label><citation-alternatives><element-citation id="ec-CR534" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsova</surname><given-names>T</given-names></name><name><surname>Prange</surname><given-names>KHM</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>de Winther</surname><given-names>MPJ</given-names></name></person-group><article-title>Transcriptional and epigenetic regulation of macrophages in atherosclerosis</article-title><source>Nat. Rev. Cardiol.</source><year>2020</year><volume>17</volume><fpage>216</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/s41569-019-0265-3</pub-id><pub-id pub-id-type="pmid">31578516</pub-id>
</element-citation><mixed-citation id="mc-CR534" publication-type="journal">Kuznetsova, T., Prange, K. H. M., Glass, C. K. &#x00026; de Winther, M. P. J. Transcriptional and epigenetic regulation of macrophages in atherosclerosis. <italic>Nat. Rev. Cardiol.</italic><bold>17</bold>, 216&#x02013;228 (2020).<pub-id pub-id-type="pmid">31578516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR535"><label>535.</label><citation-alternatives><element-citation id="ec-CR535" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CP</given-names></name><name><surname>Su</surname><given-names>YC</given-names></name><name><surname>Hu</surname><given-names>CW</given-names></name><name><surname>Lei</surname><given-names>HY</given-names></name></person-group><article-title>TLR2-dependent selective autophagy regulates NF-&#x003ba;B lysosomal degradation in hepatoma-derived M2 macrophage differentiation</article-title><source>Cell Death Differ.</source><year>2013</year><volume>20</volume><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1038/cdd.2012.146</pub-id><pub-id pub-id-type="pmid">23175187</pub-id>
</element-citation><mixed-citation id="mc-CR535" publication-type="journal">Chang, C. P., Su, Y. C., Hu, C. W. &#x00026; Lei, H. Y. TLR2-dependent selective autophagy regulates NF-&#x003ba;B lysosomal degradation in hepatoma-derived M2 macrophage differentiation. <italic>Cell Death Differ.</italic><bold>20</bold>, 515&#x02013;523 (2013).<pub-id pub-id-type="pmid">23175187</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR536"><label>536.</label><citation-alternatives><element-citation id="ec-CR536" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><etal/></person-group><article-title>DNA methyltransferase 1 deficiency improves macrophage motility and wound healing by ameliorating cholesterol accumulation</article-title><source>NPJ Regen. Med.</source><year>2023</year><volume>8</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1038/s41536-023-00306-2</pub-id><pub-id pub-id-type="pmid">37291182</pub-id>
</element-citation><mixed-citation id="mc-CR536" publication-type="journal">Zhao, C. et al. DNA methyltransferase 1 deficiency improves macrophage motility and wound healing by ameliorating cholesterol accumulation. <italic>NPJ Regen. Med.</italic><bold>8</bold>, 29 (2023).<pub-id pub-id-type="pmid">37291182</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR537"><label>537.</label><citation-alternatives><element-citation id="ec-CR537" publication-type="journal"><person-group person-group-type="author"><name><surname>Mill&#x000e1;n-Zambrano</surname><given-names>G</given-names></name><name><surname>Burton</surname><given-names>A</given-names></name><name><surname>Bannister</surname><given-names>AJ</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name></person-group><article-title>Histone post-translational modifications - cause and consequence of genome function</article-title><source>Nat. Rev. Genet.</source><year>2022</year><volume>23</volume><fpage>563</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/s41576-022-00468-7</pub-id><pub-id pub-id-type="pmid">35338361</pub-id>
</element-citation><mixed-citation id="mc-CR537" publication-type="journal">Mill&#x000e1;n-Zambrano, G., Burton, A., Bannister, A. J. &#x00026; Schneider, R. Histone post-translational modifications - cause and consequence of genome function. <italic>Nat. Rev. Genet.</italic><bold>23</bold>, 563&#x02013;580 (2022).<pub-id pub-id-type="pmid">35338361</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR538"><label>538.</label><citation-alternatives><element-citation id="ec-CR538" publication-type="journal"><person-group person-group-type="author"><name><surname>Bannister</surname><given-names>AJ</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><article-title>Regulation of chromatin by histone modifications</article-title><source>Cell Res.</source><year>2011</year><volume>21</volume><fpage>381</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1038/cr.2011.22</pub-id><pub-id pub-id-type="pmid">21321607</pub-id>
</element-citation><mixed-citation id="mc-CR538" publication-type="journal">Bannister, A. J. &#x00026; Kouzarides, T. Regulation of chromatin by histone modifications. <italic>Cell Res.</italic><bold>21</bold>, 381&#x02013;395 (2011).<pub-id pub-id-type="pmid">21321607</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR539"><label>539.</label><citation-alternatives><element-citation id="ec-CR539" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Id2 epigenetically controls CD8(+) T-cell exhaustion by disrupting the assembly of the Tcf3-LSD1 complex</article-title><source>Cell Mol. Immunol.</source><year>2024</year><volume>21</volume><fpage>292</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-01118-6</pub-id><pub-id pub-id-type="pmid">38287103</pub-id>
</element-citation><mixed-citation id="mc-CR539" publication-type="journal">Li, Y. et al. Id2 epigenetically controls CD8(+) T-cell exhaustion by disrupting the assembly of the Tcf3-LSD1 complex. <italic>Cell Mol. Immunol.</italic><bold>21</bold>, 292&#x02013;308 (2024).<pub-id pub-id-type="pmid">38287103</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR540"><label>540.</label><citation-alternatives><element-citation id="ec-CR540" publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>MME</given-names></name><etal/></person-group><article-title>Trained immunity is regulated by T cell-induced CD40-TRAF6 signaling</article-title><source>Cell Rep.</source><year>2024</year><volume>43</volume><fpage>114664</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114664</pub-id><pub-id pub-id-type="pmid">39178113</pub-id>
</element-citation><mixed-citation id="mc-CR540" publication-type="journal">Jacobs, M. M. E. et al. Trained immunity is regulated by T cell-induced CD40-TRAF6 signaling. <italic>Cell Rep.</italic><bold>43</bold>, 114664 (2024).<pub-id pub-id-type="pmid">39178113</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR541"><label>541.</label><citation-alternatives><element-citation id="ec-CR541" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><etal/></person-group><article-title>Histone lactylation boosts reparative gene activation post-myocardial infarction</article-title><source>Circ. Res.</source><year>2022</year><volume>131</volume><fpage>893</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.320488</pub-id><pub-id pub-id-type="pmid">36268709</pub-id>
</element-citation><mixed-citation id="mc-CR541" publication-type="journal">Wang, N. et al. Histone lactylation boosts reparative gene activation post-myocardial infarction. <italic>Circ. Res.</italic><bold>131</bold>, 893&#x02013;908 (2022).<pub-id pub-id-type="pmid">36268709</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR542"><label>542.</label><citation-alternatives><element-citation id="ec-CR542" publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction</article-title><source>EBioMedicine</source><year>2022</year><volume>82</volume><fpage>104139</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104139</pub-id><pub-id pub-id-type="pmid">35810562</pub-id>
</element-citation><mixed-citation id="mc-CR542" publication-type="journal">Lan, C. et al. Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction. <italic>EBioMedicine</italic><bold>82</bold>, 104139 (2022).<pub-id pub-id-type="pmid">35810562</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR543"><label>543.</label><citation-alternatives><element-citation id="ec-CR543" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Targeting NPM1 epigenetically promotes postinfarction cardiac repair by reprogramming reparative macrophage metabolism</article-title><source>Circulation</source><year>2024</year><volume>149</volume><fpage>1982</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.123.065506</pub-id><pub-id pub-id-type="pmid">38390737</pub-id>
</element-citation><mixed-citation id="mc-CR543" publication-type="journal">Zhang, S. et al. Targeting NPM1 epigenetically promotes postinfarction cardiac repair by reprogramming reparative macrophage metabolism. <italic>Circulation</italic><bold>149</bold>, 1982&#x02013;2001 (2024).<pub-id pub-id-type="pmid">38390737</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR544"><label>544.</label><citation-alternatives><element-citation id="ec-CR544" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeksema</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions</article-title><source>EMBO Mol. Med.</source><year>2014</year><volume>6</volume><fpage>1124</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.15252/emmm.201404170</pub-id><pub-id pub-id-type="pmid">25007801</pub-id>
</element-citation><mixed-citation id="mc-CR544" publication-type="journal">Hoeksema, M. A. et al. Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. <italic>EMBO Mol. Med.</italic><bold>6</bold>, 1124&#x02013;1132 (2014).<pub-id pub-id-type="pmid">25007801</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR545"><label>545.</label><mixed-citation publication-type="other">Vlad, M. L. et al. Histone acetyltransferase-dependent pathways mediate upregulation of NADPH oxidase 5 in human macrophages under inflammatory conditions: a potential mechanism of reactive oxygen species overproduction in atherosclerosis. <italic>Oxid. Med. Cell Longev.</italic><bold>2019</bold>, 3201062 (2019).</mixed-citation></ref><ref id="CR546"><label>546.</label><citation-alternatives><element-citation id="ec-CR546" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>LNCGM1082-mediated NLRC4 activation drives resistance to bacterial infection</article-title><source>Cell Mol. Immunol.</source><year>2023</year><volume>20</volume><fpage>475</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-00995-1</pub-id><pub-id pub-id-type="pmid">36941318</pub-id>
</element-citation><mixed-citation id="mc-CR546" publication-type="journal">Gao, Y. et al. LNCGM1082-mediated NLRC4 activation drives resistance to bacterial infection. <italic>Cell Mol. Immunol.</italic><bold>20</bold>, 475&#x02013;488 (2023).<pub-id pub-id-type="pmid">36941318</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR547"><label>547.</label><citation-alternatives><element-citation id="ec-CR547" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>An enhancer RNA recruits KMT2A to regulate transcription of Myb</article-title><source>Cell Rep.</source><year>2024</year><volume>43</volume><fpage>114378</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114378</pub-id><pub-id pub-id-type="pmid">38889007</pub-id>
</element-citation><mixed-citation id="mc-CR547" publication-type="journal">Kim, J., et al. An enhancer RNA recruits KMT2A to regulate transcription of Myb. <italic>Cell Rep.</italic><bold>43</bold>, 114378 (2024).<pub-id pub-id-type="pmid">38889007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR548"><label>548.</label><citation-alternatives><element-citation id="ec-CR548" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The NF-&#x003ba;B-responsive long noncoding RNA FIRRE regulates posttranscriptional regulation of inflammatory gene expression through interacting with hnRNPU</article-title><source>J. Immunol.</source><year>2017</year><volume>199</volume><fpage>3571</fpage><lpage>3582</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700091</pub-id><pub-id pub-id-type="pmid">28993514</pub-id>
</element-citation><mixed-citation id="mc-CR548" publication-type="journal">Lu, Y. et al. The NF-&#x003ba;B-responsive long noncoding RNA FIRRE regulates posttranscriptional regulation of inflammatory gene expression through interacting with hnRNPU. <italic>J. Immunol.</italic><bold>199</bold>, 3571&#x02013;3582 (2017).<pub-id pub-id-type="pmid">28993514</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR549"><label>549.</label><citation-alternatives><element-citation id="ec-CR549" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>A novel piwi-interacting RNA associates with type 2-high asthma phenotypes</article-title><source>J. Allergy Clin. Immunol.</source><year>2024</year><volume>153</volume><fpage>695</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2023.10.032</pub-id><pub-id pub-id-type="pmid">38056635</pub-id>
</element-citation><mixed-citation id="mc-CR549" publication-type="journal">Li, J. et al. A novel piwi-interacting RNA associates with type 2-high asthma phenotypes. <italic>J. Allergy Clin. Immunol.</italic><bold>153</bold>, 695&#x02013;704 (2024).<pub-id pub-id-type="pmid">38056635</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR550"><label>550.</label><citation-alternatives><element-citation id="ec-CR550" publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>K</given-names></name><name><surname>Bayraktar</surname><given-names>R</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name></person-group><article-title>Non-coding RNAs in disease: from mechanisms to therapeutics</article-title><source>Nat. Rev. Genet.</source><year>2024</year><volume>25</volume><fpage>211</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1038/s41576-023-00662-1</pub-id><pub-id pub-id-type="pmid">37968332</pub-id>
</element-citation><mixed-citation id="mc-CR550" publication-type="journal">Nemeth, K., Bayraktar, R., Ferracin, M. &#x00026; Calin, G. A. Non-coding RNAs in disease: from mechanisms to therapeutics. <italic>Nat. Rev. Genet.</italic><bold>25</bold>, 211&#x02013;232 (2024).<pub-id pub-id-type="pmid">37968332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR551"><label>551.</label><citation-alternatives><element-citation id="ec-CR551" publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>CPC</given-names></name><etal/></person-group><article-title>Regulatory RNAs in heart failure</article-title><source>Circulation</source><year>2020</year><volume>141</volume><fpage>313</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.042474</pub-id><pub-id pub-id-type="pmid">31986093</pub-id>
</element-citation><mixed-citation id="mc-CR551" publication-type="journal">Gomes, C. P. C. et al. Regulatory RNAs in heart failure. <italic>Circulation</italic><bold>141</bold>, 313&#x02013;328 (2020).<pub-id pub-id-type="pmid">31986093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR552"><label>552.</label><citation-alternatives><element-citation id="ec-CR552" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Silencing of H19 inhibits the adipogenesis and inflammation response in ox-LDL-treated Raw264.7 cells by up-regulating miR-130b</article-title><source>Mol. Immunol.</source><year>2018</year><volume>93</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2017.11.017</pub-id><pub-id pub-id-type="pmid">29172088</pub-id>
</element-citation><mixed-citation id="mc-CR552" publication-type="journal">Han, Y., Ma, J., Wang, J. &#x00026; Wang, L. Silencing of H19 inhibits the adipogenesis and inflammation response in ox-LDL-treated Raw264.7 cells by up-regulating miR-130b. <italic>Mol. Immunol.</italic><bold>93</bold>, 107&#x02013;114 (2018).<pub-id pub-id-type="pmid">29172088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR553"><label>553.</label><citation-alternatives><element-citation id="ec-CR553" publication-type="journal"><person-group person-group-type="author"><name><surname>Fasolo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization</article-title><source>Circulation</source><year>2021</year><volume>144</volume><fpage>1567</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.052023</pub-id><pub-id pub-id-type="pmid">34647815</pub-id>
</element-citation><mixed-citation id="mc-CR553" publication-type="journal">Fasolo, F. et al. Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization. <italic>Circulation</italic><bold>144</bold>, 1567&#x02013;1583 (2021).<pub-id pub-id-type="pmid">34647815</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR554"><label>554.</label><mixed-citation publication-type="other">Shin, J. J. et al. Roles of lncRNAs in NF-&#x003ba;B-mediated macrophage inflammation and their implications in the pathogenesis of human diseases. <italic>Int. J. Mol. Sci</italic>. <bold>25</bold>, 2670 (2024).</mixed-citation></ref><ref id="CR555"><label>555.</label><citation-alternatives><element-citation id="ec-CR555" publication-type="journal"><person-group person-group-type="author"><name><surname>Cynn</surname><given-names>E</given-names></name><etal/></person-group><article-title>Human macrophage long intergenic noncoding RNA, SIMALR, suppresses inflammatory macrophage apoptosis via NTN1 (Netrin-1)</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2023</year><volume>43</volume><fpage>286</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.122.318353</pub-id><pub-id pub-id-type="pmid">36546321</pub-id>
</element-citation><mixed-citation id="mc-CR555" publication-type="journal">Cynn, E. et al. Human macrophage long intergenic noncoding RNA, SIMALR, suppresses inflammatory macrophage apoptosis via NTN1 (Netrin-1). <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>43</bold>, 286&#x02013;299 (2023).<pub-id pub-id-type="pmid">36546321</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR556"><label>556.</label><citation-alternatives><element-citation id="ec-CR556" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>LncRNA CCRR attenuates postmyocardial infarction inflammatory response by inhibiting the TLR signalling pathway</article-title><source>Can. J. Cardiol.</source><year>2024</year><volume>40</volume><fpage>710</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2023.12.003</pub-id><pub-id pub-id-type="pmid">38081511</pub-id>
</element-citation><mixed-citation id="mc-CR556" publication-type="journal">Wang, S. et al. LncRNA CCRR attenuates postmyocardial infarction inflammatory response by inhibiting the TLR signalling pathway. <italic>Can. J. Cardiol.</italic><bold>40</bold>, 710&#x02013;725 (2024).<pub-id pub-id-type="pmid">38081511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR557"><label>557.</label><citation-alternatives><element-citation id="ec-CR557" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramanujam</surname><given-names>D</given-names></name><etal/></person-group><article-title>MicroRNA-21-dependent macrophage-to-fibroblast signaling determines the cardiac response to pressure overload</article-title><source>Circulation</source><year>2021</year><volume>143</volume><fpage>1513</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.050682</pub-id><pub-id pub-id-type="pmid">33550817</pub-id>
</element-citation><mixed-citation id="mc-CR557" publication-type="journal">Ramanujam, D. et al. MicroRNA-21-dependent macrophage-to-fibroblast signaling determines the cardiac response to pressure overload. <italic>Circulation</italic><bold>143</bold>, 1513&#x02013;1525 (2021).<pub-id pub-id-type="pmid">33550817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR558"><label>558.</label><citation-alternatives><element-citation id="ec-CR558" publication-type="journal"><person-group person-group-type="author"><name><surname>Nosalski</surname><given-names>R</given-names></name><etal/></person-group><article-title>T-cell-derived miRNA-214 mediates perivascular fibrosis in hypertension</article-title><source>Circ. Res.</source><year>2020</year><volume>126</volume><fpage>988</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.315428</pub-id><pub-id pub-id-type="pmid">32065054</pub-id>
</element-citation><mixed-citation id="mc-CR558" publication-type="journal">Nosalski, R. et al. T-cell-derived miRNA-214 mediates perivascular fibrosis in hypertension. <italic>Circ. Res.</italic><bold>126</bold>, 988&#x02013;1003 (2020).<pub-id pub-id-type="pmid">32065054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR559"><label>559.</label><citation-alternatives><element-citation id="ec-CR559" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4</article-title><source>Cardiovasc. Res.</source><year>2020</year><volume>116</volume><fpage>1323</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvz215</pub-id><pub-id pub-id-type="pmid">31397837</pub-id>
</element-citation><mixed-citation id="mc-CR559" publication-type="journal">Li, H. et al. Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4. <italic>Cardiovasc. Res.</italic><bold>116</bold>, 1323&#x02013;1334 (2020).<pub-id pub-id-type="pmid">31397837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR560"><label>560.</label><citation-alternatives><element-citation id="ec-CR560" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>CircUbe3a from M2 macrophage-derived small extracellular vesicles mediates myocardial fibrosis after acute myocardial infarction</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>6315</fpage><lpage>6333</lpage><pub-id pub-id-type="doi">10.7150/thno.52843</pub-id><pub-id pub-id-type="pmid">33995660</pub-id>
</element-citation><mixed-citation id="mc-CR560" publication-type="journal">Wang, Y. et al. CircUbe3a from M2 macrophage-derived small extracellular vesicles mediates myocardial fibrosis after acute myocardial infarction. <italic>Theranostics</italic><bold>11</bold>, 6315&#x02013;6333 (2021).<pub-id pub-id-type="pmid">33995660</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR561"><label>561.</label><citation-alternatives><element-citation id="ec-CR561" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The RNA m(6)A demethylase ALKBH5 drives emergency granulopoiesis and neutrophil mobilization by upregulating G-CSFR expression</article-title><source>Cell Mol. Immunol.</source><year>2024</year><volume>21</volume><fpage>6</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-01115-9</pub-id><pub-id pub-id-type="pmid">38114747</pub-id>
</element-citation><mixed-citation id="mc-CR561" publication-type="journal">Liu, Y. et al. The RNA m(6)A demethylase ALKBH5 drives emergency granulopoiesis and neutrophil mobilization by upregulating G-CSFR expression. <italic>Cell Mol. Immunol.</italic><bold>21</bold>, 6&#x02013;18 (2024).<pub-id pub-id-type="pmid">38114747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR562"><label>562.</label><citation-alternatives><element-citation id="ec-CR562" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><etal/></person-group><article-title>TMK4-mediated FIP37 phosphorylation regulates auxin-triggered N(6)-methyladenosine modification of auxin biosynthetic genes in Arabidopsis</article-title><source>Cell Rep.</source><year>2024</year><volume>43</volume><fpage>114597</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114597</pub-id><pub-id pub-id-type="pmid">39106180</pub-id>
</element-citation><mixed-citation id="mc-CR562" publication-type="journal">Li, B. et al. TMK4-mediated FIP37 phosphorylation regulates auxin-triggered N(6)-methyladenosine modification of auxin biosynthetic genes in Arabidopsis. <italic>Cell Rep.</italic><bold>43</bold>, 114597 (2024).<pub-id pub-id-type="pmid">39106180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR563"><label>563.</label><citation-alternatives><element-citation id="ec-CR563" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>RNA modification in cardiovascular disease: implications for therapeutic interventions</article-title><source>Signal Transduct. Target Ther.</source><year>2023</year><volume>8</volume><fpage>412</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01638-7</pub-id><pub-id pub-id-type="pmid">37884527</pub-id>
</element-citation><mixed-citation id="mc-CR563" publication-type="journal">Wang, C. et al. RNA modification in cardiovascular disease: implications for therapeutic interventions. <italic>Signal Transduct. Target Ther.</italic><bold>8</bold>, 412 (2023).<pub-id pub-id-type="pmid">37884527</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR564"><label>564.</label><citation-alternatives><element-citation id="ec-CR564" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L</given-names></name><etal/></person-group><article-title>RNA modifications: importance in immune cell biology and related diseases</article-title><source>Signal Transduct. Target Ther.</source><year>2022</year><volume>7</volume><fpage>334</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-01175-9</pub-id><pub-id pub-id-type="pmid">36138023</pub-id>
</element-citation><mixed-citation id="mc-CR564" publication-type="journal">Cui, L. et al. RNA modifications: importance in immune cell biology and related diseases. <italic>Signal Transduct. Target Ther.</italic><bold>7</bold>, 334 (2022).<pub-id pub-id-type="pmid">36138023</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR565"><label>565.</label><citation-alternatives><element-citation id="ec-CR565" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>MM</given-names></name></person-group><article-title>RNA modification in the immune system</article-title><source>Annu. Rev. Immunol.</source><year>2023</year><volume>41</volume><fpage>73</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-101921-045401</pub-id><pub-id pub-id-type="pmid">37126422</pub-id>
</element-citation><mixed-citation id="mc-CR565" publication-type="journal">Han, D. &#x00026; Xu, M. M. RNA modification in the immune system. <italic>Annu. Rev. Immunol.</italic><bold>41</bold>, 73&#x02013;98 (2023).<pub-id pub-id-type="pmid">37126422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR566"><label>566.</label><citation-alternatives><element-citation id="ec-CR566" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Dendritic cells with METTL3 gene knockdown exhibit immature properties and prolong allograft survival</article-title><source>Genes Immun.</source><year>2020</year><volume>21</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1038/s41435-020-0099-3</pub-id><pub-id pub-id-type="pmid">32457372</pub-id>
</element-citation><mixed-citation id="mc-CR566" publication-type="journal">Wu, H. et al. Dendritic cells with METTL3 gene knockdown exhibit immature properties and prolong allograft survival. <italic>Genes Immun.</italic><bold>21</bold>, 193&#x02013;202 (2020).<pub-id pub-id-type="pmid">32457372</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR567"><label>567.</label><citation-alternatives><element-citation id="ec-CR567" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Low RNA stability signifies increased post-transcriptional regulation of cell identity genes</article-title><source>Nucleic Acids Res.</source><year>2023</year><volume>51</volume><fpage>6020</fpage><lpage>6038</lpage><pub-id pub-id-type="doi">10.1093/nar/gkad300</pub-id><pub-id pub-id-type="pmid">37125636</pub-id>
</element-citation><mixed-citation id="mc-CR567" publication-type="journal">Li, Y. et al. Low RNA stability signifies increased post-transcriptional regulation of cell identity genes. <italic>Nucleic Acids Res.</italic><bold>51</bold>, 6020&#x02013;6038 (2023).<pub-id pub-id-type="pmid">37125636</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR568"><label>568.</label><citation-alternatives><element-citation id="ec-CR568" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>METTL3 (Methyltransferase Like 3)-dependent N6-methyladenosine modification on braf mRNA promotes macrophage inflammatory response and atherosclerosis in mice</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2023</year><volume>43</volume><fpage>755</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.122.318451</pub-id><pub-id pub-id-type="pmid">36951060</pub-id>
</element-citation><mixed-citation id="mc-CR568" publication-type="journal">Li, Q. et al. METTL3 (Methyltransferase Like 3)-dependent N6-methyladenosine modification on braf mRNA promotes macrophage inflammatory response and atherosclerosis in mice. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>43</bold>, 755&#x02013;773 (2023).<pub-id pub-id-type="pmid">36951060</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR569"><label>569.</label><citation-alternatives><element-citation id="ec-CR569" publication-type="journal"><person-group person-group-type="author"><name><surname>Jian</surname><given-names>D</given-names></name><etal/></person-group><article-title>METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>8939</fpage><lpage>8956</lpage><pub-id pub-id-type="doi">10.7150/thno.45178</pub-id><pub-id pub-id-type="pmid">32802173</pub-id>
</element-citation><mixed-citation id="mc-CR569" publication-type="journal">Jian, D. et al. METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications. <italic>Theranostics</italic><bold>10</bold>, 8939&#x02013;8956 (2020).<pub-id pub-id-type="pmid">32802173</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR570"><label>570.</label><citation-alternatives><element-citation id="ec-CR570" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-&#x003ba;B/IL-6 signaling pathway</article-title><source>Cell Mol. Life Sci.</source><year>2022</year><volume>79</volume><fpage>311</fpage><pub-id pub-id-type="doi">10.1007/s00018-022-04331-0</pub-id><pub-id pub-id-type="pmid">35598196</pub-id>
</element-citation><mixed-citation id="mc-CR570" publication-type="journal">Zheng, Y. et al. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-&#x003ba;B/IL-6 signaling pathway. <italic>Cell Mol. Life Sci.</italic><bold>79</bold>, 311 (2022).<pub-id pub-id-type="pmid">35598196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR571"><label>571.</label><citation-alternatives><element-citation id="ec-CR571" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>PF</given-names></name><etal/></person-group><article-title>m6A regulator-mediated RNA methylation modification patterns are involved in the regulation of the immune microenvironment in ischaemic cardiomyopathy</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><fpage>5904</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-32919-4</pub-id><pub-id pub-id-type="pmid">37041267</pub-id>
</element-citation><mixed-citation id="mc-CR571" publication-type="journal">Zheng, P. F., et al. m6A regulator-mediated RNA methylation modification patterns are involved in the regulation of the immune microenvironment in ischaemic cardiomyopathy. <italic>Sci. Rep.</italic><bold>13</bold>, 5904 (2023).<pub-id pub-id-type="pmid">37041267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR572"><label>572.</label><citation-alternatives><element-citation id="ec-CR572" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>HNEAP regulates necroptosis of cardiomyocytes by suppressing the m(5) C methylation of Atf7 mRNA</article-title><source>Adv. Sci.</source><year>2023</year><volume>10</volume><fpage>e2304329</fpage><pub-id pub-id-type="doi">10.1002/advs.202304329</pub-id></element-citation><mixed-citation id="mc-CR572" publication-type="journal">Wang, K. et al. HNEAP regulates necroptosis of cardiomyocytes by suppressing the m(5) C methylation of Atf7 mRNA. <italic>Adv. Sci.</italic><bold>10</bold>, e2304329 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR573"><label>573.</label><citation-alternatives><element-citation id="ec-CR573" publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>J</given-names></name><etal/></person-group><article-title>TGM1/3-mediated transamidation of Exo70 promotes tumor metastasis upon LKB1 inactivation</article-title><source>Cell Rep.</source><year>2024</year><volume>43</volume><fpage>114604</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114604</pub-id><pub-id pub-id-type="pmid">39146185</pub-id>
</element-citation><mixed-citation id="mc-CR573" publication-type="journal">Hou, J., et al. TGM1/3-mediated transamidation of Exo70 promotes tumor metastasis upon LKB1 inactivation. <italic>Cell Rep.</italic><bold>43</bold>, 114604 (2024).<pub-id pub-id-type="pmid">39146185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR574"><label>574.</label><citation-alternatives><element-citation id="ec-CR574" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name></person-group><article-title>SENP6 restricts the IFN-I-induced signaling pathway and antiviral activity by deSUMOylating USP8</article-title><source>Cell Mol. Immunol.</source><year>2024</year><volume>21</volume><fpage>892</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1038/s41423-024-01193-3</pub-id><pub-id pub-id-type="pmid">38906982</pub-id>
</element-citation><mixed-citation id="mc-CR574" publication-type="journal">Guo, J., Zheng, H. &#x00026; Xiong, S. SENP6 restricts the IFN-I-induced signaling pathway and antiviral activity by deSUMOylating USP8. <italic>Cell Mol. Immunol.</italic><bold>21</bold>, 892&#x02013;904 (2024).<pub-id pub-id-type="pmid">38906982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR575"><label>575.</label><citation-alternatives><element-citation id="ec-CR575" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><article-title>Post-translational modification control of innate immunity</article-title><source>Immunity</source><year>2016</year><volume>45</volume><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.06.020</pub-id><pub-id pub-id-type="pmid">27438764</pub-id>
</element-citation><mixed-citation id="mc-CR575" publication-type="journal">Liu, J., Qian, C. &#x00026; Cao, X. Post-translational modification control of innate immunity. <italic>Immunity</italic><bold>45</bold>, 15&#x02013;30 (2016).<pub-id pub-id-type="pmid">27438764</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR576"><label>576.</label><citation-alternatives><element-citation id="ec-CR576" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group><article-title>Unraveling novel strategies: targeting Miz1 for degradation to enhance antiviral defense against influenza A virus</article-title><source>J. Respir. Biol. Transl. Med.</source><year>2024</year><volume>1</volume><fpage>10009</fpage><pub-id pub-id-type="pmid">39086612</pub-id>
</element-citation><mixed-citation id="mc-CR576" publication-type="journal">Xia, B. &#x00026; Zhao, J. Unraveling novel strategies: targeting Miz1 for degradation to enhance antiviral defense against influenza A virus. <italic>J. Respir. Biol. Transl. Med.</italic><bold>1</bold>, 10009 (2024).<pub-id pub-id-type="pmid">39086612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR577"><label>577.</label><citation-alternatives><element-citation id="ec-CR577" publication-type="journal"><person-group person-group-type="author"><name><surname>Taleb</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Molecular regulation of transforming growth factor-&#x003b2;1-induced thioredoxin-interacting protein ubiquitination and proteasomal degradation in lung fibroblasts: implication in pulmonary fibrosis</article-title><source>J. Respir. Biol. Transl. Med.</source><year>2024</year><volume>1</volume><fpage>10002</fpage><pub-id pub-id-type="pmid">38529321</pub-id>
</element-citation><mixed-citation id="mc-CR577" publication-type="journal">Taleb, S. J. et al. Molecular regulation of transforming growth factor-&#x003b2;1-induced thioredoxin-interacting protein ubiquitination and proteasomal degradation in lung fibroblasts: implication in pulmonary fibrosis. <italic>J. Respir. Biol. Transl. Med.</italic><bold>1</bold>, 10002 (2024).<pub-id pub-id-type="pmid">38529321</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR578"><label>578.</label><citation-alternatives><element-citation id="ec-CR578" publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-&#x003ba;B signaling in macrophages</article-title><source>Cell Cycle</source><year>2019</year><volume>18</volume><fpage>2928</fpage><lpage>2938</lpage><pub-id pub-id-type="doi">10.1080/15384101.2019.1662678</pub-id><pub-id pub-id-type="pmid">31496351</pub-id>
</element-citation><mixed-citation id="mc-CR578" publication-type="journal">An, Z. et al. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-&#x003ba;B signaling in macrophages. <italic>Cell Cycle</italic><bold>18</bold>, 2928&#x02013;2938 (2019).<pub-id pub-id-type="pmid">31496351</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR579"><label>579.</label><citation-alternatives><element-citation id="ec-CR579" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway</article-title><source>Cell Death Dis.</source><year>2023</year><volume>14</volume><fpage>419</fpage><pub-id pub-id-type="doi">10.1038/s41419-023-05960-4</pub-id><pub-id pub-id-type="pmid">37443105</pub-id>
</element-citation><mixed-citation id="mc-CR579" publication-type="journal">Yang, B., et al. Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway. <italic>Cell Death Dis.</italic><bold>14</bold>, 419 (2023).<pub-id pub-id-type="pmid">37443105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR580"><label>580.</label><citation-alternatives><element-citation id="ec-CR580" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Macrophage K63-linked ubiquitination of YAP promotes its nuclear localization and exacerbates atherosclerosis</article-title><source>Cell Rep.</source><year>2020</year><volume>32</volume><fpage>107990</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107990</pub-id><pub-id pub-id-type="pmid">32755583</pub-id>
</element-citation><mixed-citation id="mc-CR580" publication-type="journal">Liu, M., et al. Macrophage K63-linked ubiquitination of YAP promotes its nuclear localization and exacerbates atherosclerosis. <italic>Cell Rep.</italic><bold>32</bold>, 107990 (2020).<pub-id pub-id-type="pmid">32755583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR581"><label>581.</label><citation-alternatives><element-citation id="ec-CR581" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>The E3 ubiquitin ligase WWP2 regulates pro-fibrogenic monocyte infiltration and activity in heart fibrosis</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>7375</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-34971-6</pub-id><pub-id pub-id-type="pmid">36450710</pub-id>
</element-citation><mixed-citation id="mc-CR581" publication-type="journal">Chen, H., et al. The E3 ubiquitin ligase WWP2 regulates pro-fibrogenic monocyte infiltration and activity in heart fibrosis. <italic>Nat. Commun.</italic><bold>13</bold>, 7375 (2022).<pub-id pub-id-type="pmid">36450710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR582"><label>582.</label><citation-alternatives><element-citation id="ec-CR582" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>LL</given-names></name><etal/></person-group><article-title>E3 ubiquitin ligase RNF5 attenuates pathological cardiac hypertrophy through STING</article-title><source>Cell Death Dis.</source><year>2022</year><volume>13</volume><fpage>889</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-05231-8</pub-id><pub-id pub-id-type="pmid">36270989</pub-id>
</element-citation><mixed-citation id="mc-CR582" publication-type="journal">Yang, L. L., et al. E3 ubiquitin ligase RNF5 attenuates pathological cardiac hypertrophy through STING. <italic>Cell Death Dis.</italic><bold>13</bold>, 889 (2022).<pub-id pub-id-type="pmid">36270989</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR583"><label>583.</label><citation-alternatives><element-citation id="ec-CR583" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Amor</surname><given-names>M</given-names></name><etal/></person-group><article-title>Interferon-stimulated gene 15 pathway is a novel mediator of endothelial dysfunction and aneurysms development in angiotensin II infused mice through increased oxidative stress</article-title><source>Cardiovasc. Res.</source><year>2022</year><volume>118</volume><fpage>3250</fpage><lpage>3268</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvab321</pub-id><pub-id pub-id-type="pmid">34672341</pub-id>
</element-citation><mixed-citation id="mc-CR583" publication-type="journal">Gonz&#x000e1;lez-Amor, M. et al. Interferon-stimulated gene 15 pathway is a novel mediator of endothelial dysfunction and aneurysms development in angiotensin II infused mice through increased oxidative stress. <italic>Cardiovasc. Res.</italic><bold>118</bold>, 3250&#x02013;3268 (2022).<pub-id pub-id-type="pmid">34672341</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR584"><label>584.</label><citation-alternatives><element-citation id="ec-CR584" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><etal/></person-group><article-title>Local thiamet-G delivery by a thermosensitive hydrogel confers ischemic cardiac repair via myeloid M2-like activation in a STAT6 O-GlcNAcylation-dependent manner</article-title><source>Int. Immunopharmacol.</source><year>2024</year><volume>131</volume><fpage>111883</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2024.111883</pub-id><pub-id pub-id-type="pmid">38503016</pub-id>
</element-citation><mixed-citation id="mc-CR584" publication-type="journal">Zhou, W., et al. Local thiamet-G delivery by a thermosensitive hydrogel confers ischemic cardiac repair via myeloid M2-like activation in a STAT6 O-GlcNAcylation-dependent manner. <italic>Int. Immunopharmacol.</italic><bold>131</bold>, 111883 (2024).<pub-id pub-id-type="pmid">38503016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR585"><label>585.</label><citation-alternatives><element-citation id="ec-CR585" publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatakrishnan</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Molecular signatures of G-protein-coupled receptors</article-title><source>Nature</source><year>2013</year><volume>494</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nature11896</pub-id><pub-id pub-id-type="pmid">23407534</pub-id>
</element-citation><mixed-citation id="mc-CR585" publication-type="journal">Venkatakrishnan, A. J. et al. Molecular signatures of G-protein-coupled receptors. <italic>Nature</italic><bold>494</bold>, 185&#x02013;194 (2013).<pub-id pub-id-type="pmid">23407534</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR586"><label>586.</label><citation-alternatives><element-citation id="ec-CR586" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Fine-tuning GPCR-mediated neuromodulation by biasing signaling through different G protein subunits</article-title><source>Mol. Cell</source><year>2023</year><volume>83</volume><fpage>2540</fpage><lpage>2558.e2512</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2023.06.006</pub-id><pub-id pub-id-type="pmid">37390816</pub-id>
</element-citation><mixed-citation id="mc-CR586" publication-type="journal">Park, J. C. et al. Fine-tuning GPCR-mediated neuromodulation by biasing signaling through different G protein subunits. <italic>Mol. Cell</italic><bold>83</bold>, 2540&#x02013;2558.e2512 (2023).<pub-id pub-id-type="pmid">37390816</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR587"><label>587.</label><citation-alternatives><element-citation id="ec-CR587" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Structural basis of CXC chemokine receptor 2 activation and signalling</article-title><source>Nature</source><year>2020</year><volume>585</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2492-5</pub-id><pub-id pub-id-type="pmid">32610344</pub-id>
</element-citation><mixed-citation id="mc-CR587" publication-type="journal">Liu, K. et al. Structural basis of CXC chemokine receptor 2 activation and signalling. <italic>Nature</italic><bold>585</bold>, 135&#x02013;140 (2020).<pub-id pub-id-type="pmid">32610344</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR588"><label>588.</label><citation-alternatives><element-citation id="ec-CR588" publication-type="journal"><person-group person-group-type="author"><name><surname>Bajpai</surname><given-names>G</given-names></name><etal/></person-group><article-title>Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury</article-title><source>Circ. Res.</source><year>2019</year><volume>124</volume><fpage>263</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.314028</pub-id><pub-id pub-id-type="pmid">30582448</pub-id>
</element-citation><mixed-citation id="mc-CR588" publication-type="journal">Bajpai, G. et al. Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. <italic>Circ. Res.</italic><bold>124</bold>, 263&#x02013;278 (2019).<pub-id pub-id-type="pmid">30582448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR589"><label>589.</label><citation-alternatives><element-citation id="ec-CR589" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Resident cardiac macrophages mediate adaptive myocardial remodeling</article-title><source>Immunity</source><year>2021</year><volume>54</volume><fpage>2072</fpage><lpage>2088.e2077</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.07.003</pub-id><pub-id pub-id-type="pmid">34320366</pub-id>
</element-citation><mixed-citation id="mc-CR589" publication-type="journal">Wong, N. R. et al. Resident cardiac macrophages mediate adaptive myocardial remodeling. <italic>Immunity</italic><bold>54</bold>, 2072&#x02013;2088.e2077 (2021).<pub-id pub-id-type="pmid">34320366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR590"><label>590.</label><citation-alternatives><element-citation id="ec-CR590" publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development</article-title><source>Dev. cell</source><year>2014</year><volume>30</volume><fpage>528</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2014.07.012</pub-id><pub-id pub-id-type="pmid">25203207</pub-id>
</element-citation><mixed-citation id="mc-CR590" publication-type="journal">Klein, K. R. et al. Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development. <italic>Dev. cell</italic><bold>30</bold>, 528&#x02013;540 (2014).<pub-id pub-id-type="pmid">25203207</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR591"><label>591.</label><citation-alternatives><element-citation id="ec-CR591" publication-type="journal"><person-group person-group-type="author"><name><surname>Lill</surname><given-names>NL</given-names></name><name><surname>Sever</surname><given-names>NI</given-names></name></person-group><article-title>Where EGF receptors transmit their signals</article-title><source>Sci. Signal.</source><year>2012</year><volume>5</volume><fpage>pe41</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2003341</pub-id><pub-id pub-id-type="pmid">23012653</pub-id>
</element-citation><mixed-citation id="mc-CR591" publication-type="journal">Lill, N. L. &#x00026; Sever, N. I. Where EGF receptors transmit their signals. <italic>Sci. Signal.</italic><bold>5</bold>, pe41 (2012).<pub-id pub-id-type="pmid">23012653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR592"><label>592.</label><citation-alternatives><element-citation id="ec-CR592" publication-type="journal"><person-group person-group-type="author"><name><surname>Okyere</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Myeloid cell-specific deletion of epidermal growth factor receptor aggravates acute cardiac injury</article-title><source>Clin. Sci.</source><year>2023</year><volume>137</volume><fpage>1513</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1042/CS20230804</pub-id></element-citation><mixed-citation id="mc-CR592" publication-type="journal">Okyere, A. D. et al. Myeloid cell-specific deletion of epidermal growth factor receptor aggravates acute cardiac injury. <italic>Clin. Sci.</italic><bold>137</bold>, 1513&#x02013;1531 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR593"><label>593.</label><citation-alternatives><element-citation id="ec-CR593" publication-type="journal"><person-group person-group-type="author"><name><surname>Korf-Klingebiel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Myeloid-derived growth factor protects against pressure overload-induced heart failure by preserving sarco/endoplasmic reticulum Ca(2+)-ATPase expression in cardiomyocytes</article-title><source>Circulation</source><year>2021</year><volume>144</volume><fpage>1227</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.053365</pub-id><pub-id pub-id-type="pmid">34372689</pub-id>
</element-citation><mixed-citation id="mc-CR593" publication-type="journal">Korf-Klingebiel, M. et al. Myeloid-derived growth factor protects against pressure overload-induced heart failure by preserving sarco/endoplasmic reticulum Ca(2+)-ATPase expression in cardiomyocytes. <italic>Circulation</italic><bold>144</bold>, 1227&#x02013;1240 (2021).<pub-id pub-id-type="pmid">34372689</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR594"><label>594.</label><citation-alternatives><element-citation id="ec-CR594" publication-type="journal"><person-group person-group-type="author"><name><surname>Zeboudj</surname><given-names>L</given-names></name><etal/></person-group><article-title>Selective EGF-receptor inhibition in CD4(+) T Cells Induces anergy and limits atherosclerosis</article-title><source>J. Am. Coll. Cardiol.</source><year>2018</year><volume>71</volume><fpage>160</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.10.084</pub-id><pub-id pub-id-type="pmid">29325640</pub-id>
</element-citation><mixed-citation id="mc-CR594" publication-type="journal">Zeboudj, L. et al. Selective EGF-receptor inhibition in CD4(+) T Cells Induces anergy and limits atherosclerosis. <italic>J. Am. Coll. Cardiol.</italic><bold>71</bold>, 160&#x02013;172 (2018).<pub-id pub-id-type="pmid">29325640</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR595"><label>595.</label><citation-alternatives><element-citation id="ec-CR595" publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>D</given-names></name><etal/></person-group><article-title>Interleukin-35 promotes macrophage survival and improves wound healing after myocardial infarction in mice</article-title><source>Circ. Res.</source><year>2019</year><volume>124</volume><fpage>1323</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.314569</pub-id><pub-id pub-id-type="pmid">30832557</pub-id>
</element-citation><mixed-citation id="mc-CR595" publication-type="journal">Jia, D. et al. Interleukin-35 promotes macrophage survival and improves wound healing after myocardial infarction in mice. <italic>Circ. Res.</italic><bold>124</bold>, 1323&#x02013;1336 (2019).<pub-id pub-id-type="pmid">30832557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR596"><label>596.</label><citation-alternatives><element-citation id="ec-CR596" publication-type="journal"><person-group person-group-type="author"><name><surname>Singla</surname><given-names>B</given-names></name><etal/></person-group><article-title>CD47 activation by thrombospondin-1 in lymphatic endothelial cells suppresses lymphangiogenesis and promotes atherosclerosis</article-title><source>Arterioscler Thromb. Vasc. Biol.</source><year>2023</year><volume>43</volume><fpage>1234</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.122.318904</pub-id><pub-id pub-id-type="pmid">37259865</pub-id>
</element-citation><mixed-citation id="mc-CR596" publication-type="journal">Singla, B. et al. CD47 activation by thrombospondin-1 in lymphatic endothelial cells suppresses lymphangiogenesis and promotes atherosclerosis. <italic>Arterioscler Thromb. Vasc. Biol.</italic><bold>43</bold>, 1234&#x02013;1250 (2023).<pub-id pub-id-type="pmid">37259865</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR597"><label>597.</label><citation-alternatives><element-citation id="ec-CR597" publication-type="journal"><person-group person-group-type="author"><name><surname>Higashi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Insulin-like growth factor-1 receptor deficiency in macrophages accelerates atherosclerosis and induces an unstable plaque phenotype in apolipoprotein E-deficient mice</article-title><source>Circulation</source><year>2016</year><volume>133</volume><fpage>2263</fpage><lpage>2278</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.021805</pub-id><pub-id pub-id-type="pmid">27154724</pub-id>
</element-citation><mixed-citation id="mc-CR597" publication-type="journal">Higashi, Y. et al. Insulin-like growth factor-1 receptor deficiency in macrophages accelerates atherosclerosis and induces an unstable plaque phenotype in apolipoprotein E-deficient mice. <italic>Circulation</italic><bold>133</bold>, 2263&#x02013;2278 (2016).<pub-id pub-id-type="pmid">27154724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR598"><label>598.</label><citation-alternatives><element-citation id="ec-CR598" publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Cationic proteins from eosinophils bind bone morphogenetic protein receptors promoting vascular calcification and atherogenesis</article-title><source>Eur. Heart J.</source><year>2023</year><volume>44</volume><fpage>2763</fpage><lpage>2783</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad262</pub-id><pub-id pub-id-type="pmid">37279475</pub-id>
</element-citation><mixed-citation id="mc-CR598" publication-type="journal">Meng, Z. et al. Cationic proteins from eosinophils bind bone morphogenetic protein receptors promoting vascular calcification and atherogenesis. <italic>Eur. Heart J.</italic><bold>44</bold>, 2763&#x02013;2783 (2023).<pub-id pub-id-type="pmid">37279475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR599"><label>599.</label><citation-alternatives><element-citation id="ec-CR599" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Macrophage Smad3 protects the infarcted heart, stimulating phagocytosis and regulating inflammation</article-title><source>Circ. Res.</source><year>2019</year><volume>125</volume><fpage>55</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.315069</pub-id><pub-id pub-id-type="pmid">31092129</pub-id>
</element-citation><mixed-citation id="mc-CR599" publication-type="journal">Chen, B. et al. Macrophage Smad3 protects the infarcted heart, stimulating phagocytosis and regulating inflammation. <italic>Circ. Res.</italic><bold>125</bold>, 55&#x02013;70 (2019).<pub-id pub-id-type="pmid">31092129</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR600"><label>600.</label><citation-alternatives><element-citation id="ec-CR600" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Myocardial protection by heparin-based coacervate of FGF10</article-title><source>Bioact. Mater.</source><year>2021</year><volume>6</volume><fpage>1867</fpage><lpage>1877</lpage><pub-id pub-id-type="pmid">33336117</pub-id>
</element-citation><mixed-citation id="mc-CR600" publication-type="journal">Wang, Z. et al. Myocardial protection by heparin-based coacervate of FGF10. <italic>Bioact. Mater.</italic><bold>6</bold>, 1867&#x02013;1877 (2021).<pub-id pub-id-type="pmid">33336117</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR601"><label>601.</label><citation-alternatives><element-citation id="ec-CR601" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy</article-title><source>Cell Commun. Signal.</source><year>2023</year><volume>21</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s12964-023-01077-5</pub-id><pub-id pub-id-type="pmid">36918950</pub-id>
</element-citation><mixed-citation id="mc-CR601" publication-type="journal">Shi, S., et al. Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. <italic>Cell Commun. Signal.</italic><bold>21</bold>, 61 (2023).<pub-id pub-id-type="pmid">36918950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR602"><label>602.</label><mixed-citation publication-type="other">Cai, S. et al. Mitochondrial dysfunction in macrophages promotes inflammation and suppresses repair after myocardial infarction. <italic>J. Clin. Invest</italic>. <bold>133</bold>, e159498 (2023).</mixed-citation></ref><ref id="CR603"><label>603.</label><citation-alternatives><element-citation id="ec-CR603" publication-type="journal"><person-group person-group-type="author"><name><surname>Dikalova</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Mitochondrial deacetylase Sirt3 reduces vascular dysfunction and hypertension while Sirt3 depletion in essential hypertension is linked to vascular inflammation and oxidative stress</article-title><source>Circ. Res.</source><year>2020</year><volume>126</volume><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.315767</pub-id><pub-id pub-id-type="pmid">31852393</pub-id>
</element-citation><mixed-citation id="mc-CR603" publication-type="journal">Dikalova, A. E. et al. Mitochondrial deacetylase Sirt3 reduces vascular dysfunction and hypertension while Sirt3 depletion in essential hypertension is linked to vascular inflammation and oxidative stress. <italic>Circ. Res.</italic><bold>126</bold>, 439&#x02013;452 (2020).<pub-id pub-id-type="pmid">31852393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR604"><label>604.</label><citation-alternatives><element-citation id="ec-CR604" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YP</given-names></name><name><surname>Lei</surname><given-names>QY</given-names></name></person-group><article-title>Metabolite sensing and signaling in cell metabolism</article-title><source>Signal. Transduct. Target Ther.</source><year>2018</year><volume>3</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1038/s41392-018-0024-7</pub-id><pub-id pub-id-type="pmid">30416760</pub-id>
</element-citation><mixed-citation id="mc-CR604" publication-type="journal">Wang, Y. P. &#x00026; Lei, Q. Y. Metabolite sensing and signaling in cell metabolism. <italic>Signal. Transduct. Target Ther.</italic><bold>3</bold>, 30 (2018).<pub-id pub-id-type="pmid">30416760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR605"><label>605.</label><citation-alternatives><element-citation id="ec-CR605" publication-type="journal"><person-group person-group-type="author"><name><surname>Bekkering</surname><given-names>S</given-names></name><etal/></person-group><article-title>Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo</article-title><source>Atherosclerosis</source><year>2016</year><volume>254</volume><fpage>228</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.10.019</pub-id><pub-id pub-id-type="pmid">27764724</pub-id>
</element-citation><mixed-citation id="mc-CR605" publication-type="journal">Bekkering, S. et al. Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. <italic>Atherosclerosis</italic><bold>254</bold>, 228&#x02013;236 (2016).<pub-id pub-id-type="pmid">27764724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR606"><label>606.</label><citation-alternatives><element-citation id="ec-CR606" publication-type="journal"><person-group person-group-type="author"><name><surname>Mouton</surname><given-names>AJ</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hall</surname><given-names>ME</given-names></name><name><surname>Hall</surname><given-names>JE</given-names></name></person-group><article-title>Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation</article-title><source>Circ. Res.</source><year>2020</year><volume>126</volume><fpage>789</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.312321</pub-id><pub-id pub-id-type="pmid">32163341</pub-id>
</element-citation><mixed-citation id="mc-CR606" publication-type="journal">Mouton, A. J., Li, X., Hall, M. E. &#x00026; Hall, J. E. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation. <italic>Circ. Res.</italic><bold>126</bold>, 789&#x02013;806 (2020).<pub-id pub-id-type="pmid">32163341</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR607"><label>607.</label><citation-alternatives><element-citation id="ec-CR607" publication-type="journal"><person-group person-group-type="author"><name><surname>Shirai</surname><given-names>T</given-names></name><etal/></person-group><article-title>The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease</article-title><source>J. Exp. Med.</source><year>2016</year><volume>213</volume><fpage>337</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1084/jem.20150900</pub-id><pub-id pub-id-type="pmid">26926996</pub-id>
</element-citation><mixed-citation id="mc-CR607" publication-type="journal">Shirai, T. et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. <italic>J. Exp. Med.</italic><bold>213</bold>, 337&#x02013;354 (2016).<pub-id pub-id-type="pmid">26926996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR608"><label>608.</label><citation-alternatives><element-citation id="ec-CR608" publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>R</given-names></name><etal/></person-group><article-title>Glucose metabolism controls disease-specific signatures of macrophage effector functions</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><fpage>e123047</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.123047</pub-id><pub-id pub-id-type="pmid">30333306</pub-id>
</element-citation><mixed-citation id="mc-CR608" publication-type="journal">Watanabe, R. et al. Glucose metabolism controls disease-specific signatures of macrophage effector functions. <italic>JCI Insight</italic><bold>3</bold>, e123047 (2018).<pub-id pub-id-type="pmid">30333306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR609"><label>609.</label><citation-alternatives><element-citation id="ec-CR609" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name></person-group><article-title>Regulation of inflammasome by autophagy</article-title><source>Adv. Exp. Med. Biol.</source><year>2019</year><volume>1209</volume><fpage>109</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1007/978-981-15-0606-2_7</pub-id><pub-id pub-id-type="pmid">31728867</pub-id>
</element-citation><mixed-citation id="mc-CR609" publication-type="journal">Liu, T. Regulation of inflammasome by autophagy. <italic>Adv. Exp. Med. Biol.</italic><bold>1209</bold>, 109&#x02013;123 (2019).<pub-id pub-id-type="pmid">31728867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR610"><label>610.</label><citation-alternatives><element-citation id="ec-CR610" publication-type="journal"><person-group person-group-type="author"><name><surname>Del Re</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Fundamental mechanisms of regulated cell death and implications for heart disease</article-title><source>Physiol. Rev.</source><year>2019</year><volume>99</volume><fpage>1765</fpage><lpage>1817</lpage><pub-id pub-id-type="doi">10.1152/physrev.00022.2018</pub-id><pub-id pub-id-type="pmid">31364924</pub-id>
</element-citation><mixed-citation id="mc-CR610" publication-type="journal">Del Re, D. P. et al. Fundamental mechanisms of regulated cell death and implications for heart disease. <italic>Physiol. Rev.</italic><bold>99</bold>, 1765&#x02013;1817 (2019).<pub-id pub-id-type="pmid">31364924</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR611"><label>611.</label><citation-alternatives><element-citation id="ec-CR611" publication-type="journal"><person-group person-group-type="author"><name><surname>Linton</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Macrophage apoptosis and efferocytosis in the pathogenesis of atherosclerosis</article-title><source>Circ. J.</source><year>2016</year><volume>80</volume><fpage>2259</fpage><lpage>2268</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-16-0924</pub-id><pub-id pub-id-type="pmid">27725526</pub-id>
</element-citation><mixed-citation id="mc-CR611" publication-type="journal">Linton, M. F. et al. Macrophage apoptosis and efferocytosis in the pathogenesis of atherosclerosis. <italic>Circ. J.</italic><bold>80</bold>, 2259&#x02013;2268 (2016).<pub-id pub-id-type="pmid">27725526</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR612"><label>612.</label><citation-alternatives><element-citation id="ec-CR612" publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>Y</given-names></name><etal/></person-group><article-title>CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis</article-title><source>Nature</source><year>2016</year><volume>536</volume><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/nature18935</pub-id><pub-id pub-id-type="pmid">27437576</pub-id>
</element-citation><mixed-citation id="mc-CR612" publication-type="journal">Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. <italic>Nature</italic><bold>536</bold>, 86&#x02013;90 (2016).<pub-id pub-id-type="pmid">27437576</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR613"><label>613.</label><citation-alternatives><element-citation id="ec-CR613" publication-type="journal"><person-group person-group-type="author"><name><surname>Gerlach</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Efferocytosis induces macrophage proliferation to help resolve tissue injury</article-title><source>Cell Metab.</source><year>2021</year><volume>33</volume><fpage>2445</fpage><lpage>2463.e2448</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.10.015</pub-id><pub-id pub-id-type="pmid">34784501</pub-id>
</element-citation><mixed-citation id="mc-CR613" publication-type="journal">Gerlach, B. D. et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. <italic>Cell Metab.</italic><bold>33</bold>, 2445&#x02013;2463.e2448 (2021).<pub-id pub-id-type="pmid">34784501</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR614"><label>614.</label><citation-alternatives><element-citation id="ec-CR614" publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>CD147 sparks atherosclerosis by driving M1 phenotype and impairing efferocytosis</article-title><source>Circ. Res.</source><year>2024</year><volume>134</volume><fpage>165</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.123.323223</pub-id><pub-id pub-id-type="pmid">38166463</pub-id>
</element-citation><mixed-citation id="mc-CR614" publication-type="journal">Lv, J. J. et al. CD147 sparks atherosclerosis by driving M1 phenotype and impairing efferocytosis. <italic>Circ. Res.</italic><bold>134</bold>, 165&#x02013;185 (2024).<pub-id pub-id-type="pmid">38166463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR615"><label>615.</label><citation-alternatives><element-citation id="ec-CR615" publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>S</given-names></name><etal/></person-group><article-title>IRGM/Irgm1 facilitates macrophage apoptosis through ROS generation and MAPK signal transduction: Irgm1(+/-) mice display increases atherosclerotic plaque stability</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>9358</fpage><lpage>9375</lpage><pub-id pub-id-type="doi">10.7150/thno.62797</pub-id><pub-id pub-id-type="pmid">34646375</pub-id>
</element-citation><mixed-citation id="mc-CR615" publication-type="journal">Fang, S. et al. IRGM/Irgm1 facilitates macrophage apoptosis through ROS generation and MAPK signal transduction: Irgm1(+/-) mice display increases atherosclerotic plaque stability. <italic>Theranostics</italic><bold>11</bold>, 9358&#x02013;9375 (2021).<pub-id pub-id-type="pmid">34646375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR616"><label>616.</label><mixed-citation publication-type="other">Guntupalli, V. et al. Solute carrier family 26 member 4 (SLC26A4), a potential therapeutic target for asthma. <italic>J. Respir. Biol. Transl. Med</italic>. <bold>1</bold>, (2024).</mixed-citation></ref><ref id="CR617"><label>617.</label><citation-alternatives><element-citation id="ec-CR617" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>N</given-names></name></person-group><article-title>Inhibiting SLC26A4 reverses cardiac hypertrophy in H9C2 cells and in rats</article-title><source>PeerJ</source><year>2020</year><volume>8</volume><fpage>e8253</fpage><pub-id pub-id-type="doi">10.7717/peerj.8253</pub-id><pub-id pub-id-type="pmid">31998553</pub-id>
</element-citation><mixed-citation id="mc-CR617" publication-type="journal">Tang, L., Yu, X., Zheng, Y. &#x00026; Zhou, N. Inhibiting SLC26A4 reverses cardiac hypertrophy in H9C2 cells and in rats. <italic>PeerJ</italic><bold>8</bold>, e8253 (2020).<pub-id pub-id-type="pmid">31998553</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR618"><label>618.</label><citation-alternatives><element-citation id="ec-CR618" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Macrophage migration inhibitory factor plays a permissive role in the maintenance of cardiac contractile function under starvation through regulation of autophagy</article-title><source>Cardiovasc. Res.</source><year>2013</year><volume>99</volume><fpage>412</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt116</pub-id><pub-id pub-id-type="pmid">23674514</pub-id>
</element-citation><mixed-citation id="mc-CR618" publication-type="journal">Xu, X. et al. Macrophage migration inhibitory factor plays a permissive role in the maintenance of cardiac contractile function under starvation through regulation of autophagy. <italic>Cardiovasc. Res.</italic><bold>99</bold>, 412&#x02013;421 (2013).<pub-id pub-id-type="pmid">23674514</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR619"><label>619.</label><citation-alternatives><element-citation id="ec-CR619" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Autophagy protects mitochondrial health in heart failure</article-title><source>Heart Fail Rev.</source><year>2024</year><volume>29</volume><fpage>113</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1007/s10741-023-10354-x</pub-id><pub-id pub-id-type="pmid">37823952</pub-id>
</element-citation><mixed-citation id="mc-CR619" publication-type="journal">Tang, Y. et al. Autophagy protects mitochondrial health in heart failure. <italic>Heart Fail Rev.</italic><bold>29</bold>, 113&#x02013;123 (2024).<pub-id pub-id-type="pmid">37823952</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR620"><label>620.</label><citation-alternatives><element-citation id="ec-CR620" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>SH</given-names></name><etal/></person-group><article-title>SIRT1 inhibition causes oxidative stress and inflammation in patients with coronary artery disease</article-title><source>Redox Biol.</source><year>2017</year><volume>13</volume><fpage>301</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2017.05.027</pub-id><pub-id pub-id-type="pmid">28601780</pub-id>
</element-citation><mixed-citation id="mc-CR620" publication-type="journal">Chan, S. H. et al. SIRT1 inhibition causes oxidative stress and inflammation in patients with coronary artery disease. <italic>Redox Biol.</italic><bold>13</bold>, 301&#x02013;309 (2017).<pub-id pub-id-type="pmid">28601780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR621"><label>621.</label><mixed-citation publication-type="other">Administration., U. S. F. A. D. <italic>What are biologics? Questions and answers</italic>., <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers">https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers</ext-link> (2018).</mixed-citation></ref><ref id="CR622"><label>622.</label><citation-alternatives><element-citation id="ec-CR622" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group><article-title>A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>e159498</fpage></element-citation><mixed-citation id="mc-CR622" publication-type="journal">Zhu, X. et al. A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice. <italic>Front. Immunol.</italic><bold>14</bold>, e159498 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR623"><label>623.</label><citation-alternatives><element-citation id="ec-CR623" publication-type="journal"><person-group person-group-type="author"><name><surname>De Maio</surname><given-names>A</given-names></name></person-group><article-title>Extracellular heat shock proteins, cellular export vesicles, and the stress Observation System: a form of communication during injury, infection, and cell damage. It is never known how far a controversial finding will go! Dedicated to Ferruccio Ritossa</article-title><source>Cell Stress Chaperones</source><year>2011</year><volume>16</volume><fpage>235</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1007/s12192-010-0236-4</pub-id><pub-id pub-id-type="pmid">20963644</pub-id>
</element-citation><mixed-citation id="mc-CR623" publication-type="journal">De Maio, A. Extracellular heat shock proteins, cellular export vesicles, and the stress Observation System: a form of communication during injury, infection, and cell damage. It is never known how far a controversial finding will go! Dedicated to Ferruccio Ritossa. <italic>Cell Stress Chaperones</italic><bold>16</bold>, 235&#x02013;249 (2011).<pub-id pub-id-type="pmid">20963644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR624"><label>624.</label><citation-alternatives><element-citation id="ec-CR624" publication-type="journal"><person-group person-group-type="author"><name><surname>Bochaton</surname><given-names>T</given-names></name><etal/></person-group><article-title>Heat shock protein 70 as a biomarker of clinical outcomes after STEMI</article-title><source>J. Am. Coll. Cardiol.</source><year>2020</year><volume>75</volume><fpage>122</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.10.044</pub-id><pub-id pub-id-type="pmid">31918818</pub-id>
</element-citation><mixed-citation id="mc-CR624" publication-type="journal">Bochaton, T. et al. Heat shock protein 70 as a biomarker of clinical outcomes after STEMI. <italic>J. Am. Coll. Cardiol.</italic><bold>75</bold>, 122&#x02013;124 (2020).<pub-id pub-id-type="pmid">31918818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR625"><label>625.</label><citation-alternatives><element-citation id="ec-CR625" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Yang</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name></person-group><article-title>CCL4 Inhibition in Atherosclerosis: Effects on Plaque Stability, Endothelial Cell Adhesiveness, and Macrophages Activation</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><fpage>6567</fpage><pub-id pub-id-type="doi">10.3390/ijms21186567</pub-id><pub-id pub-id-type="pmid">32911750</pub-id>
</element-citation><mixed-citation id="mc-CR625" publication-type="journal">Chang, T. T., Yang, H. Y., Chen, C. &#x00026; Chen, J. W. CCL4 Inhibition in Atherosclerosis: Effects on Plaque Stability, Endothelial Cell Adhesiveness, and Macrophages Activation. <italic>Int. J. Mol. Sci.</italic><bold>21</bold>, 6567 (2020).<pub-id pub-id-type="pmid">32911750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR626"><label>626.</label><citation-alternatives><element-citation id="ec-CR626" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakahashi-Oda</surname><given-names>C</given-names></name><etal/></person-group><article-title>CD300a blockade enhances efferocytosis by infiltrating myeloid cells and ameliorates neuronal deficit after ischemic stroke</article-title><source>Sci. Immunol.</source><year>2021</year><volume>6</volume><fpage>eabe7915</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abe7915</pub-id><pub-id pub-id-type="pmid">34652960</pub-id>
</element-citation><mixed-citation id="mc-CR626" publication-type="journal">Nakahashi-Oda, C. et al. CD300a blockade enhances efferocytosis by infiltrating myeloid cells and ameliorates neuronal deficit after ischemic stroke. <italic>Sci. Immunol.</italic><bold>6</bold>, eabe7915 (2021).<pub-id pub-id-type="pmid">34652960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR627"><label>627.</label><citation-alternatives><element-citation id="ec-CR627" publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>D</given-names></name><etal/></person-group><article-title>A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>525</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-02896-8</pub-id><pub-id pub-id-type="pmid">29410422</pub-id>
</element-citation><mixed-citation id="mc-CR627" publication-type="journal">Wolf, D. et al. A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense. <italic>Nat. Commun.</italic><bold>9</bold>, 525 (2018).<pub-id pub-id-type="pmid">29410422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR628"><label>628.</label><citation-alternatives><element-citation id="ec-CR628" publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clearing and replacing tissue-resident myeloid cells with an anti-CD45 antibody-drug conjugate</article-title><source>Blood Adv.</source><year>2023</year><volume>7</volume><fpage>6964</fpage><lpage>6973</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2023010561</pub-id><pub-id pub-id-type="pmid">37748049</pub-id>
</element-citation><mixed-citation id="mc-CR628" publication-type="journal">Gustafsson, K. et al. Clearing and replacing tissue-resident myeloid cells with an anti-CD45 antibody-drug conjugate. <italic>Blood Adv.</italic><bold>7</bold>, 6964&#x02013;6973 (2023).<pub-id pub-id-type="pmid">37748049</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR629"><label>629.</label><citation-alternatives><element-citation id="ec-CR629" publication-type="journal"><person-group person-group-type="author"><name><surname>Shvedova</surname><given-names>M</given-names></name><etal/></person-group><article-title>c-Jun N-terminal kinases (JNKs) in myocardial and cerebral ischemia/reperfusion injury</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>715</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00715</pub-id><pub-id pub-id-type="pmid">30026697</pub-id>
</element-citation><mixed-citation id="mc-CR629" publication-type="journal">Shvedova, M. et al. c-Jun N-terminal kinases (JNKs) in myocardial and cerebral ischemia/reperfusion injury. <italic>Front. Pharmacol.</italic><bold>9</bold>, 715 (2018).<pub-id pub-id-type="pmid">30026697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR630"><label>630.</label><citation-alternatives><element-citation id="ec-CR630" publication-type="journal"><person-group person-group-type="author"><name><surname>Zidar</surname><given-names>N</given-names></name><name><surname>Dolenc-Strazar</surname><given-names>Z</given-names></name><name><surname>Jeruc</surname><given-names>J</given-names></name><name><surname>Stajer</surname><given-names>D</given-names></name></person-group><article-title>Immunohistochemical expression of activated caspase-3 in human myocardial infarction</article-title><source>Virchows Arch.</source><year>2006</year><volume>448</volume><fpage>75</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s00428-005-0073-5</pub-id><pub-id pub-id-type="pmid">16205944</pub-id>
</element-citation><mixed-citation id="mc-CR630" publication-type="journal">Zidar, N., Dolenc-Strazar, Z., Jeruc, J. &#x00026; Stajer, D. Immunohistochemical expression of activated caspase-3 in human myocardial infarction. <italic>Virchows Arch.</italic><bold>448</bold>, 75&#x02013;79 (2006).<pub-id pub-id-type="pmid">16205944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR631"><label>631.</label><citation-alternatives><element-citation id="ec-CR631" publication-type="journal"><person-group person-group-type="author"><name><surname>Balsam</surname><given-names>LB</given-names></name><name><surname>Kofidis</surname><given-names>T</given-names></name><name><surname>Robbins</surname><given-names>RC</given-names></name></person-group><article-title>Caspase-3 inhibition preserves myocardial geometry and long-term function after infarction</article-title><source>J. Surg. Res.</source><year>2005</year><volume>124</volume><fpage>194</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2004.09.017</pub-id><pub-id pub-id-type="pmid">15820248</pub-id>
</element-citation><mixed-citation id="mc-CR631" publication-type="journal">Balsam, L. B., Kofidis, T. &#x00026; Robbins, R. C. Caspase-3 inhibition preserves myocardial geometry and long-term function after infarction. <italic>J. Surg. Res.</italic><bold>124</bold>, 194&#x02013;200 (2005).<pub-id pub-id-type="pmid">15820248</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR632"><label>632.</label><citation-alternatives><element-citation id="ec-CR632" publication-type="journal"><person-group person-group-type="author"><name><surname>Seropian</surname><given-names>IM</given-names></name><name><surname>Cassaglia</surname><given-names>P</given-names></name><name><surname>Miksztowicz</surname><given-names>V</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>GE</given-names></name></person-group><article-title>Unraveling the role of galectin-3 in cardiac pathology and physiology</article-title><source>Front. Physiol.</source><year>2023</year><volume>14</volume><fpage>1304735</fpage><pub-id pub-id-type="doi">10.3389/fphys.2023.1304735</pub-id><pub-id pub-id-type="pmid">38170009</pub-id>
</element-citation><mixed-citation id="mc-CR632" publication-type="journal">Seropian, I. M., Cassaglia, P., Miksztowicz, V. &#x00026; Gonz&#x000e1;lez, G. E. Unraveling the role of galectin-3 in cardiac pathology and physiology. <italic>Front. Physiol.</italic><bold>14</bold>, 1304735 (2023).<pub-id pub-id-type="pmid">38170009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR633"><label>633.</label><citation-alternatives><element-citation id="ec-CR633" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>Value of galectin-3 in acute myocardial infarction</article-title><source>Am. J. Cardiovasc. Drugs</source><year>2020</year><volume>20</volume><fpage>333</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1007/s40256-019-00387-9</pub-id><pub-id pub-id-type="pmid">31784887</pub-id>
</element-citation><mixed-citation id="mc-CR633" publication-type="journal">Li, M. et al. Value of galectin-3 in acute myocardial infarction. <italic>Am. J. Cardiovasc. Drugs</italic><bold>20</bold>, 333&#x02013;342 (2020).<pub-id pub-id-type="pmid">31784887</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR634"><label>634.</label><citation-alternatives><element-citation id="ec-CR634" publication-type="journal"><person-group person-group-type="author"><name><surname>Frangogiannis</surname><given-names>NG</given-names></name></person-group><article-title>Targeting galectin-3 in myocardial infarction: a unique opportunity for biomarker-guided therapy</article-title><source>Cardiovasc. Res.</source><year>2023</year><volume>119</volume><fpage>2495</fpage><lpage>2496</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvad156</pub-id><pub-id pub-id-type="pmid">37772841</pub-id>
</element-citation><mixed-citation id="mc-CR634" publication-type="journal">Frangogiannis, N. G. Targeting galectin-3 in myocardial infarction: a unique opportunity for biomarker-guided therapy. <italic>Cardiovasc. Res.</italic><bold>119</bold>, 2495&#x02013;2496 (2023).<pub-id pub-id-type="pmid">37772841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR635"><label>635.</label><citation-alternatives><element-citation id="ec-CR635" publication-type="journal"><person-group person-group-type="author"><name><surname>Poznyak</surname><given-names>AV</given-names></name><etal/></person-group><article-title>NADPH oxidases and their role in atherosclerosis</article-title><source>Biomedicines</source><year>2020</year><volume>8</volume><fpage>206</fpage><pub-id pub-id-type="doi">10.3390/biomedicines8070206</pub-id><pub-id pub-id-type="pmid">32664404</pub-id>
</element-citation><mixed-citation id="mc-CR635" publication-type="journal">Poznyak, A. V. et al. NADPH oxidases and their role in atherosclerosis. <italic>Biomedicines</italic><bold>8</bold>, 206 (2020).<pub-id pub-id-type="pmid">32664404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR636"><label>636.</label><citation-alternatives><element-citation id="ec-CR636" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Murugesan</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name></person-group><article-title>NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets</article-title><source>Nat. Rev. Cardiol.</source><year>2020</year><volume>17</volume><fpage>170</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/s41569-019-0260-8</pub-id><pub-id pub-id-type="pmid">31591535</pub-id>
</element-citation><mixed-citation id="mc-CR636" publication-type="journal">Zhang, Y., Murugesan, P., Huang, K. &#x00026; Cai, H. NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets. <italic>Nat. Rev. Cardiol.</italic><bold>17</bold>, 170&#x02013;194 (2020).<pub-id pub-id-type="pmid">31591535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR637"><label>637.</label><citation-alternatives><element-citation id="ec-CR637" publication-type="journal"><person-group person-group-type="author"><name><surname>Ulleryd</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Stimulation of alpha 7 nicotinic acetylcholine receptor (&#x003b1;7nAChR) inhibits atherosclerosis via immunomodulatory effects on myeloid cells</article-title><source>Atherosclerosis</source><year>2019</year><volume>287</volume><fpage>122</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2019.06.903</pub-id><pub-id pub-id-type="pmid">31260875</pub-id>
</element-citation><mixed-citation id="mc-CR637" publication-type="journal">Ulleryd, M. A. et al. Stimulation of alpha 7 nicotinic acetylcholine receptor (&#x003b1;7nAChR) inhibits atherosclerosis via immunomodulatory effects on myeloid cells. <italic>Atherosclerosis</italic><bold>287</bold>, 122&#x02013;133 (2019).<pub-id pub-id-type="pmid">31260875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR638"><label>638.</label><citation-alternatives><element-citation id="ec-CR638" publication-type="journal"><person-group person-group-type="author"><name><surname>Garscha</surname><given-names>U</given-names></name><etal/></person-group><article-title>BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly</article-title><source>Biochem. Pharmacol.</source><year>2016</year><volume>119</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.08.023</pub-id><pub-id pub-id-type="pmid">27592027</pub-id>
</element-citation><mixed-citation id="mc-CR638" publication-type="journal">Garscha, U. et al. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly. <italic>Biochem. Pharmacol.</italic><bold>119</bold>, 17&#x02013;26 (2016).<pub-id pub-id-type="pmid">27592027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR639"><label>639.</label><citation-alternatives><element-citation id="ec-CR639" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Magid</surname><given-names>AF</given-names></name></person-group><article-title>Endothelial lipase inhibitors for the treatment of atherosclerosis and cardiovascular disorders</article-title><source>ACS Med. Chem. Lett.</source><year>2013</year><volume>4</volume><fpage>1016</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1021/ml400361q</pub-id><pub-id pub-id-type="pmid">24900598</pub-id>
</element-citation><mixed-citation id="mc-CR639" publication-type="journal">Abdel-Magid, A. F. Endothelial lipase inhibitors for the treatment of atherosclerosis and cardiovascular disorders. <italic>ACS Med. Chem. Lett.</italic><bold>4</bold>, 1016&#x02013;1017 (2013).<pub-id pub-id-type="pmid">24900598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR640"><label>640.</label><citation-alternatives><element-citation id="ec-CR640" publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname><given-names>T</given-names></name><etal/></person-group><article-title>Endothelial lipase is increased by inflammation and promotes LDL uptake in macrophages</article-title><source>J. Atheroscler. Thromb.</source><year>2007</year><volume>14</volume><fpage>192</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.5551/jat.E502</pub-id><pub-id pub-id-type="pmid">17726294</pub-id>
</element-citation><mixed-citation id="mc-CR640" publication-type="journal">Yasuda, T. et al. Endothelial lipase is increased by inflammation and promotes LDL uptake in macrophages. <italic>J. Atheroscler. Thromb.</italic><bold>14</bold>, 192&#x02013;201 (2007).<pub-id pub-id-type="pmid">17726294</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR641"><label>641.</label><citation-alternatives><element-citation id="ec-CR641" publication-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Moreton</surname><given-names>S</given-names></name></person-group><article-title>Targeting leukocyte derived MPO in heart failure</article-title><source>Blood</source><year>2017</year><volume>130</volume><fpage>3570</fpage></element-citation><mixed-citation id="mc-CR641" publication-type="journal">Wald, D., Gupta, K., Lu, Y. &#x00026; Moreton, S. Targeting leukocyte derived MPO in heart failure. <italic>Blood</italic><bold>130</bold>, 3570 (2017).</mixed-citation></citation-alternatives></ref><ref id="CR642"><label>642.</label><citation-alternatives><element-citation id="ec-CR642" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>N</given-names></name><etal/></person-group><article-title>Abstract 14871: APD588, a novel, selective S1P receptor modulator, regulates inflammatory responses and attenuates cardiac dysfunction following experimental myocardial infarction in mice</article-title><source>Circulation</source><year>2020</year><volume>142</volume><fpage>A14871</fpage><lpage>A14871</lpage><pub-id pub-id-type="doi">10.1161/circ.142.suppl_3.14871</pub-id></element-citation><mixed-citation id="mc-CR642" publication-type="journal">Nguyen, N. et al. Abstract 14871: APD588, a novel, selective S1P receptor modulator, regulates inflammatory responses and attenuates cardiac dysfunction following experimental myocardial infarction in mice. <italic>Circulation</italic><bold>142</bold>, A14871&#x02013;A14871 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR643"><label>643.</label><citation-alternatives><element-citation id="ec-CR643" publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Sphingosine-1-phosphate signalling in the heart: exploring emerging perspectives in cardiopathology</article-title><source>FEBS Lett.</source><year>2024</year><volume>598</volume><fpage>2641</fpage><lpage>2655</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.14973</pub-id><pub-id pub-id-type="pmid">38965662</pub-id>
</element-citation><mixed-citation id="mc-CR643" publication-type="journal">Phan, F. et al. Sphingosine-1-phosphate signalling in the heart: exploring emerging perspectives in cardiopathology. <italic>FEBS Lett.</italic><bold>598</bold>, 2641&#x02013;2655 (2024).<pub-id pub-id-type="pmid">38965662</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR644"><label>644.</label><citation-alternatives><element-citation id="ec-CR644" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Sphingosine 1-phosphate signaling contributes to cardiac inflammation, dysfunction, and remodeling following myocardial infarction</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2016</year><volume>310</volume><fpage>H250</fpage><lpage>H261</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00372.2015</pub-id><pub-id pub-id-type="pmid">26589326</pub-id>
</element-citation><mixed-citation id="mc-CR644" publication-type="journal">Zhang, F. et al. Sphingosine 1-phosphate signaling contributes to cardiac inflammation, dysfunction, and remodeling following myocardial infarction. <italic>Am. J. Physiol. Heart Circ. Physiol.</italic><bold>310</bold>, H250&#x02013;H261 (2016).<pub-id pub-id-type="pmid">26589326</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR645"><label>645.</label><citation-alternatives><element-citation id="ec-CR645" publication-type="journal"><person-group person-group-type="author"><name><surname>Reitz</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome</article-title><source>Commun. Biol.</source><year>2019</year><volume>2</volume><fpage>353</fpage><pub-id pub-id-type="doi">10.1038/s42003-019-0595-z</pub-id><pub-id pub-id-type="pmid">31602405</pub-id>
</element-citation><mixed-citation id="mc-CR645" publication-type="journal">Reitz, C. J. et al. SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome. <italic>Commun. Biol.</italic><bold>2</bold>, 353 (2019).<pub-id pub-id-type="pmid">31602405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR646"><label>646.</label><citation-alternatives><element-citation id="ec-CR646" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group><article-title>GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease</article-title><source>Nat. Rev. Endocrinol.</source><year>2021</year><volume>17</volume><fpage>592</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/s41574-021-00529-7</pub-id><pub-id pub-id-type="pmid">34381196</pub-id>
</element-citation><mixed-citation id="mc-CR646" publication-type="journal">Wang, D. et al. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. <italic>Nat. Rev. Endocrinol.</italic><bold>17</bold>, 592&#x02013;607 (2021).<pub-id pub-id-type="pmid">34381196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR647"><label>647.</label><citation-alternatives><element-citation id="ec-CR647" publication-type="journal"><person-group person-group-type="author"><name><surname>Toldo</surname><given-names>S</given-names></name><name><surname>Abbate</surname><given-names>A</given-names></name></person-group><article-title>The NLRP3 inflammasome in acute myocardial infarction</article-title><source>Nat. Rev. Cardiol.</source><year>2018</year><volume>15</volume><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2017.161</pub-id><pub-id pub-id-type="pmid">29143812</pub-id>
</element-citation><mixed-citation id="mc-CR647" publication-type="journal">Toldo, S. &#x00026; Abbate, A. The NLRP3 inflammasome in acute myocardial infarction. <italic>Nat. Rev. Cardiol.</italic><bold>15</bold>, 203&#x02013;214 (2018).<pub-id pub-id-type="pmid">29143812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR648"><label>648.</label><citation-alternatives><element-citation id="ec-CR648" publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>L</given-names></name><etal/></person-group><article-title>Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease</article-title><source>Atherosclerosis</source><year>2013</year><volume>228</volume><fpage>346</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2013.01.027</pub-id><pub-id pub-id-type="pmid">23566804</pub-id>
</element-citation><mixed-citation id="mc-CR648" publication-type="journal">Jia, L. et al. Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease. <italic>Atherosclerosis</italic><bold>228</bold>, 346&#x02013;352 (2013).<pub-id pub-id-type="pmid">23566804</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR649"><label>649.</label><citation-alternatives><element-citation id="ec-CR649" publication-type="journal"><person-group person-group-type="author"><name><surname>Komal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Epigenetic regulation of macrophage polarization in cardiovascular diseases</article-title><source>Pharmacuticals</source><year>2023</year><volume>16</volume><fpage>141</fpage><pub-id pub-id-type="doi">10.3390/ph16020141</pub-id></element-citation><mixed-citation id="mc-CR649" publication-type="journal">Komal, S. et al. Epigenetic regulation of macrophage polarization in cardiovascular diseases. <italic>Pharmacuticals</italic><bold>16</bold>, 141 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR650"><label>650.</label><citation-alternatives><element-citation id="ec-CR650" publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Dysfunctional and proinflammatory regulatory T-lymphocytes are essential for adverse cardiac remodeling in ischemic cardiomyopathy</article-title><source>Circulation</source><year>2019</year><volume>139</volume><fpage>206</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.036065</pub-id><pub-id pub-id-type="pmid">30586716</pub-id>
</element-citation><mixed-citation id="mc-CR650" publication-type="journal">Bansal, S. S. et al. Dysfunctional and proinflammatory regulatory T-lymphocytes are essential for adverse cardiac remodeling in ischemic cardiomyopathy. <italic>Circulation</italic><bold>139</bold>, 206&#x02013;221 (2019).<pub-id pub-id-type="pmid">30586716</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR651"><label>651.</label><mixed-citation publication-type="other">Lu, X. et al. Reactive oxygen species responsive multifunctional fusion extracellular nanovesicles: prospective treatments for acute heart transplant rejection. <italic>Adv. Mater.</italic><bold>36</bold>, e2406758 (2024).</mixed-citation></ref><ref id="CR652"><label>652.</label><citation-alternatives><element-citation id="ec-CR652" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Natural melanin/alginate hydrogels achieve cardiac repair through ROS scavenging and macrophage polarization</article-title><source>Adv. Sci.</source><year>2021</year><volume>8</volume><fpage>e2100505</fpage><pub-id pub-id-type="doi">10.1002/advs.202100505</pub-id></element-citation><mixed-citation id="mc-CR652" publication-type="journal">Zhou, J., et al. Natural melanin/alginate hydrogels achieve cardiac repair through ROS scavenging and macrophage polarization. <italic>Adv. Sci.</italic><bold>8</bold>, e2100505 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR653"><label>653.</label><citation-alternatives><element-citation id="ec-CR653" publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Low-dose methotrexate for the prevention of atherosclerotic events</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>752</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1809798</pub-id><pub-id pub-id-type="pmid">30415610</pub-id>
</element-citation><mixed-citation id="mc-CR653" publication-type="journal">Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. <italic>N. Engl. J. Med.</italic><bold>380</bold>, 752&#x02013;762 (2019).<pub-id pub-id-type="pmid">30415610</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR654"><label>654.</label><citation-alternatives><element-citation id="ec-CR654" publication-type="journal"><person-group person-group-type="author"><name><surname>Cormack</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of ciclosporin on safety, lymphocyte kinetics and left ventricular remodelling in acute myocardial infarction</article-title><source>Br. J. Clin. Pharmacol.</source><year>2020</year><volume>86</volume><fpage>1387</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1111/bcp.14252</pub-id><pub-id pub-id-type="pmid">32067256</pub-id>
</element-citation><mixed-citation id="mc-CR654" publication-type="journal">Cormack, S. et al. Effect of ciclosporin on safety, lymphocyte kinetics and left ventricular remodelling in acute myocardial infarction. <italic>Br. J. Clin. Pharmacol.</italic><bold>86</bold>, 1387&#x02013;1397 (2020).<pub-id pub-id-type="pmid">32067256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR655"><label>655.</label><citation-alternatives><element-citation id="ec-CR655" publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon</article-title><source>JACC Cardiovasc. Inter.</source><year>2019</year><volume>12</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2018.11.040</pub-id></element-citation><mixed-citation id="mc-CR655" publication-type="journal">Ali, R. M. et al. Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon. <italic>JACC Cardiovasc. Inter.</italic><bold>12</bold>, 558&#x02013;566 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR656"><label>656.</label><citation-alternatives><element-citation id="ec-CR656" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial</article-title><source>Catheter Cardiovasc. Inter.</source><year>2012</year><volume>80</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1002/ccd.23352</pub-id></element-citation><mixed-citation id="mc-CR656" publication-type="journal">Rodriguez, A. E. et al. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial. <italic>Catheter Cardiovasc. Inter.</italic><bold>80</bold>, 385&#x02013;394 (2012).</mixed-citation></citation-alternatives></ref><ref id="CR657"><label>657.</label><citation-alternatives><element-citation id="ec-CR657" publication-type="journal"><person-group person-group-type="author"><name><surname>St&#x000e4;hli</surname><given-names>BE</given-names></name><etal/></person-group><article-title>Mammalian target of rapamycin inhibition in patients with ST-segment elevation myocardial infarction</article-title><source>J. Am. Coll. Cardiol.</source><year>2022</year><volume>80</volume><fpage>1802</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2022.08.747</pub-id><pub-id pub-id-type="pmid">36049557</pub-id>
</element-citation><mixed-citation id="mc-CR657" publication-type="journal">St&#x000e4;hli, B. E. et al. Mammalian target of rapamycin inhibition in patients with ST-segment elevation myocardial infarction. <italic>J. Am. Coll. Cardiol.</italic><bold>80</bold>, 1802&#x02013;1814 (2022).<pub-id pub-id-type="pmid">36049557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR658"><label>658.</label><citation-alternatives><element-citation id="ec-CR658" publication-type="journal"><person-group person-group-type="author"><name><surname>El Sayed</surname><given-names>H</given-names></name><etal/></person-group><article-title>A randomized phase II study of Xilonix, a targeted therapy against interleukin 1&#x003b1;, for the prevention of superficial femoral artery restenosis after percutaneous revascularization</article-title><source>J. Vasc. Surg.</source><year>2016</year><volume>63</volume><fpage>133</fpage><lpage>141.e131</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2015.08.069</pub-id><pub-id pub-id-type="pmid">26433546</pub-id>
</element-citation><mixed-citation id="mc-CR658" publication-type="journal">El Sayed, H. et al. A randomized phase II study of Xilonix, a targeted therapy against interleukin 1&#x003b1;, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. <italic>J. Vasc. Surg.</italic><bold>63</bold>, 133&#x02013;141.e131 (2016).<pub-id pub-id-type="pmid">26433546</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR659"><label>659.</label><citation-alternatives><element-citation id="ec-CR659" publication-type="journal"><person-group person-group-type="author"><name><surname>Abbate</surname><given-names>A</given-names></name><etal/></person-group><article-title>Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction</article-title><source>J. Am. Heart Assoc.</source><year>2020</year><volume>9</volume><fpage>e014941</fpage><pub-id pub-id-type="doi">10.1161/JAHA.119.014941</pub-id><pub-id pub-id-type="pmid">32122219</pub-id>
</element-citation><mixed-citation id="mc-CR659" publication-type="journal">Abbate, A. et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction. <italic>J. Am. Heart Assoc.</italic><bold>9</bold>, e014941 (2020).<pub-id pub-id-type="pmid">32122219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR660"><label>660.</label><citation-alternatives><element-citation id="ec-CR660" publication-type="journal"><person-group person-group-type="author"><name><surname>Myachikova</surname><given-names>VY</given-names></name><etal/></person-group><article-title>Treatment of idiopathic recurrent pericarditis with goflikicept: phase II/III study results</article-title><source>J. Am. Coll. Cardiol.</source><year>2023</year><volume>82</volume><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2023.04.046</pub-id><pub-id pub-id-type="pmid">37380301</pub-id>
</element-citation><mixed-citation id="mc-CR660" publication-type="journal">Myachikova, V. Y. et al. Treatment of idiopathic recurrent pericarditis with goflikicept: phase II/III study results. <italic>J. Am. Coll. Cardiol.</italic><bold>82</bold>, 30&#x02013;40 (2023).<pub-id pub-id-type="pmid">37380301</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR661"><label>661.</label><citation-alternatives><element-citation id="ec-CR661" publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><etal/></person-group><article-title>IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>2060</fpage><lpage>2069</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00520-1</pub-id><pub-id pub-id-type="pmid">34015342</pub-id>
</element-citation><mixed-citation id="mc-CR661" publication-type="journal">Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. <italic>Lancet</italic><bold>397</bold>, 2060&#x02013;2069 (2021).<pub-id pub-id-type="pmid">34015342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR662"><label>662.</label><citation-alternatives><element-citation id="ec-CR662" publication-type="journal"><person-group person-group-type="author"><name><surname>Kleveland</surname><given-names>O</given-names></name><etal/></person-group><article-title>Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial</article-title><source>Eur. Heart J.</source><year>2016</year><volume>37</volume><fpage>2406</fpage><lpage>2413</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw171</pub-id><pub-id pub-id-type="pmid">27161611</pub-id>
</element-citation><mixed-citation id="mc-CR662" publication-type="journal">Kleveland, O. et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. <italic>Eur. Heart J.</italic><bold>37</bold>, 2406&#x02013;2413 (2016).<pub-id pub-id-type="pmid">27161611</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR663"><label>663.</label><citation-alternatives><element-citation id="ec-CR663" publication-type="journal"><person-group person-group-type="author"><name><surname>Broch</surname><given-names>K</given-names></name><etal/></person-group><article-title>Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction</article-title><source>J. Am. Coll. Cardiol.</source><year>2021</year><volume>77</volume><fpage>1845</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.02.049</pub-id><pub-id pub-id-type="pmid">33858620</pub-id>
</element-citation><mixed-citation id="mc-CR663" publication-type="journal">Broch, K. et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. <italic>J. Am. Coll. Cardiol.</italic><bold>77</bold>, 1845&#x02013;1855 (2021).<pub-id pub-id-type="pmid">33858620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR664"><label>664.</label><citation-alternatives><element-citation id="ec-CR664" publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>MAS</given-names></name><etal/></person-group><article-title>Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (The IMICA Trial): a double-blinded, placebo-controlled, single-center, randomized, clinical trial</article-title><source>Circulation</source><year>2021</year><volume>143</volume><fpage>1841</fpage><lpage>1851</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.053318</pub-id><pub-id pub-id-type="pmid">33745292</pub-id>
</element-citation><mixed-citation id="mc-CR664" publication-type="journal">Meyer, M. A. S. et al. Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (The IMICA Trial): a double-blinded, placebo-controlled, single-center, randomized, clinical trial. <italic>Circulation</italic><bold>143</bold>, 1841&#x02013;1851 (2021).<pub-id pub-id-type="pmid">33745292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR665"><label>665.</label><citation-alternatives><element-citation id="ec-CR665" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>FS</given-names></name><etal/></person-group><article-title>Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review</article-title><source>Acta Pharmacol. Sin.</source><year>2022</year><volume>43</volume><fpage>2173</fpage><lpage>2190</lpage><pub-id pub-id-type="doi">10.1038/s41401-021-00835-w</pub-id><pub-id pub-id-type="pmid">35046517</pub-id>
</element-citation><mixed-citation id="mc-CR665" publication-type="journal">Zhang, F. S. et al. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. <italic>Acta Pharmacol. Sin.</italic><bold>43</bold>, 2173&#x02013;2190 (2022).<pub-id pub-id-type="pmid">35046517</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR666"><label>666.</label><citation-alternatives><element-citation id="ec-CR666" publication-type="journal"><person-group person-group-type="author"><name><surname>Kl&#x000fc;ck</surname><given-names>V</given-names></name><etal/></person-group><article-title>Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial</article-title><source>Lancet Rheumatol.</source><year>2020</year><volume>2</volume><fpage>e270</fpage><lpage>e280</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30065-5</pub-id><pub-id pub-id-type="pmid">33005902</pub-id>
</element-citation><mixed-citation id="mc-CR666" publication-type="journal">Kl&#x000fc;ck, V. et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. <italic>Lancet Rheumatol.</italic><bold>2</bold>, e270&#x02013;e280 (2020).<pub-id pub-id-type="pmid">33005902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR667"><label>667.</label><citation-alternatives><element-citation id="ec-CR667" publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlford</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure</article-title><source>J. Cardiovasc. Pharmacol.</source><year>2020</year><volume>77</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1097/FJC.0000000000000931</pub-id><pub-id pub-id-type="pmid">33235030</pub-id>
</element-citation><mixed-citation id="mc-CR667" publication-type="journal">Wohlford, G. F. et al. Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure. <italic>J. Cardiovasc. Pharmacol.</italic><bold>77</bold>, 49&#x02013;60 (2020).<pub-id pub-id-type="pmid">33235030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR668"><label>668.</label><citation-alternatives><element-citation id="ec-CR668" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Treatment with TNF-&#x003b1; inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation</article-title><source>J. Dermatol. Sci.</source><year>2018</year><volume>91</volume><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2018.05.009</pub-id><pub-id pub-id-type="pmid">29914850</pub-id>
</element-citation><mixed-citation id="mc-CR668" publication-type="journal">Lin, S. H. et al. Treatment with TNF-&#x003b1; inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation. <italic>J. Dermatol. Sci.</italic><bold>91</bold>, 276&#x02013;284 (2018).<pub-id pub-id-type="pmid">29914850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR669"><label>669.</label><citation-alternatives><element-citation id="ec-CR669" publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>A</given-names></name><etal/></person-group><article-title>A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis</article-title><source>EuroIntervention</source><year>2016</year><volume>12</volume><fpage>e1385</fpage><lpage>e1394</lpage><pub-id pub-id-type="doi">10.4244/EIJY15M12_03</pub-id><pub-id pub-id-type="pmid">26690313</pub-id>
</element-citation><mixed-citation id="mc-CR669" publication-type="journal">Colombo, A. et al. A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. <italic>EuroIntervention</italic><bold>12</bold>, e1385&#x02013;e1394 (2016).<pub-id pub-id-type="pmid">26690313</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR670"><label>670.</label><citation-alternatives><element-citation id="ec-CR670" publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>CSP</given-names></name><etal/></person-group><article-title>Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE trial results</article-title><source>J. Card. Fail</source><year>2024</year><volume>30</volume><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.cardfail.2023.04.003</pub-id><pub-id pub-id-type="pmid">37072105</pub-id>
</element-citation><mixed-citation id="mc-CR670" publication-type="journal">Lam, C. S. P. et al. Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE trial results. <italic>J. Card. Fail</italic><bold>30</bold>, 104&#x02013;110 (2024).<pub-id pub-id-type="pmid">37072105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR671"><label>671.</label><citation-alternatives><element-citation id="ec-CR671" publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez-Jim&#x000e9;nez</surname><given-names>M</given-names></name><etal/></person-group><article-title>First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers</article-title><source>Mol. Ther. Nucleic Acids</source><year>2022</year><volume>28</volume><fpage>124</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2022.03.005</pub-id><pub-id pub-id-type="pmid">35402075</pub-id>
</element-citation><mixed-citation id="mc-CR671" publication-type="journal">Hern&#x000e1;ndez-Jim&#x000e9;nez, M. et al. First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers. <italic>Mol. Ther. Nucleic Acids</italic><bold>28</bold>, 124&#x02013;135 (2022).<pub-id pub-id-type="pmid">35402075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR672"><label>672.</label><citation-alternatives><element-citation id="ec-CR672" publication-type="journal"><person-group person-group-type="author"><name><surname>Willingham</surname><given-names>SB</given-names></name><etal/></person-group><article-title>The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>6662</fpage><lpage>6667</lpage><pub-id pub-id-type="doi">10.1073/pnas.1121623109</pub-id><pub-id pub-id-type="pmid">22451913</pub-id>
</element-citation><mixed-citation id="mc-CR672" publication-type="journal">Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>109</bold>, 6662&#x02013;6667 (2012).<pub-id pub-id-type="pmid">22451913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR673"><label>673.</label><citation-alternatives><element-citation id="ec-CR673" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Amico</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment</article-title><source>Faseb J.</source><year>2000</year><volume>14</volume><fpage>1867</fpage><lpage>1869</lpage><pub-id pub-id-type="doi">10.1096/fj.99-0602fje</pub-id><pub-id pub-id-type="pmid">11023969</pub-id>
</element-citation><mixed-citation id="mc-CR673" publication-type="journal">D&#x02019;Amico, M. et al. Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. <italic>Faseb J.</italic><bold>14</bold>, 1867&#x02013;1869 (2000).<pub-id pub-id-type="pmid">11023969</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR674"><label>674.</label><citation-alternatives><element-citation id="ec-CR674" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraro</surname><given-names>B</given-names></name><etal/></person-group><article-title>Pro-angiogenic macrophage phenotype to promote myocardial repair</article-title><source>J. Am. Coll. Cardiol.</source><year>2019</year><volume>73</volume><fpage>2990</fpage><lpage>3002</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.03.503</pub-id><pub-id pub-id-type="pmid">31196457</pub-id>
</element-citation><mixed-citation id="mc-CR674" publication-type="journal">Ferraro, B. et al. Pro-angiogenic macrophage phenotype to promote myocardial repair. <italic>J. Am. Coll. Cardiol.</italic><bold>73</bold>, 2990&#x02013;3002 (2019).<pub-id pub-id-type="pmid">31196457</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR675"><label>675.</label><citation-alternatives><element-citation id="ec-CR675" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>The annexin-A1 mimetic RTP-026 promotes acute cardioprotection through modulation of immune cell activation</article-title><source>Pharmacol. Res.</source><year>2023</year><volume>198</volume><fpage>107005</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2023.107005</pub-id><pub-id pub-id-type="pmid">37992916</pub-id>
</element-citation><mixed-citation id="mc-CR675" publication-type="journal">Chen, J. et al. The annexin-A1 mimetic RTP-026 promotes acute cardioprotection through modulation of immune cell activation. <italic>Pharmacol. Res.</italic><bold>198</bold>, 107005 (2023).<pub-id pub-id-type="pmid">37992916</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR676"><label>676.</label><citation-alternatives><element-citation id="ec-CR676" publication-type="journal"><person-group person-group-type="author"><name><surname>Gelevski</surname><given-names>D</given-names></name><etal/></person-group><article-title>Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: experience with expanded access protocol</article-title><source>Muscle Nerve</source><year>2023</year><volume>67</volume><fpage>354</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1002/mus.27775</pub-id><pub-id pub-id-type="pmid">36533976</pub-id>
</element-citation><mixed-citation id="mc-CR676" publication-type="journal">Gelevski, D. et al. Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: experience with expanded access protocol. <italic>Muscle Nerve</italic><bold>67</bold>, 354&#x02013;362 (2023).<pub-id pub-id-type="pmid">36533976</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR677"><label>677.</label><citation-alternatives><element-citation id="ec-CR677" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><etal/></person-group><article-title>Recent advances in CXCL12/CXCR4 antagonists and nano-based drug delivery systems for cancer therapy</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><fpage>1541</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14081541</pub-id><pub-id pub-id-type="pmid">35893797</pub-id>
</element-citation><mixed-citation id="mc-CR677" publication-type="journal">Zhao, R. et al. Recent advances in CXCL12/CXCR4 antagonists and nano-based drug delivery systems for cancer therapy. <italic>Pharmaceutics</italic><bold>14</bold>, 1541 (2022).<pub-id pub-id-type="pmid">35893797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR678"><label>678.</label><citation-alternatives><element-citation id="ec-CR678" publication-type="journal"><person-group person-group-type="author"><name><surname>Means</surname><given-names>CK</given-names></name><name><surname>Brown</surname><given-names>JH</given-names></name></person-group><article-title>Sphingosine-1-phosphate receptor signalling in the heart</article-title><source>Cardiovasc. Res.</source><year>2009</year><volume>82</volume><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvp086</pub-id><pub-id pub-id-type="pmid">19282351</pub-id>
</element-citation><mixed-citation id="mc-CR678" publication-type="journal">Means, C. K. &#x00026; Brown, J. H. Sphingosine-1-phosphate receptor signalling in the heart. <italic>Cardiovasc. Res.</italic><bold>82</bold>, 193&#x02013;200 (2009).<pub-id pub-id-type="pmid">19282351</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR679"><label>679.</label><citation-alternatives><element-citation id="ec-CR679" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The therapeutic potential of mesenchymal stem cells for cardiovascular diseases</article-title><source>Cell Death Dis.</source><year>2020</year><volume>11</volume><fpage>349</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-2542-9</pub-id><pub-id pub-id-type="pmid">32393744</pub-id>
</element-citation><mixed-citation id="mc-CR679" publication-type="journal">Guo, Y., et al. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. <italic>Cell Death Dis.</italic><bold>11</bold>, 349 (2020).<pub-id pub-id-type="pmid">32393744</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR680"><label>680.</label><citation-alternatives><element-citation id="ec-CR680" publication-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>JM</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction</article-title><source>J. Am. Coll. Cardiol.</source><year>2009</year><volume>54</volume><fpage>2277</fpage><lpage>2286</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2009.06.055</pub-id><pub-id pub-id-type="pmid">19958962</pub-id>
</element-citation><mixed-citation id="mc-CR680" publication-type="journal">Hare, J. M. et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. <italic>J. Am. Coll. Cardiol.</italic><bold>54</bold>, 2277&#x02013;2286 (2009).<pub-id pub-id-type="pmid">19958962</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR681"><label>681.</label><citation-alternatives><element-citation id="ec-CR681" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JW</given-names></name><etal/></person-group><article-title>A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction</article-title><source>J. Korean Med. Sci.</source><year>2014</year><volume>29</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.3346/jkms.2014.29.1.23</pub-id><pub-id pub-id-type="pmid">24431901</pub-id>
</element-citation><mixed-citation id="mc-CR681" publication-type="journal">Lee, J. W. et al. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. <italic>J. Korean Med. Sci.</italic><bold>29</bold>, 23&#x02013;31 (2014).<pub-id pub-id-type="pmid">24431901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR682"><label>682.</label><citation-alternatives><element-citation id="ec-CR682" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Intracoronary infusion of Wharton&#x02019;s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial</article-title><source>BMC Med.</source><year>2015</year><volume>13</volume><fpage>162</fpage><pub-id pub-id-type="doi">10.1186/s12916-015-0399-z</pub-id><pub-id pub-id-type="pmid">26162993</pub-id>
</element-citation><mixed-citation id="mc-CR682" publication-type="journal">Gao, L. R., et al. Intracoronary infusion of Wharton&#x02019;s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. <italic>BMC Med.</italic><bold>13</bold>, 162 (2015).<pub-id pub-id-type="pmid">26162993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR683"><label>683.</label><citation-alternatives><element-citation id="ec-CR683" publication-type="journal"><person-group person-group-type="author"><name><surname>Qayyum</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure</article-title><source>ESC Heart Fail</source><year>2023</year><volume>10</volume><fpage>1170</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14281</pub-id><pub-id pub-id-type="pmid">36638837</pub-id>
</element-citation><mixed-citation id="mc-CR683" publication-type="journal">Qayyum, A. A. et al. Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure. <italic>ESC Heart Fail</italic><bold>10</bold>, 1170&#x02013;1183 (2023).<pub-id pub-id-type="pmid">36638837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR684"><label>684.</label><citation-alternatives><element-citation id="ec-CR684" publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immunomodulatory cell therapy using &#x003b1;GalCer-pulsed dendritic cells ameliorates heart failure in a murine dilated cardiomyopathy model</article-title><source>Circ. Heart Fail</source><year>2022</year><volume>15</volume><fpage>e009366</fpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.122.009366</pub-id><pub-id pub-id-type="pmid">36268712</pub-id>
</element-citation><mixed-citation id="mc-CR684" publication-type="journal">Ikeda, M. et al. Immunomodulatory cell therapy using &#x003b1;GalCer-pulsed dendritic cells ameliorates heart failure in a murine dilated cardiomyopathy model. <italic>Circ. Heart Fail</italic><bold>15</bold>, e009366 (2022).<pub-id pub-id-type="pmid">36268712</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR685"><label>685.</label><citation-alternatives><element-citation id="ec-CR685" publication-type="journal"><person-group person-group-type="author"><name><surname>Chullikana</surname><given-names>A</given-names></name><etal/></person-group><article-title>Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction</article-title><source>Cytotherapy</source><year>2015</year><volume>17</volume><fpage>250</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2014.10.009</pub-id><pub-id pub-id-type="pmid">25484310</pub-id>
</element-citation><mixed-citation id="mc-CR685" publication-type="journal">Chullikana, A. et al. Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. <italic>Cytotherapy</italic><bold>17</bold>, 250&#x02013;261 (2015).<pub-id pub-id-type="pmid">25484310</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR686"><label>686.</label><citation-alternatives><element-citation id="ec-CR686" publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>J</given-names></name><etal/></person-group><article-title>Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-A randomized trial</article-title><source>Circ. Res.</source><year>2017</year><volume>120</volume><fpage>332</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309717</pub-id><pub-id pub-id-type="pmid">27856497</pub-id>
</element-citation><mixed-citation id="mc-CR686" publication-type="journal">Butler, J. et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-A randomized trial. <italic>Circ. Res.</italic><bold>120</bold>, 332&#x02013;340 (2017).<pub-id pub-id-type="pmid">27856497</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR687"><label>687.</label><citation-alternatives><element-citation id="ec-CR687" publication-type="journal"><person-group person-group-type="author"><name><surname>Florea</surname><given-names>V</given-names></name><etal/></person-group><article-title>Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study)</article-title><source>Circ. Res.</source><year>2017</year><volume>121</volume><fpage>1279</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311827</pub-id><pub-id pub-id-type="pmid">28923793</pub-id>
</element-citation><mixed-citation id="mc-CR687" publication-type="journal">Florea, V. et al. Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study). <italic>Circ. Res.</italic><bold>121</bold>, 1279&#x02013;1290 (2017).<pub-id pub-id-type="pmid">28923793</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR688"><label>688.</label><citation-alternatives><element-citation id="ec-CR688" publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolucci</surname><given-names>J</given-names></name><etal/></person-group><article-title>Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy])</article-title><source>Circ. Res.</source><year>2017</year><volume>121</volume><fpage>1192</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.310712</pub-id><pub-id pub-id-type="pmid">28974553</pub-id>
</element-citation><mixed-citation id="mc-CR688" publication-type="journal">Bartolucci, J. et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). <italic>Circ. Res.</italic><bold>121</bold>, 1192&#x02013;1204 (2017).<pub-id pub-id-type="pmid">28974553</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR689"><label>689.</label><citation-alternatives><element-citation id="ec-CR689" publication-type="journal"><person-group person-group-type="author"><name><surname>Ulus</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART Trial)</article-title><source>Int. J. Stem Cells</source><year>2020</year><volume>13</volume><fpage>364</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.15283/ijsc20075</pub-id><pub-id pub-id-type="pmid">32840230</pub-id>
</element-citation><mixed-citation id="mc-CR689" publication-type="journal">Ulus, A. T. et al. Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART Trial). <italic>Int. J. Stem Cells</italic><bold>13</bold>, 364&#x02013;376 (2020).<pub-id pub-id-type="pmid">32840230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR690"><label>690.</label><citation-alternatives><element-citation id="ec-CR690" publication-type="journal"><person-group person-group-type="author"><name><surname>Nidorf</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Colchicine in patients with chronic coronary disease</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>1838</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2021372</pub-id><pub-id pub-id-type="pmid">32865380</pub-id>
</element-citation><mixed-citation id="mc-CR690" publication-type="journal">Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. <italic>N. Engl. J. Med.</italic><bold>383</bold>, 1838&#x02013;1847 (2020).<pub-id pub-id-type="pmid">32865380</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>